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  Summ)r? 
Cancer cells extend critically short telomeres either by reactivating the reverse transcriptase telomerase 
or by employing alternative lengthening of telomeres (ALT). The ALT mechanism depends on proteins 
involved in DNA repair and homologous recombination (HR). High-throughput sequencing is 
increasingly used to analyze whole genome sequences (WGS) and gene expression in patient samples, 
and potentially, provides a rich resource of information on ALT. However, in ALT cancers the only 
recurrent mutations identified so far are in the chromatin remodeler ATRX (alpha thalassemia/ mental 
retardation syndrome X-linked), the histone chaperone DAXX (death domain associated protein), and 
the histone variant H3.3. In addition, gene expression signatures for patient stratification into ALT-
positive and ALT-negative as well as a systematic approach to identify genes involved in telomere 
maintenance (TM) and in particular ALT via functional annotation are currently missing. One well-
established hallmark of ALT is the dislocation of the PML (promyelocytic leukemia) protein to 
telomeres in ALT-associated PML nuclear bodies (APBs). These colocalizations are reliable biomarkers 
for ALT-positive tumors, but the functional role of PML during the development of ALT remains 
elusive. In this thesis, I have addressed the issues raised above by work in three areas: First, the TelNet 
database was developed as a comprehensive compilation of TM genes. Proteins involved in TM were 
collected, functionally categorized, and evaluated by applying a significance score. In addition to 
various search modes, a statistics page was implemented for TM pathway analysis and for prediction of 
the active TM mechanism (TMM). Second, ALT candidate genes were identified by gene expression 
analysis using four different approaches and isogenic cellular systems: (i) ALT suppression by HDAC 
inhibitor SAHA in U2OS cells, (ii) ALT induction by ASF1 depletion in HeLa cells with long 
telomeres (LT), (iii) reduced ALT induction capacity of the ASF1 depletion in HeLa LT cells by SAHA 
treatment, and (iv) deletion of EST2 (ever shorter telomeres 2), the telomerase protein subunit, in 
budding yeast to generate survivors that maintain telomeres by type II recombination, equivalent to the 
human ALT mechanism. A differential gene expression analysis comparing perturbed cells with the 
unperturbed control cells revealed a positive correlation of WNT and TGFb signaling with the presence 
of ALT and on the other hand a negative association of TNF/ NFkB/ MAP kinase signaling. 
Furthermore, a role as potential ALT enhancers was predicted for KCTD15 and TNNC1. In budding 
yeast type II survivors, approximately 30 genes showed a relatively small albeit statistically significant 
change in gene expression as compared to pre-senescent cells. Genes within the iron-regulon were 
overrepresented among downregulated genes, including FIT1, FIT2, ARN2, and FRE4, indicating stress 
response. Third, I investigated the functional role of PML in the ALT pathway by recruiting PML to 
telomeres in cells with and without ALT background. The formation of artificial APBs induced telomere 
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clustering and subsequently increased the abundance of extrachromosomal repeats as an ALT feature in 
both ALT-positive and ALT-negative cells. The results obtained in this thesis facilitate patient 
stratification based on deep sequencing data according to their TM mechanism and provide a better 
understanding of the functional role of APBs for ALT.
  \X 
  Zus)mmenf)ssung 
 
Krebszellen verlängern kritisch kurze Telomere entweder durch Reaktivierung der reversen 
Transkriptase Telomerase oder durch alternative Telomerverlängerung (ALT). Der ALT-Mechanismus 
hängt von Proteinen ab, die an der DNA-Reparatur und der homologen Rekombination (HR) beteiligt 
sind. Die Hochdurchsatzsequenzierung wird zunehmend zur Analyse der Genomsequenz und 
Genexpression in Patientenproben verwendet und bietet möglicherweise eine reichhaltige 
Informationsquelle über ALT. Bei ALT-Karzinomen wurden bisher nur rekurrente Mutationen in den 
Genen des Chromatin-modellierenden Faktors ATRX, des Histon-Chaperons DAXX und der 
Histonvariante H3.3 identifiziert. Darüber hinaus fehlen derzeit Genexpressionssignaturen für die 
Stratifizierung von Patienten in ALT-positive und ALT-negative Patientengruppen. Weiterhin mangelt 
es an einem systematischen Ansatz zur Identifizierung von an der Telomer-Erhaltung und insbesondere 
an ALT beteiligten Genen mittels funktioneller Annotation. Ein bekanntes Merkmal von ALT ist die 
Dislokation des PML-Proteins an Telomere in ALT-assoziierten PML-Kernkörpern (APBs). Diese Ko-
lokalisationen sind zuverlässige Biomarker für ALT-positive Tumore, aber die funktionelle Rolle von 
PML während der Entwicklung von ALT ist nicht bekannt. In dieser Arbeit habe ich die oben genannten 
Inhalte durch Arbeiten in drei Abschnitten behandelt: Zuerst wurde die TelNet-Datenbank als 
umfassende Zusammenstellung von TM-Genen entwickelt. Proteine, die an der Erhaltung der Telomere 
beteiligt sind, wurden gesammelt, funktional kategorisiert und mit einem Signifikanzwert bewertet. 
Zusätzlich zu verschiedenen Suchmodi wurde eine Statistikseite für die TM-Analyse und für die 
Vorhersage des aktiven Telomer-Erhaltungsmechanismus implementiert. Zweitens wurden ALT-
Kandidatengene durch Genexpressionsanalyse unter Verwendung von vier verschiedenen Ansätzen und 
isogenen zellulären Systemen identifiziert: (i) ALT - Suppression durch den Histondeacetylase Inhibitor 
SAHA in U2OS-Zellen, (ii) ALT-Induktion durch ASF1-Depletion in HeLa-Zellen mit langen 
Telomeren (LT), (iii) reduzierte ALT-Induktionskapazität der ASF1-Depletion in HeLa-LT-Zellen 
durch SAHA-Behandlung und (iv) Deletion von katalytischen Telomerase-Einheit EST2 in Hefe, um 
Hefezellen zu erhalten, die Telomere mithilfe von Rekombination erhalten, äquivalent zum humanen 
ALT Mechanismus. Eine differentielle Genexpressionsanalyse ergab eine positive Korrelation des 
WNT und TGFb Signalwegs und auf der anderen Seite eine negative Korrelation des TNF/ NFkB/ MAP 
Kinase Signalwegs mit aktivem ALT Mechanismus. Darüber hinaus wurden KCTD15 und TNNC1 als 
potentielle ALT-Gene vorhergesagt. Bei ALT-Hefezellen zeigten ca. 30 Gene eine relativ geringe, wenn 
auch statistisch signifikante Veränderung der Genexpression im Vergleich zu pre-seneszenten Zellen. 
Zus)mmenf)ssung 
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Herunterreguliert waren Gene des Eisen-Regulons, einschließlich FIT1, FIT2, ARN2 und FRE4, was 
auf eine Stressreaktion hinweisen könnte. Drittens untersuchte ich die funktionelle Rolle von PML im 
ALT Mechanismus durch Rekrutierung von PML zu Telomeren in Zellen mit und ohne aktiven ALT-
Mechanismus. Die Bildung von künstlichen APBs induzierte eine Ansammlung von Telomeren und 
erhöhte anschließend die Menge an extrachromosomalen Telomersequenzen sowohl in ALT-positiven 
als auch in ALT-negativen Zellen. Die in dieser Arbeit erzielten Ergebnisse erleichtern die 
Stratifizierung von Patienten basierend auf Transkriptomsequenzierungsdaten gemäß ihrem TM-
Mechanismus und ermöglichen ein besseres Verständnis der funktionellen Rolle von APBs für ALT. 
 
  X\ 
  Lis. of figures 
Figure 1. Telomere structure in human and budding yeast. .................................................................. 2	
Figure 2. Telomere maintenance. ......................................................................................................... 4	
Figure 3. Measuring hallmarks of the alternative lengthening of telomeres (ALT) pathway. ................. 7	
Figure 4. PML isoforms. ...................................................................................................................... 13	
Figure 5. Tet-On 3G system for the generation of stable inducible cell lines. ..................................... 24	
Figure 6. FACS gating and compensation. ......................................................................................... 26	
Figure 7. C-circle assay principle. ....................................................................................................... 29	
Figure 8. Automatic 3D confocal fluorescence microscopy platform. .................................................. 33	
Figure 9. Sources for identification of genes associated to TM. .......................................................... 42	
Figure 10. General part of a gene card. .............................................................................................. 43	
Figure 11. TM part of a gene card. ...................................................................................................... 45	
Figure 12. Usage chart for the TelNet database. ................................................................................ 47	
Figure 13. TelNet statistics page of all human genes. ........................................................................ 48	
Figure 14. Correlation of gene expression data with telomere lengths. .............................................. 50	
Figure 15. SAHA treated U2OS cells show decreased number of APBs and C-circle levels. ............ 52	
Figure 16. FACS analysis of cells treated with SAHA or ATRi VE-821. .............................................. 53	
Figure 17. Gene expression analysis of SAHA treated U2OS cells. ................................................... 56	
Figure 18. Reduction of ASF1 protein and transcript levels upon siRNA kd. ...................................... 63	
Figure 19. Circle levels after ASF1 kd. ................................................................................................ 64	
Figure 20. Genes deregulated upon ALT induction by ASF1 kd in HeLa LT. ..................................... 65	
Figure 21. Circle levels of SAHA treated ASF1 kd cells. ..................................................................... 71	
Figure 22. Gene expression analysis of ASF1 kd cells treated with SAHA. ........................................ 72	
Figure 23. Differential gene expression analysis of budding yeast type II survivors. .......................... 76	
Figure 24. Recruiting PML to telomeres. ............................................................................................. 78	
Figure 25. Recruitment of PML to majority of telomeres in ALT-positive U2OS cells. ........................ 79	
Figure 26. Recruitment of PML to the majority of telomeres in ALT-negative HeLa cells ................... 80	
Figure 27. Quantification of telomere properties in U2OS and HeLa cells upon transfection of GFP, 
PML-GFP, TRF1-GFP and TRF1-PML-GFP. .................................................................... 81	
Lis.  of  f igures 
 X\\ 
Figure 28. C-circle levels in U2OS and HeLa cells after induction of expression of GFP, PML-GFP, 
TRF1-PML, or TRF1-PML-GFP. ........................................................................................ 84	
Figure 29. ALT suppressor candidate genes. ..................................................................................... 91	
Figure 30. ALT enhancer candidate genes. ........................................................................................ 92	
Figure 31. Model for ALT by homologous recombination in APBs. ..................................................... 96	
Figure 32. Workflow of strategies to investigate TMMs. ...................................................................... 99	
  X\\\ 
  Lis. of .)b0es 
Table 1. Nomenclature of PML isoforms. ............................................................................................ 12	
Table 2. Essential components of ALT-associated PML nuclear bodies (APBs). ............................... 14	
Table 3. Buffer composition. ................................................................................................................ 19	
Table 4. Kits and reagents. ................................................................................................................. 19	
Table 5. Instruments. ........................................................................................................................... 20	
Table 6. Software. ............................................................................................................................... 20	
Table 7. Primers. ................................................................................................................................. 21	
Table 8. Plasmids. ............................................................................................................................... 22	
Table 9. Materials used for cloning experiments. ................................................................................ 22	
Table 10. Cell lines. ............................................................................................................................. 23	
Table 11. Cell culture material. ............................................................................................................ 23	
Table 12. siRNAs used for ASF1 knockdown. .................................................................................... 25	
Table 13. Primary antibodies used for Western blot. .......................................................................... 28	
Table 14. Secondary antibodies used for Western blot. ...................................................................... 28	
Table 15. Primary antibodies used for immunofluorescence. ............................................................. 31	
Table 16. Secondary antibodies used for immunofluorescence. ......................................................... 31	
Table 17. Settings for annotation files downloaded from the UCSC table browser. ............................ 37	
Table 18. FileMaker tables. ................................................................................................................. 39	
Table 19. General gene annotations. .................................................................................................. 44	
Table 20. Fields of the TM part of a gene card. .................................................................................. 45	
Table 21. Calculation of the TelNet score. .......................................................................................... 46	
Table 22. Pathway analysis of genes upregulated in SAHA treated U2OS cells. ............................... 56	
Table 23. TelNet genes, upregulated in U2OS treated with 2 µM SAHA. ........................................... 57	
Table 24. Pathway analysis of genes downregulated in SAHA treated U2OS cells. .......................... 58	
Table 25. TelNet genes, downregulated in SAHA treated U2OS cells. ............................................... 59	
Table 26. Pathway enrichment analysis of genes, higher expressed in HeLa LT versus ST. ............. 60	
Table 27. Pathway enrichment analysis of genes, lower expressed in HeLa LT versus ST. .............. 61	
Table 28. TelNet genes that are higher expressed in HeLa LT versus ST. ........................................ 62	
Lis.  of  .)b0es 
 X\V 
Table 29. TelNet genes that are lower expressed in HeLa LT versus ST. .......................................... 62	
Table 30. Pathway analysis of genes, upregulated in ASF1 depleted HeLa ST cells. ........................ 66	
Table 31. Pathway analysis of genes, upregulated in ASF1 depleted HeLa LT cells. ........................ 67	
Table 32. TelNet genes, upregulated in ASF1 depleted HeLa LT cells. ............................................. 69	
Table 33. Pathway analysis of genes, downregulated in ASF1 depleted HeLa LT cells. .................... 69	
Table 34. TelNet genes, downregulated in ASF1 depleted HeLa LT cells. ......................................... 70	
Table 35. GO analysis of upregulated genes, in ASF1 depleted HeLa LT, treated with SAHA. ......... 73	
Table 36. TelNet genes, upregulated in ASF1 depleted HeLa LT, treated with SAHA. ...................... 74	
Table 37. GO analysis of downregulated genes, in ASF1 depleted HeLa LT, treated with SAHA. ..... 75	
Table 38. TelNet genes, downregulated in ASF1 depleted HeLa LT, treated with SAHA. .................. 75	
Table 39. TelNet genes, upregulated in type II survivors. ................................................................... 77	
Table 40. Quantification of telomere and APB properties in transiently transfected U2OS cells. ....... 82	
Table 41. Quantification of telomere and APB properties in transiently transfected HeLa cells. ........ 82	
  XV 
  Abbrevi).ions 
ABCC8 ............ ATP binding cassette subfamily C member 8 
ALT .................. alternative lengthening of telomeres  
aka ................... also known as 
APB ................. ALT-associated PML nuclear body 
ASF1A/ B ......... anti-silencing function 1A/ B histone chaperone 
ATM ................. ataxia telangiectasia mutated protein 
ATR ................. ataxia telangiectasia and Rad3-related protein 
ATRi ................. ATR inhibitor 
ATRX ............... alpha thalassemia/ mental retardation syndrome X-linked  
BH/ FDR .......... method of Benjamini, Hochberg, and Yekutieli to control the false discovery rate 
BiFC ................. PCA/ bimolecular fluorescent complementation 
BSA  ................ bovine serum albumin 
C-circles ........... circular C-rich extrachromosomal telomeric repeats 
CC-assay ......... C-circle assay 
cDNA  .............. complementary DNA 
CLSM .............. confocal laser scanning microscopy 
CST ................. protein complex: CDC13, STN1, TEN1 
Ctrl ................... control 
D-loop .............. displacement loop 
DAXX ............... death-associated protein 6 
DAPI  ............... 4',6-diamidino-2-phenylindole 
dATP ............... deoxyadenosine triphosphate 
DAVID.............. database for annotation, visualization and integrated discovery (Dennis et al., 2003) 
dCTP ............... deoxycytidine triphosphate 
DDR ................. DNA damage response 
DESeq ............. Differential expression analysis for sequence count data,  
DESeq2 package (Love et al., 2014) 
dGTP ............... deoxyguanosine triphosphate 
DMEM  ............. dulbecco's modifed eagle medium 
DMSO .............. dimethylsulfoxid 
DNA ................. deoxyribonucleic acid 
dNTP  .............. deoxynucleoside triphosphate 
DSB ................. DNA double-strand break 
dTTP ................ deoxythymidine triphosphate 
ECTRs ............. extrachromosomal telomeric repeats 
EDTA  .............. ethylenediaminetetraacetic acid 
EST2 ............... ever shorter telomeres, catalytic subunit of budding yeast telomerase 
EtOH ................ ethanol 
FACS ............... fluorescence activated cell sorting 
FBS ................. fetal bovine serum 
Abbrevi). ions 
 XV\ 
FDR ................. false discovery rate 
FISH  ............... fluorescence in situ hybridization 
FITC ................. fluorescein isothiocyanate 
FLAG ............... protein tag (DYKDDDDK) 
FWHM  ............ full width at half maximum 
G ...................... plasmid encoding GFP (in the context of this thesis) 
G4 .................... G-quadruplex 
gDNA ............... genomic DNA 
GFP ................. green fluorescent protein 
GO ................... gene ontology 
GRN163 .......... telomerase inhibitor (Geron, USA) 
GST ................. glutathione S-transferase 
H3.3 ................. histone 3 variant 3 
H3.3-K27M ...... H3.3 with lysine 27-to-methionine mutation 
HDAC .............. histone deacetylase 
HDACi .............. histone deacetylase inhibitor 
HDR ................. homology-directed repair 
HeLa ................ human cervical cancer cell line (derived from cancer cells taken from Henrietta Lacks) 
HeLa 1.2.11 ..... HeLa cervical carcinoma subclone 1.2.11,  
telomerase-positive cell line with long telomeres 
HeLa LT ........... HeLa cells with long telomeres (average of 20 kb) 
HeLa ST .......... HeLa cells with short telomeres (average of 9 kb) 
HEPES ............ 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HGNC .............. HUGO gene nomenclature committee,  
http://www.genenames.org (Yates et al., 2017) 
HP1  ................ heterochromatin protein 1 
HR ................... homologous recombination 
HRP  ................ horseradish peroxidase 
ICGC ................ international cancer genome consortium 
ID ..................... identifier 
IF  .................... immunofluorescence 
IGV  ................. integrative genomics viewer 
kb ..................... kilobase 
kd ..................... knockdown 
kDa .................. kilo Dalton 
KNS42 ............. pediatric glioblastoma cell line, also known as ICGC_GBM73 
l2fc/ log2 fc ...... fold change of log2 transformed values 
lacO  ................ lac operon 
LC-MS/ MS  ..... liquid chromatography - tandem mass spectrometry 
LT .................... long telomeres (see HeLa LT) 
MAPK .............. mitogen-activated protein kinase 
MGBM1 ........... pediatric glioblastoma cell line, also known as 10-801, ICGC_GBM39 
MMS21 ............ methyl methanesulfonate sensitivity protein 21 
MRN ................ protein complex: MRE11, RAD50, NBS1 
MudPIT ............ multidimensional protein identification technology 
NCBI ................ national center for biotechnology information (Coordinators, 2017) 
Abbrevi). ions 
 XV\\ 
NHEJ ............... non-homologous end joining 
NLS  ................ nuclear localization signal 
NTP  ................ nucleotide triphosphate 
p/ p-value ......... probability value 
padj .................. corrected/ adjusted p-value (method: FDR/ BH) 
pATM ............... phosphorylated ATM 
PBS  ................ phosphate buffered saline 
PCA ................. protein complementation assay 
PCR  ................ polymerase chain reaction 
PDK4 ............... pyruvate dehydrogenase kinase 4 
pedGBM .......... pediatric glioblastoma 
PFA ................. paraformaldehyde 
PG ................... plasmid encoding a fusion of PML with GFP (in the context of this thesis) 
PI ..................... propidium iodide 
PICh ................ proteomics of isolated chromatin segments 
PLCB2 ............. phospholipase C beta 2 
PML ................. promyelocytic leukemia 
PML-NBs ......... PML nuclear bodies  
PMSF  .............. phenylmethylsulfonylfluoride 
PNA ................. peptide nucleic acid 
POT1 ............... protection of telomeres protein 1 
qRT-PCR ......... quantitative real-time PCR  
QTIP ................ quantitative telomeric chromatin isolation protocol (Grolimund et al., 2013) 
qTRAP ............. quantitative TRAP (Cerone et al., 2011) 
RAP1 ............... repressor/ activator protein 1 
RBCC/ TRIM .... RING-finger, B-Box, and coiled-coil/ TRIpartite motif 
rlog .................. regularized log transformation, DESeq2 package (Love et al., 2014) 
RNA ................. ribonucleic acid 
RNA-seq  ......... RNA-sequencing 
RPKM  ............. reads per kilobase of exon per million mapped reads 
rpm .................. rounds per minute 
RT  ................... room temperature 
RT-qPCR ......... reverse transcription quantitative real-time PCR  
SAHA ............... suberoylanilide hydroxamic acid (vorinostat), pan HDAC inhibitor 
SDS  ................ sodium dodecyl sulfate 
SF188 .............. pediatric glioblastoma cell line, also known as ICGC_GBM40 
SGD ................. saccharomyces genome database (Cherry et al., 2012) 
siRNA .............. small/ short interfering RNA 
SJ-G2 .............. pediatric glioblastoma cell line, also known as SJ-02, ICGC_GBM41 
SSC  ................ saline-sodium citrate 
ssDNA ............. single-stranded DNA  
SUMO .............. small ubiquitin-related modifier 	
SMC 5/ 6 ......... structural maintenance of chromosomes complex 5/ 6 
ST .................... short telomeres (see HeLa ST) 
T-loop .............. telomeric loop 
Abbrevi). ions 
 XV\\\ 
T-SCE .............. telomere sister chromatid exchange  
TAE ................. tris base, acetic acid, EDTA 
TBS.................. Tris-buffered saline 
TBST ............... Tris-buffered saline with additional Tween 20 
TCGA ............... the cancer genome atlas 
TelNet .............. database containing genes, proteins, and transcripts involved in telomere 
maintenance 
TelSeq ............. method for estimating telomere length from WGS data (Ding et al., 2014) 
TERRA ............ telomeric repeat-containing RNA  
TERT ............... telomerase reverse transcriptase  
tetO  ................. tet operon 
TG .................... plasmid encoding a fusion of TRF1 with GFP (in the context of this thesis) 
TIN2 ................. TRF1-interacting protein 2  
TM ................... telomere maintenance 
TMM ................ telomere maintenance mechanism 
TP53 ................ tumor protein p53 
TPE.................. telomere position effect 
TPG ................. plasmid encoding a fusion of TRF1, PML, and GFP (in the context of this thesis) 
TPP1 ............... TIN2- and POT1-interacting protein 
TRAP ............... telomere repeat amplification protocol 
TRF1 ................ telomere repeat binding factor 1, official symbol: TERF1 
TRF2 ................ telomere repeat binding factor 2, official symbol: TERF2 
Tris ................... tris(hydroxymethyl)aminomethane 
U2OS ............... human bone osteosarcoma epithelial cell line 
VE-821 ............ selective ATRi, 3-Amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-
carboxamide,  
vst .................... variance stabilizing transformation, DESeq2 package (Love et al., 2014) 
WB  .................. Western blot 
WGS ................ whole genome sequencing 
wt  .................... wild-type 
γH2A.X ............ histone variant H2A.X with phosphorylated serine 139  
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  !n.roduc.ion 
1 Te0omeres )nd .e0omere m)in.en)nce 
Telomeres form the nucleoprotein structures at the ends of linear chromosomes (Blackburn, 1984; 
Blackburn, 1991). The term telomere originates from the Greek telos (τέλος) “end” and méros (µέρος) 
“part”. Telomeric DNA consists of double-stranded G-rich tandem repeats with single-stranded 3’ G-
overhang (Makarov et al., 1997). Telomeric DNA is bound by proteins that constitute telosome, which 
in mammalian cells is also called the shelterin complex (Wright et al., 1992; Dmitriev et al., 2003; Liu 
et al., 2004; de Lange, 2005b; Palm & de Lange, 2008). The single-stranded overhang folds back to 
form a protective displacement loop (D-loop) with duplex telomere DNA (Griffith et al., 1999). The 
telomeric loop structure is termed t-loop and has been reported to exist in both mammals (de Lange, 
2004) and in budding yeast (Luke-Glaser et al., 2012). The telosome/ shelterin complex shields the ends 
of chromosomes from degradation, accidental recognition as DNA double-strand break and 
chromosome end fusions, thereby protecting from degradation and DNA repair (Denchi & de Lange, 
2007). Telomeres are generally conserved among vertebrates and share common structural features 
among eukaryotes (Blackburn, 1990). The budding yeast Saccharomyces cerevisiae is a model organism 
that is well-studied with regard to telomere biology (Kupiec, 2014). However, extrapolations from 
budding yeast to mammals can be specious with respect to telomere biology, because the telosome 
complex is different between human and budding yeast (de Lange, 2005b). 
1.1 Te0omere s.ruc.ure )nd func.ion  
The proper function of a telomere is sustained by a minimum length and integrity of shelterin (Chan & 
Blackburn, 2002; de Lange, 2005b). Human telomeres in somatic cells have a length of 3-12 kb (Greider, 
1993; Mondello et al., 1999; Friedrich et al., 2000) and consist of regular [TTAGGG]n repeats (Moyzis 
et al., 1988). Telomeric DNA is bound by the shelterin complex consisting of six proteins (de Lange, 
2005b), depicted in Figure 1A. TRF1 and TRF2 (DNA-binding telomere repeat factors 1 and 2) directly 
bind to double-stranded telomeric DNA (Smith & de Lange, 1997). TRF2 prevents end-to-end fusions, 
and its deletion leads to activation of DNA repair processes at telomeres mediated by ATM (van Steensel 
et al., 1998). However, artificially induced DNA double-strand breaks at telomeres are efficiently 
repaired by ATM-dependent signaling (Doksani & de Lange, 2016). RAP1 (TERF interacting protein) 
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is interacting with TRF2 (Li et al., 2000). TRF1 and TRF2 homodimers are bridged by TIN2 (TRF1-
interacting nuclear factor 2) (Ye et al., 2004). The single-stranded G-overhang is covered by POT1 
(protection of telomeres 1) forming a heterodimer with TPP1 (also known as ACD, shelterin complex 
subunit and telomerase recruitment factor) (Hockemeyer et al., 2007). POT1/ TPP1 is recruited to the 
shelterin complex via its interaction with TIN2 (Takai et al., 2011). POT1 protects telomeres from the 
repair processes mediated by the ATR signaling pathway (Hockemeyer et al., 2005). 
 
Figure 1. Telomere structure in human and budding yeast. 
Telomeres and telomere binding proteins. (A) Human telomeres consist of TTAGGG repeats and form 
a t-loop by strand invasion of the G-rich overhang into duplex DNA, forming the D-loop. The shelterin 
complex is formed by TRF1, TRF2, TIN2, TPP1, POT1 and RAP1. TRF1 and TRF2 homodimers bind 
duplex telomeric DNA, while POT1/ TPP1 binds to the ssDNA of telomeres. TRF2 and POT1 protect 
telomeres from the DNA damage response activated by ATM and ATR signaling, respectively. 
(B) Budding yeast telomeres have an irregular telomeric sequence of TG1-3, and a fold-back structure 
is proposed, however not visualized yet. The subtelomere is densely packed by nucleosomes covered 
with SIR2/ 3/ 4. Telomeres are nucleosome-free and are bound by RAP1 that interacts with the SIR 
complex and RIF1/ 2. The G-rich single-stranded overhang is bound by the CST complex that protects 
telomeres from exonucleases, such as EXO1. 
With an average length of 300 bp budding yeast telomeres are significantly shorter than human 
telomeres and consist of varying [TG1–3]n repeats (Wellinger & Zakian, 2012). The CST complex 
(CDC13, STN1, TEN1) covers the telomeric overhang with CDC13 directly binding to the single-
stranded repeats (Grandin et al., 2001a; Gao et al., 2007; Giraud-Panis et al., 2010). The CST complex 
is essential for viability and ensures end protection by blocking exonucleases, such as EXO1 
(exonuclease 1) (Grandin et al., 2001b; Jia et al., 2004). Double-stranded telomeric DNA is bound by 
RAP1 (repressor activator protein 1) (Wright & Zakian, 1995). RAP1 is essential for a proper telomere 
function because it protects the ends from chromosome fusions (Conrad et al. 1990; Lustig et al. 1990; 
Marcand et al. 2008) and degradation (Vodenicharov et al., 2010). Furthermore, RAP1 recruits RIF1/ 2 
that are heterogeneously distributed over the duplex part of the telomere (Shi et al., 2013). SIR2/ 3/ 4, 
proteins of the SIR (silence information regulator) complex also interact with RAP1 via SIR3 (Moretti 
et al., 1994; Gotta et al., 1996). In addition, proteins of the SIR complex deacetylate and bind to histones 
of the subtelomeres (Imai et al., 2000; Liou et al., 2005).  
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In budding yeast, only the subtelomeres are covered by nucleosomes, but telomeres are not (Wright et 
al., 1992; Strahl-Bolsinger et al., 1997). At human telomeres, canonical histones and histone variants 
such as macroH2A and testis-specific H2B have been identified (Dejardin & Kingston, 2009). Shelterin 
and nucleosomes both bind to TTAGGG repeats and might thus compete for the same binding site 
(Galati et al., 2012; Galati et al., 2015). Yeast telomeres and mammalian subtelomeres are hetero-
chromatic. The characteristic of heterochromatin marks in the telomere comprises of HP1 (Hetero-
chromatin protein 1), enrichment of H3K9 and H4K20 trimethylation, and heavy DNA methylation 
(Garcia-Cao et al., 2004; Gonzalo et al., 2005; Gonzalo et al., 2006; Blasco, 2007). The non-coding 
telomere repeat containing RNA RNA (TERRA) is transcribed from subtelomeres into telomeres and 
might have functional roles in telomere integrity and telomerase regulation (Azzalin et al., 2007; Luke 
et al., 2008; Schoeftner & Blasco, 2008; Cusanelli & Chartrand, 2015; Rippe & Luke, 2015). 
1.2 Te0omere m)in.en)nce mech)nisms (TMM) 
As described above, the default telomere state can therefore be described as fully protected by shelterin 
and closed due to the protective t-loop formation (Cesare & Reddel, 2010). The limited cell proliferation 
of human somatic cells is mainly explained by the so-called end-replication problem (Hayflick, 1965; 
Olovnikov, 1973). It describes the incomplete replication of telomeres and the resulting shortening after 
each round of replication (Harley et al., 1990; Levy et al., 1992). Additionally, telomere shortening is 
accelerated by additional processes like oxidative stress (Saretzki & Von Zglinicki, 2002). Due to loss 
of telomeric repeats, shelterin is removed resulting in deprotection of telomeres and exposure of linear 
ends that become accessible to the DNA damage response machinery (Cesare et al., 2013). By activation 
of ATM signaling, p53 is upregulated and replicative senescence is triggered potentially resulting in 
apoptosis (Lundblad & Szostak, 1989; d'Adda di Fagagna et al., 2003) (Figure 2). In budding yeast 
experiments it has been shown that the shortest telomere controls induction of replicative senescence 
(Hemann et al., 2001; Xu et al., 2013). Loss of p53 and RB function allows cells to escape from 
senescence and continue proliferation (Chin et al., 1999; Maciejowski & de Lange, 2017). Further 
telomere loss leads to end-to-end fusions as observed in TRF2 deficient cells (van Steensel et al., 1998), 
leading to a state called crisis. Repetitive cycles of fusions and subsequent breakage results in genomic 
instability, a hallmark of cancer (Hanahan & Weinberg, 2000; de Lange, 2005a; Hanahan & Weinberg, 
2011). During crisis, genetic alterations are accumulated and rare events of survivor formation have 
been observed (Shay & Wright, 1989). Cancer cells can escape from crisis by achieving a mechanism 
for extending telomeric repeats (Kim et al., 1994; Counter et al., 1998; Yeager et al., 1999; Zhu et al., 
1999; Lu et al., 2016; Min et al., 2017). Telomere maintenance is either accomplished by reactivation 
of the reverse transcriptase telomerase (Greider & Blackburn, 1985; Greider, 1993; Bryan & Reddel, 
1997; Chan & Blackburn, 2002) or alternative lengthening of telomeres (ALT) in the absence of 
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telomerase (Lundblad & Blackburn, 1993; Bryan et al., 1995; Bryan et al., 1997; Teng & Zakian, 1999; 
Dunham et al., 2000; Shay et al., 2012). Cell lines and primary tumors without telomere maintenance 
(TM) have been reported (Dagg et al., 2017) and termed after the yeast terminology “ever shorter 
telomeres” (Lundblad & Szostak, 1989). Telomeres are very long in these cells, but telomeres shorten 
continuously due to ongoing proliferation. 
 
Figure 2. Telomere maintenance. 
Due to the end-replication problem, cells lose telomere repeats during proliferation. Upon deprotection 
of telomeres, replicative senescence is triggered and followed by apoptosis. Cells can escape from 
senescence by (epi)mutations of for example tumor suppressor genes like p53. Further telomere 
shortening leads to activation of DNA damage checkpoints and cells enter a state called crisis. Additional 
(epi)mutations enable malignant transformation to cancer cells that either reactivate telomerase or make 
use of alternative lengthening of telomeres (ALT). By maintaining telomeres, cancer cells achieve 
unlimited proliferative potential (Hanahan & Weinberg, 2011). 
Human telomerase consists of the protein TERT (telomerase reverse transcriptase) and the non-coding 
RNA template TERC (telomerase RNA component) and extends short telomeres by adding TTAGGG 
repeats (Morin, 1989). In budding yeast, telomerase is constitutively expressed and its deletion causes 
cellular senescence (Lundblad, 2002). Yeast cells that overcome crisis by the use of homologous 
recombination are called survivors and are categorized into type I and II defined by dependence on 
RAD50 or RAD51 (Lundblad & Blackburn, 1993; Le et al., 1999; Teng & Zakian, 1999; Chen et al., 
2001; Lundblad, 2002). Type II survivors, dependent on RAD51, have telomeres that are heterogeneous 
in length, similar to human ALT cells (Le et al., 1999; Teng & Zakian, 1999; Chen et al., 2001). Despite 
the differences of telomere biology between budding yeast and human, orthologues exist for many genes 
involved in TM, chromatin organization and DNA repair and recombination. In budding yeast, genetic 
deletion screens are extensively used. Thus, transferring knowledge about TM from budding yeast will 
help to elucidate the alternative lengthening of telomeres (Kupiec, 2014; Lippuner et al., 2014).  
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2 A0.ern).ive 0eng.hening of .e0omeres (ALT) 
In the absence of telomerase, cancer cells maintain their telomeres via the alternative lengthening of 
telomeres (ALT) (O'Sullivan & Almouzni, 2014; Sobinoff & Pickett, 2017; De Vitis et al., 2018). 
Therefore, ALT has been defined as “de novo synthesis of telomeric DNA via a mechanism other than 
telomerase” (Sobinoff & Pickett, 2017). The ALT mechanism has been investigated over the past two 
decades and a number of molecular and cytological hallmarks have been defined that are used as 
biomarkers to characterize cell lines and tumor samples as described in the next section (Pickett & 
Reddel, 2015). In addition, it is well accepted that ALT cells use homology-directed DNA repair 
mechanisms to copy repeats from a template to extend telomeric DNA. However, the mechanistic details 
remain elusive.  
2.1 Mo0ecu0)r )nd c?.o0ogic)0 h)00m)rYs of ALT 
A number of well-established molecular and cytological hallmarks of ALT are used for determining the 
active TMM in cancer cells (Henson & Reddel, 2010; Sobinoff & Pickett, 2017) (Figure 3). The extent 
of each feature can vary between different ALT cell lines and the relationships between the features are 
only partly understood.  
Absence of telomerase activity 
The absence of telomerase activity can be determined via lack of signal in the telomere repeat 
amplification protocol (TRAP) assay (Mender & Shay, 2015) (Figure 3A). Expression of TERT can also 
be accessed via RNA-seq (Figure 3E), however, even in telomerase-positive cells read counts are very 
low due to low abundance of transcripts (Fagerberg et al., 2014). Expression of the RNA template TERC 
is also needed for active telomerase (Xi & Cech, 2014; Min et al., 2017), but ALT can be active in spite 
of normal TERC expression levels (Zhang et al., 2011).  
ALT-associated PML bodies (APBs) 
Telomeres aggregate with PML protein in ALT-associated PML nuclear bodies (APBs) in ALT cells 
(Chung et al., 2012). The functional role of these biomarkers is only partly understood. APBs harbor a 
number of HR and DDR proteins and de novo telomeric synthesis was observed at telomeres in APBs, 
indicating that APBs are the place of telomere extension in ALT cells (Nabetani et al., 2004; Chung et 
al., 2011; Nabetani & Ishikawa, 2011). Due to the high correlation with ALT activity, APBs are an 
excellent marker for ALT (Henson et al., 2005; Chung et al., 2012). They can be visualized by staining 
of telomeres via TRF1/ TRF2 immunofluorescence (IF) or telomere FISH and PML IF (Figure 3B) 
(Yeager et al., 1999) and a detailed description of their role for ALT is provided in introduction section 4. 
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Telomere dysfunction induced foci (TIFs) 
Accumulations of DNA damage response proteins at telomeres indicate telomere dysfunction induced 
foci (TIFs) and are frequently found in ALT cells (Cesare et al., 2009). TIFs can be visualized by 
immunofluorescence and detection of co-localization of telomeres with marker proteins of DNA repair 
as for example phosphorylated forms of ATM, the histone variant H2A.X (gH2AX) or 53BP1. 
Heterogeneous telomere length 
Telomeres in ALT cells are heterogeneous in length and range from very short to over 50 kb (Bryan et 
al., 1995; Dunham et al., 2000; Perrem et al., 2001). The intracellular heterogeneity in telomere length 
might come from disproportional extension of lagging strands that are then exposed to telomere 
trimming processes resulting in short telomeres in turn (Min et al., 2017). Furthermore, a high number 
of chromosomes have only very short telomeres (<0.15 kb)(Poon et al., 1999), which has been used as 
a marker for the lack of telomerase (Hemann et al., 2001; Perrem et al., 2001). Methods to analyze 
telomere lengths have recently been reviewed (Montpetit et al., 2014; Lai et al., 2018). With the terminal 
restriction fragment (TRF) blot of telomeric DNA separated on an agarose gel qualitative heterogeneity 
within one sample can be visualized, but the resolution is very poor (Figure 3C) (Moyzis et al., 1988; 
Aubert et al., 2012). The TRF blot gives an estimate on the distribution of telomere length and the 
average length can be extracted (Kimura et al., 2010). A higher resolution- and chromosome-specific 
analysis can be done with quantitative fluorescence in situ hybridization (Q-FISH) on metaphase 
chromosomes (Figure 3D) (Meyne & Moyzis, 1994; Uhlmann et al., 2000; Poon & Lansdorp, 2001).  
TERRA 
The abundance of the telomeric RNA TERRA can be measured via RT-qPCR (Figure 3F). For 
measuring total TERRA levels primers that consist of UUAGGG repeats and bind to the telomeric part 
of TERRA can be used (Deeg, 2015). Furthermore, for chromosome-specific analysis primers that bind 
to proposed promotor sites in the subtelomeres of chromosomes 15q, 1q-2q-10q-13q, 9p-15q-Xq-Yq, 
11q and Xp-Yp have been reported (Arnoult et al., 2012; Deeg, 2015). 
Extrachromosomal telomeric repeats (ECTRs) 
In ALT cells, extrachromosomal telomeric repeats accumulate, which can be both linear or circular, 
single-stranded or double-stranded, and C-rich or G-rich. One abundant type are C-circles, which are 
mostly single-stranded, C-rich and circular ECTRs. The cause and mechanism of C-circle formation is 
not fully understood. It has been hypothesized that C-circles might be a byproduct from homologous 
recombination or result from telomere trimming of very long telomeres (Pickett et al., 2009). 
Furthermore, it has been suggested that C-circles could serve as template for telomere synthesis by 
rolling circle amplification (Fasching et al., 2007). Recently, cytosolic DNA sensing has been linked to 
ALT (Chen et al., 2017). A very straightforward and robust technique to quantify C-circle levels is the 
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C-circle assay, which makes use of the self-priming capacity of the circular partly double-stranded 
nature and a rolling circle amplification utilizing F29 polymerase (Figure 3G) (Henson et al., 2009). 
Amplified C-circles can subsequently be blotted on a membrane and detected via a telomeric probe. The 
C-circle assay serves as reliable indicator for ALT-positive tumors, as elevated C-circle levels highly 
correlate with ALT activity in cell lines and tissue samples from cancer patients (Deeg et al., 2017; 
Henson et al., 2017).  
 
Figure 3. Measuring hallmarks of the alternative lengthening of telomeres (ALT) pathway. 
(A) Telomere repeat amplification protocol (TRAP) assay to determine lack of telomerase activity. 
(B) Detection of ALT-associated PML nuclear bodies (APBs) by telomere fluorescence in situ 
hybridization (FISH) and immunofluorescence of PML. This can be combined with subsequent 
automated image acquisition and analysis to determine the number of APBs. (C) Telomere restriction 
fragment (TRF) blot to measure the absolute telomere length distribution. (D) Metaphase spreads and 
subsequent telomere FISH to yield relative telomere lengths for each chromosome. (E) RNA-
sequencing to determine the lack of telomerase RNA (TERC) and protein (TERT) subunit expression. 
(F) Quantitative PCR with subtelomeric primers to determine the abundance of telomere repeat 
containing RNA (TERRA). (G) C-circle assay to determine the circular C-rich form of extrachromosomal 
telomeric repeats. (H) Chromosome orientation (CO)-FISH to detect telomere sister chromatid 
exchange (T-SCE). 
Homologous recombination (HR) 
De novo synthesis of telomere repeats in ALT cells is facilitated by homologous recombination (HR), 
namely strand invasion of single-stranded telomeres into double-stranded telomeric DNA. 
Intertelomeric copying of an artificially integrated gene from one telomere to another was demonstrated 
by integration of an exogenous gene into a telomere. This gene was then copied to another telomere 
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(Dunham et al., 2000). The copy template can either be the same DNA strand (t-loop), another 
chromosome or extrachromosomal telomeric repeats. Non-replicative telomeric synthesis can be 
detected by BrdU assay of interphase cells and subsequent microscopy analysis. Homologous 
recombination events between different chromosomes can result in telomeric sister chromatid 
exchanges (T-SCE) (Londono-Vallejo et al., 2004), which can be accessed by chromosome orientation 
FISH (CO-FISH) (Figure 3H) (Meyne & Goodwin, 1994; Bailey et al., 2010; Falconer et al., 2010). 
CO-FISH requires BrdU incorporation into newly synthesized telomeric DNA, selective digestion of 
BrdU containing strands, strand-specific labeling of telomeres on metaphase spreads, and subsequent 
imaging. During homologous recombination, another telomere might be involved in de novo telomeric 
synthesis, resulting in telomeric clustering, which can also be accessed by microscopy (Draskovic et al., 
2009; Cho et al., 2014; Osterwald et al., 2015). 
2.2 O.her ALT fe).ures 
In addition to the well-established characteristics of ALT telomeres described above, a number of other 
features have been reported. The chromatin state of ALT telomeres appears to be altered in comparison 
to telomerase-positive cells. In ALT cells, telomeric chromatin was shown to be more accessible to 
digestion by MNase and have higher levels of TERRA transcription than telomeric chromatin in cells 
that maintain their chromosomal ends by telomerase (Episkopou et al., 2014). Upon telomerase 
overexpression, H3K9me3 was increased at telomeres and TERRA levels were reduced, indicating a 
more relaxed chromatin state of ALT telomeres (Episkopou et al., 2014). Telomeres in APBs however, 
are bound by all three members of the heterochromatin protein (HP1) family, indicating a condensed 
chromatin state at telomeres within APBs (Jiang et al., 2009). Recruitment of HP1g was sufficient to 
induce de novo formation of APBs (Chung et al., 2011), while chromatin decondensation of telomeric 
chromatin by overexpression HMGN5 or HDAC inhibition/ depletion was shown to reduce the number 
of APBs (Osterwald, 2012; Jamiruddin et al., 2016). These observations give rise to the assumption that 
epigenetic changes are linked to ALT emergence (O'Sullivan & Almouzni, 2014; Voon et al., 2016).  
Furthermore, the emergence of ALT in a cancer subtype is dependent on the tissue of origin. For 
example, a very high ALT prevalence is found in osteosarcoma (64%), leiomyosarcoma (53-58%), high-
frequency microsatellite instability gastric carcinoma (57%), pancreatic neuroendocrine tumors (53%), 
pediatric glioblastoma multiforme (44%), diffuse astrocytoma (63%), and anaplastic astrocytoma (63%) 
(Heaphy et al., 2011b; Chudasama et al., 2018; De Vitis et al., 2018). Recurrent mutations that correlate 
with the ALT status are found in ATRX (α-thalassemia mental retardation X-linked protein), DAXX 
(death-associated protein 6) and H3F3A, encoding for the non-canonical histone H3 variant H3.3 
(Heaphy et al., 2011a; Lovejoy et al., 2012; Schwartzentruber et al., 2012). However, single knockdown 
of neither of them is sufficient to induce ALT (Lovejoy et al., 2012; Episkopou et al., 2014; O'Sullivan 
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et al., 2014; Flynn et al., 2015; Napier et al., 2015; Udugama et al., 2015; Danussi et al., 2018). On the 
other hand, loss of ATRX was shown to facilitate ALT activation (Napier et al., 2015) and reexpression 
of ATRX in previous ATRX-negative cell lines suppressed the ALT mechanism (Clynes et al., 2015; 
Deeg et al., 2016). This indicates that loss of a combination of multiple factors is needed for ALT 
activation. Introducing hTERT into ALT cells repressed some features of the ALT pathway (Perrem et 
al., 1999). One possible explanation for this finding is that the telomerase-positive environment harbors 
factors that suppress homologous recombination. Proteins related to the ALT pathway have been 
reviewed recently (Nabetani & Ishikawa, 2011). Those investigated with regard to localization to APBs 
or APB formation have been summarized in (Suppl. table S1).  
2.3 D).)b)ses wi.h .e0omere m)in.en)nce (TM) inform).ion 
The exact ALT mechanism and reasons for its emergence remain elusive, despite the certainty of 
involvement of homology-directed DNA repair (Londono-Vallejo et al., 2004; Conomos et al., 2013). 
However, a large number of proteins have been described to be related to the TM and ALT. For example, 
at least 53 different proteins localize to APBs in ALT cells and have a role of APB formation. They are 
summarized in the appendix (Suppl. table S1). Furthermore, experimental screens were set up to 
investigate proteins involved in TM yielding many hits (Dejardin & Kingston, 2009; Lee et al., 2011; 
Uziel et al., 2015). Thus, the amount of information has become substantial, and systematic approaches 
are needed to collect the available information. A database with a compilation of TMM proteins should 
provide comprehensive information on the TMM phenotype that can be accessed easily. Furthermore, 
the identification of TMM genes in a results list from an experimental screen or bioinformatics pipeline 
should be anticipated, considering the increasing use of deep sequencing for dissecting TMM (Barthel 
et al., 2017; Chudasama et al., 2018; Sieverling et al., 2018). There are some publicly available 
databases that partly include relevant information to TM. According to HumanMine, a number of 267 
genes have been annotated with a GO term containing the term “telo” (Smith et al., 2012; Gene 
Ontology, 2015). TeloPIN (telomeric proteins interaction network), which is no longer available, 
contained interaction data of shelterin compounds with interaction partners (Luo et al., 2015). The 
telomerase database (http://telomerase.asu.edu/) is dedicated to the structure and function of telomerase 
across organisms (Podlevsky et al., 2008). Information on the localization of proteins during cell cycle 
progression is collected in the MiCroKiTS (midbody, centrosome, kinetochore, telomere and spindle) 
database (http://microkit.biocuckoo.org/) (Huang et al., 2015). The websites mentioned above include 
parts of telomere-related information that is available from the literature. However, a database that 
integrates all these information, especially on proteins in the ALT mechanism is currently missing. 
Having such a resource would facilitate the understanding of the complex process of TM as well as the 
identification of novel drug targets that are related to this process.  
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3 T)rge.ing .e0omere m)in.en)nce  
Telomere maintenance (TM) is a common feature to all cancer cells. Thus, it is a highly attractive 
therapeutic target, since it could be exploited for the development of “pan-cancer drugs”. However, 
targeting TM currently has several limitations. There are different pathways, and in the case of ALT, a 
specific molecular target is currently missing. In general, targeting TM would lead to the blocking of 
active telomere lengthening without causing immediate cell death. Senescence or cell death is induced 
in cells with critically short telomeres, resulting from telomere shortening due to cell proliferation. 
Depending on the initial telomere length, this can sum up to 21–24 population doublings (Min et al., 
2017) or in other terms 20 months’ time (Uziel et al., 2015). During this time of uncontrolled growth of 
cancer cells, the tumor mass would already be largely increased. Another problem is the evasiveness of 
TMM treatment, which has been observed for telomerase-depleted cells and the subsequent emergence 
of ALT-positive cells from crisis (Chang et al., 2003; Bechter et al., 2004; Chen et al., 2010; Hu et al., 
2012; Min et al., 2017). Therefore a combined treatment of telomerase and ALT has been proposed to 
prevent drug resistance in either direction (Shay et al., 2012). Indeed, simultaneous depletion of TERT 
and ALT-related proteins (RAD51, NBS1 and TRF2) resulted in the reduction of cell viability of 
laryngeal squamous carcinoma cells (Xu et al., 2016). Since TM is a common feature of all cancer cells 
(with a few rare exceptions), a treatment that simultaneously targets ALT and telomerase would be rated 
as very effective (De Vitis et al., 2018). 
3.1 !nhibi.ing .e0omer)se 
Telomerase appears to be an ideal target for cancer therapy because the majority of cancer cells depend 
on telomerase-mediated TM (Romaniuk et al., 2014; Jager & Walter, 2016). Inhibition of telomerase 
can be achieved by targeting either the telomerase RNA component TERC by the antisense oligo 
GRN163L (Imetelstat, by Geron Corporation, Menlo Park, CA, USA) (Roth et al., 2010) or the 
telomerase protein TERT by small-molecule inhibitors such as BIBR1532 (Pascolo et al., 2002). 
Imetelstat has been subjected to pre-clinical and clinical trials phase I/II for treatment of e.g. breast 
cancer, glioblastoma or non-small lung cancer (Dikmen et al., 2005; Hochreiter et al., 2006; Goldblatt 
et al., 2009; Marian et al., 2010; Frink et al., 2016). Unfortunately, treatment of tumors with telomerase 
inhibitors was faced with therapeutic limitations (Rousseau & Autexier, 2015; Shay, 2016). In a phase 
II clinical trial 17 from 116 patients with advanced non-small-cell lung cancer had to discontinue the 
treatment because of severe adverse effects (Chiappori et al., 2015). The outcome of the study was a 
non-significant improvement of progression-free survival of patients treated with Imetelstat. A clinicial 
trial phase II testing Imetelstat in children suffering from recurrent medulloblastoma, high-grade glioma 
(HGG) or ependymoma had to be closed because of toxicity (Salloum et al., 2016). Furthermore, the 
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presence of ALT has been detected in some of the tumors. It is not clear if these tumors already utilized 
the ALT mechanism prior to treatment, or if the treatment caused ALT as a resistance mechanism. since 
inhibiting telomerase can lead to cellular crisis, consequently allowing the emergence of ALT (Chang 
et al., 2003; Bechter et al., 2004; Chen et al., 2010; Hu et al., 2012; Min et al., 2017).  
The switch from telomerase-positive cells to ALT cells was not possible by single knockdown of ATRX 
or DAXX (Lovejoy et al., 2012; Episkopou et al., 2014; O'Sullivan et al., 2014; Napier et al., 2015). 
However, combinatorial depletion of ATRX and DAXX together with induced DNA damage and partial 
inhibition of telomerase has been shown to cause a TMM switch from telomerase-mediated to ALT (Hu 
et al., 2016). Depletion of both isoforms of the histone chaperone ASF1, a and b, in telomerase-positive 
cells with long telomeres (HeLa LT) rapidly induced ALT within three days (O'Sullivan et al., 2014). 
Also, both mechanisms can co-exist in one cell population (Cerone et al., 2001; Grobelny et al., 2001; 
Perrem et al., 2001), demonstrating the dynamic mode of TM (De Vitis et al., 2018). 
3.2 Suppressing .he ALT mech)nism 
ALT-mediated TM currently does not offer one specific molecular target and a clinically approved drug 
against ALT is currently missing. It is challenging to identify a druggable target specific to ALT without 
adverse side-effects in normal somatic cells, because here ALT-driving proteins are also present only 
usually not localized to telomeres. Blockage of recombination-mediated telomere lengthening can be 
achieved by the dominating effect as hybrid formation of telomerase-positive and –negative cells or 
telomerase overexpression in ALT cells led to ALT suppression (Perrem et al., 1999; Ford et al., 2001). 
It might also be necessary to target several ALT sustaining steps (Dilley & Greenberg, 2015), since 
depletion of different proteins related to the ALT pathway has been observed to reduce some but not all 
ALT hallmarks and examples are described in the following. It has been reported that SP100-related 
sequestering or depletion of the MRE11/ RAD50/ NBS1 (MRN) complex resulted in telomere 
shortening (Jiang et al., 2005; Zhong et al., 2007). Targeting the CST complex has been supposed to 
inhibit the ALT mechanism (Huang et al., 2017). In addition to decreasing ECTRs and APBs, shRNA-
mediated knockdown of CST members CTC1 or STN1 resulted in increased T-SCE and telomere 
fragility. Reduction of MUS81 has been shown to decrease T-SCE without affecting the abundance of 
ECTRs. (Zeng et al., 2009). A therapeutic approach to induce apoptosis in ALT cells by the ATR 
inhibitor (ATRi) VE-821 has been tested on some ALT cell lines (Flynn et al., 2015). However the 
observed hypersensitivity specific to ALT cells could not be confirmed (Deeg et al., 2016).  
As outlined above, TM might be regulated by epigenetic processes (Naderlinger & Holzmann, 2017). 
Indeed, treatment with histone deacetylase (HDAC) inhibitors has been described to suppress APB 
formation and decrease levels of ECTRs (Osterwald et al., 2015). In addition, treatment with HDAC 
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inhibitors (HDACi) has been shown to regulate transcription of the hTERT gene (Rahman & Grundy, 
2011). The HDACi trichostatin A is only used in cell culture systems because of its relatively high 
cytotoxicity, whereas Vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) has already been 
approved by the FDA for the treatment of relapsed and refractory cutaneous T-cell lymphoma 
(Eckschlager et al., 2017). However, little is known about a relation of HDAC treatment to TM. A 
current clinical phase I/II trial treating children with solid tumors, lymphoma or leukemia that did not 
respond to the standard therapy involves vorinostat, a pan-inhibitor of HDACs I/II (Witt et al., 2012). 
A therapy targeting PML might be promising, because knockdown of PML in ALT cells resulted in 
telomere shortening (Osterwald et al., 2012; Deeg, 2015). However, depletion of the protein as an anti-
tumor therapy appears unfeasible, since PML is an essential compound of PML-NBs and has a role in 
tumor suppression (Reineke & Kao, 2009; Marchesini et al., 2015). Thus, the role of PML in TM has 
to be studied in more detail to consider targeting PML localization. In summary, treatment of ALT is 
still in its early steps and it is required to investigate the mechanistic details of ALT. 
4 PML pro.ein in .he ALT p).hw)? 
4.1 Prom?e0oc?.ic 0euYemi) nuc0e)r bodies (PML-NBs) 
PML-NBs have been defined as “mobile subnuclear organelles formed by PML and SP100 protein” 
(Lang et al., 2010). They exist in most somatic cells and have a role in various molecular processes 
summarized in (Guan & Kao, 2015). The PML protein forms spheres with a size of 0.1-1.0 µM and can 
by visualized by microscopy methods (Lang et al., 2010). Several isoforms result from alternative 
splicing from the PML gene that contains 9 exons (Fagioli et al., 1992; Nisole et al., 2013). Because of 
the confusing PML nomenclature in the literature a table for a better overview referring to (Nisole et 
al., 2013) is shown (Table 1). In the following, the nomenclature from Jensen et al. will be used (roman 
numerals). 
Table 1. Nomenclature of PML isoforms. 
(Jensen et 
al., 2001) NCBI name Uniprot name Uniprot ID TRIM name Other names 
Protein 
length 
PML-I Isoform 1 PML-1 P29590-1 TRIM19 alpha  882aa 
  PML-11 P29590-11  PML-1A, PML-IA 834aa 
PML-II Isoform 9 PML-2 P29590-8 TRIM19 kappa  829aa 
 Isoform 11 PML-13 P29590-13  PML-2A, PML-IIA 781aa 
  PML-8 P29590-3 TRIM19 gamma PML-2G, PML-IIG 824aa 
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(Jensen et 
al., 2001) NCBI name Uniprot name Uniprot ID TRIM name Other names 
Protein 
length 
PML-III  PML-3 P29590-9   641aa 
PML-IV Isoform 6 PML-4 P29590-5 TRIM19 zeta PML-X 633aa 
 Isoform 10 PML-12 P29590-12 TRIM19 lambda PML-4A, PML-IVA 585aa 
PML-V Isoform 2 PML-5 P29590-2 TRIM19 beta PML-2 611aa 
PML-VI Isoform 5 PML-6 P29590-4 TRIM19 epsilon PML-3B 560aa 
 Isoform 7 PML-14 P29590-14 TRIM19 eta/ iota PML-6B, PML-VIB  423aa 
PML-VIIb Isoform 8 PML-7 P29590-10 TRIM19 theta PML-7, PML-VII 435aa 
Names for PML isoforms from (Jensen et al., 2001), NCBI and Uniprot names as well as the TRIM 
names and other names are given in this table. The last column shows the size of translated proteins. 
Table adapted from (Nisole et al., 2013). 
Different isoforms can have different functions. For example, PML III is capable to induce de novo 
APBs at telomeres in U2OS cells (Chung et al., 2011). PML IV interacts with p53 and modifies its 
activity by recruiting p53 to PML nuclear bodies (Fogal et al., 2000; Guo et al., 2000; Pearson et al., 
2000). PML IV also binds to hTERT and negatively regulates its activity (Oh et al., 2009). PML I, PML 
III, PML IV and PML V form hollow spheres, whereas nuclear bodies containing PML II and PML VI 
are filled out (Li et al., 2017). All PML isoforms share the same N-terminus but harbor unique C-
terminal regions (Jensen et al., 2001) (Figure 4).  
 
Figure 4. PML isoforms. 
Upper panel shows the RBCC/ TRIM motif of the unique C-terminus, the nuclear localization signal 
(NLS) and the SUMO interacting motif (SIM). SUMOylation sites were marked with S in circles. Middle 
panel shows exons of PML. Lower panel shows exon composition of different PML isoforms. Dark blue 
rectangles and asterisks for smaller regions indicate retained introns. Right panel shows alternatively 
spliced N-terminus. Image adapted from (Nisole et al., 2013) and (Jensen et al., 2001). 
The N-terminal region contains a RING-finger, two B-boxes and coiled-coil domain (RBCC) or 
TRIpartite (TRIM) motif that is present in all isoforms (Reymond et al., 2001). At three lysines, K65, 
K160, and K190, PML can be post-translationally modified by the small ubiquitin-like modifier 
(SUMO) by a group of enzymes involving SUMO-activating enzymes, the SUMO-conjugating enzyme 
UBC9 and E3 ligases (Kamitani et al., 1998; Zhong et al., 2000; Jurgendohmen, 2004; Brand et al., 
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2010). Isoforms I to V contain a SUMO interacting motif (SIM) in exon 7a (Song et al., 2004; Shen et 
al., 2006). SUMO:SIM interactions are important for multimerization of PML proteins and nuclear body 
formation. Furthermore, a variety of proteins is recruited to PML-NBs through SUMO-mediated 
interaction, that dynamically compose their structure (Lallemand-Breitenbach & de The, 2010, 2018). 
Van Damme et al. have mapped the composition of PML-NBs and reviewed the implications of 
SUMOylating proteins recruited to PML-NBs (Van Damme et al., 2010). The functional roles of PML, 
such as oxidative stress response, senescence, viral infections, or stemness, are versatile and only partly 
understood (Dellaire & Bazett-Jones, 2004; Sahin et al., 2014; Chang et al., 2017). In somatic cells, 
PML-NBs do not contain nucleic acids (Boisvert et al., 2000), however in ALT cells a subset of PML-
NBs are localized around telomeric DNA forming ALT-associated PML-NBs (APBs) (Yeager et al., 
1999; Lang et al., 2010). 
4.2 ALT-)ssoci).ed PML nuc0e)r bodies (APBs)  
As mentioned above, APBs are defined as subset of PML protein that form a complex with telomeric 
DNA (Yeager et al., 1999). In ALT cells, PML protein forms a shell (Lang et al., 2010) around both 
chromosomal telomeric DNA and extrachromosomal telomeric repeats (Nabetani et al., 2004; Fasching 
et al., 2007). The average number of APBs, as determined via telomere FISH and PML IF, ranges from 
4 in U2OS cells (a typical ALT-positive reference cell line), to over 8 for MGBM1 (ALT-positive 
glioblastoma cell line) (Deeg, 2015; Osterwald et al., 2015). Aside from shelterin compounds, proteins 
related to the DNA repair, the recombination machinery and DNA damage response pathways localize 
to APBs and are summarized in the appendix (Suppl. table S1). Testing effects of their depletion several 
proteins have been identified to be essential for APB formation (Table 2). Some APB components (PML, 
TRF1, TRF2, MMS21, NBS1) have been demonstrated to be capable of inducing de novo formation of 
functional APBs by their recruitment to telomeres (Chung et al., 2011). 
Table 2. Essential components of ALT-associated PML nuclear bodies (APBs). 
Protein References for localization to APBs References for decrease in APBs upon protein depletion 
BLM 
(Yankiwski et al., 2000; Stavropoulos et al., 2002; 
Bhattacharyya et al., 2009; O'Sullivan et al., 2014; 
Osterwald et al., 2015; Sobinoff et al., 2017) 
decrease (Gocha et al., 2014; 
Osterwald et al., 2015) 
CDKN1A (aka p21 partly (Jiang et al., 2009) decrease (Osterwald et al., 2015) 
DNMT1  decrease (Osterwald et al., 2015) 
ERCC4 (aka XPF) (Zhu et al., 2003) decrease (Osterwald et al., 2015) 
FEN1  decrease (Osterwald et al., 2015) 
HDAC7  decrease (Osterwald et al., 2015) 
HDAC9  decrease (Jamiruddin et al., 2016) 
HP1g (aka CBX5) (Jiang et al., 2009) decrease (Osterwald et al., 2015) 
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Protein References for localization to APBs References for decrease in APBs upon protein depletion 
KAT2B (aka PCAF)  decrease (Jeitany et al., 2017) 
LSD1 (aka KDM1A)  decrease (Osterwald et al., 2015) 
MORC3  decrease (Osterwald et al., 2015) 
MRE11 (Zhu et al., 2000; Spardy et al., 2008; Cesare et al., 2009) 
decrease (Jiang et al., 2007; Zhong 
et al., 2007; O'Sullivan et al., 2014);  
no sign. effect (Osterwald et al., 
2015) 
NBS1 (aka NBN or p95) 
(Wu et al., 2000; Zhu et al., 2000; Johnson et al., 
2001; Wu et al., 2003; Cesare et al., 2009; Wilson et 
al., 2016) 
decrease (Wu et al., 2003; Jiang et 
al., 2007; Zhong et al., 2007);  
no effect (Osterwald et al., 2015) 
NR2C2 (Marzec et al., 2015) decrease (Osterwald et al., 2015) 
NR2F2 (Marzec et al., 2015) decrease (Osterwald et al., 2015) 
NSMCE2 (aka MMS21) (Potts & Yu, 2007; Chung et al., 2011) 
decrease (Potts & Yu, 2007; 
Osterwald et al., 2012; Osterwald 
et al., 2015) 
P300  decrease (Jeitany et al., 2017) 
PARP2 (Dantzer et al., 2004) decrease (Osterwald et al., 2015) 
PML (Yeager et al., 1999) 
decrease (Jiang et al., 2007; 
Osterwald et al., 2012; O'Sullivan et 
al., 2014; Osterwald et al., 2015) 
RAD50 (Zhu et al., 2000; Jiang et al., 2007) 
decrease (Jiang et al., 2007) 
(Zhong et al., 2007; Osterwald et 
al., 2015) 
RAP1 (Yeager et al., 1999; Wu et al., 2003; Cesare et al., 2009; Wilson et al., 2016) decrease (Jiang et al., 2007) 
RBBP8 (aka CTIP)  decrease (O'Sullivan et al., 2014) 
SMC5/ 6 (Potts & Yu, 2007) decrease (Potts & Yu, 2007) 
SUMO1/ 2/ 3 (Chung et al., 2011) decrease (Osterwald et al., 2012; 
Osterwald et al., 2015) 
SUV420H2  decrease (Osterwald et al., 2015) 
TIN2 (Cesare et al., 2009; Wilson et al., 2016) decrease (Jiang et al., 2007; Osterwald et al., 2015) 
TOP2B (Hsieh et al., 2015) decrease (Hsieh et al., 2015) 
TOP3A (Temime-Smaali et al., 2008) decrease (Osterwald et al., 2015) 
TRF1 
(Yeager et al., 1999) (Zeng et al., 2009; Wilson et al., 
2016) 
decrease (Jiang et al., 2007);  
increase (Osterwald et al., 2012; 
Osterwald et al., 2015) 
TRF2 
(Yeager et al., 1999; Cesare et al., 2009; Zeng et al., 
2009; Osterwald et al., 2012; O'Sullivan et al., 2014; 
Wilson et al., 2016) 
decrease (Jiang et al., 2007; 
O'Sullivan et al., 2014);  
no effect (Osterwald et al., 2015) 
UBE2I (aka UBC9)  decrease (Osterwald et al., 2012; 
Osterwald et al., 2015) 
XRCC6  decrease (Osterwald et al., 2015) 
The table summarizes proteins that have been shown to co-localize with PML and telomeres in ALT 
cells. The first column shows the protein name and in some cases an alias. The second column contains 
references for the localization to APBs and the last column for the APB phenotype upon protein 
depletion, indicating the requirement of the specific protein for APB formation. 
The functionality of APBs in the ALT pathway is controversially discussed. It has been suggested that 
APBs serve as a collection reservoir for sequestering linear ECTRs (Fasching et al., 2007) or are 
associated with cellular stress and senescence (Jiang et al., 2009; Jiang et al., 2011). In absence of 
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telomerase, ALT cell lines without APBs have been reported, which raises the possibility that more than 
one ALT mechanism might exist. Indeed, the human fibroblast cell line, AG11395, without APBs has 
been reported to utilize a variant ALT mechanism similar to the budding yeast type I recombination 
(Fasching et al., 2005; Marciniak et al., 2005). Exogenous expression of the WRN helicase in the 
AG11395 cell line has been reported to induce APBs (Siddiqa et al., 2012; Gocha et al., 2014), 
indicating that variant ALT mechanisms exists that might require a different set of expressed proteins. 
Another cell line, C3-cl6, has been shown to stably maintain short telomeres in the absence of telomerase 
and APBs (Cerone et al., 2005). In the latter case, the absence of APBs was concluded from the missing 
co-localization of TRF2 and PML signal. However, since the telomeres in the C3-cl6 cell line are very 
short, shelterin might not bind sufficiently, making an immunostaining of TRF2 difficult.  
Several reports support a functional role of APBs in the ALT mechanism. First, suppression of ALT 
leads to absence of APBs, as is evident in hybrids formed by fusion of ALT and telomerase-positive 
cells (Perrem et al., 2001), while induction of ALT by depletion of ASF1A and B was accompanied by 
the formation of APBs (O'Sullivan et al., 2014). Also, disruption of APBs for example by depletion of 
or sequestering the MRE11/ RAD50/ NBS1 complex away from telomeres (Jiang et al., 2005; Zhong et 
al., 2007), by depletion of the structural maintenance of chromosomes (SMC) 5/ 6 complex (Potts & 
Yu, 2007), or by depletion of all PML isoforms in the ALT-positive cell line U2OS (Osterwald et al., 
2012; Deeg, 2015) results in telomere shortening. It is necessary to take into account that different PML 
isoforms have various effects on the formation of PML nuclear bodies and therefore APBs. Hence, if 
one isoform is overexpressed, the equilibrium of PML isoforms is misbalanced and the resulting 
consequences have to be considered. For example, exogenous expression of PML-III, -V  
and -VI in ALT cells decreased the number of APBs, whereas PML-IV resulted in more APBs per cell 
(Osterwald et al., 2012). Induction of stress-associated APBs by methionine starvation is specific to 
ALT cells (Jiang et al., 2005). De novo formation of APBs by recruitment of shelterin compounds or 
recombination factors to telomeres induced telomere lengthening (Chung et al., 2011). Furthermore, it 
has been hypothesized that APBs provide an environment required for telomere recombination, because 
factors like MMS21, SMC5, SMC6, and MUS81 are not only required for APB formation but also for 
telomeric recombination (Nabetani et al., 2004; Potts & Yu, 2007; Zeng et al., 2009). Artificially 
enlarged PML-NBs in ALT cells have been shown to accumulate chromosomal telomeres and facilitate 
telomere clustering only in APB-positive cells (Draskovic et al., 2009). In summary, APBs can be used 
as markers for the ALT mechanism, but it is not clear if APBs have a functional role in the induction of 
the ALT pathway. 
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5 Scope of .he .hesis 
The only known recurrent mutation that is strongly correlated with ALT in cancer is the loss of function 
mutation in ATRX and, to a lesser degree, mutations in H3F3A, encoding histone variant H3.3, and 
DAXX (Heaphy et al., 2011a; Schwartzentruber et al., 2012; Sturm et al., 2014; Barthel et al., 2017). 
However, numerous proteins have been reported to have a role in telomere maintenance (TM), and ALT 
can also emerge in the absence of mutations in ATRX and DAXX (Chudasama et al., 2018). Accordingly, 
it would be expected that multiple genes are differentially expressed in dependence of ALT activity. 
While a number of putative gene expression signatures were proposed for patient stratification into 
ALT-positive and ALT-negative by RNA-seq, these do not reliably differentiate between ALT-positive 
and ALT-negative tumors (Lafferty-Whyte et al., 2009; Doyle et al., 2012; Barthel et al., 2017). One 
explanation for that might be that tissue cell type specific effects can scarcely be separated from TM 
associated deregulation of genes. On the other hand, the localization of PML to telomeres in APBs is a 
characteristic hallmark of ALT-positive cells and frequently used as reliable and robust biomarker for 
ALT (Henson & Reddel, 2010; Chung et al., 2012). However, neither recurrent mutations in PML nor 
a deregulation at the gene expression level have been observed in ALT cells (Lovejoy et al., 2012; Deeg 
et al., 2017). Thus, the formation of APBs must be driven by other currently unknown factors. While a 
functional contribution of APBs to the process of telomere elongation in ALT cells has been reported 
previously (Chung et al., 2011), the underlying mechanism remains elusive. Thus, there is a currently 
unmet need to develop new strategies for the identification of novel candidate genes and to elucidate the 
function of ALT biomarkers like APBs.  
With this thesis, I addressed these issues in three areas. (i) A compilation and annotation of known TM 
genes was conducted. (ii) Strategies were developed and applied to identify novel candidate genes from 
ALT induction and suppression. (iii) The functional role of PML during ALT development was 
dissected. The results obtained in this thesis, provide new insights into the role of APBs as an ALT 
driver and provide a basis for patient stratification into ALT-positive and ALT-negative groups. The 
latter has a direct impact on the clinical setting because of a high incidence of ALT-positive tumors in 
cancer entities like leiomyosarcoma (53-78%) or pediatric glioblastoma (44%), where TMMs are 
correlated with patient outcome and overall survival (Heaphy et al., 2011b; Sturm et al., 2014; 
Chudasama et al., 2018).  
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1 M).eri)0s 
1.1 Buffers 
Table 3. Buffer composition. 
buffer composition 
1× CSK buffer 100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM PIPES pH 6.8, 0.5 % Triton X 100 
1× FACS binding buffer 10 mM HEPES, 2.5 mM CaCl2, 140 mM NaCl 
1× FISH hybridization buffer  75% formamide, 20 mM NaCl, 20 mM Tris, 0.1% BSA 
1× PBS  2.7 mM KCl, 1.7 mM KH2PO4, 137 mM NaCl 10 mM Na2HPO4 pH 7.4 
1× RIPA buffer 150 mM NaCl, 1 % NP40, 0.5 % Na-desoxy-cholate, 0.1 % SDS, 50 mM Tris pH 8.0, 1× complete protease inhibitor cocktail (Roche, Germany) 
1× TBS 25 mM Tris, 0.15 M NaCl, pH 7.5 
1× TBST 25 mM Tris, 0.15 M NaCl, pH 7.5, 0,1% Tween20 
1× transfer buffer 25 mM Tris, 192 mM glycine, 0.5 % (w/v) SDS; freshly added: 200 mL MeOH to 800 mL 
transfer buffer 
10× SDS running buffer 250 mM Tris,1920 mM glycine, 1% (w/v) SDS, pH 8.3 
20× SSC 3 M NaCl, 0.3 M C6H8O7Na3, pH 7 
50× TAE 40 mM Tris, 20 mM acetic acid, 1 mM EDTA 
6× Laemmli buffer  375 mM Tris pH 6.8, 300 mM DTT, 12% SDS, 60% Glycerol, 0.06% bromphenol blue 
AE buffer 50 mM sodium acetate pH 5.3, 10 mM EDTA 
1.2 hi.s )nd re)gen.s 
Table 4. Kits and reagents. 
kit/ reagent company 
Bioanalyzer chip, high sensitivity DNA Agilent Technologies, USA 
Biozym gold agarose Biozym, Germany  
clarity Western ECL substrate Bio-Rad, Germany  
complete protease inhibitor cocktail Roche, Germany  
NEBNext adapters, #E7337A New England Biolabs, USA 
NEBNext Multiplex Oligos for Illumina New England Biolabs, USA 
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kit/ reagent company 
NEBNext ultra directional RNA library prep kit New England Biolabs, USA 
NEBNext ultraII directional RNA library prep kit New England Biolabs, USA 
nitrocellulose membrane Bio-Rad, Germany  
ProLong gold antifade with DAPI  ThermoFisher Scientific, USA  
Puregene core Kit ThermoFisher Scientific, USA 
Qubit dsDNA HS assay Kit ThermoFisher Scientific, USA 
Qubit RNA HS assay Kit ThermoFisher Scientific, USA 
Ribo-Zero gold rRNA removal kit (human/ mouse/ rat) Illumina, USA 
Ribo-Zero magnetic gold kit (yeast) Epicentre Biotechnologies, USA 
RiboLock RNase inhibitor  Thermofisher Scientific, USA   
RNeasy cleanup kit Qiagen, Netherlands 
Roti-Free stripping buffer  Carl Roth, Germany  
ScreenTapes, D1000 Agilent Technologies, USA 
TeloTAGGG telomere length assay Roche, Germany 
1.3 !ns.rumen.s 
Table 5. Instruments. 
instrument company 
Bioanalyzer Agilent Technologies, USA 
Bio-Dot Apparatus Bio-Rad, Germany 
ChemiDoc MP System Bio-Rad, Germany 
FACS Canto II BD Biosciences, USA 
HiSeq 2000 Illumina, USA 
HiSeq 4000 Illumina, USA 
Leica TCS SP5 (DMI6000) Leica Microsystems, Germany 
Luna automated cell counter Logos Biosystems, South Korea 
MACSQuant VYB Miltenyi Biotec, Germany 
Qubit 2.0 Fluorometer ThermoFisher Scientific, USA 
Spectrophotometer NanoDrop ThermoFisher Scientific, USA 
T100 Thermo Cycler Bio-Rad, Germany 
TapeStation Agilent Technologies, USA 
1.4 Sof.w)re 
Table 6. Software. 
software version source 
Adobe Illustrator 15.0.2 Adobe systems, USA 
bedtools v2.17.0 (Quinlan & Hall, 2010) 
cell segmentation 3D 1.12.1 (Wörz et al., 2010; Osterwald et al., 2012) 
FIJI ImageJ 1.48g (Schindelin et al., 2012) 
Filemaker Pro 13 Advanced 13.0v9 Filemaker, USA 
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software version source 
Filemaker server version 15 Filemaker, USA 
Image Lab 5.2.1 Bio-Rad, Germany 
Integrative Genomics Viewer 2.3.91 (Robinson et al., 2011) 
KaleidaGraph 4.5.0 Synergy Software, USA 
LAS AF  Leica Microsystems, Germany 
Leica matrix screener  Leica Microsystems, Germany 
RStudio Version 1.0.153 RStudio, USA 
samtools 0.1.18 (Li et al., 2009) 
Serial Cloner 2-6-1 Franck Perez, Serial Basics 
STAR 020201 (Dobin et al., 2013) 
Weasel 2.7.4 Frank Battye – flow cytometry consulting, Australia 
2 C0oning 
All primers (Table 7) were designed using SerialCloner 2-6-1 (Franck Perez, Serial Basics) and ordered 
from Eurofins MWG Operon, Germany. PCR amplifications were carried out using Q5 High-Fidelity 
DNA Polymerase (New England Biolabs, USA). PCR fragments were purified and ligated to the 
respective backbone vector with T4 DNA Ligase (ThermoFisher Scientific, USA) within 4 h. 
Transformations were carried out in the XL10-Gold cells (Agilent Technologies, USA). Plasmid DNA 
was purified using the NucleoSpin plasmid purification kit (Macherey-Nagel, Germany) according to 
manufacturer’s protocol and eluted in 30 µL H2O. 
All plasmids and backbone vectors are summarized in Table 8. The pEGFP-N1-TRF1 plasmid was con-
structed by insertion of TRF1 cDNA, amplified from pDEST53-GFP-TRF1 and digested with NheI/ 
SacI. Subsequently, PMLIII cDNA, amplified from pEGFP-C1-PMLIII and cut by BamHI/ AgeI was 
inserted. The resulting pEGFP-N1-TRF1-PMLIII (TPG) plasmid was then digested with NheI/ AgeI, 
NheI/ BamHI and BamHI/ AgeI and the 5’ overhang was filled up using Klenow fragment in 1× Klenow 
buffer (both Fermentas/ ThermoFisher Scientific, USA) for 10 min at 37 °C. Blunt end ligation was 
performed for 2 h at 37 °C to receive pEGFP-N1 (G), pEGFP-N1-TRF1 (TG) and pEGFP-N1-PMLIII 
(PG). 
Table 7. Primers. 
primer sequence (5’-3’) application reference 
TRF1 fwd gctagcGTTCCGGACCGGAGTTagctagcGTTCCGGACCGGA amplified from pDEST53-
GFP-TRF1 
Cloning 
this thesis 
TRF1 rev gagctcGTCTTCGCTGTCTGAGGGCCCgagctcGTCTTCGCTGTCTGAGG this thesis 
PML fwd ACAGggatccaTCTAAACCGAGAATCGAAACTAA amplified from pEGFP-C1-
PMLIII 
this thesis 
PML rev ACGAaccggtaaGCGGGCTGGTGGGGAGG this thesis 
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Table 8. Plasmids. 
plasmid construct backbone vector 
cloning/  
cutting site 
reference 
pCMV_TET3G transactivator 3G   Clontech, USA 
pEGFP-N1 GFP   Clontech, USA 
pDEST53-GFP-TRF1 GFP-TRF1   (Chung et al., 2011) 
pEGFP-C1-PMLIII GFP-PMLIII   (Jegou et al., 2009) 
pEGFP-N1-TRF1 TRF1-GFP pEGFP-N1 NheI/ SacI this thesis 
pEGFP-N1-TRF1-PMLIII 
(TPG) 
TRF1-PMLIII-
GFP pEGFP-N1-TRF1 BamHI/ AgeI this thesis 
pEGFP-N1 (G) GFP pEGFP-N1-TRF1-PMLIII (TPG) NheI/ AgeI this thesis 
pEGFP-N1-TRF1 (TG) TRF1-GFP pEGFP-N1-TRF1-PMLIII (TPG) BamHI/ AgeI this thesis 
pEGFP-N1-PMLIII (PG) PML-GFP pEGFP-N1-TRF1-PMLIII (TPG) NheI/ BamHI This thesis 
Table 9. Materials used for cloning experiments. 
material company 
FastDigest AgeI ThermoFisher Scientific, USA 
FastDigest BamHI ThermoFisher Scientific, USA 
FastDigest NheI ThermoFisher Scientific, USA 
FastDigest SacI ThermoFisher Scientific, USA 
Klenow fragment, Klenow buffer Fermentas/ ThermoFisher Scientific, USA 
NucleoSpin Plasmid Kit Macherey-Nagel, Germany 
Q5 High-Fidelity DNA Polymerase New England Biolabs, USA 
T4 DNA ligase ThermoFisher Scientific, USA 
XL10-Gold cells Agilent Technologies, USA 
3 Ce00 cu0.ure )nd .r)nsfec.ion 
Cell lines and cell culture materials used within this thesis are listed in Table 10 and Table 11, 
respectively. U2OS and HeLa cells were obtained from the German Collection of Microorganisms and 
Cell Cultures (DSMZ, Braunschweig, Germany). U2OS cells were maintained in low glucose DMEM 
(1.0 g/L) without phenol red (ThermoFisher Scientific, USA) and supplemented with 10% FBS (PAN 
Biotech GmbH, Germany), 2 mM L-glutamine (PAN Biotech GmbH, Germany), 100 µg/mL penicillin/ 
streptomycin (PAN Biotech GmbH, Germany). HeLa cells were cultured in RPMI without phenol red 
(ThermoFisher Scientific, USA) with the same supplements.  
For transient transfection of U2OS and HeLa cells, Effectene (Qiagen, Germany), 
Lipofectamin 3000 (ThermoFisher Scientific, USA), or XtremeGene9 (Roche, Germany) were used 
according to manufacturer’s protocol, respectively.  
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Table 10. Cell lines. 
cell line growth medium reference 
U2OS 
low glucose DMEM, 10% FBS,  
2 mM L-glutamine, 100 μg/mL penicillin/ 
streptomycin 
DSMZ (Braunschweig, 
Germany) 
U2OS Tet-On 3G 
low glucose DMEM, 10% tet-free FBS,  
2 mM L-glutamine,  
100 μg/mL penicillin/ streptomycin,  
1 mg/mL geniticin 
Katharina Deeg (Prof. 
Karsten Rippe, DKFZ) 
U2OSG, U2OSPG, U2OSTG, U2OSTPG Tet-On 3G 
low glucose DMEM, 10% tet-free FBS,  
2 mM L-glutamine,  
100 μg/mL penicillin/ streptomycin,  
0.2 µg/mL geniticin 
0.5 µg/mL puromycin 
this thesis 
HeLa RPMI, 10% FBS, 2 mM L-glutamine,  
100 μg/mL penicillin/ streptomycin 
DSMZ (Braunschweig, 
Germany) 
HeLa Tet-On 3G 
RPMI, 10% FBS, 2 mM L-glutamine,  
100 μg/mL penicillin/ streptomycin,  
1 mg/mL geniticin 
Dominik Niopek (Prof. 
Roland Eils, DKFZ) 
HeLa G, HeLa PG, HeLa TG, HeLa TPG Tet-On 3G 
RPMI10% FBS, 2 mM L-glutamine,  
100 μg/mL penicillin/ streptomycin,  
0.1 µg/mL geniticin,  
0.5 µg/mL puromycin 
this thesis 
SJ-G2 (also known as SJ-02, ICGC_GBM41) 
high glucose DMEM, 10% FBS,  
2 mM L-glutamine,  
100 μg/mL penicillin/ streptomycin 
1 mM sodium pyruvate 
Prof. Stefan Pfister, DKFZ 
MGBM1 (also known as 10-801, ICGC_GBM39) 
SF188 (ICGC_GBM40) 
KNS42 (ICGC_GBM73) 
HeLa ST 
(O'Sullivan et al., 2014) 
HeLa LT 
Table 11. Cell culture material. 
medium/ supplement company 
DMEM medium, low (1.0 g/L) or high (4.5 g/L) glucose without phenol red ThermoFisher Scientific, USA 
doxycycline  Sigma-Aldrich, Germany  
fetal bovine serum (FBS) PAN Biotech GmbH, Germany 
FBS tet-free PAN Biotech GmbH, Germany 
geneticin (G418 sulfate)  ThermoFisher Scientific, USA  
L-glutamine PAN Biotech GmbH, Germany 
OptiMEM I Reduced Serum Medium  ThermoFisher Scientific, USA 
penicillin/ streptomycin PAN Biotech GmbH, Germany 
puromycin  Sigma-Aldrich, Germany  
RPMI without phenol red ThermoFisher Scientific, USA 
sodium pyruvate ThermoFisher Scientific, USA 
For generation of stable inducible cell lines, the doxycycline inducible Tet-On 3G system (Figure 5, 
Clontech, USA) was used according to the manufacturer’s protocol. U2OS Tet-On 3G cells were 
generated by stable transfection of the geniticin-resistant pCMV_TET3G plasmid by Katharina Deeg 
(Prof. Karsten Rippe, DKFZ) under the same culturing conditions as U2OS with additional 1 mg/mL 
G-418 (ThermoFisher Scientific, USA) in order to select for plasmid carrying cells. U2OSG, U2OSPG, 
U2OSTG, U2OSTPG Tet-On 3G were generated by stable transfection with puromycin-resistant plasmids 
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pEGFP-N1 (G), pEGFP-N1-PMLIII (PG), pEGFP-N1-TRF1 (TG), or pEGFP-N1-TRF1-PMLIII 
(TPG), and maintained with the same supplements except for only 0.2 µg/mL geniticin (ThermoFisher 
Scientific, USA) and additional 0.5 µg/mL puromycin (Sigma-Aldrich, Germany). To induce stable 
expression of GFP, PML-GFP, TRF1-GFP or TRF1-PML-GFP, the respective cell line was treated with 
50 ng/mL doxycycline (Sigma-Aldrich, Germany). 
 
HeLa Tet-On 3G cells were kindly provided by Dominik Niopek (Prof. Roland Eils, DKFZ) and were 
cultured in RPMI without phenol red (ThermoFisher Scientific, USA) with the same supplements as 
U2OS Tet-On 3G cells. HeLaG, HeLaPG, HeLaTG, HeLaTPG Tet-On 3G were generated as described for 
stable U2OS cells and maintained with the same supplements except for only 0.1 µg/mL 
geniticin (ThermoFisher Scientific, USA). To induce expression of GFP, PML-GFP, TRF1-GFP or 
TRF1-PML-GFP in the respective cell line, 100 ng/mL doxycycline (Sigma-Aldrich, Germany) was 
added. HeLa ST and HeLa LT, described previously (O'Sullivan et al., 2014), were kindly provided by 
Jan Karlseder (Salk Institute, USA) and cultured in high glucose DMEM (ThermoFisher Scientific, 
USA) and supplemented as described for U2OS and HeLa cells above with additional 1 mM sodium 
pyruvate solution (ThermoFisher Scientific, USA). Pediatric glioblastoma cell lines SJ-G2, MGBM1, 
SF188 and KNS42 were kindly provided by Prof. Stefan Pfister (DKFZ, Germany) and were maintained 
as described for HeLa ST and LT cells. All cells were cultured at 37 °C and 5% CO2. Every 2-3 days, 
cells were split 1:3 by briefly washing with PBS (1×), and thereafter treating with trypsin/ EDTA (0.05/ 
0.02% in 1× PBS) and incubated for in 3-5 min at 37 °C. 
3.1 siRNA .r)nsfec.ions 
HeLa ST and HeLa LT cells were transfected with siASF1A and B as described previously (O’Sullivan 
et al 2014). Briefly, cells were seeded in 15-cm dishes and after 24 h transfected with a final 
concentration of 50 nM On-Target Plus SMARTpool siRNA, which was dissolved in 1× siRNA buffer, 
and Dharmafect (Dharmacon, USA), and previously incubated for 20 min in OptiMEM (ThermoFisher 
Scientific). After 24 h, transfection medium was exchanged with complete growth medium and cells 
were harvested ~72 h after transfection.  
Figure 5. Tet-On 3G system for the generation of 
stable inducible cell lines. 
Strategy for inducible gene expression. The 3G 
transactivator protein can only bind to the TRE promotor 
when doxycycline is added. Image taken from User 
manual for Tet-On® Advanced Inducible Gene 
Expression Systems User Manual (Clontech, USA).  
M).eri)0s )nd Me.hods 
Cepp cuprure qnd rrqnsfecrion 
 25 
Table 12. siRNAs used for ASF1 knockdown. 
siRNA target Sequences (5’-3’) company 
ON-TARGETplus  
SMARTpool: ASF1A siRNA  
1) CGAUCAAGUUUUAGACUCU  
2) CAUUAGACCAGGUUGUAAA  
3) AGCCAUAUGAUGCAGGUUA  
4) GGCAUAUGUUUGUAUUUCA 
Dharmacon, USA  
ON-TARGETplus  
SMARTpool: ASF1B siRNA  
1) GCAGGGAGACACAUGUUUG  
2) CGGACGACCUGGAGUGGAA  
3) GACAGGAGUUCAUCCGAGU  
4) GCACUCCUAUCAAGGGCUU 
Dharmacon, USA 
ON-TARGETplus  
Non- targeting control pool  
1) UGGUUUACAUGUCGACUAA  
2) UGGUUUACAUGUUGUGUGA  
3) UGGUUUACAUGUUUUCUGA  
4) UGGUUUACAUGUUUUCCUA 
Dharmacon, USA 
3.2 Sm)00 mo0ecu0e inhibi.ors  
The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA, Millipore, Germany) was 
dissolved in absolute ethanol. For the treatment, fresh drug was added anew every 24 h to complete 
growth medium of treated cells, since the in vitro half-live of SAHA is 75 min in human plasma 
(Konsoula & Jung, 2008), and is therefore assumed to be degraded after 24 h in aqueous solution. For 
combined ASF1 knockdown (kd) and SAHA treatment, the SAHA was added in 10 µL absolute ethanol, 
so that a final concentration of 0, 0.5 µM or 2 µM was achieved. SAHA was added first after 3-4 h of 
transfection, and then every 24 h, without changing the medium. The ATRi, VE-821 (Selleckchem, 
USA), was solved in DMSO. 3×105 cells were either treated with 3 µM VE-821 or with the same volume 
of DMSO for the control samples for 6 days, as described before (Flynn et al., 2015). 
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4 F0uorescence )c.iv).ed ce00 sor.ing (FACS) 
For FACS, cells were harvested with trypsin/ EDTA as described above (methods section 3). Both cells 
in washing buffer and trypsinated cells were merged and cells were counted on a Luna automated cell 
counter (Logos Biosystems, South Korea). Cells were resuspended to a final concentration of 2×106 cells 
in FACS binding buffer (1×) and filtrated. Single stained and unstained samples were prepared for each 
cell line. For this, cells were stained with a final concentration of 20 µM Vybrant Dyecycle Violet 
(ThermoFisher Scientific, USA), 5 µL annexin V-FITC (Lot#177338, BioLegend, USA) for 15 min at 
room temperature and immediately before the measurement, 1 µL propidium iodide (1 mg/mL, 
Invitrogen/ ThermoFisher Scientific, USA) to a final concentration of 2.5 µg/mL was added. Samples 
were then analyzed by flow cytometry on a FACS Canto II (BD Biosciences, USA) at the DKFZ flow 
cytometry core facility or on a MACSQuant VYB (Miltenyi Biotec, Germany) kindly provided by 
Andres Florez (Prof. Thomas Höfer, DKFZ). Per sample 10’000 total cells were counted using a middle 
flow rate of ~60 cells/s. 
 
Figure 6. FACS gating and compensation. 
U2OC cells were analyzed by FACS. (A) Gating was done for side scatter vs forward scatter to exclude 
small artifacts and large cell aggregates (gate was termed “cells”). Height vs area of the forward scatter 
was used to gate out duplets (gate was called “singlets”). (B) + (C) Annexin V vs propidium iodide signal 
are shown for (B) unstained and single-stained cells, and (C) untreated and SAHA-treated cells. 
Unstained cells were used as a negative control and single stained cells were used for compensation 
of spill-over from green to red channel. Statistic markers were set to separate living (lower left) from 
apoptotic (upper left) and dead (upper right) cell clusters.  
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4.1 An)0?sis of induced )pop.osis 
For FACS analysis the Weasel software (Frank Battye – flow cytometry Consulting, Australia) was 
used. After compensation of both FITC and propidium iodide (PI), cells were gated to remove small 
artifacts and duplets (examples are shown in Figure 6). Cells positive for PI were specified as dead cells, 
whereas cells only positive for annexin V-FITC were labeled as apoptotic. Cells negative for both 
signals were the fraction of viable cells. Induced apoptosis aind was calculated as in (Deeg et al., 2016):  
𝐚𝒊𝒏𝒅 = 	%	𝐨𝐟	𝐚𝐩𝐨𝐩𝐭𝐨𝐭𝐢𝐜	𝐜𝐞𝐥𝐥𝐬 − %	𝐨𝐟	𝐚𝐩𝐨𝐩𝐭𝐨𝐭𝐢𝐜	𝐜𝐞𝐥𝐥𝐬	 𝐜𝐭𝐫𝐥𝐯𝐢𝐚𝐛𝐥𝐞	𝐜𝐞𝐥𝐥𝐬	 𝐜𝐭𝐫𝐥  
4.2 Ce00 c?c0e )n)0?sis 
Weasel was also used for visualization and fitting of cell cycle phases. Histograms of FACS-analyzed 
cells that incorporated membrane-permeant Vybrant Dyecycle Violet dye were plotted. A curve fit for 
cell cycle curves was performed, to obtain the percentages of subG0, G0, S, G2/M and super G2 phases.  
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5 Wes.ern b0o. 
For protein extraction, 5 × 105 cells were harvested and washed with ice-cold PBS (1×). Cell pellets 
were then resuspended in ice-cold RIPA buffer and lysed for 60 min at 4 °C. After centrifugation for 
30 min at full speed and 4 °C, lysates (25 µL aliquots) were stored at -20 °C. For Western blotting, 6 µL 
Laemmli buffer (6×, see Table 3) was added to 24 µL lysate and the sample was denatured at 95 °C for 
5 min. Denatured proteins were loaded onto a stain-free acrylamide gel (4-20%, Bio-Rad Laboratories, 
USA) and separated for 45 min at 160 V. Separated proteins were then transferred to a nitrocellulose 
membrane (Bio-Rad Laboratories, USA) by semi-dry Western blotting in 1× transfer buffer at room 
temperature and 200 mA for 60 min. After transfer, the membrane was blocked with 5% skim milk 
powder (Lot# 040216, Gerbu, Germany) in TBST (1×, see Table 3) for 60 min at room temperature. 
Primary antibodies were diluted as indicated (Table 13) in 5% bovine serum albumin (BSA) in TBST 
(1×) and incubated overnight at 4 °C. After the incubation, the membrane was washed three times with 
TBST (1×) and then incubated with the secondary antibody, conjugated to horseradish peroxidase (HRP) 
and diluted as indicated (Table 14) with 5% milk in TBST (1×), for 60 min at room temperature. 
Table 13. Primary antibodies used for Western blot.  
antigen host dilution Lot, company 
ASF1A rabbit 1:500 #2990, Cell Signaling, USA 
ASF1B rabbit 1:500 #2902, Cell Signaling, USA 
GAPDH mouse 1:3000 AM4300, Ambion/ Thermofisher Scientific, USA 
Table 14. Secondary antibodies used for Western blot. 
antigen host dilution company 
HRP-linked anti-rabbit IgG goat 1:2000 Cell Signaling, USA 
HRP-linked anti-mouse IgG goat 1:2000 Cell Signaling, USA 
For developing the membrane, Clarity Western ECL (Bio-Rad Laboratories, USA) was used according 
to manufacturer’s protocol. For subsequent detection of the chemiluminescence signal, the ChemiDoc 
MP System (Bio-Rad, Germany) was used and the analysis was done with the corresponding Image Lab 
4.1 software (Bio-Rad, Germany). 
  
M).eri)0s )nd Me.hods 
C-circpe qssqv 
 2u 
R C-circ0e )ss)? 
The C-circle assay was performed as previously described (Henson et al., 2009; Henson et al., 2017). 
Briefly, DNA was extracted from 1×106 cells using the Puregene core Kit (Qiagen, Germany) according 
to the manufacturer’s protocol. Genomic DNA (gDNA) was eluted with 100 µL 10 mmol Tris pH 7.5 
and quantified using Qubit (ThermoFisher Scientific, USA). Subsequently, gDNA was diluted in 
triplicates to 20 ng in 10 µL. For the rolling circle amplification (Figure 7), 0.2 mg/mL BSA, 0.1% (v/v) 
Tween 20, 1 mM each dATP, dGTP and dTTP (ThermoFisher Scientific, USA), Φ29 Buffer (1×) and 
7.5 U Φ29 DNA polymerase (both New England Biolabs, USA) were added to gDNA in a final volume 
of 20 µL.  
 
For every sample, a “no polymerase” control was used, and for every sample set an ALT-positive U2OS 
as well as an ALT-negative HeLa wild-type (wt) sample were used as a standard reference controls for 
each blot. The mixtures were first incubated for 8 h at 30 °C and then for 20 min at 65 °C. After the 
amplification step, the samples were mixed with 40 µl SSC (2×) and utilizing a Bio-Dot Apparatus (Bio-
Rad, Germany) blotted onto a Roti Nylon plus membrane with a pore size 0.45 µm (Carl Roth, 
Germany), which was previously soaked in SSC (2×). The membrane was baked for 20 min at 120 °C 
and subsequently hybridized and developed using the TeloTAGGG Telomere Length Assay Kit (Roche, 
Germany) following the manufacturer’s protocol. Roughly 60 min after the detection step, 
chemiluminescence signal was visualized using the high sensitivity program of the ChemiDoc MP 
System (Bio-Rad, Germany). In the accumulation modes, a series of images was taken. The image with 
maximum signal but no oversaturation was used for analysis with Image Lab 4.1 (Bio-Rad, Germany). 
The signals were first background-corrected and then the signal for “no polymerase” control subtracted 
from the “+ polymerase” signal. Finally, the signals for C-circle levels were normalized to a U2OS wt 
control (ALT-positive reference cell line).  
  
Figure 7. C-circle assay principle. 
C-rich telomeric circles (red) that are partly double-
stranded with G-rich (grey) telomere repeats are 
submitted to a rolling circle amplification. The G-rich 
fragment can serve as a primer and to specifically 
synthesize the G-rich telomeric DNA dATP, dGTP, 
dTTP but no dCTP is added. Φ29 polymerase 
amplifies telomere repeats. These are subsequently 
blotted and detected on a nylon membrane 
subsequently. Image adapted from (Henson et al., 
2017).  
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7 F0uorescence microscop?  
7.1 Fix).ion )nd perme)bi0iz).ion 
For fluorescent microscopy cells were seeded on slides and fixed with PFA as described previously 
(Chung et al., 2011). Briefly, cells were seeded on 24mm glass slides and treated as indicated in the 
respective results sections. After washing with PBS (1×), cells were fixed in 4% PFA in PBS (1×) for 
12 min and subsequently washed with PBS (1×). Then cells were permeabilized with ice-cold 
0.2% Triton X-100 in PBS (1×) for 5 min and again washed with PBS (1×).  
7.2 Te0omere PNA F!SH 
Telomere PNA FISH of cells was performed as described previously (Chung et al., 2011). Briefly, cells 
were grown on coverslips and fixed and permeabilized cells as described above (methods section 7.1). 
After dehydration in a series of ethanol dilutions in water (70%, 85% and 100%), coverslips were 
allowed to air-dry and placed on a drop of 0.1 µM Cy3-labeled (CCCTAA)3 PNA probe (Panagene, 
Korea) in hybridization buffer (75% formamide, 20 mM NaCl, 20 mM Tris, 0.1% BSA) on a coverslip. 
Coverslips were sealed with fixogum and let dry in the dark. After a denaturing step for 3 min at 80 °C, 
hybridization was performed overnight at 30 °C. Subsequently, coverslips were washed consecutively 
in 70% formamide (in 10 mM Tris-HCl, pH 7.4), 2× SSC, 0.1× SSC at 55 °C and 0.05% (v/v) Tween-
20 in 2× SSC. Finally, coverslips were washed thrice in PBS (1×). Following PNA FISH either 
immunofluorescence against PML was performed as described in methods section 7.3 starting with the 
blocking step, or DAPI staining was performed as described in methods section 7.4. As denaturation step 
of the PNA FISH procedure destroys GFP signal of tagged proteins, an antibody against GFP was used 
for immunofluorescence, to enhance the GFP signal. Alternatively, an APB staining was performed with 
anti-TRF2-ms-A568 and anti-PML-rb-ATTO633. 
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7.3 !mmunof0uorescence 
Immunostaining was performed as described previously (Chung et al., 2011). Briefly, fixed and 
permeabilized cells (from methods section 7.1 or 7.2) were blocked for 60 min with 10% goat serum in 
PBS (1×). After blocking, slides were incubated with primary and secondary antibodies, diluted as 
indicated (Table 15, Table 16) in blocking solution, for 60 min at room temperature or overnight at 4 °C. 
Between primary and secondary antibody incubations, slides were washed thrice with 0.002% NP40 in 
PBS (1×). Finally, slides were washed thrice in PBS (1×) and DAPI staining performed as described in 
methods section 7.4.  
Table 15. Primary antibodies used for immunofluorescence.  
antigen host dilution Lot, company 
TRF2 rabbit 1:250 NB110-57130, Novus Biologicals 
PML mouse 1:100 sc-966, Santa Cruz, USA 
GFP rabbit 1:500 ab290, Abcam, UK 
Table 16. Secondary antibodies used for immunofluorescence. 
antigen conjugate host dilution company 
anti-rabbit IgG  Alexa 568 goat 1:300 Life Technologies/ ThermoFisher Scientific, USA 
anti-rabbit IgG  Alexa 633 goat 1:200 Life Technologies/ ThermoFisher Scientific, USA 
anti-mouse IgG  Alexa 568 goat 1:300 Life Technologies/ ThermoFisher Scientific, USA 
anti-rabbit IgG  Alexa 488 goat 1:300 Life Technologies/ ThermoFisher Scientific, USA 
7.4 DAP! s.)ining 
After fixed and permeabilized cells were stained with telomere FISH (methods section 7.2) and/ or 
immunofluorescence (methods section 7.3), slides were subsequently washed. After another PBS wash, 
the coverslips were mounted with Prolong Gold antifade reagent (ThermoFisher Scientific, USA) 
containing DAPI. 
7.5 M)nu)0 )nd )u.om).ic confoc)0 im)ge )cXuisi.ion  
For confocal image acquisition, a motorized inverted DMI6000 Leica TCS SP5 confocal laser scanning 
microscope (Leica Microsystems, Germany) with an oil immersion objective (63×/ 1.40 PL APO) was 
used. Four laser sources were used for excitation with wavelengths of 405 nm (UV diode), 488 nm, 
561 nm and 633 nm (all three from a multiline argon laser). Microscope parameters were set in the LAS 
AF software (Leica Microsystems, Germany) for manual and automatic image acquisition (scan speed 
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400 Hz, resolution of 512 × 512 pixel, 3× zoom, pinhole: 1 airy, 8-bit depth, sequential mode, switch 
between stacks). The general procedure for screening a high number of cells is depicted in (Figure 8A). 
For automated image acquisition, the Leica MatrixScreener software (Leica Microsystems, Germany) 
was used as described previously (Osterwald et al., 2012). First, a predictive focus map was generated 
and used for the noise-based autofocus job to determine the central z-position of the cells. Then, 
50 images with a spacing of 1 µm were taken around the z-position of the predictive focus map with a 
scan speed of 600 Hz and a resolution of 64 × 64 pixel in the DAPI channel. After the autofocus job, 
the screening job was started automatically with z-positions from -5 µM to 5 µM around the specified 
position of the autofocus job. 
7.R Au.om).ic im)ge )n)0?sis 
For manually acquired images, FIJI/ Image J (Schindelin et al., 2012) was used to generate maximum 
image projections. To analyze telomere and PML spots in manually or automatic acquired images, the 
cell segmentation 3D software was used (Wörz et al., 2010; Osterwald et al., 2012) (Figure 8B). Briefly, 
raw images were converted into 3D image stacks using the Stack Builder Plugin 
(https://imagej.nih.gov/ij/plugins/builder.html, Nicolas Roggli and Wayne Rasband). For 3D segmen-
tation of nuclei, a standard deviation of s=1.2 for Gaussian smoothing was used. Telomeres and PML 
nuclear bodies were detected in a 2-pass system for larger and smaller spots with a standard deviation 
of s=1.1 for Gaussian smoothing. Border cells with more than 300 voxels on the image margins were 
excluded from the analysis. Parameters for clipping and the region size for local maxima search of 
telomere and PML spots were set to detect all visually detectable telomeres in untransfected or GFP 
transfected cells. The output file contained information on number, volume and integrated intensities of 
detected spots, as well as overall integrated intensities of all channels in the segmented nuclei. The 
results files were loaded into R to extract and visualize these data for all spots and cells.  
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Figure 8. Automatic 3D confocal fluorescence microscopy platform. 
(A) Confocal image acquisition of fixed cells. After cell seeding and treatment, cells were fixed and 
stained via immunfluorescence or telomere FISH. Images were acquired automatically using the Leica 
matrix screener software (Leica Microsystems, Germany). (B) Automated 3D image analysis of confocal 
stacks in four channels. First, the nucleus segmentation was done in the DAPI channel. Next, spots in 
the red (telomere) and green (PML) channel were detected and quantified to perform a 3D colocalization 
analysis. For all spots number, volume and integrated intensity was calculated. Overall, the total 
intensity was summarized for four channels in the segmented area. (C) Visualization of colocalizing 
telomere (red) and PML (green) signals. White arrows indicate colocalizing signals. (D) The 12 
categories for the assembly of two spots are shown. The white squares mark all possible colocalizations, 
however only the first, third, fifth and sevenths mark highest overlapping cases.  
M).eri)0s )nd Me.hods 
RNA isopqrion for RNA-se 
 34 
8 RNA iso0).ion for RNA-seX 
Human 
1×107 cells were harvested and RNA was isolated using the NucleoSpin RNA plus kit (Macherey Nagel, 
USA). First, cell pellets were lysed in LBP buffer and stored at -80 °C until all lysates of a sample set 
were collected. RNA was extracted according to the manufacturer’s protocol. Finally, only long RNA 
was eluted twice in 2× 25 µL RNase-free H2O with 1 µL ribolock (ThermoFisher Scientific, USA). 
RNA concentration was measured by Qubit (RNA high sensitivity, ThermoFisher Scientific, USA). For 
complete removal of genomic DNA, 1 U/µg RQ1 DNase (Promega, USA) and 1 µL ribolock 
(ThermoFisher Scientific, USA) were added for 30 min at 37 °C in RNase-free RQ1 DNase reaction 
buffer (1×, Promega, USA). Depleted RNA was precipitated by adding sodium acetate to a final volume 
of 200 mM, 0.5 mg/mL glycoblue and 3 volumes of ethanol. The mixture was incubated for 60 min at -
20 °C and subsequently pelleted by centrifugation at full speed and 4 °C. The air-dried RNA pellet was 
then resuspended in 30 µL RNase-free H2O with 1 µL ribolock (ThermoFisher Scientific, USA).  
Budding yeast 
S. cerevisiae est2D cells were derived from meiotic products of a heterozygous diploid budding yeast 
strain 281 (est2 sir2 exo1) (Balk et al., 2013). Cell pellets were prepared in two replicates on days 2, 6 
and 10 of the survivor formation (start, crisis, survivor). RNA was isolated by phenol/ chloroform 
extraction as described previously (Schmitt et al., 1990). Briefly, cells pellets were resuspended in 400 
µL AE buffer and mixed with 40 µL 10% SDS. The mixture was incubated with an equal volume of 
phenol for 4 min at 65 °C. After quickly cooling the emulsion to form phenol crystals, a centrifugation 
step at maximum speed and 2 min separated the aqueous and the organic phases. The aqueous phase 
was extracted with phenol/ chloroform for 5 min at room temperature. RNA was precipitated by adding 
sodium acetate to a final volume of 300 mM and 2.5 volumes of absolute ethanol. Total RNA was eluted 
in 20 µL RNase-free water and stored at -80 °C. To remove genomic DNA, RNA samples were DNase 
treated for 35 min at 37 °C. Subsequent RNA purification was done with RNeasy Cleanup Kit (Qiagen, 
Netherlands).  
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O RNA 0ibr)r? prep)r).ion 
Human 
Preparation of libraries for the second replicate was performed independent of the first replicate. First, 
RNA concentrations were determined by NanoDrop (ThermoFisher Scientific, USA) and RNA integrity 
was measured for 100-500 ng RNA on the TapeStation (RNA ScreenTapes, Agilent Technologies, 
USA), following the manufacturer’s protocol.  
For rRNA removal in 2.5 µg input RNA, the Ribo-Zero Gold rRNA removal Kit (human/ mouse/ rat) 
(Illumina, USA) was used according to the manufacturer’s protocol. Depleted RNA was purified using 
the Agencourt RNAClean XP beads Kit (Beckman Coulter, USA) and eluted in 15 µL H2O. RNA 
concentrations were measured by Qubit (RNA high sensitivity, ThermoFisher Scientific, USA).  
For the RNA library preparation of 6-11 ng RNA, the NEBNext Ultra II directional RNA library Prep 
Kit for Illumina (#E7760, New England Biolabs, USA) was used according to the manufacturer’s 
protocol. According to the amount of input RNA, NEBNext adapters (#E7337A) were diluted 5 or 25-
fold. NEBNext primers i501-i508 were uniquely combined with i701-i708 primers from dual index 
primers set 1 (NEBNext Multiplex Oligos for Illumina, New England Biolabs, USA). 
PCR enrichment was performed in 10-13 PCR cycles. Libraries were eluted in 20 µL of 10 mM Tris 
pH 7.5 and concentrations were measured by Qubit (DNA high sensitivity, ThermoFisher Scientific, 
USA). Subsequently, size and quality of the libraries were determined on the TapeStation (D1000 
ScreenTapes, Agilent Technologies, USA). Finally, 7-8 libraries were pooled to one multiplexed library.  
Each multiplexed library was sequenced on a separate lane on a HiSeq 4000 (Illumina, USA) as single-
read 50 bp and subsequently demultiplexed by the DKFZ sequencing core facility.  
Budding yeast 
All budding yeast libraries of replicates were prepared at the same time. First, RNA concentrations were 
measured by NanoDrop (ThermoFisher Scientific, USA). To determine RNA integrity, 200 ng RNA 
were mixed with an equal volume formamide to a final volume of 20 µL. After incubation for 5 min at 
65 °C, samples were stored on ice and loaded onto a 2% E-gel EX (ThermoFisher Scientific, USA) and 
run for 10 min (program 7).  
To remove rRNA, the Ribo-Zero Magnetic Gold Kit (Yeast) (Epicentre Biotechnologies, USA) was 
used according to the manufacturer’s protocol. Depleted RNA was precipitated by adding sodium 
acetate to a final volume of 300 mM, 0.1 mg/mL Glycoblue and 3 volumes of absolute ethanol. The 
mixture was incubated for 60 min at -20 °C and subsequently pelleted by centrifugation at full speed 
and 4 °C. The air-dried RNA pellet was then resuspended in 10 µL RNase-free H2O with 0.3 µL ribolock 
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(ThermoFisher Scientific, USA). RNA concentration was measured by Qubit (RNA high sensitivity, 
ThermoFisher Scientific, USA).  
For the RNA library preparation of ~100 ng RNA, the NEBNext Ultra Directional RNA Library Prep 
Kit for Illumina #E7420, New England Biolabs, USA) was used according to the manufacturer’s 
protocol for use with purified or ribosome depleted RNA. NEBNext adapters (#E7337A, New England 
Biolabs, USA) were diluted 3-fold.  
PCR library enrichment was performed in 13 PCR cycles with NEBNext primers #1, #3, #8, #9, #10 
and #11 from Index Primers Set 1, NEBNext Multiplex Oligos for Illumina (New England Biolabs, 
USA). The library was then eluted in 20 µL of RNase-free H2O and concentrations were measured by 
Qubit (DNA high sensitivity, ThermoFisher Scientific, USA). Finally, size and quality of the libraries 
were determined on a bioanalyzer chip (High sensitivity DNA, Agilent Technologies, USA).  
Libraries were pooled, sequenced on a HiSeq 2000 (Illumina, USA) as single-read 50 bp and 
subsequently demultiplexed by the DKFZ sequencing core facility.  
10 RNA-seX d).) )n)0?sis 
10.1 M)pping 
First, the human genome sequence (GRCh38/ hg38) were downloaded from 
UCSC (http://hgdownload.cse.ucsc.edu/goldenPath/hg38/bigZips/hg38.fa.zip). The budding yeast 
genome sequence (SacCer_Apr2011/ sacCer3) was downloaded as single files per chromosome from 
UCSC (http://hgdownload.soe.ucsc.edu/goldenPath/sacCer3/chromosomes/) and merged to one file for 
all chromosomes (sacCer3.fa). The budding yeast annotation file was taken from UCSC table browser 
(gtf and bed (per whole gene), http://genome.ucsc.edu/cgi-bin/hgTables) (Table 17).  
All budding yeast or human reads from unprocessed files (fastq) were uniquely mapped to the sacCer3 
or hg38 assembly of the reference genome, respectively, without allowing mismatches using the spliced 
read aligner STAR (Dobin et al., 2013). The sorted output bam files “Aligned.sortedByCoord.out.bam” 
were indexed using samtools (Li et al., 2009).  
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Table 17. Settings for annotation files downloaded from the UCSC table browser. 
 human budding yeast 
clade  mammal other 
genome  human S. cerevisiae 
assembly  Dec. 2013 (GRCh38/ hg38) Apr. 2011 (SacCer_Apr2011/ sacCer3) 
group  genes and gene predictions genes and gene predictions 
track  NCBI RefSeq SGD Genes 
table  RefSeq all (ncbi RefSeq) sgdGene 
region  genome genome 
10.2 !n.egr).ive genomics viewer (!GV) 
For visualizing gene expression profiles in the IGV (Robinson et al., 2011), bedgraph files were 
generated by bedtools (Quinlan & Hall, 2010) with the following line:  
bedtools genomecov -ibam $i -bga -split -scale $factor > $i".bedgraph" 
With $i being the name of the *.bam files and $factor being the per million scaling factor of each sample, 
that was calculated to normalize for sequencing depth (all mapped reads divided by 1,000,000). 
Bedgraph files were then loaded into IGV and an auto group scale was set. Human hg38 was used as 
reference genome. 
10.3 Differen.i)0 gene expression )nd GO p).hw)? )n)0?sis 
For the generation of a count table, multiBamCov (samtools) (Li et al., 2009) with the same genome 
annotation (hg38/ sacCer3) as for mapping was used. Differential expression analysis was done in R 
using the DESeq2 package (Love et al., 2014). The count table was loaded and all Isoforms or genes 
with zero read counts in all conditions were eliminated. For the human count table, containing all iso-
forms, the data set was reduced to one isoform per gene, selecting the longest isoform of the gene. 
DESeq analysis was performed according to the provided manual. The pheatmap package 
(https://CRAN.R-project.org/package=pheatmap) was used for generating all heatmaps. To access the 
similarities of samples, the DESeqDataSet was submitted to variance stabilizing transformation (vst) 
that selects a representative subset of 1000 genes. The sample distances were calculated (dist) and 
plotted using pheatmap. For further analysis, the DESeqDataSet was regularized–logarithm trans-
formed (rlog). A result table was extracted for pairs of samples that were compared on the expression 
level. A histogram plot for the distribution of log2 fold changes was fitted with a centered Gaussian 
curve. At the points of convergence, the cut-off for the log2 fold change for deregulation was set. The 
adjusted p-value (FDR) was set to 0.05. For the gene ontology pathway analysis, the functional 
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annotation chart tool from DAVID based on biological process terms was used (Dennis et al., 2003). 
Only enriched pathways with a p-value <0.05 were listed.  
In order to take potential cell-cycle effects due to the perturbations into account, a study investigating 
the dependence of gene expression on the cell cycle was consulted (Grant et al., 2013). The lists provided 
for U2OS and HeLa cells are partly overlapping with the TelNet genes (271 of 1813 for U2OS). 
Furthermore, the expression or localization of some known TMM genes are also dependent on the cell 
cycle, e.g. TRF1, MRE11, POT1, ATM, and NBS1 (Zhu et al., 2000) (Verdun et al., 2005). Therefore, 
genes from the Grant et al. lists were marked with a °circle but were not excluded from the analysis. 
TMM pathway analysis was performed using the TelNet database. At all occurrences in the text and in 
the tables, TelNet genes were marked in bold.  
11 !mp0emen.).ion of .he Te#Ne% d).)b)se 
For the implementation of the database, Filemaker Pro Advanced (Filemaker, USA) was used. The 
database is distributed via Filemaker server and access is provided via the Filmaker webdirect software 
at http://www.cancertelsys.org/TelNet. Currently, no password is necessary and the database is free to 
use via the guest account.  
Databases in Filemaker consist of tables that have a number of different fields (Table 18). In TelNet, 
each organism has a separate table that covers all fields described in Table 19 and Table 20. Another set 
of tables, i.e. “organism”, “TM significance”, “cellular function”, “TM function” and “TMM 
annotations”, were generated to contain value lists for some of the fields in the human or budding yeast 
table. Additional tables were set up with records to provide value lists for fields in the organism table or 
for background calculations, such as “statistics”, “start” and “virtual”. The table “info buttons” serves 
as help page. Value lists for the tables “organism”, “TM significance”, “cellular function” and “TM 
function” as well as all TMM annotations can be found in Table 19 and Table 20.  
The info buttons table contains help terms and an appropriate description of each field. The start page 
serves as front page and is used for processing search requests. The statistics table does only contain 
one record for display and temporarily saves ID lists for visual display. The “virtual” table is needed for 
all background calculations as well as temporary storage required for the statistics page. In summary, 
Filemaker served as implementation platform for setting up the TelNet database.  
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Table 18. FileMaker tables. 
table records Fields 
TelNet_human human genes/ proteins 
see table (Table 19 and Table 20) 
TelNet_budding yeast budding yeast genes/ proteins 
organism designation of organisms - 
TM significance predicted, screened, validated - 
cellular function list of cellular functions (Table 19) - 
TM function list of TM functions (Table 20) - 
human TMM annotation list of respective TMM annotations and activity 
(Table 20) TMM annotations, regulation activity budding yeast TMM annotation 
info buttons list of help terms help term and description 
start every new list search generates a new record search and selection fields  
statistics - ID lists for export 
virtual only for background calculations calculation storage for statistics page 
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  Resu0.s 
1 Te#Ne% d).)b)se 
Telomere maintenance comprises complex processes from reverse transcription to homologous 
recombination with the help of a variety of different proteins. However, a systematic approach that 
integrates annotations with regard to TMMs is desirable. Therefore, the TelNet database as a 
comprehensive compilation of genes with a role in telomere maintenance (TM) has been developed. 
Furthermore, besides providing a comprehensive collection of TM genes, TelNet resulted in a helpful 
tool that enables identification of TM networks.  
1.1 Screening s.udies provide )n ini.i)0 source of TM genes 
To establish a solid foundation for the TelNet database, at first gene lists from screening studies or 
reviews that address TM in human and budding yeast have been selected (Figure 9). By applying 
proteomics of isolated chromatin segments (PICh) in ALT-positive Wi38-VA13 and telomerase-
positive HeLa 1.2.11 cells Déjardin and Kingston identified proteins that bind to a telomere probe and 
296 records were included into the database (Dejardin & Kingston, 2009). Grolimund et al. determined 
the telomere protein composition of HeLa cells with different telomeric states by quantitative telomeric 
chromatin isolation protocol (QTIP) and identified 34 proteins (Grolimund et al., 2013). Among the 
34 identified proteins they found a number of factors that have not been characterized at telomeres 
before. In another work, over 200 proteins were found in the protein network surrounding telomere 
repeat binding factors, TRF1, TRF2, and POT1 using dual-tag affinity purification in combination with 
multidimensional protein identification technology liquid chromatography-tandem mass spectrometry 
(MudPIT LC-MS/ MS) (Giannone et al., 2010). In a broad interaction screen of telomeric core proteins 
with a vast amount of human proteins by protein complementation assay (PCA/ bimolecular fluorescent 
complementation (BiFC)) Lee et al. found over 300 proteins that occur in proximity to shelterin 
compounds (Lee et al., 2011). They also confirmed their results by a secondary analysis with a GST-
pulldown of FLAG-tagged candidate genes and subsequent dot blotting of respective telomeric proteins. 
Notably, their approach also captures transient, infrequent and low affinity interactions. Lovejoy et al. 
comprised a gene set of 297 genes with potential relevance to telomeres and the ALT pathway assigned 
with functional annotations (Lovejoy et al., 2012). The RNA interference screen of Osterwald et al. 
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directly measured the effect of protein knockdown by two independent siRNAs on the number of APBs 
(Osterwald et al., 2015). Another TM study dealt with the effect of telomere attrition caused by the 
telomerase inhibitor GRN163 (Geron) (Uziel et al., 2015). Proteomic analyses identified 99 proteins 
that were deregulated in the process of telomere shortening. 
Figure 9. Sources for identification of genes associated to TM. 
Gene lists from human and budding yeast screens or reviews and from GO (term “telo”) are shown as 
circles. The color scheme indicates the TM significance, based on the source of the genes: blue, 
predicted; orange, screened or reviewed; red, validated by approved experimental research. Histograms 
display the distribution of the TelNet scores of all included genes and proteins per species. Overall, 
more than 2,000 human genes, and over 1,000 genes were included and manually curated for the 
TelNet database. Figure adapted from (Braun et al., 2018). 
Over 100 potential regulators of telomerase from a library screen of kinases were determined by 
quantitative TRAP assay (QTRAP) (Cerone et al., 2011). Another set of telomerase regulators that act 
on the transcriptional level was reviewed recently (Ramlee et al., 2016). Comparison of different 
published telomerase activity signatures resulted in 43 genes that can reliably predict telomerase activity 
from gene expression data (Barthel et al., 2017). In budding yeast, it is possible to perform deletion 
screens and monitor alterations for instance in telomere length, and work from such screens has provided 
326 genes to TelNet (Askree et al., 2004; Gatbonton et al., 2006; Ungar et al., 2009). Another 270 genes 
from Hu et al., who knocked out the RNA component of telomerase and subsequently investigated 
telomere structures of post-senescent survivors, were also implemented (Hu et al., 2013). According to 
the type of study the gene was found or investigated we assigned a TM significance. (i) Genes with a 
suggested role in TM but lacking experimentally validation were ranked as “predicted”. (ii) Genes 
collected from screening or review sources were classified as “screened”. (iii) Proteins with detailed 
experimental evidence for a connection to TM were assigned as “validated”. The proteins collected from 
the prior mentioned literature were mostly classified as “screened’. In addition, genes were included in 
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the database by homology assignment, if the orthologues’ TM significance is categorized as “screened” 
or “validated’. For instance, even if no analysis comparable to budding yeast deletion screens exists in 
human, a human orthologue to a hit from such a screen was still included according to this procedure. 
As another source for TelNet, GO annotations of human and budding yeast genes were searched 
containing the term “telo” for subsequent inclusion in the database. Currently, additional 170 studies on 
human and 45 articles on budding yeast proteins that specifically characterized and validated the TM 
phenotype for example for ASF1, a and b, were taken into account (O'Sullivan et al., 2014). Thus, 
screening studies, reviews, homology assignments and the GO database provided the basic compilation 
of proteins involved in TM, which was further extended by studies of single TM proteins. 
1.2 Gener)0 gene )nno.).ions )re g)ined from ex.ern)0 d).)b)ses 
In order to provide some standard information on each entry, external databases were consulted for 
names, descriptions and commonly used identifiers (Figure 10 and Table 19). The ID conversion tool 
from the database for annotation, visualization and integrated discovery (DAVID, 
https://david.ncifcrf.gov) was accessed to unitize extracted identifier from the literature to a common 
set (Huang da et al., 2008).  
 
Figure 10. General part of a gene card. 
The general part of the gene card view contains information from various external databases. Available 
terms for the annotation of a cellular function are listed.  
The general part of each gene card consists of the full name, synonyms, Entrez Gene ID and RefSeq IDs 
(NCBI, www.ncbi.nlm.nih.gov) (Coordinators, 2017), HGNC Gene ID (HGNC, www.genenames.org) 
(Yates et al., 2017), Ensembl Gene ID (Ensembl, www.ensembl.org) (Aken et al., 2016; Aken et al., 
2017), Uniprot ID and functional description (UniProt, www.uniprot.org) (The UniProt, 2017) and for 
budding yeast, SGD ID  and the Locus tag (SGD, www.yeastgenome.org) (Cherry, 2015). YeastMine 
(Balakrishnan et al., 2012) from the saccharomyces genome database (SGD, www.yeastgenome.org) 
(Cherry et al., 2012) was used to retrieve orthologues. 
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Table 19. General gene annotations. 
Fields Type Comment 
organism entry field H. sapiens or S. cerevisiae 
approved symbol entry field official gene symbol 
full name entry field full name as specified in external databases 
synonyms entry field synonyms and aliases specified in external databases 
description entry field general gene information 
cellular function entry field, value list 
cell cycle; cell death; cell differentiation, cell membrane/ wall; cellular 
structure; chromatin organization; DNA replication and repair; meta-
bolism; mitochondria; nuclear organization; nucleocytoplasmic trans-
port; protein modification; protein synthesis and degradation; protein 
transport; RNA transcription and processing; signaling; telomere 
biology 
gene ID entry field 
gene identifiers 
human 
HGNC ID entry field 
ensembl gene ID entry field 
budding yeast 
SGD ID entry field 
locus tag entry field 
RefSeq ID entry field 
transcript identifiers 
isoforms entry field 
Uniprot entry field protein identifiers 
orthologues entry field orthologues of the respective other organisms are entered and 
linked 
source entry fields references categorized into three groups: “validated by”; 
“screened by”; “predicted by” 
DOI entry fields DOI of the respective journal articles 
Based on the functional annotations from gene ontology (GO, www.geneontology.org) and in line with 
biocuration guidelines, a list with concise terms annotating the cellular function was generated similar 
to curation procedures at SGD (Table 19). Every gene was manually annotated with the respective term 
that is most representative for its cellular function. Orthologous genes are listed and for those included 
in the database, an internal database link was integrated. In addition, literature information was 
referenced in the categories “predicted by”, “screened by” and “validated by” according to the TM 
significance. Web links are available for all external databases and literature articles. In summary, 
external databases served as source for composing the general part of each gene card. 
1.3 Genes )re )nno.).ed wi.h TM inform).ion  
In order to annotate each gene and protein with TM relevant information, peer-reviewed literature, such 
as above-mentioned screening and review papers, were exploited. The TM part of a gene card consists 
of text fields containing TM annotations (Figure 11, Table 20). A free-text summary of detailed 
information from experimental results can be found in the TM comment field.  
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Figure 11. TM part of a gene card. 
The TM part of the gene card contains information extracted from the literature. The descriptions of 
specific fields can be found in the text. Figure adapted from (Braun et al., 2018). 
Each protein can be assigned with up to five TM functions, such as molecular processes and functions 
as well as cellular structures associated with TM (Figure 11, Table 20). Furthermore, an effect resulting 
from knockout or knockdown that is linked to telomere length, telomerase activity or ALT hallmarks 
were documented in the field “TM phenotype”. For distinguishing whether the wild-type (wt) gene is 
associated with telomerase-mediated TM mechanism (TMM) or the ALT pathway, the “TMM 
annotation” is provided. 
Table 20. Fields of the TM part of a gene card. 
fields type comment 
TM significance entry field,  
value list 
“predicted”, “screened” or “validated” (reflecting the experimental 
evidence on the association with TM) 
TelNet score calculation field see Table 21 
TM comment entry field all telomere-relevant information of a factor is summarized here. 
human TMM 
annotation 
entry fields 
telomerase-mediated or ALT 
budding yeast type I/II recombination or telomerase-mediated 
TMM regulation activity entry field,  
value list 
repressing, enhancing or ambiguous 
TM function [1-5] entry field,  value list 
ALT associated PML-NBs (APBs); chromatid cohesion; chromatin 
remodelling; chromatin structure; DNA methylation; DNA recombination; 
DNA repair/ damage response; DNA replication; extrachromosomal 
telomeric repeat formation; gene regulation; histone assembly; histone 
modification, or variant; protein degradation; protein folding; protein 
modification; RNA processing; shelterin binding; shelterin component; 
SUMOylation; telosome; telomerase activity; telomerase component; 
telomerase localization; telomere length; telomere repeat binding; 
telomere structure; telosome; TERRA; transcription 
TM phenotype entry field 
phenotype observed upon knock-down or knock-out related to TM 
features such as alterations in telomere length, increased or decreased 
ALT hallmarks, or effects on telomerase of the gene is given here. 
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For budding yeast genes, it can be additionally differentiated between type I and II survivors, with the 
latter having common features with the human ALT mechanism. Details of the regulation on each TMM 
as extracted from the literature were given in the enclosed activity field. Here, the options are an 
“enhancing”, “repressing’, or “ambiguous” regulation activity. The annotation “ambiguous” is selected 
for genes with opposing information from the literature or a lack of regulation description.  
Table 21. Calculation of the TelNet score.  
condition score  
if the TM significance is “predicted”, the gene yields 5% of the orthologue’s TelNet score  0-1 
if the protein was identified in a TM related screen (added up if present in multiple screens) 1 
if the TM significance is “validated” 3 
if the cellular function contains the term “telomere' 1.5 
if a TM function is assigned (added up for multiple functions) 0.5 
extra score, if a TM function is “shelterin”, “telosome” or “telomerase” (added up for multiple functions) 0.5 
The TelNet score is calculated as a sum of information that was entered into the TelNet database. The 
maximum TelNet score is 10. Table adapted from (Braun et al., 2018). 
As outlined above (results section 1.1) the TM significance indicates experimental evidence of a genes 
connection to TM. The TM significance directly influences the TelNet score, that was established in this 
work to rank a gene according to several relevant parameters. It quantifies the TM significance and 
additionally takes the cellular function and TM functions into account (Table 21). The TelNet score is 
calculated as a sum of information that was entered into the TelNet database. The maximum TelNet 
score is 10. Thus, peer-reviewed literature was exploited for functional categorizing TM information, 
compositing of a comprehensive gene card for each entry, validating its TM significance and transferring 
it into a quantifiable score. 
1.4 Te#Ne% offers differen. se)rch modes 
For a convenient user interface, a decent front layout was designed that requires the selection of an 
organism (Figure 12). In order to cover all sorts of search requests, the TelNet database offers three 
search modes, “quick search”, “list search”, and “advanced card search”. By pressing the button “show 
all” after selecting an organism, the user can explore all included genes of an organism.  
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Figure 12. Usage chart for the TelNet database. 
The navigation options and search modes of the TelNet database are depicted as flow chart. First the 
user has to select an organism. Next, either all entries can be selected or one of the three search modes 
can be applied. The resulting set of genes can be explored on list or card view. Finally, a statistics page 
displays a graphical overview over the different annotations. Figure adapted from (Braun et al., 2018). 
Alternatively, the user can perform a search request to find a set of interesting genes. A set of genes or 
proteins can be studied in the scrollable list view. From here, data export enables further bioinformatic 
analysis. The navigation menu on top allows a switch from list to gene card view for inspecting a single 
protein or gene of interest. The info buttons give a brief explanation of each field on the gene card. Thus, 
the TelNet database offers a user-friendly navigation and a comprehensive help page. To provide a 
thorough overview of annotations, a statistics page for a set of genes generated by a specific search was 
developed (Figure 12). Whole lists of genes can be directly copied from two fields containing the names 
and respective identifiers. Furthermore, a log-scaled histogram of the TelNet score is provided. Other 
annotations, such as TM significance, cellular and TM functions were charted as counts. Hence, the 
functional annotations enable a pathway analysis tailored for TM specific questions.  
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Figure 13. TelNet statistics page of all human genes. 
A screen shot of the TelNet statistics page is displayed for all human genes. Gene symbols and IDs are 
stored in text fields for direct copying. The TelNet score, TM significance, cellular and TM functions, as 
well as TMM annotations are counted over all entries. 
For the further analysis of the wt TMM annotation, the genes are grouped into three categories, “ALT”, 
“telomerase-mediated” and “ambiguous”. Proteins that drive the ALT mechanism and/ or repress 
telomerase fall into the category “ALT’. Those proteins repressing ALT and/ or promote telomerase 
activity fall into the category telomerase-mediated. For those that have no annotation or are 
indeterminate, the category ambiguous is chosen. For the predicted wt TMM, the user has to tick the 
respective field before the result is shown. Here, the TelNet score for each gene gives weight to the count 
of each category to calculate a probability for the proposed active TM mechanism. Thus, the TelNet 
statistics page is tailored for TM pathway analysis and for indication of the probable active TMM. 
1.5 Te#Ne% is ) vers).i0e .oo0 for .he iden.ific).ion of TM genes 
For the “quick search’, the user can enter any search term and select the fields of interest. (for example: 
telomerase regulation, PML-NBs, serine/ threonine kinases). To identify gene candidates that are 
associated to TM from a gene list, the list search is the most appropriate search mode. The TelNet list 
search has a main application in bioinformatics data analysis pipeline as part of a TMM analysis, for 
which two examples are given in the following.  
Sieverling et al. used the TelNet database for correlation of a gene list retrieved from a bioinformatics 
analysis pipeline (Sieverling et al., 2018). In the ICGC pan-cancer project, whole-genome 
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sequencing (WGS) data of 2,594 matched tumor-control samples from 35 different tumor types have 
been analyzed. A systematic search discovered 2,759 somatic integrations of telomeric sequences into 
non-telomeric DNA. These telomere insertions were distributed across the genome and strongly 
correlated with increased telomere content, genomic breakpoint frequency and ALT-associated 
mutations. A list of genes that were found to harbor telomere insertions or mutations that correlated with 
telomere length was generated. Genes with telomere insertions and mutated genes were then passed into 
the TelNet list search to identify TM-associated genes. This procedure revealed a number of genes 
known to be associated with TM. Notably, among them were two genes, PLCB2 (phospholipase C beta 
2) and ABCC8 (ATP binding cassette subfamily C member 8), that have been implemented in TelNet 
because their budding yeast homologues have been found to control telomere length. Based on the link 
provided by the TelNet database, it can be assumed that a functional association with telomeres also 
exists in humans, which has to be validated in further experiments.  
In another example, a correlation was performed with data from the TCGA data set. In the TCGA pan-
cancer project, Barthel et al. used the gene expression data of an “extended set” of 8953 tumor samples 
(Barthel et al., 2017). The group estimated telomere lengths of matching samples by TelSeq (Ding et 
al., 2014), a tool that counts telomere repeats from WGS data. As compared to Barthel et al., the data 
set for the present analysis was reduced to a final patient set (n=281), within which matching normal 
control samples for each tumor sample were available. The ratio of tumor over normal was calculated 
for either telomere lengths as well as log2 of gene expression data. Next, the data was correlated using 
the spearman method, resulting in 1022 genes that significantly (p<0.01) (anti-)correlated with telomere 
length changes or that were differentially expressed (Figure 14). In order to filter for those genes that 
are related to TM, the TelNet database was used. Consequently, the list with gene candidates was passed 
into the TelNet “List search’, which resulted in a set of 132 genes (12.9%) (Suppl. table S2). The 
1,022 genes were also submitted to the HumanMine database that includes a GO enrichment analysis 
(Smith et al., 2012). None of the enriched GO terms or pathways returned were related to telomeres. 
When simply searching for GO terms “telomere maintenance”, “telomere organization” or “regulation 
of telomerase activity” only 13 genes (RAD51, CCNE1, BRCA2, HIST1H4H, RECQL4, RFC4, FEN1, 
EXO1, BLM and HIST2H4A, PPARG, KLF4 and PARM1) were found. In contrast, TelNet found 
132 genes associated with TM (including the 13 genes found with HumanMine). TelNet finds more 
genes, because it includes homology assignments in both directions and genes that do not have a GO 
term related to telomeres despite reported telomere related activities. In this analysis, no significantly 
upregulated genes (l2fc>0.852) that also significantly correlated (Rho>0.186) with telomere length 
changes were found. Also, none of the significantly downregulated TelNet genes (l2fc<-0.782) showed 
a significant anti-correlation (Rho<0.184) of gene expression and changes in telomere length. 
Furthermore, expression of ARL4D (ADP ribosylation factor like GTPase 4D) correlated with telomere 
length changes (Rho=0.22) and the gene was downregulated in tumors, indicating a role in telomere 
trimming. The gene was included in TelNet because telomeres get longer upon deletion of the budding 
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yeast homologue (Gatbonton et al., 2006; Hu et al., 2013). For the human genes, validation of a role in 
regulating telomere length awaits experimental testing. 
 
Figure 14. Correlation of gene expression data with telomere lengths. 
Gene expression data from TCGA was correlated with telomere length values that were estimated by 
(Barthel et al., 2017) using spearman correlation. The log2 fold change tumor over normal was plotted 
against the resulting correlation coefficients Rho. For gene expression as well as Rho values, 
histograms were plotted and fitted with a Gaussian fit. The 1% tails of both histograms were marked in 
light blue. Black dots reflect genes that are above at least one threshold, red dots are additionally 
included in the TelNet data base. Light grey dots miss both thresholds, dark grey spots are included in 
the TelNet database but miss both thresholds. Figure taken from (Braun et al., 2018). 
These examples show that TelNet is able to identify TM candidate genes for further validation in 
knockdown or overexpression experiments. Thus, the TelNet list search serves as helpful tool for the 
identification of TM networks. Overall, the TelNet database proves as a versatile resource that can be 
used for the identification of genes associated with TM from bioinformatic analysis pipelines. 
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2 ALT suppression )nd induc.ion 
Only few recurrent mutations are known to correlate with ALT and for instance in pediatric high-grade 
gliomas, with a high incidence of ALT, altered histone and DNA methylation have been observed 
(Bender et al., 2013). Therefore, also epigenetic changes might induce or suppress ALT. In this part of 
the thesis, multiple ways of perturbing TMM were investigated by differential gene expression analysis. 
(i) Suppression of the ALT pathway by the HDACi SAHA, (ii) rapid ALT induction by ASF1 depletion 
in HeLa cells with long but not short telomeres, (iii) suppression of ALT induction by simultaneous 
treatment of ASF1 depleted cells with SAHA and (iv) ALT induction in survivors formed after EST2 
deletion in budding yeast. 
2.1 His.one de)ce.?0)se inhibi.or SAHA reduces ALT m)rYers 
SAHA (Vorinostat) is a pan inhibitor for HDACs of class I and II with an IC50 of 21 nM (HDAC1), 
37 nM (HDAC3), 25 nM (HDAC6), and 1.2 µM (HDAC8) (Beckers et al., 2007). Among other proteins, 
histones thus become hyperacetylated and the chromatin more open. Recently, it has been demonstrated 
that in ALT-positive U2OS cells, treatment with 2 µM SAHA significantly reduced the number of APBs 
(mean±SEM, –49.4±6.9%, p<0.001, Figure 15A +B) and C-circle levels (–45.3±10.3%, p<0.001) 
(Osterwald et al., 2015). However, a concentration of 2 µM SAHA lies above the IC50 for cytotoxicity 
of 1.5 µM for HeLa cells after 72 h of treatment (Beckers et al., 2007). Therefore, these results were 
revisited in this work using lower amounts of SAHA. 
2.1.1 SAHA reduces ALT m)rYers )0re)d? ). 0ow concen.r).ion  
In order to investigate which SAHA dose has minimal toxicity, yet can affect the ALT mechanism, 
SAHA concentration was titrated with respect to a decrease in the number of APBs as well as C-circle 
levels. Treatment of U2OS cells with SAHA resulted in a significant reduction in the number of APBs 
for 0.1 µM (-15.2±3.1%, p<0.001) over 0.25 µM (-40.1±3.0%, p<0.001) to 0.5 µM SAHA (-38.2±
3.1%, p <0.001). Furthermore, a general trend towards reduction of C-circle levels was observed for 
0.5 µM SAHA (-29.6±9.6, p=0.08, Figure 15C). Thus, a concentration of 0.5 µM SAHA was found to 
also significantly reduce the number of APBs and decrease C-circle levels after 24 h. 
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Figure 15. SAHA treated U2OS cells show decreased number of APBs and C-circle levels. 
(A) Microscopy images of cells that were treated with solvent, 0.1, 0.25, 0.5 or 2 µM SAHA for 24h. Cells 
were stained with anti-TRF2-ms-A568, anti-PML-rb-A488 and DAPI. Scale bars are 10 µM. (B) Bar plot 
showing quantification of microscopy images of (A). PML and telomere foci were detected and 
colocalizations were calculated using Cell Segmentation 3D software. Resulting colocalizations were 
plotted as box plots. More than 2,400 cells were imaged per condition. (C) C-circle assay of U2OS cells 
treated with 0.5 or 2 µM SAHA for three days. Above the bar plots, exemplary dot blots of the C-circle 
assay are depicted. The upper row contains samples after amplification with polymerase addition, and 
the lower row shows the control without polymerase. Genomic DNA from two independent replicates 
was extracted for the C-circle assay that was performed in triplicates. Significance is indicated with 
asterisks, **p<0.001. Error bars represent the standard error of the mean (SEM). C-circle assay was 
performed by Caroline Bauer (Prof. Karsten Rippe, DKFZ, Heidelberg) 
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2.1.2 SAHA does no. specific)00? induce )pop.osis in ALT ce00s 
In order to analyze the link of apoptosis induction by SAHA with TMM, different ALT-positive and 
ALT-negative cell lines were subjected to SAHA treatment followed by apoptosis staining and FACS 
analysis. ALT-positive U2OS and -negative HeLa cells served as well-studied reference cell lines. In 
addition, a panel of four pediatric glioblastoma (pedGBM) cell lines that was recently characterized in 
respect to their ALT status, was tested (Deeg et al., 2017). FACS of annexin V and propidium iodide 
(PI) stained cells was used to quantify apoptotic cells treated with SAHA (Figure 16A and B). 
 
Figure 16. FACS analysis of cells treated with SAHA or ATRi VE-821. 
(A) Exemplary cell death analysis of U2OS and HeLa ST cells (ST for short telomeres, average of 9 kb). 
Cells were treated with solvent, 0.5 or 2 µM SAHA for 24 h. Cells were stained with propidium iodide 
and annexin V-FITC and analyzed on a FACS Canto II. Subsequent data analysis was done with 
Weasel. (B) Quantification of apoptotic cells. Cells positive for annexin V, but negative for PI were 
classified as apoptotic and quantified in a bar plot. U2OS (ALT-positive reference cell line), SJ-G2 and 
MGBM1 (ALT-positive pedGBM cell lines), SF188 and KNS42 (telomerase-positive pedGBM cell lines), 
HeLa LT (LT for long telomeres, average of 20 kb) and HeLa ST (telomerase-positive reference cell 
line) (C) Cell cycle analysis of U2OS and HeLa cells treated with 2 µM SAHA or solvent. Estimation of 
cell cycle phase proportions was done using Weasel. (D) Quantification of apoptotic cells after treatment 
with 3 µM ATRi VE-821 or solvent. Cells positive for annexin V, but negative for PI were classified as 
apoptotic and quantified in a bar plot. Error bars represent the standard error of the mean from three 
independent experiments with two technical replicates each. 
Cells were gated to exclude small artefacts and large cell aggregates (detailed description in methods 
section 4). For calculation of induced apoptosis, apoptotic cells were quantified as annexin V-positive 
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but PI-negative cells and translated via the formula of induced apoptosis (methods section 4.1). As 
depicted in Figure 16B, the range of induced apoptosis by 2 µM SAHA in ALT-positive cells reached 
from 2.7% in U2OS to 24.3% in SJ-G2. In the panel of ALT-negative cells, KNS42 cells did not show 
any response, whereas in 2.6% of HeLa LT cells (LT for long telomeres, average of 20 kb) and in 14.5% 
of HeLa ST cells (ST for short telomeres, average of 9 kb) apoptosis was induced. Therefore, no 
correlation of induced apoptosis with the active TMM was observed. HDACi have been shown to 
increase the acetylation of p53 and therefore lead to upregulated p21 levels resulting in apoptosis 
(Richon et al., 2000). However, no correlation with the p53 mutational status was observed since all 
pedGBM cell lines have mutated TP53 and only U2OS and HeLa cells are wild-type (Deeg, 2015). 
Thus, ALT-positive pedGBM cells are not specifically hypersensitive to apoptosis due to SAHA 
treatment.  
Furthermore, cells treated with a lower SAHA concentration of 0.5 µM were analyzed with the same 
method. The percentage of cells with induced apoptosis was lower than the percentage detected for 2 
µM SAHA. The greatest difference in sensitivity was observed in MGMB1, where only in 0.9% of cells 
were apoptotic. In comparison, in 14.8% of SJ-G2 cells apoptosis was induced. In ALT-negative cells 
the percentage of cells with induced apoptosis ranged from non-responding KNS42 cells, over 0.1% in 
HeLa LT and 1.9% of HeLa ST cells to 2.8% in SF188 cells. Thus, a concentration of 0.5 µM SAHA 
only led to a low percentage of apoptotic cells after 24 h. 
To investigate cell cycle effects due to treatment with SAHA, simultaneous staining of live cells with 
cell membrane-permeant Vybrant Dyecycle Violet was performed (Figure 16C). In ALT-positive U2OS 
cells treated with 2 µM SAHA, an increase of 14% more cells in G0/1 and a decrease of 3% in G2 were 
detected, and the percentage of S-phase was reduced by 11%. However, in ALT-negative HeLa cells, 
SAHA treatment lead to 13.3% more cells in G2 and 23.9% fewer cells in G0/1-phase, whereas the 
percentage of cells in S-phase did not change. Thus, in cells treated with 2 µM for 24 h, SAHA appears 
to induce cell cycle arrest in a cell-type specific manner. In summary, SAHA did not selectively induce 
apoptosis in ALT-positive or -negative cell lines, but variations in the responses rather originated from 
other parameters in the different cell lines.  
2.1.3 ALT-posi.ive ce00s )re no. h?persensi.ive .o ATR inhibi.or (ATRi) 
As the shelterin complex blocks telomeres from DNA damage response proteins and accidental 
recognition as DNA double-strand breaks, the ATR kinase, a major component of the DNA damage 
repair machinery, appears as a promising therapeutic target to treat ALT-positive tumors. It has been 
reported that treatment of ALT cells with ATRi VE-821 was able to decrease ALT hallmarks (O'Sullivan 
et al., 2014; Flynn et al., 2015). In order to evelaute these findings, the same panel of pediatric ALT-
positive and -negative cell lines as described above were treated with 3 µM VE-821 for 6 days 
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(Figure 16D). Subsequently, the cells were stained with PI and annexin V to investigate induced 
apoptosis by FACS. No correlation of TMM and induced apoptosis was observed. In the ALT-positive 
SJ-G2 cell line, 40±12% of cells responded by induction of apoptosis, whereas in the other ALT-
positive cell line MGBM1 only 3±1% of cells were sensitive to the treatment (Figure 16D). 
Additionally, among the ALT-negative cell lines SF188 had a stronger apoptotic response of 17±4% 
compared to 5±1% KNS42 cells with induced apoptosis. Thus, ALT-positive cell lines are not per se 
hypersensitive to apoptosis due to ATRi.  
2.1.4 !nf0)mm).or? )nd immune response genes were deregu0).ed upon SAHA 
It is known that HDACi have effects on different pathways such as autophagy, cell cycle and cellular 
signaling pathways. However, only little work has been done to investigate the impact on TM, especially 
the ALT pathway. To dissect gene expression changes and find pathways and genes related to TM that 
are affected by SAHA treatment, RNA-sequencing (RNA-seq) data from U2OS cells treated with SAHA 
in different concentrations was generated and analyzed. U2OS cells were cultured with medium 
containing 0, 0.5 and 2 µM SAHA, with medium changed every 24 h. After three days, RNA was 
extracted and libraries for sequencing were prepared. Sequencing data was generated and analyzed as 
described in methods sections 9 + 10. For quality control of the two replicates per condition, sample 
distances for a representative subset of genes were calculated using the DESeq2 package (Love et al., 
2014) (Figure 17A). The similarity between replicates was higher between different conditions.  
U2OS wt cells showed a high similarity to solvent-treated control (ctrl) cells (data not shown) and only 
one significantly (p<0.05) downregulated gene (log2 fold change (l2fc) =-1.62, p<0.0001), GDF15 
(growth differentiation factor 15), a cell cycle regulated gene (Grant et al., 2013), was identified. As this 
was the only deregulated gene, solvent effects were minor. Since the amount of ethanol was the same 
for all samples, the ethanol treated cells were used as control cells in the further analysis. To evaluate 
gene expression changes upon SAHA treatment, results were called for the two concentrations over 
solvent control cells. Frequencies of l2fc were plotted as histograms and fitted with a centered gauss 
curve to set thresholds at the points of convergence (Figure 17B). Differentially expressed genes 
(n=1,269) with a l2fc<-2.5 or >2.5 for 2 µM SAHA over EtOH ctrl cells and an adjusted p-value 
(padj)<0.05 were identified, while gene expression did not change significantly (padj>0.05) or in the 
same direction (up or down) in the 0.5 µM SAHA over EtOH ctrl cells. 1,016 genes were significantly 
upregulated by 2 µM SAHA treatment for 3 days in U2OS cells and 253 genes were downregulated 
with statistical significance (padj<0.05). The gene signature of 1,269 deregulated genes was able to 
hierarchically cluster the samples according to the C-circle levels (Figure 17C). 
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For all differentially expressed genes, RPKM (reads per kilobase of exon per million mapped reads) 
values were calculated to normalize raw counts for sequencing depth and gene length. Notably, many 
genes had a low coverage. Therefore, the gene set was further reduced by excluding all genes with an 
RPKM <1 in the highest expressed sample. This filtering step resulted in 318 up and 183 downregulated 
genes, listed in Suppl. table S3. Functional annotation analysis revealed a number of genes involved in 
the GO pathway “immune response”, “signal transduction” and “cellular response to interleukin-1” 
(Table 22).  
Table 22. Pathway analysis of genes upregulated in SAHA treated U2OS cells.  
category GO term # genes 
GO:0007269 neurotransmitter secretion** 6 
GO:0019882 antigen processing and presentation* 5 
GO:0006955 immune response* 11 
GO:0006928 movement of cell or subcellular component* 5 
GO:0046847 filopodium assembly 3 
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II 3 
GO:0007165 signal transduction 20 
GO:0043547 positive regulation of GTPase activity 12 
GO:0042361 menaquinone catabolic process 2 
GO:0042377 vitamin K catabolic process 2 
GO:0071805 potassium ion transmembrane transport 5 
GO:0042376 phylloquinone catabolic process 2 
GO:0071347 cellular response to interleukin-1 4 
Figure 17. Gene expression analysis of SAHA treated 
U2OS cells. 
(A) Heat map of variance stabilizing transformed data 
showing distances between the samples ranging from 
0 (dark blue) to ≥120 (white). The treatment of the cells is 
annotated in yellow (solvent), orange (0.5 µM) and 
red (2 µM). C-circle levels, normalized on the solvent 
control, range from 0 (white) to 1 (dark red). For samples 
with C-circle levels >0.5, ALT (dark red) was assigned as 
the present TMM, for C-circle levels <0.5, samples were 
marked in dark blue for an ALT-negative phenotype.  
(B) Histogram showing the frequency of log2 fold change 
values (2 µM SAHA over solvent control). A centered 
gaussian curve was fitted to the plot. Thresholds for the l2fc 
change were set to <-1.5 and >1.5, where the fitting curve 
has converged against 0. (C) Unclustered heatmap 
showing the top 1,269 deregulated genes with a log2 fold 
change <-1.5 or >1.5 and an padj<0.05. Samples have the 
same order and annotation as in (A) and genes were sorted 
according to the log2 fold change, annotated from -6 (blue) 
to 6 (red). Normalized and log2 transformed gene 
expression values range from ≤0 (white) to ≥15 (dark red).  
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category GO term # genes 
GO:0007267 cell-cell signaling 7 
GO:0031295 T cell costimulation 4 
GO:2001013 epithelial cell proliferation involved in renal tubule morphogenesis 2 
GO:0006813 potassium ion transport 4 
GO:0002503 peptide antigen assembly with MHC class II protein complex 2 
From the 318 upregulated genes in U2OS upon SAHA treatment 56 genes were included in the 
functional annotation chart with biological processes using DAVID. Pathways that were enriched with 
statistical significance were marked with asterisks (*p<0.01, **p<0.001).  
Since no TM pathway emerged from the analysis, TM pathway analysis was performed using the TelNet 
database. At all appearances in the text and in the tables throughout this thesis, TelNet genes were 
marked in bold. The link between the genes or encoding proteins and TM and respective genes were 
listed in (Table 23). Previous work by Grant et al. identified 1,813 cell-cycle-regulated genes in U2OS 
and 615 genes in HeLa, including some histone coding genes (Grant et al., 2013). Furthermore, other 
histone coding genes might also be cell cycle-dependent. In order to take potential cell cycle effects into 
account, genes that were identified to be expressed periodically in dependence of cell cycle phase were 
marked with a °circle.  
Table 23. TelNet genes, upregulated in U2OS treated with 2 µM SAHA. 
TM comment gene symbols 
Genes were included in a gene set with potential relevance to telomeres and the ALT pathway and is 
annotated with the term “repair” or “APB’. (Lovejoy et al., 2012) EID3, SP110 
Proteins were found in close proximity to a shelterin compound. (Lee et al., 2011) CRYM, MT1X 
Telomeres get longer upon deletion of the budding yeast homolog. (Askree et al., 2004), (Gatbonton 
et al., 2006) or (Ungar et al., 2009) 
SP140, SP110, 
DAW1, ARL14° 
telomerase repressor (Lafferty-Whyte et al., 2010) TCEAL7° 
The table shows the results of TelNet analysis. Columns reflecting the TelNet TM comment, providing 
information that linked the gene or encoded protein to TM and gene symbols of upregulated genes. 
Genes reported to be cell cycle-regulated in HeLa cells (Grant et al., 2013) were marked with a °circle. 
In disagreement with ALT repression by SAHA, EID3 was upregulated, which is part of the SMC5-
SMC6 complex (Taylor et al., 2008) that was shown to be involved in homologous recombination in 
ALT cells (Potts, 2009). A possible explanation might be an unknown functional role of EID3. Another 
reason could be the partly repression of ALT, only affecting some of the ALT characteristics. Since 
homologous recombination was not directly measured, further investigations are needed to complete the 
comprehensiveness of ALT suppression. Genes encoding the PML-NB components SP110 and SP140 
showed a higher expression in SAHA treated cells. A result of this upregulation might be the 
sequestering of APB compounds away from telomeres, as it has been observed for overexpression of 
SP100 (Jiang et al., 2005). Furthermore, TCEAL7° encoding for a known telomerase repressor 
(Lafferty-Whyte et al., 2010) was upregulated upon SAHA treatment.  
GO pathway enrichment analysis for downregulated genes was summarized in Table 24. Notably, genes 
encoding canonical histones were enriched among downregulated genes and therefore annotated GO 
pathways such as “nucleosome assembly”, “chromatin silencing”, but also “telomere organization/ 
capping”. Furthermore, also “inflammatory response” (CCL24, TNFRSF11B, RARRES2, NMI, CCL2, 
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SERPINA3, TRIL, BMPR1B, CD180) and “JAK-STAT cascade” (NMI, CCL2, STAT5A) were among 
enriched GO terms. The GO terms “positive regulation of gene expression/ transcription” included genes 
of the WNT-signaling pathway (WNT11, WNT3A) that were enriched without statistical significance. 
For the TelNet gene RARRES2 (retinoic acid receptor responder 2) a tumor suppressive role by 
inhibiting the p38 MAP kinase pathway has been reported (Liu-Chittenden et al., 2017). The 
transcription factor KLF17 (Krüppel-like factor 17), included in TelNet, has been observed to be 
involved in potentiating TGFb/ SMAD signaling (Ali et al., 2015).  
Table 24. Pathway analysis of genes downregulated in SAHA treated U2OS cells.  
GO identifier GO term # genes 
GO:0006342 chromatin silencing*** 9 
GO:0006334 nucleosome assembly*** 12 
GO:0045814 negative regulation of gene expression, epigenetic*** 6 
GO:0032200 telomere organization*** 5 
GO:0006335 DNA replication-dependent nucleosome assembly*** 5 
GO:0000183 chromatin silencing at rDNA ** 5 
GO:0051290 protein heterotetramerization** 5 
GO:0030198 extracellular matrix organization** 8 
GO:0045815 positive regulation of gene expression, epigenetic* 5 
GO:0006954 inflammatory response* 9 
GO:0045653 negative regulation of megakaryocyte differentiation* 3 
GO:0031047 gene silencing by RNA* 5 
GO:0044267 cellular protein metabolic process 5 
GO:0016233 telomere capping 3 
GO:0006935 chemotaxis 5 
GO:0032972 regulation of muscle filament sliding speed 2 
GO:0002227 innate immune response in mucosa 3 
GO:0006366 transcription from RNA polymerase ii promoter 10 
GO:0071300 cellular response to retinoic acid 4 
GO:0006336 dna replication-independent nucleosome assembly 3 
GO:0051301 cell division 8 
GO:0001654 eye development 3 
GO:0048706 embryonic skeletal system development 3 
GO:0010332 response to gamma radiation 3 
GO:0007259 JAK-STAT cascade 3 
GO:0006352 DNA -templated transcription, initiation 3 
GO:0048839 inner ear development 3 
GO:0045893 positive regulation of transcription, DNA -templated 9 
GO:0034080 cenp-a containing nucleosome assembly 3 
GO:1904837 beta-catenin-TCF complex assembly 3 
GO:0000082 G1/S transition of mitotic cell cycle 4 
GO:0007062 sister chromatid cohesion 4 
GO:0019731 antibacterial humoral response 3 
GO:0001649 osteoblast differentiation 4 
GO:0007187 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger 3 
GO:0010628 positive regulation of gene expression 6 
GO:0051726 regulation of cell cycle 4 
GO:0060044 negative regulation of cardiac muscle cell proliferation 2 
GO:0019221 cytokine-mediated signaling pathway 4 
From the 183 downregulated genes in U2OS upon SAHA treatment 75 genes were included in the 
functional annotation chart with biological processes using DAVID. Pathways that are enriched with 
statistical significance were marked with asterisks (*p<0.01, **p<0.001, ***p<0.0001).  
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In order to identify genes that are related to TM, the TelNet database was used (Table 25). Most of the 
downregulated histone coding genes were also listed in the TelNet database because of telomere capping 
(Dejardin & Kingston, 2009). Both, telomerase repressors and activators have been identified as TMM-
related from the downregulated genes. In summary, SAHA treatment leads to chromatin silencing and 
therefore, negative regulation of gene expression and in addition to deregulated immune and 
inflammatory response pathways. However, no clear correlation with previously reported functions 
regarding TMM as extracted from the TelNet database was found. 
Table 25. TelNet genes, downregulated in SAHA treated U2OS cells. 
TM comment Gene symbols 
Genes were included in a gene set with potential relevance to telomeres and the ALT 
pathway and is annotated with the term “replication” or “repair” (Lovejoy et al., 2012). FANCD2, MCM5°, RAD51AP1 
Protein negatively affects APB formation (Osterwald et al., 2012). FANCD2 
Proteins were found bound to telomeres (Dejardin & Kingston, 2009) or in close 
proximity to a shelterin compound (Giannone et al., 2010; Lee et al., 2011). 
H2AFY2, HIST1H4H, MCM5°, 
HIST1H4A, HIST1H3B°, 
HIST1H3D, HIST1H4I, KCTD15, 
CRYBB1, ANXA8L1 
Genes are members of telomerase activity signature (Barthel et al., 2017). RAD51AP1, RARRES2, TRIM22, ALPL 
positive regulator of telomerase (Mac et al., 2000), (Cerone et al., 2011), or (Ramlee et 
al., 2016) STAT5A, EDN2, MYCN 
negative regulator of telomerase (Racek et al., 2005; Toh et al., 2005; Beitzinger et al., 
2006) TP73° 
Gene was downregulated upon telomere shortening caused by the telomerase inhibitor 
GRN163 (Geron) in SK-N-MC cells (Uziel et al., 2015). SERPINH1° 
The budding yeast homologue NAM7 is required for Type II survivor formation (Hu et 
al., 2013) and telomeres get shorter upon budding yeast homologue NAM7 deletion 
(Askree et al., 2004; Gatbonton et al., 2006). 
MOV10L1 
Telomeres get longer upon budding yeast homologue deletion (Askree et al., 2004; 
Ungar et al., 2009; Hu et al., 2013). TNNC1, FOXM1, PLCH1 
Yeast homologues are potential transcription factors of telomerase (from Yeastract) 
(Teixeira et al., 2014). KLF17, FOXM1 
See legend of Table 23.  
2.2 hnocYdown of his.one ch)perone ASF1 induces ALT  
To investigate gene expression changes upon induction of ALT, knockdown (kd) of histone chaperone 
ASF1 was performed. ASF1 kd in HeLa cells with long telomeres (HeLa LT) is the only system 
described up to date, in which ALT is rapidly induced in an ALT-negative cell line (O'Sullivan et al., 
2014). In other HeLa cells with shorter telomeres (HeLa ST), ALT was not induced. HeLa ST and HeLa 
LT originate from the same parental cell line (HeLa 1.2.11) and differ in telomere length being 9 kb and 
20 kb in average, respectively (O'Sullivan et al., 2014).  
2.2.1 HeL) LT ce00s differ in sever)0 p).hw)?s )nd show 0ow 0eve0s of PDH4 
In order to answer the question, what makes telomeres longer in HeLa LT and predisposed for ALT 
induction, gene expression levels in both wt cell lines were compared using RNA-sequencing. Raw 
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reads were mapped to GRCh38/ hg38 by STAR (Dobin et al., 2013) and analyzed with the DESEq2 
package (Love et al., 2014). For quality control, RNA-seq data was accessed by a sample distance matrix 
of a representative subset of genes (Figure 20A) showing that replicates were highly similar. Differential 
gene expression analysis of the two cell lines revealed 229 upregulated genes with respect to a log2 fold 
change (l2fc) >4 and an adjusted p-value (padj) <0.05 and 74 downregulated genes, with a l2fc <-4 and 
padj <0.05, listed in the appendix (Suppl. table S4). Gene expression level analysis of telomerase 
compounds TERT and TERC resulted in unchanged RPKM values for TERT and significantly higher 
expression of TERC (l2fc=1.33, padj=0.00045) in HeLa LT. 
Next, a GO pathway enrichment analysis was performed. HeLa LT and ST cells differed in some genes 
that were annotated with a biological process. From the 229 higher expressed genes in HeLa LT, 158 
were annotated with a biological process that was included in the functional annotation analysis 
(Table 26). GO pathway analysis of the 55 lower genes with a biological process annotation resulted in 
a number of enriched GO terms. (Table 27). None of the deregulated pathways that were identified by 
GO pathway analysis was related to TM, neither was any biological process annotation of the 
differentially expressed genes.  
Table 26. Pathway enrichment analysis of genes, higher expressed in HeLa LT versus ST. 
GO identifier GO term # genes 
GO:1901700 response to oxygen-containing compound* 36 
GO:0009605 response to external stimulus* 43 
GO:0072359 circulatory system development* 26 
GO:0032101 regulation of response to external stimulus  21 
GO:0033993 response to lipid  24 
GO:0048585 negative regulation of response to stimulus  32 
GO:0072358 cardiovascular system development  19 
GO:0001944 vasculature development  19 
GO:0051270 regulation of cellular component movement  22 
GO:0001568 blood vessel development  18 
GO:0042221 response to chemical  64 
GO:0044767 single-organism developmental process  81 
GO:0010033 response to organic substance  49 
GO:2000145 regulation of cell motility  20 
GO:0009887 animal organ morphogenesis  24 
GO:0032502 developmental process  82 
GO:0071230 cellular response to amino acid stimulus  6 
GO:0030728 ovulation  4 
GO:0032496 response to lipopolysaccharide  12 
GO:0007275 multicellular organism development  72 
GO:0048731 system development  66 
GO:0048856 anatomical structure development  77 
GO:0044707 single-multicellular organism process  83 
GO:0009719 response to endogenous stimulus  30 
GO:0009968 negative regulation of signal transduction  26 
GO:0061383 trabecula morphogenesis  5 
GO:0040012 regulation of locomotion  20 
GO:0002237 response to molecule of bacterial origin  12 
GO:0043062 extracellular structure organization  12 
GO:0061098 positive regulation of protein tyrosine kinase activity  5 
GO:0070887 cellular response to chemical stimulus  46 
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GO identifier GO term # genes 
GO:0030198 extracellular matrix organization  12 
GO:0060384 innervation  4 
GO:0048514 blood vessel morphogenesis  15 
GO:0010648 negative regulation of cell communication  27 
GO:0009653 anatomical structure morphogenesis  42 
GO:0048661 positive regulation of smooth muscle cell proliferation  6 
GO:0032501 multicellular organismal process  92 
GO:0023057 negative regulation of signaling  27 
GO:0060343 trabecula formation  4 
GO:0010575 positive regulation of vascular endothelial growth factor production  4 
GO:0031663 lipopolysaccharide-mediated signaling pathway  5 
From the 229 higher expressed genes in HeLa LT over HeLa ST 158 genes were included in the 
functional annotation chart with biological processes using DAVID. *stands for significantly enriched 
pathway (p<0.01).  
Table 27. Pathway enrichment analysis of genes, lower expressed in HeLa LT versus ST. 
GO identifier GO term # genes 
GO:0052696 flavonoid glucuronidation***  7 
GO:0052697 xenobiotic glucuronidation*** 7 
GO:0009812 flavonoid metabolic process*** 7 
GO:0052695 cellular glucuronidation*** 7 
GO:0006063 uronic acid metabolic process*** 7 
GO:0019585 glucuronate metabolic process*** 7 
GO:0006805 xenobiotic metabolic process*** 7 
GO:0071466 cellular response to xenobiotic stimulus** 7 
GO:0009410 response to xenobiotic stimulus** 7 
GO:0005996 monosaccharide metabolic process** 9 
GO:0051552 flavone metabolic process** 3 
GO:0042573 retinoic acid metabolic process* 4 
GO:0044723 single-organism carbohydrate metabolic process* 10 
GO:0032787 monocarboxylic acid metabolic process* 11 
GO:0019752 carboxylic acid metabolic process* 14 
GO:0006720 isoprenoid metabolic process* 6 
GO:0043436 oxoacid metabolic process* 14 
GO:0006789 bilirubin conjugation* 2 
GO:0006082 organic acid metabolic process* 14 
GO:0005975 carbohydrate metabolic process  10 
GO:0001523 retinoid metabolic process  5 
GO:0016101 diterpenoid metabolic process  5 
GO:0006721 terpenoid metabolic process  5 
GO:0002175 protein localization to paranode region of axon  2 
GO:0042440 pigment metabolic process  4 
From the 74 lower expressed in HeLa LT over HeLa ST 55 genes were included in the functional 
annotation chart with biological processes using DAVID. GO terms that were significantly enriched were 
marked with asterisks (*p<0.01, **p<0.001, ***p<0.0001). 
In order to further explore whether the identified genes were involved in TM, the TelNet database was 
used. Notably, for 9 higher expressed and 2 lower expressed genes, a connection to TM was retrieved 
from TelNet (Table 28 + Table 29). For ETV1 a role as a TERT activator has been reported and the mouse 
homologue of human ZNF32 has been shown to increase mTERT expression (Goueli & Janknecht, 
2004; Gao et al., 2014). Furthermore, UCHL1 was found at telomeres of ALT cells (Dejardin & 
Kingston, 2009) and in close proximity to the shelterin complex (Lee et al., 2011), as well as RYR2 
(Giannone et al., 2010), JSPRP1 and HNMT (Lee et al., 2011). 
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Table 28. TelNet genes that are higher expressed in HeLa LT versus ST. 
TM comment Gene symbols 
Protein was bound to telomeres of ALT cells (Dejardin & Kingston, 2009). UCHL1 
Proteins were found in close proximity to a shelterin compound (Giannone et al., 2010) or 
(Lee et al., 2011). RYR2, JSRP1, UCHL1, HNMT 
Genes are members of telomerase activity signature. (Barthel et al., 2017) RARRES2, COCH 
Overexpression of mouse homologue increased mTERT expression (Gao et al., 2014). ZNF32 
telomerase activator (Goueli & Janknecht, 2004)  ETV1 
Telomeres get longer upon deletion of budding yeast homologue (Ungar et al., 2009). TNNC1 
The table shows the results of TelNet list search with the first column reflecting the TM comment, 
providing the experimental information that linked the gene or encoded protein to TM. In the second 
column gene symbols were listed.  
It will be interesting to clarify the role of UCHL1, since it is upregulated in HeLa LT and localized at 
telomeres of ALT-positive cells both cell lines harboring long telomeres. The budding yeast homologue 
deletion phenotypes indicate a role in telomere length regulation for TNNC1 and PDK4. For CMD1, 
the budding yeast homologue of TNNC1, the deletion has been reported to result in longer telomeres 
(Ungar et al., 2009), however, TNNC1 was higher expressed in HeLa cells with long telomeres. On the 
other hand, deletion of PKP1, the budding yeast homologue of PDK4, has been shown to shorten 
telomeres (Askree et al., 2004), and PDK4 expression was strongly reduced in the HeLa cells with long 
telomeres. This might indicate an ongoing process of telomere shortening in HeLa LT cells, despite long 
telomeres. Also, telomerase activity, measured by the TRAP assay, has been shown to be slightly higher 
in HeLa ST cells (O'Sullivan et al., 2014). It will be interesting to monitor telomere length in HeLa LT 
over a longer period to determine if telomeres get shorter. 
Table 29. TelNet genes that are lower expressed in HeLa LT versus ST. 
TM comment gene symbols 
Telomeres get shorter upon deletion of the budding yeast homologue PKP1 (Askree et al., 
2004). PDK4 
Genes is a member of telomerase activity signature (Barthel et al., 2017). ST6GAL1 
The table shows the results of TelNet list search with the first column reflecting the TM comment, 
providing the experimental information that linked the gene or encoded protein to TM. In the second 
column gene symbols were listed.  
A possible explanation for the long telomeres in HeLa LT might be that a telomere elongation process 
has happened in the past that was then re-balanced. In this scenario, the current state of TM might only 
compensate for telomere attrition at short telomeres, without a gain of additional telomere length. For a 
complete picture, differences in HeLa LT and ST have to be further investigated to identify e.g. genomic 
rearrangements or copy number variations. This is important to decide if HeLa LT and ST are essentially 
isogenic and only differ in telomere length. In summary, HeLa LT cells showed a similar telomerase 
expression as HeLa ST but had a strongly reduced in PDK4 expression. 
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2.2.2 ASF1 dep0e.ion induces ALT in HeL) LT bu. no. HeL) ST ce00s 
For the siRNA mediated kd, the same materials were used as described in the original paper (O'Sullivan 
et al., 2014). HeLa cells with long (LT) and short telomeres (ST) were treated with siRNA against 
ASF1A and ASF1B or a scrambled control siRNA (siCtrl). The kd efficiency of the siRNA pool 
targeting both ASF1A and ASF1B was confirmed by Western blot (Figure 18A).  
Quantification of protein levels in HeLa LT revealed a reduction to 24% for ASF1A (p<0.0001) and 
11% for ASF1B (p<0.0001) (Figure 18B) as demonstrated previously (Deeg, 2015). In order to address 
the kd efficiency on the transcript level, gene expression values in RPKM for ASF1A and ASF1B were 
calculated from RNA-sequencing data. RPKM values were reduced to 12±1% (P<0.0001) for ASF1A 
and 23±0.8% (P<0.0001) for ASF1B in HeLa LT upon the respective knockdown (Figure 18C).  
 
Figure 18. Reduction of ASF1 protein and transcript levels upon siRNA kd. 
(A) Western blots showing ASF1A, ASF1B and GAPDH bands. HeLa cells with long and short 
telomeres (LT and ST) were transfected with or siRNA targeted against ASF1A and ASF1B or scrambled 
control (siCtrl) and treated with 0, 0.5 µM or 2 µM SAHA. (B) Bar plot showing protein levels of ASF1 A 
and B, quantified from Western blots (WB) after siASF1 kd (dark grey) or siCtrl (light grey). Error bars 
represent the SEM. Experiment was performed in two independent replicates. (C) RPKM values from 
RNA-seq analysis. Raw counts were normalized to sequencing depth and on gene lengths. SAHA 
treatment was performed in concentrations of 0 (dotted), 0.5 µM (diagonal) or 2 µM SAHA (crossed). 
Significance is indicated with asterisks, ***p<0.0001. Experimental parts of the WB were conducted by 
Caroline Bauer (Prof. Karsten Rippe, DKFZ, Heidelberg). 
Next, to determine the effect of the kd on the induction of ALT, extrachromosomal telomeric repeats 
were measured by C-circle assay. C-circle levels were normalized to U2OS wt cells, which serve as a 
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ALT-positive reference cell line (Figure 19). The C-circle signal of HeLa LT transfected with siRNA 
targeted against ASF1 was increased 6-fold over the scrambled control (+84±3%, p=0.003). 
 
With C-circle levels of 85±14%, ASF1 depleted cells (HeLa LT) were in the range of U2OS wt cells 
(100±15%) confirming previous results (O'Sullivan et al., 2014; Deeg, 2015). As reported before, no 
ALT induction was observed in HeLa ST cells. Thus, induction of ALT by ASF1 kd in HeLa with long, 
but not short, telomeres was verified. 
2.2.3 HeL) LT )nd ST ce00s respond differen.i)00? .o ASF1 dep0e.ion 
To investigate gene expression changes upon ASF1 depletion, RNA-seq libraries were prepared for 
HeLa LT and ST cells that were transfected with siRNA against ASF1. Sequencing data was processed 
as described above (results sections 2.1.4 + 2.2.1) and in methods sections 9 + 10. A sample distance matrix 
was calculated for all replicates and samples within HeLa LT and ST clustered well together 
(Figure 20A). Within the HeLa LT samples, the solvent-treated and the 0.5 µM SAHA treated cells were 
more similar than the 2 µM SAHA treated cells. The distributions of log2 fold changes were plotted as 
histograms and fitted with a centered Gaussian function (Figure 20B). Thresholds for significance 
(p<0.05) and l2fc were set for HeLa LT (l2fc <-1.6 or >1.6) and for HeLa ST (l2fc <-1.2 or >1.2). 
Deregulated genes in HeLa LT and ST were partly overlapping, visualized with VENN diagrams 
(Figure 20B). ASF1A and B and the H4 histone family, member M HIST1H4I were the only genes that 
were significantly downregulated in both cell lines. A subset of 139 genes was upregulated in both cell 
lines. The GO terms “multicellular organismal process” and “regulation of hormone levels”, were the 
only significantly enriched pathways from the overlapping genes. As siRNA kd might have an effect on 
cell cycle progression, and especially ASF1 kd leads to a G2/M arrest (O'Sullivan et al., 2014), 
deregulated genes were checked for cell cycle-regulated genes. Therefore, a list of 615 of cell cycle-
dependent genes identified in HeLa cells has been used (Grant et al., 2013) to identify cell-cycle 
Figure 19. Circle levels after ASF1 kd. 
Dot blot and quantification of the C-circle assay of 
HeLa LT and ST wt (white) cells and cells 
transfected with siRNA against ASF1 A and B (dark 
grey) or scrambled control (light grey). Above the 
bar plots, exemplary dot blots of the C-circle assay 
are depicted. The upper row contains samples after 
amplification with polymerase addition, and the 
lower row shows the control without polymerase. 
U2OS and HeLa wt cells were used positive and 
negative reference cell lines. The experiments were 
performed in two independent replicates, the C-
circle assay in technical triplicates. Significance is indicated with an asterisk, *p<0.01. Experimental 
parts of the C-circle assays were conducted by Caroline Bauer (Prof. Karsten Rippe, DKFZ, Heidelberg) 
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regulated genes, which were marked with a °circle at all appearances in the text or in tables. HeLa LT 
and ST samples transfected with siRNA against ASF1 or scrambled control were submitted to 
hierarchical clustering by the gene signature from exclusively differentially expressed genes in HeLa 
LT siASF1 over siCtrl (n=522, l2fc <-1.6 or >1.6, padj <0.05) and not in HeLa ST siASF1 over siCtrl 
(Figure 20C).  
 
Interestingly, HeLa LT cells without siRNA or siCtrl clustered together with the HeLa ST samples, thus 
all ALT-negative samples clustered together. RPKM values were calculated for the differentially 
expressed genes as described above and all genes with an RPKM <1 in the highest expressed sample 
were excluded from the analysis. This filtering step resulted in 1 down- and 71 upregulated genes for 
Figure 20. Genes deregulated upon ALT induction 
by ASF1 kd in HeLa LT. 
(A) Heat map of variance stabilizing transformed data 
showing distances between the samples ranging from 
0 (dark blue) to ≥120 (white). Cell lines are annotated 
in middle blue (HeLa ST) and in dark blue (HeLa LT). 
The siRNAs transfected are annotated in dark green 
(siASF1 A and B), light green (siCtrl) and white (no 
siRNA). C-circle levels, normalized on U2OS wt cells, 
range from 0 (white) to 1 (dark red). For samples with 
C-circle levels >0.5, ALT (dark red) was assigned as 
the active TMM, for C-circle levels <0.5, samples were 
marked in dark blue for an ALT-negative phenotype.  
(B) Histograms showing the frequency of log2 fold change values (siASF1 over siCtrl) in HeLa LT (upper 
histogram) and HeLa ST (lower histogram). Centered gaussian curve was fitted to the plots. Thresholds 
for the log2 fold change were set to <-1.6 and >1.6 (HeLa LT) and l2fc <1.2 and >1.2 (HeLa ST), where 
the fitting curve has converged against 0. VENN-diagrams in the middle showing overlaps of 
downregulated genes (left) and upregulated genes (right) according to the log2 fold change thresholds 
and with an adjusted p-value <0.05. (C) Unclustered heatmap showing the top 522 genes that are 
significantly deregulated in HeLa LT siASF1 over siCtrl with log2 fold change <-1.5 or >1.5 and no 
significant expression change in HeLa ST. Samples have the same annotation as in (A) and genes were 
sorted according to the log2 fold change, annotated from -6 (blue) to 6 (red). Normalized and log2 
transformed gene expression values range from ≤ 0 (white) to ≥ 15 (dark red).  
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HeLa ST and 36 down- as well as 284 upregulated genes for HeLa LT, listed Suppl. table S5 and Suppl. 
table S6. Thus, gene expression changed in dependence of the HeLa cell line that harbor different 
telomere length. 
2.2.4 HeL) ST ce00s respond wi.h immune response )nd virus defense .o ASF1 Yd 
Pathway enrichment analysis for upregulated genes in ASF1 depleted HeLa ST revealed significant 
enrichment of the pathways “response to virus” (DDX58, IFIT3, IFIT2, IFIT1, OASL, IFI44, OAS2, 
CCL5, DHX58), “defense response to virus” (IFIT3, IFIT2, IFIT1, IL6, OASL, ISG15, OAS2, DHX58), 
“type I interferon signaling pathway” (IFIT3, IFIT2, IFIT1, OASL, ISG15, OAS2), “immune response” 
(IL6, CCR4, SUSD2, TNFSF15, OAS2, CCL5, IL7R) and “MAPK cascade” (EPGN, PPM1L, CCL5, 
SCG2) (Table 30).  
Table 30. Pathway analysis of genes, upregulated in ASF1 depleted HeLa ST cells.  
GO identifier GO term # genes 
GO:0009615 response to virus*** 9 
GO:0051607 defense response to virus*** 8 
GO:0060337 type I interferon signaling pathway*** 6 
GO:0045071 negative regulation of viral genome replication*** 5 
GO:0006955 immune response* 7 
GO:0007159 leukocyte cell-cell adhesion* 3 
GO:0035987 endodermal cell differentiation* 3 
GO:0030198 extracellular matrix organization* 5 
GO:0032480 negative regulation of type I interferon production* 3 
GO:0045429 positive regulation of nitric oxide biosynthetic process* 3 
GO:0016049 cell growth 3 
GO:0050679 positive regulation of epithelial cell proliferation 3 
GO:0006508 proteolysis 6 
GO:0035457 cellular response to interferon-alpha 2 
GO:0048245 eosinophil chemotaxis 2 
GO:0008544 epidermis development 3 
GO:0006954 inflammatory response 5 
GO:0031581 hemidesmosome assembly 2 
GO:0001525 angiogenesis 4 
GO:0048872 homeostasis of number of cells 2 
GO:0007229 integrin-mediated signaling pathway 3 
GO:0000165 MAPK cascade 4 
GO:0010628 positive regulation of gene expression 4 
GO:0050900 leukocyte migration 3 
GO:0007155 cell adhesion 5 
GO:0046427 positive regulation of JAK-STAT cascade 2 
GO:0048870 cell motility 2 
GO:0045070 positive regulation of viral genome replication 2 
GO:0043542 endothelial cell migration 2 
From the 74 upregulated genes in ASF1 depleted HeLa ST cells 37 genes were included in the 
functional annotation chart with biological processes using DAVID. Pathways that are significantly 
enriched were marked with asterisks (*p<0.01, **p<0.001, ***p<0.0001).  
Also, inflammatory response genes were upregulated as well as genes involved in the positive regulation 
of JAK-STAT signaling. From the upregulated genes, only ISG15 and SNCG were included in the 
TelNet database. ISG15 (Ubiquitin-like protein ISG15) was found at ALT telomere repeats (Dejardin & 
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Kingston, 2009) and SNCG (gamma-synuclein) in close proximity to TRF1 (Lee et al., 2011). 
Furthermore, expression of ISG15 has been reported to be regulated by telomere length (Lou et al., 
2009; Robin et al., 2014; Hirashima & Seimiya, 2015). The only downregulated gene was TNFAIP6, 
coding for TNFa-induced protein 6, a suppressor of inflammatory response. The deregulated genes in 
HeLa ST are neither enriched in TelNet nor in cell cycle-regulated genes. Thus, HeLa ST cells show an 
upregulation of immune response and virus defense pathways upon ASF1 kd. 
2.2.5 ALT induc.ion corre0).es wi.h expression of TGFb )nd WNT sign)0ing genes 
Next, differentially expressed genes upon ASF1 depletion and concomitant ALT induction in HeLa LT 
cells were submitted to the pathway enrichment analysis (Table 31). From the 284 upregulated genes, 
160 were annotated with a biological process. Pathway enrichment was obtained for extracellular matrix 
organization, positive regulation of cell migration, inflammatory response, immune response, and cell 
differentiation pathways. Genes encoding proteins that are involved in these signaling pathways were 
upregulated upon ASF1 depletion and are explained in more detail in the following.  
Table 31. Pathway analysis of genes, upregulated in ASF1 depleted HeLa LT cells.  
GO identifier GO term # genes 
GO:0006954 inflammatory response*** 17 
GO:0030198 extracellular matrix organization*** 12 
GO:0030335 positive regulation of cell migration*** 10 
GO:0010596 negative regulation of endothelial cell migration** 4 
GO:0007267 cell-cell signaling** 10 
GO:0045766 positive regulation of angiogenesis** 7 
GO:0001649 osteoblast differentiation** 6 
GO:0030574 collagen catabolic process* 5 
GO:0071526 semaphorin-plexin signaling pathway* 4 
GO:0001525 angiogenesis* 8 
GO:0010951 negative regulation of endopeptidase activity* 6 
GO:0050900 leukocyte migration* 6 
GO:0070374 positive regulation of ERK1 and ERK2 cascade* 7 
GO:0006955 immune response* 11 
GO:0030194 positive regulation of blood coagulation* 3 
GO:0048011 neurotrophin TRK receptor signaling pathway* 3 
GO:0007155 cell adhesion 11 
GO:0030336 negative regulation of cell migration 5 
GO:0038178 complement component C5a signaling pathway 2 
GO:0045669 positive regulation of osteoblast differentiation 4 
GO:0071356 cellular response to tumor necrosis factor 5 
GO:0002040 sprouting angiogenesis 3 
GO:0007219 notch signaling pathway 5 
GO:0007200 phospholipase C-activating G-protein coupled receptor signaling pathway 4 
GO:0001958 endochondral ossification 3 
GO:0048843 negative regulation of axon extension involved in axon guidance 3 
GO:0001938 positive regulation of endothelial cell proliferation 4 
GO:2000726 negative regulation of cardiac muscle cell differentiation 2 
GO:1903588 negative regulation of blood vessel endothelial cell proliferation involved in sprouting 
angiogenesis 
2 
GO:0045746 negative regulation of Notch signaling pathway 3 
GO:0030449 regulation of complement activation 3 
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GO identifier GO term # genes 
GO:0060325 face morphogenesis 3 
GO:0071773 cellular response to BMP stimulus 3 
GO:0008285 negative regulation of cell proliferation 9 
GO:0070830 bicellular tight junction assembly 3 
GO:0043524 negative regulation of neuron apoptotic process 5 
GO:0007204 positive regulation of cytosolic calcium ion concentration 5 
GO:0010718 positive regulation of epithelial to mesenchymal transition 3 
GO:0050919 negative chemotaxis 3 
GO:0001837 epithelial to mesenchymal transition 3 
GO:0030282 bone mineralization 3 
GO:0000122 negative regulation of transcription from RNA polymerase II promoter 13 
GO:0007611 learning or memory 3 
GO:0051897 positive regulation of protein kinase B signaling 4 
GO:0007166 cell surface receptor signaling pathway 7 
GO:0010757 negative regulation of plasminogen activation 2 
GO:0030823 regulation of cGMP metabolic process 2 
GO:0007162 negative regulation of cell adhesion 3 
GO:0001822 kidney development 4 
GO:0007565 female pregnancy 4 
GO:0045668 negative regulation of osteoblast differentiation 3 
GO:0030199 collagen fibril organization 3 
GO:0006824 cobalt ion transport 2 
GO:0030182 neuron differentiation 4 
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway 4 
GO:0051549 positive regulation of keratinocyte migration 2 
GO:0003209 cardiac atrium morphogenesis 2 
GO:0090090 negative regulation of canonical WNT signaling pathway 5 
GO:0042493 response to drug 7 
GO:0045165 cell fate commitment 3 
GO:0045600 positive regulation of fat cell differentiation 3 
GO:0060972 left/ right pattern formation 2 
GO:0010954 positive regulation of protein processing 2 
GO:0015889 cobalamin transport 2 
GO:0008284 positive regulation of cell proliferation 9 
GO:0010862 positive regulation of pathway-restricted SMAD protein phosphorylation 3 
GO:0016477 cell migration 5 
GO:0000187 activation of MAPK activity 4 
GO:0002544 chronic inflammatory response 2 
GO:0010469 regulation of receptor activity 2 
GO:0061314 notch signaling involved in heart development 2 
GO:0060586 multicellular organismal iron ion homeostasis 2 
GO:0007165 signal transduction 17 
GO:0043547 positive regulation of GTPase activity 10 
GO:0051918 negative regulation of fibrinolysis 2 
GO:0060548 negative regulation of cell death 3 
GO:2000178 negative regulation of neural precursor cell proliferation 2 
GO:0048711 positive regulation of astrocyte differentiation 2 
GO:0010759 positive regulation of macrophage chemotaxis 2 
From the 284 upregulated genes in ASF1 depleted HeLa LT cells 101 genes were included in the 
functional annotation chart with biological processes using DAVID. Pathways that are significantly 
enriched were marked with asterisks (*p<0.01, **p<0.001, ***p<0.0001).  
For S100A9 a repressive role in regulation of NFkB expression has been demonstrated (Wu et al., 2017). 
IRF7 has been shown to have a role in transcriptional regulation of genes involved in the IFNb pathway 
(Honda et al., 2005). NGFR, highly expressed in a fraction of human gliomas, has been shown to have 
a role in p53 inactivation, thus preventing cells from activating apoptosis (Zhou et al., 2016). WNT11, 
a member of the WNT signaling pathway, has been reported to be highly expressed in squamous cell 
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carcinoma and has therefore been suggested as prognostic marker for cervical carcinoma (Wei et al., 
2014). THBS1 (aka TSP1) expression has been reported to be inducible by TNFa, mediated by p38 
MAP kinase signaling (Fairaq et al., 2015). Furthermore, a role for THBS1 in the positive regulation of 
TGFb signaling has been shown (Rojas et al., 2008). The IL10 cytokine IL24 has been demonstrated to 
induce apoptosis in a variety of cancers for example gliomas (Su et al., 2003). BMP2 and BMP6 belong 
to a subfamily of TGFb signaling factors. BMP2 has been demonstrated to form a heterodimer with 
BMP6, which can activate of SMADs and the MAP kinase signaling pathways (Valera et al., 2010). 
Furthermore, a tumor suppressor role has been proposed for BMP2 based on its capability to induce p21 
expression, thus inducing cell cycle arrest (Mitsui et al., 2015). In addition, KLF17 has been reported 
to be involved in TGFb/ SMAD signaling (Ali et al., 2015).  
Table 32. TelNet genes, upregulated in ASF1 depleted HeLa LT cells. 
TM comment gene symbols 
The proteins were found in close proximity or bound to telomeres or a shelterin compound 
(Dejardin & Kingston, 2009) or a shelterin compound (Lee et al., 2011) or (Cerone et al., 2011). 
HIST1H2AA, 
HIST1H2BA, TUBB2A°, 
GFPT2, TUBB3, NTRK1, 
HIST3H3 
Telomeres get longer upon budding yeast homologue deletion (Askree et al., 2004; Ungar et 
al., 2009). TNNC1, FOXJ1 
telomerase repressor (Kumar et al., 2013; Yoo et al., 2015) CEBPA, SNAI1 
Yeast homologues are potentially transcription factors of telomerase (from Yeastract) (Teixeira 
et al., 2014). KLF17, FOXJ1 
Telomeres get shorter upon budding yeast homologue deletion (Askree et al., 2004; Ungar et 
al., 2009). 
TUBB2A°, TUBB3, 
PCSK9 
The table shows the results of TelNet list search with the first column reflecting the TM comment, 
providing the experimental information that linked the gene or encoded protein to TM. In the second 
column gene symbols were listed. Genes reported to be cell cycle-regulated in HeLa cells (Grant et al., 
2013) were marked with a °circle. 
However, no TM related pathway was found to be enriched among the upregulated genes. Therefore, 
the TelNet list search was consulted to select for genes that have previously been connected to telomeres. 
From 182 upregulated genes, 13 were implemented in the TelNet database (Table 32). Most of them 
were histone coding genes coding for proteins that have been found near the telosome (Dejardin & 
Kingston, 2009; Cerone et al., 2011; Lee et al., 2011). Furthermore, CEBPA (CCAAT/ enhancer 
binding protein alpha) and SNAI1 (snail family transcriptional repressor 1) have been reported to exhibit 
telomerase repressive features (Kumar et al., 2013; Yoo et al., 2015). SWI5, a budding yeast homologue 
of KLF17 (Krüppel-like factor 17) has been listed as a telomerase inhibitor in the Yeastract database. 
All downregulated genes with a biological process annotation were genes encoding canonical histones. 
GO pathway enrichment analysis resulted in “nucleosome assembly” and “chromatin silencing” terms 
(Table 33).  
Table 33. Pathway analysis of genes, downregulated in ASF1 depleted HeLa LT cells.  
GO identifier GO term # genes 
GO:0006334 nucleosome assembly*** 14 
GO:0000183 chromatin silencing at rDNA*** 8 
GO:0045814 negative regulation of gene expression, epigenetic*** 8 
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GO identifier GO term # genes 
GO:0032200 telomere organization*** 7 
GO:0045815 positive regulation of gene expression, epigenetic*** 8 
GO:0006335 DNA replication-dependent nucleosome assembly*** 7 
GO:0051290 protein heterotetramerization*** 7 
GO:0006342 chromatin silencing*** 7 
GO:0031047 gene silencing by RNA*** 8 
GO:0044267 cellular protein metabolic process*** 8 
GO:0060968 regulation of gene silencing*** 4 
GO:0034080 CENP-A containing nucleosome assembly*** 4 
GO:0007596 blood coagulation** 5 
GO:0045653 negative regulation of megakaryocyte differentiation** 3 
GO:0016233 telomere capping** 3 
GO:0006336 DNA replication-independent nucleosome assembly** 3 
GO:0006352 DNA-templated transcription, initiation* 3 
GO:1904837 beta-catenin-TCF complex assembly* 3 
GO:0006303 double-strand break repair via nonhomologous end joining* 3 
GO:0098609 cell-cell adhesion* 4 
From the 36 downregulated genes in ASF1 depleted HeLa LT cells 22 genes were included in the 
functional annotation chart with biological processes using DAVID. Pathways that are significantly 
enriched were marked with asterisks (*p<0.01, **p<0.001, ***p<0.0001).   
TelNet genes were significantly enriched among downregulated genes (11 out of 35, p<0.0001) (Table 
34). For example, histone H3 and H4 coding genes, were included in the TelNet database, because 
histones have been identified in direct proximity or bound to telomere repeats (Dejardin & Kingston, 
2009; Lee et al., 2011).  
Table 34. TelNet genes, downregulated in ASF1 depleted HeLa LT cells. 
TM comment Gene symbols 
Yeast homologue KAE1 is required for Type II survivor formation (Hu et al., 2013) 
and a suppressor of CDC13 (Downey et al., 2006). OSGEPL1 
The proteins were found in close proximity or bound to telomeres or a shelterin 
compound (Dejardin & Kingston, 2009) or a shelterin compound (Lee et al., 2011). 
HIST1H4B°, HIST4H4, HSIT1H2AL, 
HIST1H3D, HIST1H3F, HIST1H3G, 
HIST1H3H, HIST1H4K 
Telomeres get longer upon budding yeast homologue GLO4 deletion (Gatbonton et 
al., 2006). HAGHL 
The gene is a member of telomerase activity signature (Barthel et al., 2017). RARRES2 
The table shows the results of TelNet list search. For details please see table legend of Table 32. 
To summarize, genes upregulated upon ASF1 kd in HeLa LT cells were mainly involved in TGFb and 
WNT signaling pathways, whereas mostly canonical histone coding genes were downregulated. 
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2.3 HDAC inhibi.or SAHA suppresses ALT induc.ion 
2.3.1 SAHA reduces ALT induc.ion c)p)ci.? of ASF1 dep0e.ion in HeL) LT ce00s  
In order to investigate the effect of SAHA on the ALT induction capacity of siRNA-mediated kd of 
ASF1, HeLa LT cells were simultaneously treated with siRNA against ASF1 and with the HDACi 
SAHA in different concentrations. As a proof-of-concept, C-circle levels were measured as a 
representative ALT hallmark (Figure 21).  
 
SAHA was added to the growth medium 4 h after transfection of siRNA to result in a final concentration 
of 0, 0.5 or 2 µM. In contrast, to EtOH ctrl cells, 2 µM SAHA treated cells showed a decrease of -66±
13% (p=0.008) of C-circle levels (Figure 21). Therefore, cells transfected with siASF1 and treated with 
2 µM SAHA were in the range of HeLa LT cells transfected with siCtrl. Furthermore, also 
administration of only 0.5 µM SAHA reduced C-circle levels, although not significantly. In summary, 
treatment of SAHA reduced the ALT induction capacity of ASF1 depletion in HeLa LT cells. 
  
Figure 21. Circle levels of SAHA treated ASF1 
kd cells. 
Dot blot and quantification of the C-circle assay of 
HeLa LT wild-type (white) cells and cells 
transfected with siRNA against ASF1 A and B (dark 
grey) or scrambled control (light grey) and treated 
with solvent (dotted), 0.5 µM (diagonal) or 2 µM 
SAHA (crossed). Above the bar plots, exemplary 
dot blots of the C-circle assay are depicted. The 
upper row contains samples after amplification with 
polymerase addition, and the lower row shows the 
control without polymerase. U2OS and HeLa wild-
type cells were used positive and negative 
reference cell lines. The experiments were 
performed in two independent replicates, the C-
circle assay in technical triplicates. Significance is 
indicated with an asterisk, *p<0.01. Experimental 
parts of the C-circle assays were conducted by 
Caroline Bauer (Prof. Karsten Rippe, DKFZ, 
Heidelberg) 
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2.3.2 !nhibi.ors of WNT sign)0ing )re up- )nd virus response genes )re 
downregu0).ed upon SAHA-medi).ed suppression of ALT induc.ion 
To better understand the mechanism behind changes in gene expression levels of ASF1 depleted HeLa 
LT cells treated with SAHA in different concentrations, RNA-seq was performed. Sequencing data was 
processed as described above (results sections 2.1.4 + 2.2.1) and in methods sections 9 and 10. To first 
assess the quality of replicates, raw counts were vst transformed and sample distances were calculated 
for a representative set of genes (Figure 22A). Replicates clustered closely together and the distance 
between 2 µM SAHA and the 0.5 µM samples was higher than the distance to the ethanol control 
samples.  
 
For the further analysis, raw counts were normalized and rlog transformed. Log2 fold changes of 2 µM 
SAHA over ethanol control were calculated and plotted as histogram (Figure 22B). After fitting the curve 
with a centered Gaussian function, the cut-offs for the log2 fold change were set to l2fc <-2.0 or >2.0, 
where the Gaussian function converged against zero. The filtering resulted in a list of 1,015 up- and 
40 downregulated genes with an adjusted p-value <0.05 that was used for hierarchical clustering of the 
SAHA treated cells. The gene signature was suited to distinguish samples according to the delivered 
SAHA concentration. To remove low abundant genes, genes with an RPKM <1 in the sample with the 
highest expression were excluded for the functional pathways analysis. With that, the final list contained 
501 up- and 35 downregulated genes (Suppl. table S7). From the 501 upregulated genes, only 137 were 
Figure 22. Gene expression analysis of ASF1 kd cells 
treated with SAHA. 
 (A) Heat map of variance stabilizing transformed data showing 
distances between the samples ranging from 0 (dark blue) to 
≥120 (white). The treatment of the cells is annotated in yellow 
(solvent), orange (0.5 µM) and red (2 µM). C-circle levels, 
normalized on the solvent control, range from 0 (white) to 1 
(dark red). For samples with C-circle levels >0.5, ALT (dark 
red) was assigned as the present TMM, for C-circle levels <0.5, 
samples were marked in dark blue for an ALT-negative 
phenotype. (B) Histogram showing the frequency of log2 fold 
change (l2fc) values (2 µM SAHA over solvent control). A 
centered gaussian curve was fitted to the plot. Thresholds for 
the l2fc were set to <-2.0 and >2.0, where the fitting curve has 
converged against zero. (C) Unclustered heatmap showing the 
top 1,055 deregulated genes with a l2fc <-2.0 or >2.0 and an 
adjusted p-value <0.05. Samples have the same order and 
annotation as in (A) and genes were sorted according to the 
l2fc, annotated from -6 (blue) to 6 (red). Normalized and log2 
transformed gene expression values range from ≤ 0 (white) to 
≥ 15 (dark red).  
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annotated with biological processes. Functional pathway enrichment analysis of this subset resulted in 
enrichment of several pathways enriched with statistical significance (Table 35).  
Table 35. GO analysis of upregulated genes, in ASF1 depleted HeLa LT, treated with SAHA. 
GO identifier GO term # genes 
GO:0035584 calcium-mediated signaling using intracellular calcium source** 5 
GO:0007155 cell adhesion* 19 
GO:0030178 negative regulation of WNT signaling pathway* 6 
GO:0007399 nervous system development* 14 
GO:0032331 negative regulation of chondrocyte differentiation* 4 
GO:0086091 regulation of heart rate by cardiac conduction* 5 
GO:0035556 intracellular signal transduction* 16 
GO:0061337 cardiac conduction 5 
GO:0043547 positive regulation of GTPase activity 20 
GO:0001578 microtubule bundle formation 4 
GO:0031175 neuron projection development 7 
GO:0001778 plasma membrane repair 3 
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules 5 
GO:0046785 microtubule polymerization 3 
GO:0019882 antigen processing and presentation 5 
GO:0007165 signal transduction 33 
GO:0006887 exocytosis 6 
GO:0007612 learning 5 
GO:0007565 female pregnancy 6 
GO:0007160 cell-matrix adhesion 6 
GO:0009967 positive regulation of signal transduction 5 
GO:0007411 axon guidance 8 
GO:2000310 regulation of N-methyl-D-aspartate selective glutamate receptor activity 3 
GO:0034332 adherens junction organization 4 
GO:0030574 collagen catabolic process 5 
GO:0007220 notch receptor processing 3 
GO:0045956 positive regulation of calcium ion-dependent exocytosis 3 
GO:0086002 cardiac muscle cell action potential involved in contraction 3 
GO:0045668 negative regulation of osteoblast differentiation 4 
GO:0019221 cytokine-mediated signaling pathway 7 
GO:0046426 negative regulation of JAK-STAT cascade 4 
GO:0009749 response to glucose 5 
GO:0000226 microtubule cytoskeleton organization 5 
GO:0001501 skeletal system development 7 
GO:0034220 ion transmembrane transport 9 
GO:0030155 regulation of cell adhesion 4 
GO:1904659 glucose transmembrane transport 3 
GO:0007267 cell-cell signaling 10 
GO:0086047 membrane depolarization during Purkinje myocyte cell action potential 2 
GO:0031652 positive regulation of heat generation 2 
GO:0007507 heart development 8 
GO:0035249 synaptic transmission, glutamatergic 3 
GO:0090103 cochlea morphogenesis 3 
GO:0007254 JNK cascade 4 
GO:0007269 neurotransmitter secretion 4 
GO:0016080 synaptic vesicle targeting 2 
GO:0043276 anoikis 2 
GO:0032386 regulation of intracellular transport 2 
GO:0006655 phosphatidylglycerol biosynthetic process 2 
GO:0051938 L-glutamate import 2 
GO:0045671 negative regulation of osteoclast differentiation 3 
GO:0035235 ionotropic glutamate receptor signaling pathway 3 
GO:0030198 extracellular matrix organization 8 
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GO identifier GO term # genes 
GO:0071805 potassium ion transmembrane transport 6 
GO:0006656 phosphatidylcholine biosynthetic process 3 
GO:0051491 positive regulation of filopodium assembly 3 
GO:0032148 activation of protein kinase B activity 3 
GO:0017157 regulation of exocytosis 3 
GO:0006836 neurotransmitter transport 3 
GO:0010976 positive regulation of neuron projection development 5 
GO:0032496 response to lipopolysaccharide 7 
GO:0021696 cerebellar cortex morphogenesis 2 
GO:0086045 membrane depolarization during AV node cell action potential 2 
GO:0086011 membrane repolarization during action potential 2 
GO:0031032 actomyosin structure organization 3 
GO:0035987 endodermal cell differentiation 3 
GO:0007264 small GTPase mediated signal transduction 9 
GO:0060079 excitatory postsynaptic potential 3 
GO:0086010 membrane depolarization during action potential 3 
GO:0043406 positive regulation of MAP kinase activity 4 
From the 501 upregulated genes in ASF1 depleted HeLa LT cells upon SAHA treatment 192 genes 
were included in the functional annotation chart with biological processes using DAVID. Pathways that 
are significantly enriched were marked with asterisks (*p<0.01, **p<0.001).  
“Negative regulators of WNT signaling” (DKK3, LRP1, NXN, DACT3, HMGA2, CITED1) were 
upregulated. From genes involved in signal transduction, PTK7 has been shown to inhibit WNT 
signaling (Peradziryi et al., 2011). Furthermore, “negative regulators of JAK-STAT cascade” 
(RTN4RL1, RTN4RL2, DCN, HMGA2), “cytokine-mediated signaling pathway” (STAT4, RTN4RL1, 
RTN4RL2, DCN, EDA, IL17RD, IL1A), and “positive regulators of MAP kinase activity” (DIRAS1, 
TENM1, PDE5A, CD40) were upregulated. 
Several of the upregulated genes were implemented in the TelNet database, thus are involved in TM 
(Table 36). For GLI2, HMGA, PRKAR2B, TNIK, MAST1, and the budding yeast homologue of CREB5 
a role in telomerase activation has been reported (Reimand et al., 2010; Cerone et al., 2011; Li et al., 
2011; Mazumdar et al., 2013).  
Table 36. TelNet genes, upregulated in ASF1 depleted HeLa LT, treated with SAHA. 
TM comment gene symbols 
telomerase activator (Mazumdar et al., 2013) or (Li et al., 2011) GLI2, HMGA2 
potential telomerase activator (Cerone et al., 2011) PRKAR2B, TNIK, MAST1 
Yeast homologue is a telomerase activator (Reimand et al., 2010). CREB5 
Telomeres get shorter upon budding yeast homologue deletion (Askree et al., 2004), 
(Ungar et al., 2009) or (Gatbonton et al., 2006). DAW1, ELOVL7, PRKD1 
Telomeres get longer upon budding yeast homologue deletion (Askree et al., 2004) or 
(Hu et al., 2013). 
ARHGAP26, CREB5, PLCL1, 
CABP1 
Yeast homologue is a telomerase repressor (Reimand et al., 2010). GATA5 
Gene was downregulated upon telomere shortening caused by the telomerase inhibitor 
GRN163 (Geron) in SK-N-MC cells (Uziel et al., 2015). IGF2BG2 
Proteins have been found in close proximity or bound to telomeres or a shelterin 
compound (Dejardin & Kingston, 2009) or a shelterin compound (Giannone et al., 2010). AZGP1, MYH10 
Gene was included in a gene set with potential relevance to telomeres and the ALT 
pathway and is annotated with the term “TUDOR” (Lovejoy et al., 2012). TDRKH 
The table shows the results of TelNet list search. For details please see table legend of Table 32. 
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Downregulated genes were significantly enriched in the GO terms “response to virus” (IFIT3, IFIT2, 
OASL, DDX60, IFI44), “type I interferon signaling pathway” (IFIT3, IFIT2, OASL, ISG15), and 
“defense response to virus” (IFIT3, IFIT2, OASL, ISG15, DDX60) (Table 37). Furthermore, in “cellular 
response to INFa” (IFIT3, IFIT2) and “positive regulators of apoptotic process” (IFIT2, NUPR1, 
GPER1) were enriched without statistical significance. 
Table 37. GO analysis of downregulated genes, in ASF1 depleted HeLa LT, treated with SAHA. 
GO identifier GO term # genes 
GO:0009615 response to virus*** 5 
GO:0060337 type I interferon signaling pathway** 4 
GO:0051607 defense response to virus** 5 
GO:0045071 negative regulation of viral genome replication* 3 
GO:0035457 cellular response to interferon-alpha 2 
GO:0015718 monocarboxylic acid transport 2 
GO:0048147 negative regulation of fibroblast proliferation 2 
GO:0051603 proteolysis involved in cellular protein catabolic process 2 
GO:0016049 cell growth 2 
GO:0043065 positive regulation of apoptotic process 3 
From the 35 downregulated genes in ASF1 depleted HeLa LT cells upon SAHA treatment 14 genes 
were included in the functional annotation chart with biological processes using DAVID. Pathways that 
are significantly enriched were marked with asterisks (*p<0.01, **p<0.001, ***p<0.0001). 
The downregulated genes ISG15 and KCTD15 were included in the TelNet database, because of the 
localization of the encoded protein was found at ALT telomere repeats (Dejardin & Kingston, 2009) or 
in close proximity to a shelterin compound (Giannone et al., 2010) (Table 38). 
Table 38. TelNet genes, downregulated in ASF1 depleted HeLa LT, treated with SAHA. 
TM comment Gene symbols 
Found in close proximity or bound to telomeres or a shelterin compound 
(Dejardin & Kingston, 2009) or a shelterin compound (Giannone et al., 2010). KCTD15, ISG15 
The table shows the results of TelNet list search. For details please see table legend of Table 32. 
Thus, SAHA treatment of HeLa LT cells, in which ALT was induced by ASF1 kd resulted in 
downregulation genes involved in response to virus pathways as well as upregulation of WNT signaling 
inhibitors and telomerase activators.  
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2.4 Ye)s. survivor form).ion m)rgin)00? ch)nges gene expression  
Deletion of the budding yeast homologue of telomerase EST2 leads to survivor type II formation after 
5-6 days in the absence of mutations (Makovets et al., 2008). These survivors show ALT features like 
telomere lengthening in the absence of telomerase and RAD50-dependent recombination resulting in 
heterogeneous telomere length Lendvay (Lendvay et al., 1996; Makovets et al., 2008). To analyze 
changes in RNA expression that accompany ALT induction in budding yeast, the telomerase gene EST2 
was deleted to generate type II survivors (Balk et al., 2013) and RNA was isolated at representative time 
points for RNA-sequencing (Figure 23A).  
 
Figure 23. Differential gene expression analysis of budding yeast type II survivors. 
(A) Relative cell density showing the growth of est2D cells. Yeast survivor formation and RNA extraction 
on days 2, 6 and 10 were performed by Bettina Balk, AG Luke, IBM Mainz. Image adapted from (Balk 
et al., 2013). (B) Sample distance heat map of start (blue), crisis (dark blue) and survivor (red) samples. 
The TMM is annotated in dark blue (telomerase-positive), white (no TMM) and red (survivor type II, ALT) 
(C) Histogram of log2 fold change with a centered Gaussian fit and dashed lines showing the l2fc cut-
offs >0.9 or <-0.9. (D) Hierarchical clustering of start, crisis and survivor samples by differentially 
expressed genes.  
RNA-seq libraries were prepared in duplicates for every time point (start, crisis and survivor) and then 
sequenced as 50 bp single-end reads. Raw reads were mapped to the budding yeast genome using STAR 
(Dobin et al., 2013) and resulting counts were analyzed with DESeq2 (Love et al., 2014). To check the 
quality of replicates, a representative set of genes was vst transformed to generated a sample distance 
matrix (Figure 23B). Hierarchical clustering showed that gene expression in the crisis state differs 
strongly from start and survivor cells, whereas start and survivor samples appeared very similar. After 
rlog transformation, log2 fold changes (l2fc) of survivor over start samples were plotted as histogram 
and a centered Gaussian curve was fitted to the data. The significance cutoff was set to a l2fc<-0.9 or 
>0.9, where the centered Gaussian fit converged against zero and p<0.05 (Figure 23 C). As expected 
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upon deletion of the protein subunit of telomerase in budding yeast (EST2), cells went through crisis 
and formed survivors. Differential expression analysis revealed heavy expression changes during crisis, 
however less than 30 genes showed a relatively small, albeit statistically significant change in gene 
expression as compared to pre-senescent cells (Figure 23D). Only 4 of the 12 upregulated and 9 out of 
15 downregulated genes were annotated with a biological process. ALD4, ALD6 and PGM2 were 
identified to be involved in metabolic processes, such as acetate biosynthesis and the glucose 1-
phosphate metabolic process. Furthermore, the gene set was enriched with 6 downregulated genes 
involved in ion transport namely, FIT1, TPO2, ARN2, FRE4, FIT2, and FIT3 (p<0.01). Genes within 
the iron-regulon were overrepresented among downregulated genes, including FIT1/ 2/ 3 (facilitator of 
iron transport 1/ 2/ 3), ARN2 (AFT1 regulon protein 2), and FRE4 (ferric reductase 4) indicating a stress 
response. 
TelNet analysis was performed to identify genes involved in TM. Among the herewith-determined 
factors, ALD4 (aldehyde dehydrogenase 4), ALD6 (aldehyde dehydrogenase 6),, and PGM2 
(phosphoglucomutase) were identified as homologues of human genes that have been reported to be 
downregulated upon telomere shortening (Uziel et al., 2015). The human phenotype therefore agrees 
with the result, because telomere lengths in survivors are likely to be elongated due to recombination 
events. COS12 is located in the subtelomeric region of chromosome 7 (Jezek et al., 2017). 
Table 39. TelNet genes, upregulated in type II survivors. 
TM comment Gene symbols 
Human homologues were downregulated after telomerase inhibition by GRN163 in SK-N-MC cells (Uziel et 
al., 2015). ALD4, ALD6 
Human homologues were found to be in close proximity of the shelterin compound TIN2 (Lee et al., 2011). PGM2 
telomere proximal gene COS12 
The table shows the results of TelNet list search with the first column reflecting the TM comment, 
providing the experimental information that linked the gene or encoded protein to TM. In the second 
column gene symbols were listed.  
In summary, budding yeast type II survivors formed after EST2 deletion show only minor changes in 
gene expression as compared to pre-senescent cells. The results show that post-senescence survivors are 
very similar to pre-senescent cells with regard to their expression profiles. Since no genomic changes 
have been reported in the past, the protein pool that is needed for alternative lengthening of telomeres 
is already expressed in pre-senescent cells. The underlying mechanism of ALT induction therefore 
might lie elsewhere, probably in a de-localization of specific proteins or a change in posttranslational 
modifications. 
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3 ALT induc.ion b? recrui.ing PML .o .e0omeres  
The role of PML in the ALT pathway is only partly understood and further validation of its function is 
needed. To investigate the functional role of PML in the ALT pathway, we asked, whether a fusion of 
PMLIII to the shelterin compound TRF1 is able to induce artificial APBs in previous ALT-negative 
cells. To this end, the recruiting construct TRF1-PML and single control proteins were cloned into a 
pEGFP backbone (Figure 24).  
 
Figure 24. Recruiting PML to telomeres. 
(A) Cloned constructs GFP, PML-GFP, TRF1-GFP and TRF1-PML-GFP. (B) Strategy: fusion protein 
TRF1-PML-GFP binds to telomere repeats and subsequent protein assembly forms a PML-NB around 
telomere (red). GFP (light green), PML (dark green), ectopic (orange) and endogenous (faint orange) 
TRF1 and endogenous TRF2 (yellow) are depticted.  
GFP (green fluorescent protein) was used as a fluorescent tag to visualize the recruited protein. To 
account for any effects upon PML or TRF1 overexpression, TRF1-GFP and PML-GFP were used as 
controls. A GFP-only construct served as transfection control. Furthermore, the GFP protein can be used 
to recruit other proteins, fused to a GFP-binder protein. This will be useful for future studies of the 
effects upon recruitment of ALT candidate genes to telomeres (Rothbauer et al., 2006; Zolghadr et al., 
2008; Chung et al., 2011). 
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3.1 PML-TRF1 fusion pro.ein 0e)ds .o )r.ifici)0 APBs ). .he m)rori.? 
of .e0omeres 
To validate the localization of cloned constructs within the nucleus, ALT-positive U2OS and ALT-
negative HeLa cells were transiently transfected with the plasmids containing GFP (G), PML-GFP (PG), 
TRF1-GFP (TG) and PML-TRF1-GFP (TPG). Immunostaining of TRF2 and PML was used to visualize 
telomeres and colocalizations with PML-NBs.  
 
Figure 25. Recruitment of PML to majority of telomeres in ALT-positive U2OS cells. 
Microcopy images of transiently transfected U2OS cells. U2OS cells were transfected with GFP (G), 
PML-GFP (PG), TRF1-GFP (TG) and TRF1-PML-GFP (TPG) encoding plasmids. After 24 h, cells were 
fixed and stained with aTRF2-rb-A568 and aPML-ms-ATTO633. Colocalizations of TRF2 
(representative for telomeres) and PML are marked with white arrows. Scale bars are 10 µm.  
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GFP was distributed throughout the whole cell, whereas transfection of PG led to a higher number of 
PML-NBs, not attached to telomeres of both U2OS and HeLa cells. TRF1-GFP did colocalized with 
telomeres but not with endogenous PML. Upon transfection of TPG A strikingly high number of 
colocalizations between PML and telomeres was detected in both U2OS (Figure 25) and HeLa cells 
(Figure 26) transfected with TPG. Thus, exogenous expression of a PML-TRF1 fusion construct 
recruited PML to the majority of telomeres in cells independent of their ALT background. 
  
Figure 26. Recruitment of PML to 
the majority of telomeres in ALT-
negative HeLa cells 
Microcopy images of transiently 
transfected HeLa cells. HeLa cells 
were transfected with GFP (G) and 
TRF1-PML-GFP (TPG). After 24 h, 
cells were fixed and stained with 
aTRF2-rb-A568 and aPML-ms-
ATTO633. Colocalizations of TRF2 
(representative for telomeres) and 
PML are marked with white arrows. 
Scale bars are 10 µm. 
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3.2 PML ). .e0omeres induces .e0omere c0us.ering 
Spot properties of signals derived from telomere and PML staining were in the acquired images were 
quantified using cell segmentation 3D (Wörz et al., 2010; Osterwald et al., 2012). For the present 
analysis, the detection spots in the telomere channel were changed to a 2-Pass segmentation, as already 
described for the PML channel, because telomere foci varied from very faint to very large dots 
(implemented by Stefan Wörz, Prof. Karl Rohr, Heidelberg). The DAPI staining was used for nucleus 
segmentation that was passed on to the next analysis step within the software to analyze the spots in the 
other three channels for telomeres, PML and GFP-construct. Parameters for the cell segmentation 3D 
software were calibrated to detect all visually detectable telomeric and PML spots in untransfected or 
GFP-transfected cells. For convenience, TRF2/ PML colocalizations are referred to as APBs in the 
following. However, it needs to be verified if recruited PML fulfills functional requirements of 
endogenous APBs.  
 
With this method the number of telomeres and APBs was determined as well as volumes of telomeres 
overall and in APBs in U2OS and HeLa cells after transfection of G, PG, TG and TPG (Figure 27 and 
(Table 40 and Table 41). U2OS wt cells have a diverging set of chromosomes with 77 chromosomes 
Figure 27. Quantification of telomere 
properties in U2OS and HeLa cells 
upon transfection of GFP, PML-GFP, 
TRF1-GFP and TRF1-PML-GFP. 
Boxplots, showing the quantification of 
telomeres and APBs in (A) U2OS and 
(B) HeLa cells. Telomere numbers, 
telomere volumes, APB numbers and 
telomere volumes in APBs were plotted 
for each transfected construct. PML and 
telomere foci and their colocalizations 
were detected using Cell segmentation 
3D software. Volumes were also 
calculated by Cell segmentation 3D 
software.  
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with 144 telomeres (Jegou et al., 2009). Since some chromosomes have signal-free ends, the obtained 
number of 129.6±9.1 for U2OSG is in the expected range. In U2OSTPG cells, the detected telomere 
number is lower than in all controls, and significantly reduced compared with the GFP-transfected 
control (33%, p = 0.0076). For calculating the number of colocalizations of TRF2 and PML spots, only 
the best colocalizations (1,3,5,7) were taken into account (see methods section 7.6).  
The number of TRF2/ PML colocalizations was unexpectedly high in the GFP control U2OS cells and 
the number of telomeres was not significantly different between control transfections (p >0.05). 
Therefore, only TG- and PG-transfected cells served as controls. The number of detectable TRF2/ PML 
colocalizations in U2OSTPG cells was significantly increased 8-fold over U2OSPG cells (p = 1.1e-3) and 
14-fold over U2OSTG cells (p = 0.00079). However, the automatically detected number did not reflecting 
the strikingly high number from visual inspection.  
Table 40. Quantification of telomere and APB properties in transiently transfected U2OS cells. 
 Telomere number APB number Telomere volume Telomere volume in APBs 
GFP 129.6±9.1 6.8±1.5 0.14±0.006 0.41±0.052 
TRF1-GFP 116.5±3.7 1.1±0.4 0.11±0.006 0.31±0.152 
PML-GFP 103.9±10.1 1.9±0.7 0.09±0.005 0.08±0.008 
TRF1-PML-GFP 87.0±10.9 15.6±3.0 0.18±0.010 0.27±0.024 
The table shows the quantification of detected telomere spots in HeLa cells transfected with GFP, PML-
GFP, TRF1-GFP or TRF1-PML-GFP. The columns reflect the telomere numbers, APB numbers, as well 
as telomere volumes and volumes of telomeres in APBs.  
In all but U2OSPG cells, telomeres in APBs had a higher volume as the mean of all telomeres confirming 
previous observations (Osterwald et al., 2015). In U2OSPG cells, the volume is similar, however, the 
volume range also included higher volumes for telomeres in APBs. The telomere volume in APBs in 
U2OSTPG cells was not increased compared to U2OSG and U2OSTG cells.  
Table 41. Quantification of telomere and APB properties in transiently transfected HeLa cells. 
 telomere number APB number telomere volume telomere volume in APBs 
GFP 46.8±3.3 0.3±0.1 0.07±0.004 0.11±0.029 
TRF1-PML-GFP 103.6±6.8 44.3±4.7 0.21±0.027 0.19±0.006 
The table shows the quantification of detected telomere spots in HeLa cells transfected with GFP or 
TRF1-PML-GFP. The columns reflect the telomere numbers, APB numbers, as well as telomere 
volumes and volumes of telomeres in APBs.  
In HeLa cells the number of telomeres in the GFP control cells was lower as expected. Since telomeres 
in HeLa cells are short, our method might not be suited to detect all telomeres. However, in HeLaTPG 
cells, the number of telomeres is higher than in HeLaG cells. Also, the percentage of telomeres 
colocalizing with PML was determined as 42%. The number of TRF2/ PML colocalizations was 
significantly (p=2.7e-06) increased from 0.3 in HeLaG to 44.3 in HeLaTPG cells. The mean volume of 
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telomeres in APBs was not different from the average volume of all telomeres. However, in HeLaTPG 
cells the telomeres not colocalizing with PML had a significantly higher volume as compared to HeLaG 
cells (p=8.0e-07). In summary, a telomere-repeat foci increased in volume while their absolute number 
was reduced indicating enhanced telomere clustering. 
3.3 PML recrui.men. .o .e0omeres incre)ses C-circ0e 0eve0s  
Experiments conducted with transiently transfected cells are limited because of low transfection 
efficiencies, variances in expression levels, and short time of overexpression. The generation of stable 
cell lines was required for further experiments to overcome these issues.  
To enable long-term and bulk population experiments stable inducible U2OS and HeLa cell lines were 
generated using the Tet-On pTRE3G system. Different strategies for generating stable and inducible 
cell lines were taken into consideration. (a) The FlpIn-TRex system allows locus-specific integration, 
however it is restricted to commercially available cell lines. The (b) The PiggyBac system is a flexible 
system, which can be integrated into numerous cell lines, although the integration is not locus-specific. 
Furthermore, in our labaoratory up to now integration of a construct different from one encoding GFP 
was not successful. For the (c) TetOn pTRE3G system, U2OS and HeLa Tet-On cell lines already 
existed that were used for generating DOX inducible stable cell lines (see methods Figure 5). Thus, 
inducible U2OS and HeLa cells were generated utilizing the Tet-On 3G system. Therefore, the full 
construct (TRF1-PML-GFP) as well as control constructs (GFP, PML-GFP and TRF1-GFP) were 
cloned into a pTRE3G vector. U2OS and HeLa Tet-On cells were then transfected under puromycin 
selection. Parts of the generation of the stable cell lines were done by Caroline Bauer (Prof. Karsten 
Rippe, DKFZ, Heidelberg). Stable clones with an overall high expression but low variance in 
Doxycyclin (dox) inducible expression were selected for each construct and cell line. Various amounts 
of doxycycline were tested and the optimal concentration was determined to be 50 ng for U2OS and 
100 ng for HeLa cells. Thus, stable cell lines inducible for GFP, PML-GFP, TRF1-GFP and TRF1-
PML-GFP were generated using the TetOn pTRE3G system. 
Next, it was addressed if artificial APBs as measured above have an effect on ALT activity by measuring 
C-circle levels after recruitment of PML to telomeres. C-circles are a robust marker for ongoing ALT 
activity (Henson et al., 2017). In both U2OS cells and HeLa cells, no elevated levels of C-Circle levels 
were observed after 24 h upon transient transfection (data not shown). Next, stable expression of TRF1-
PML-GFP was induced for 14 days in U2OS and HeLa cells and C-circle levels determined on day 0, 
4, 7 and day 14 (Figure 28A). C-circle levels were normalized to a U2OS wt sample that serves as an 
ALT-positive reference cell line. Prior induction, C-circle levels were similar between the various 
expressed constructs. After four days of stable expression, C-circle levels were increased in U2OSTPG 
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cells, however also U2OSG cells showed elevated C-circle levels. C-circle levels in U2OSPG and U2OSTG 
cells did not change significantly. After 7 days of induction, a further increase in C-circle levels for 
U2OSTPG was observed that was >4-fold over pre-induced U2OSTPG cells. In addition, after 7 days C-
circle levels were significantly higher in U2OSTPG as compared to all controls (p≤0.0085). For U2OSPG 
and U2OSTG, no change in C-circle levels upon stable expression was observed. After 14 days of 
continuous induction of expression, C-circle levels of all stable cell lines were back at levels of pre-
induced cells. Notably, also the percentage of positive cells for the construct as indicated by the fraction 
of GFP-positive cells decreased over induction time and was ~50% for U2OSTPG and ~30% for U2OSTG 
after 7 days of continuous doxycyclin delivery. For all pre-induced HeLa cells, only C-circle levels 
below 1% of U2OS wt were measured (Figure 28B). 
 
Figure 28. C-circle levels in U2OS and HeLa cells after induction of expression of GFP, PML-
GFP, TRF1-PML, or TRF1-PML-GFP. 
C-circle assay of (A) U2OS and (B) HeLa cells with induced expression of GFP, PML-GFP, TRF1-GFP 
and TRF1-PML-GFP after 4, 7 and 14 days. Above the bar plots, exemplary dot blots of the C-circle 
assay are depicted. The upper row contains samples after amplification with polymerase addition, and 
the lower row shows the control without polymerase. Error bars represent the SEM. Significance is 
indicated with asterisks, *p<0.01, and **p<0.001.Experiments were performed in two independent 
replicates, each in technical triplicates. 
Already after 4 days, a striking increase in C-circle levels for HeLaTPG to ~8% of U2OS levels was 
observed. None of the control constructs did show any significant change in C-circle levels. After 7 days 
of stable expression of TRF-PML-GFP, the C-circle levels did further increase to ~12% of U2OS wt 
cells. C-circle levels of all control cells stayed at the same levels as pre-induced and 4-days-induced 
cells. Thus, C-circle levels were significantly increased over controls after 4 (p≤0.0013), and 7 days 
(p≤0.0024) of stable expression of TRF1-PML-GFP in HeLa cells.  
As for the U2OS cell lines, the number of positive cells also decreased with ongoing induction of 
expression in the HeLa cell lines. After 7 days of continuous induction, only 55% HeLaTPG, 33% HeLaG 
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and 1-2% HeLaPG were positive for the construct, as determined microscopically. Continuous 
overexpression of any of the construct might be cytotoxic and potential effects of the remaining positive 
cells might not be detectable above noise. Furthermore, almost all HeLaTG were non-viable after 7 days. 
Also, the generation of non-inducible stable overexpression of TRF1 failed in ALT-negative cells 
(HeLa, MCF-7) as all attempts resulted in cell death. Thus, TRF1 overexpression was toxic for HeLa 
cells and further validation and optimization of induction conditions have to be done. In summary, the 
recruitment of PML to telomeres via the telomere binding protein TRF1, was shown to increase C-circle 
levels after stable expression for 4-7 days indicating activation of the ALT mechanism even in an ALT-
negative cell line. 
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  Discussion 
Maintenance of telomeres is one of the hallmarks of cancer and also plays a central role in other diseases 
like syndromes associated with premature aging. Furthermore, dissecting the TM is becoming 
increasingly important in the field of cancer research based on deep-sequencing approaches (Barthel et 
al., 2017; Chudasama et al., 2018; Sieverling et al., 2018). Alternative lengthening of telomeres (ALT) 
is a mechanism used by cancer cells for recombination-mediated telomere elongation in the absence of 
telomerase. In this thesis, the TelNet database was developed as a TM pathway analysis tool that helped 
to identify novel ALT candidate genes detected from RNA-seq experiments from several cellular 
systems with perturbed TMM. Furthermore, a method to recruit any protein of interest to telomeres was 
established in telomerase-positive cells that can be applied for testing the effect of ALT candidate genes 
on ALT induction. With the TelNet database, identification of putative novel ALT enhancer genes, and 
establishment of a telomere recruitment method, this thesis lays the foundation for future investigations 
in the field of telomere maintenance (TM). 
1 Anno.).ion of Ynown TM genes 
With existing tools like HumanMine (Smith et al., 2012) it is difficult to retrieve TM information on a 
given set of genes, because detailed TMM annotations are currently missing. Beyond HumanMine and 
other general gene databases, currently only the Telomerase database (Podlevsky et al., 2008) and the 
MiCroKiTS database (Huang et al., 2015) offer some telomere specific information. However, no 
information on TM phenotype upon knockdown or overexpression, or details on the active TMM are 
given. This current gap is filled with the TelNet database as a dedicated and useful resource for research 
in TM in cancer and other diseases like premature aging. The TelNet database addresses an unmet need 
of the corresponding research communities and provides an open-ended platform to compile existing 
knowledge on human and budding yeast genes involved in TM, especially the ALT pathway. Genes 
were collected from existing literature and annotated with TM information such as (i) TM mechanism 
and activity of regulation, (ii) TM functions, (iii) knockdown/ overexpression phenotype, (iv) a TM 
significance score, (v) TM summary/ comments, (vi) reference links, and (vii) orthologous genes. 
Different search and view modes can be used to explore the database, e.g. for results lists from 
bioinformatics pipelines. This is necessary and will become even more important because “omics” 
studies and screening experiments are on the advance. The most powerful tool is the TelNet list search, 
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enabling the fast identification of TMM genes from large gene lists derived from such analysis, e.g. 
genomic and transcriptomic data (Barthel et al., 2017; Chudasama et al., 2018; Sieverling et al., 2018).  
With the TelNet database, the user can retrieve detailed TM information on particular genes without any 
prior knowledge as compared to other databases. To demonstrate the advantages of TelNet, the 
transcription factors of the budding yeast telomerase protein subunit EST2 that are listed as 
“documented” in the Yeastract database (Teixeira et al., 2014), were submitted to the Saccharomyces 
genome database (SGD)/ YeastMine (Balakrishnan et al., 2012). All regulators were indeed recognized 
as transcription factors in general, however, no hint was found towards telomerase or TM, because GO 
annotations did not contain TM information. In contrast, the complete list was included in the TelNet 
database as budding yeast telomerase regulators. A clear limitation of the GO pathway analysis is the 
lack of annotations for the majority of known genes, since only 33 % of all genes hold at least one GO 
biological process. Thus, the effective domain size was small in comparison to the total number of genes. 
All enrichment scores are therefore only first approximations and also enrichments without reaching a 
significance levels were also considered. Genes without a GO term with regard to telomeres, despite a 
reported role in TMM, were included in the TelNet database. With this, the effective domain size 
regarding TM annotations was substantially increased and by using the TelNet database more potential 
candidate genes can be found, by using the TelNet database.  
The database certainly requires continuous maintenance which has to be assured over a long period of 
time. With the support of the telomere community, TelNet information will constantly be improved and 
extended by the latest research. For this process telomere researchers are encouraged to communicate 
their feedback via telnet@dkfz.de in order to constantly improve the database and keep the information 
relevant and up to date. The integration of new information requires manual curation, accordingly most 
of the fields are easy-to-fill with terms from a drop-down list. Furthermore, information from the general 
part can be copied from external databases, such as identifiers, synonyms and description. Since the 
database was designed in a way that easily enables addition of more organisms, the extension with data 
from M musculus and S. pombe and respective human and budding yeast orthologues will further 
strengthen the advantages of homology assignments in the future.  
Recurrent TMM-associated mutations in ATRX, DAXX and the TERT promoter have been found in a 
variety of cancers and are well known. However, in many tumor samples these mutations are lacking, 
suggesting the contribution of other factors to the active TM. This view is supported by a recent 
integrative genome and transcriptome analysis of leiomyosarcoma, which applied TelNet for the TMM 
analysis and identified recurrent mutations in RBL2 and SP100 as linked to ALT (Chudasama et al., 
2018). Accordingly, it is anticipated that TelNet will help to reveal this type of novel correlations 
between deregulated cellular features and active TM networks in different tumor entities. 
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2 ALT suppression )nd induc.ion 
In budding yeast, it is feasible to perform deletion screen experiments, which is challenging in human 
cell lines. Therefore, other strategies have to be applied to study the activation and repression 
mechanisms of ALT. Investigating the suppression of ALT has been challenging because specific 
molecular targets other than ATRX are missing. Furthermore, depletion or overexpression of an ALT 
related protein or pathway only reduces some ALT hallmarks, not all of them. Especially interesting are 
small molecule drugs that might have the potential in reducing ALT activity in cancer cells potentially 
reducing their viability as a consequence. The ATRi VE-821 and the HDACi SAHA have been shown 
to reduce some ALT features. Upon treatment with ATRi a decrease in C-circle levels, T-SCE, and 
APB-positive cells as well as more telomere-free chromosomes, but unchanged TERRA levels and 
localization have been observed (Flynn et al., 2015). Similarly, SAHA treatment has been demonstrated 
to reduce the number of APBs and C-circle levels (Osterwald et al., 2015). 
For detailed investigations on the mechanism underlying ALT, the defined induction of ALT is desired. 
So far, induction of ALT has been reported for (i) normal cells that went through crisis or were 
transformed to cancer cells (Yeager et al., 1999), (ii) telomerase-positive cells that underwent telomere 
shortening because of telomerase depletion and evaded senescence by activating ALT (Min et al., 2017), 
(iii) by combined depletion of ATRX and DAXX, inhibition of telomerase as well as DNA damage 
induction at telomeres (Hu et al., 2016) and (iv) rapid ALT induction by ASF1 kd in telomerase-positive 
cells with long telomeres (HeLa LT) (O'Sullivan et al., 2014). The first two processes are time-
consuming and survivor formation is rare. The third treatment is very labor-intensive and accompanied 
by severe perturbations. In contrast, the ALT induction phenotype of ASF1 depletion can be reversed 
after recovery of ASF1 and requires single siRNA transfection without generating stable cell lines 
(O'Sullivan et al., 2014). Thus, siRNA mediated-depletion of ASF1 is currently the only way to rapidly 
induce ALT in ALT-negative human cell lines, and thus the method was exploited in the present work.  
In this thesis, strategies to induce or suppress the ALT pathway in human and budding yeast were 
applied to identify novel ALT driver or suppressor candidates via a differential gene expression analysis. 
ALT-positive cells were treated with HDACi SAHA to repress ALT and ASF1 was depleted in 
telomerase-positive cells followed by ALT induction. In addition, the budding yeast type II survivors 
were studied that form upon EST2 deletion. The integrative analysis of deregulated pathways resulted 
in common and distinct signaling pathways as outlined below. 
First, the treatment conditions for SAHA were optimized in order to to find a low and effective 
concentration that still leads to reduced C-circle levels as an established marker for ALT activity. The 
reduction of APBs and C-circle levels was in agreement with previous findings (Osterwald et al., 2015). 
It is noted that SAHA treatment did not selectively induce apoptosis in ALT cells. Rather it appears that 
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drug sensitivity with respect to cell viability might be cell-type specific. This is similar to previous 
reports investigating the effects of ATRi VE-821 (Deeg et al., 2016). Next, it was confirmed that ALT 
is induced by ASF1 depletion in HeLa LT cells with long telomeres. In previous reports, it has been 
shown that the number of APBs, events of telomere recombination as well as TERRA levels were 
elevated with this approach (O'Sullivan et al., 2014; Deeg, 2015). Furthermore, a decrease in TERT 
expression, detected by qPCR, and telomerase activity was reported (O'Sullivan et al., 2014). In contrast, 
determining TERT expression levels from the RNA-seq data acquired here did not show a change upon 
ASF1 depletion in HeLa LT or ST cells. A possible explanation is the low abundance of transcript reads 
for the TERT gene that are difficult to quantify. For the lowly expressed TERT mRNA, qPCR appears 
to be better suited than RNA-seq to measure its expression.  
As shown in this thesis, ALT suppression in ALT-positive cells with SAHA also reduced the ALT 
induction capacity of ASF1 depletion in HeLa LT cells. The combination of ASF1 kd with drugs 
targeting DDR signaling pathways or cytostatica has been performed previously and indicated a role of 
replication stress sensing and ATR signaling for ALT induction (O'Sullivan et al., 2014).  
In the present thesis, differential gene expression analysis was applied to gain insight into the mechanism 
of ALT suppression and induction mechanisms. To identify genes that recurrently correlated or anti-
correlated with the ALT status in the present thesis, lists from the different induction and suppression 
experiments were checked for overlapping genes and pathways. Genes that were downregulated upon 
SAHA treatment are discussed as ALT enhancing and upregulated genes are referred to as potentially 
ALT repressing. Since, ASF1 depletion induced a number of ALT features in ALT-negative HeLa LT 
cells, upregulated genes upon ASF1 kd were considered as ALT enhancing genes and downregulated 
factors as ALT repressing. In line with previous findings, HeLa ST was incapable of ALT induction by 
depletion of ASF1. The difference between HeLa LT and ST cells could not be deduced to different 
expression levels of TERT. The response of HeLa ST to ASF1 depletion was only marginally 
investigated previously (O'Sullivan et al., 2014). Comparison of gene expression changes after ASF1 
kd in HeLa ST with those in HeLa LT allowed for the identification of genes and pathways that protect 
from ALT induction in HeLa cells with short telomeres. In the present analysis only genes exclusively 
deregulated in one of the cell lines (LT or ST) were further analyzed, in order to identify reasons for the 
different responses. Genes that were deregulated upon SAHA treatment of ASF1 depleted HeLa LT 
cells were referred to as ALT suppressor candidates for up- and ALT enhancer candidates for 
downregulated genes, respectively.  
Matching of deregulated genes from suppression and induction experiments resulted in 28 potential 
ALT suppressors (Figure 29) and 13 ALT enhancer candidates (Figure 30). ALT enhancer candidate 
KCTD15 was downregulated upon suppression of ALT maintenance as well as ALT induction. The 
protein has been found in close proximity of shelterin and was therefore included in the TelNet database. 
The zebrafish homologue (Kctd15) of the human KCTD1, a close family member of KCTD15, has been 
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demonstrated inhibit canonical WNT signaling and interacts with transcription factors of the AP-2 
family (Zarelli & Dawid, 2013; Li et al., 2014). Furthermore, AP-2 transcription factors have been 
reported to activate human TERT (Doloff et al., 2008). Thus, it can be speculated that, KCTD15 might 
be involved in repressing TERT activators. A second interesting ALT enhancer candidate is TNNC1, 
that was upregulated upon ALT induction and in agreement downregulated upon ALT suppression, thus 
correlating with the presence of ALT markers. The gene was included into the TelNet database because 
of the budding yeast homologues CMD1 phenotype of telomere elongation after deletion. Further 
investigations are suggested to confirm their role as ALT enhancers.  
 
Figure 29. ALT suppressor candidate genes. 
Merged lists of ALT suppressor candidate genes from different DESeq results of perturbed cell lines. 
Genes reported to be cell cycle-regulated in U2OS or HeLa cells (Grant et al., 2013) are marked with a 
°circle. 
Furthermore, also results from the functional annotation clustering and pathway enrichment analyses 
were checked for overlapping pathways. Global gene expression levels of ASF1 depleted HeLa LT cells 
were previously analyzed by microarray (O'Sullivan et al., 2014). From this only selected enriched 
pathways have been shown, namely upregulation of genes involved in TNFa, IL-10, NFkB and 
TGFb signaling pathways and downregulated genes were associated with the HIF-1 and AP-1 
transcription factor network. With the here-performed RNA-seq method, the transcriptome was 
analyzed in an unbiased manner, e.g. also taking pseudogenes into account. None of the in the previous 
study mentioned genes (IL1A, IL1B, IL6, CXCL8 (aka IL8), IKBKG or NFKB2 (aka p100) have been 
identified as upregulated in ASF1 depleted HeLa LT cells. However, other genes involved in 
inflammatory and/ or immune response were upregulated in ASF1 depleted HeLa LT cells but not in 
HeLa ST. It is noted, that the detection of short RNAs, for example microRNAs, is beyond the range of 
the analysis because a size selection step was used to retrieve only transcripts longer than 200 kb.  
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Figure 30. ALT enhancer candidate genes. 
Merged lists of ALT enhancer candidate genes from different DESeq results of perturbed cell lines. 
Those genes implemented in the TelNet database are marked in bold. For details please see legend of 
Figure 29.  
In terms of changes in signaling pathways, the findings from this study are consistent with the 
microarray analysis with identifying the upregulation of TNFa signaling (THBS1), the IL-10 cytokine 
IL24, and TGFb signaling (BMP2, BMP6, KLF17) in ASF1 depleted HeLa LT cells the results are 
consistent with the microarray analysis. However, IL24° was also upregulated upon SAHA treatment of 
U2OS cells, which suppressed ALT markers. In U2OS cells, a cell-cycle dependent expression has been 
observed (Grant et al., 2013), indicating a secondary effect leading to upregulation of IL24°, 
independent of the ALT status. The downregulation of the TGFb signaling factor KLF17 upon SAHA 
treatment in U2OS cells is in agreement with the upregulation of KLF17 upon ALT induction. From 
this, it can be reasoned that TGFb signaling has a positive correlation with ALT. Proteins of TGFb 
signaling have been shown to repress telomerase (Li et al., 2006; Cassar et al., 2017). Thus, it can be 
speculated that one aspect of ALT induction in ASF1 depleted HeLa LT cells is the TGFb mediated 
telomerase repression. 
SAHA treatment of U2OS cells induced ALT suppression and the downregulation of WNT signaling 
(WNT11, WNT3A, WNT5B). This is consistent with the upregulation of WNT signaling inhibitors 
(DKK3, LRP1, NXN, DACT3, HMGA2 CITED1, and PTK7) in ASF1 depleted HeLa LT treated with 
SAHA associated with suppression of ALT induction. Thus, suppression of ALT is correlated with the 
inhibition of WNT signaling. This is consistent with activated WNT signaling (WNT11), upon ALT 
induction in ASF1 depleted HeLa LT cells. Thus, WNT signaling correlates with the presence of an 
active ALT mechanism. Downregulation of canonical WNT signaling has been reported in mice 
deficient of telomerase RNA component TERC and harboring shortened telomeres (Yang et al., 2017). 
Activation of WNT signaling in these mice was shown to result in re-established telomere capping. 
Also, the telomerase catalytic subunit TERT has been reported to have a transcriptional modulator role 
in the WNT signaling pathway (Park et al., 2009; Hoffmeyer et al., 2012; Zhang et al., 2012).  
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Moreover, ALT repressor SAHA mediated the upregulation of TNF/ NFkB signaling (TRAF1, CXCL8, 
IQGAP2, TNFSF9, and CCL20), and decreased the expression of p38 MAP kinase pathway inhibitor 
RARRES2. In agreement with an ALT repressive role for TNF/ NFkB/ p38 MAP kinase signaling, 
SAHA induced the upregulation of p38 MAP kinase signaling genes (PTK7) in ASF1 depleted HeLa 
LT cells. ALT induction in ASF1 depleted HeLa LT cells was associated with the upregulation of NFkB 
repressor S100A9. Together, TNF/ NFkB/ p38 MAP kinase signaling anti-correlates with the occurrence 
of ALT. The link between signaling pathways such as TNF or NFkB has been discussed in the literature. 
TNFa treatment has been shown to induce telomere shortening (Maekawa et al., 2018). A model for the 
interaction of TERT with WNT and NFkB signaling pathways has been proposed (Li & Tergaonkar, 
2014).  
Interestingly, ASF1 depleted HeLa ST cells that did not display ALT induction, showed upregulation 
of IL6 and other genes involved in defense virus response (IL6, IFIT3, IFIT2, IFIT1°, OASL, ISG15, 
OAS2, DHX58), inflammatory response (IL6, CCR4, ITGB2, CCL5, SCG2) or immune response (IL6, 
CCR4, SUSD2, TNFSF15, OAS2, CCL5, IL7R). A portion of these genes overlap with factors of type I 
interferon signaling pathway (IFIT3, IFIT2, IFIT1°, OASL, ISG15). Furthermore, TNFAIP6, repressing 
inflammatory response was downregulated, which is in agreement with the upregulation of immune 
response on the other hand. For IFIT3, IFIT2, OASL and ISG15, basal expression levels were already 
higher in untreated HeLa LT than ST cells. Upon ASF1 depletion in HeLa LT cells, expression levels 
of IFIT3, IFIT2, OASL and ISG15 were then further increased without reaching the level of significance 
and thus not showing up in the results list. Upon SAHA treatment and associated with suppression of 
ALT induction, the type I interferon signaling genes IFIT3, IFIT2, OASL, and ISG15, were 
downregulated. Activation of type I IFN  signaling has been observed for cytosolic sensing of extra-
chromosomal telomeric repeats (Tao et al., 2016). ALT cells that lack functional ATRX on the other 
hand have been shown to be defective in cytosolic DNA sensing, because this requires intact ATRX 
(Chen et al., 2017). A possible explanation of the results might be that ASF1 depletion generates ECTRs 
that diffuse into the cytosol, activate the cGAS-STING pathway and lead to induction type I INF 
signaling. In the case of HeLa ST, cells activate an unknown downstream mechanism that protects from 
ALT induction. In contrast, HeLa LT cells lack this mechanism and develop ALT despite an intact 
cGAS-STING mediated sensing of ECTRs. Since SAHA reduced C-circles, sensing of cytosolic DNA 
and therefore type I IFN signaling might be reduced. Downregulation of IFIT3, IFIT2, OASL, and ISG15 
upon SAHA might therefore be the result of dispersed C-circles.  
Overall it can be speculated that WNT and TGFb pathways have enhancing roles in the ALT 
mechanism, and NFkB and p38 MAP kinase signaling in turn comprise ALT repressive pathways. 
Despite the dramatic changes in multiple signaling pathways of cancer cells, the role of the above-
mentioned pathways should be further investigated in the context of TMM. Investigations of ALT 
suppressor genes and pathways by their overexpression in ALT cells should help elucidate the negative 
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effect on ALT hallmarks. The identification of ALT repressors will help understanding the mechanisms 
of ALT. Equally, the role for ALT enhancing genes and pathways in the ALT mechanism remains to be 
demonstrated in validation experiments. It will be interesting to see, if single depletion experiments 
might reveal a requirement for APB formation or ECTR generation. This novel list of potential ALT 
genes offers great potential for targeting the ALT mechanism.  
It will be interesting to further investigate the role of SAHA in the process of ALT suppression. 
Assessment of other ALT features other than C-circles may significantly improve the results as well as 
confirming the effects in other ALT cell lines. Further experiments with other pan HDACi such as 
panobinostat or TSA and specific depletion of single HDACs should help determine the role of HDAC 
inhibition on ALT suppression. It will be interesting to see, how SAHA performs in a currently 
recruiting clinical I/II trial, where the pan HDACi is applied to children with solid tumors, lymphoma 
or leukemia that did not respond to the standard therapy (Witt et al., 2012). Further analysis of the data 
generated in this study may reveal a relation between TMM status and response to SAHA therapy. 
3 Func.ion)0 ro0e of PML during ALT induc.ion 
In ALT-positive tumors, PML is neither recurrently mutated nor has deregulated gene expression 
(Lafferty-Whyte et al., 2009; Doyle et al., 2012; Lovejoy et al., 2012; Deeg et al., 2017). Nevertheless, 
the delocalization of PML to telomeres is specific for ALT cells. Thus, this process is driven by the 
deregulation of other factors as investigated previously (Osterwald et al., 2015). Therefore, artificially 
recruiting PML to telomeres perfectly mimics this kind of alteration. 
For recruiting PML to telomeres in U2OS and HeLa cells, a fusion construct consisting of TRF1 and 
PML was used. In transiently transfected cells, PML recruitment to almost all telomeres induced 
telomere clustering, as concluded from the confocal image analysis of telomere number and volume. 
Stable cell lines were generated that can be used to induce telomeric PML recruitment, enabling long-
term bulk cell population experiments. The levels of extrachromosomal telomeric repeats, accessed by 
the C-circle assay, were increased in both cell lines, only between 4-7 days after induction.  
With the strategy developed here it is possible to recruit PML to all telomeres in a given cell type that 
carries the PML-TRF1 construct. In contrast to the lacO-system described previously, which only allows 
for ectopic APB formation in an ALT-positive U2OS cell line (Jegou et al., 2009; Chung et al., 2011), 
the strategy can be applied to any cell line of interest as the fusion protein is encoded on a transfectable 
plasmid. By using somatic cells or ALT-positive cells with weak levels of ALT hallmarks, the functional 
role of PML in the induction of ALT could be further investigated. Moreover, the method can be 
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extended by transfecting another protein of interest fused to a GFP-binder domain (Rothbauer et al., 
2006; Zolghadr et al., 2008; Chung et al., 2011). After transient transfection and induction of TRF1-
PML-GFP expression the GFP-binder fusion construct will be recruited to the artificial APBs. 
Subsequent analysis of an increase in ALT features will help confirming the ALT enhancing role for a 
protein of interest. 
For ectopic expression of PML it is relevant, which isoform is used, because phenotypes upon depletion 
or overexpression can vary. Since especially isoform IV interacts with TRF1 (Yu et al., 2010), 
overexpression results in an increase of APBs (Osterwald et al., 2012; Yong et al., 2012). In contrast, 
overexpression of PML isoforms III, V and VI slightly decreased the number of APBs (Osterwald et 
al., 2012) and it has been suggested that regulation of the other isoforms is affected by changing the 
expression of one isoform (Chung et al., 2011). In this thesis, PML III was used for overexpression and 
recruitment experiments since, if overexpressed at low levels, it induces a relatively low perturbation of 
endogenous PML concentrations and APB formation. Also, the selection of a telomeric binding part of 
the fusion construct is important, since its overexpression alone should not lead to a severe phenotype. 
Overexpression of TRF2 resulted in elevated levels of apoptotic cells (Osterwald et al., 2012), probably 
because of replication fork stalling (Nera et al., 2015). Overexpression of TRF1 was observed previously 
to increase homologous recombination (Munoz et al., 2009). Furthermore, exogenous TRF1 protein 
might compete with TRF2 at telomeres, which in the most extreme scenario could lead to telomere 
fusions, observed for TRF2 depleted cells (van Steensel et al., 1998). Considering these observations, 
in the present thesis cells with relatively low expression of the constructs were either manually selected 
from a transiently transfected cell pool or induced with a low doxycycline concentration in the stable 
cell lines. Under these conditions overexpression of TRF1 or PML alone in U2OS cells did not alter the 
apparent number of telomeres, localization of PML or C-circle levels. Likewise, C-circles were not 
induced in HeLa cells if only TRF1 or PML constructs were present. Telomere clustering after 24 h and 
increased C-circle levels after 4 days in HeLa cells point to the activation of ALT upon PML recruitment. 
However, telomere clustering has been also suggested to be a result of senescence (Chung et al., 2012) 
and APB induction has been observed upon starvation triggered by methionine restriction (Jiang et al., 
2009). Indeed, cells were not viable for more than 7 days of stable expression of PML or TRF1. 
However, the cells stably expressing the fusion construct TRF1-PML were still viable on day 7 with 
50% of the culture being positive for the construct. In future experiments, it would be interesting to 
investigate telomere clustering in a more direct manner, for example by high resolution microscopy. 
Further experiments involving automatic screening of stable cell lines will help confirm the results after 
optimization of induction conditions for the stable cell lines. For screening and subsequent analysis, 
quantification of the GFP signal yields an estimate of protein expression level in the nucleus. Thus, the 
degree of clustering can be calculated in dependence of the fusion protein concentration. 
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In addition to telomere clustering, also C-circles increased after 4 days in HeLa cells. A possible 
explanation might be ongoing homologous recombination in artificial APBs, since C-circles might be 
originating as a byproduct of homologous recombination (Pickett et al., 2009). The results obtained in 
this thesis already indicate the induction of ALT in a previous ALT-negative cell line due to PML 
recruitment to telomeres. To further corroborate this finding, the activity of these artificial APBs in 
comparison to endogenous APBs needs to be further characterized. It will be important to show that 
factors indicating active DNA repair and recombination at telomeres, e.g. pATM or γH2A.X or essential 
APB compounds are indeed present at artificial APBs as has been shown for artificial APBs in ALT-
positive U2OS cells. 
The stable cell lines are especially useful for studying long-term and bulk effects. In addition, the 
inducible system allows for the investigation of the same cell population before and after the initiation 
of the recruitment. In these cell lines, variation in telomere length can be monitored over a long induction 
time. The induction of ALT by recruitment of PML to telomeres implicates a fundamental role for PML 
in ALT (Figure 31).  
 
APBs might therefore not only be a characteristic hallmark of ALT-positive cells, but indeed essential 
for the organization of an environment that facilitates telomeric clustering and recombination. From 
quantification of the telomere repeat signal, it is not possible to asses if extrachromosomal telomeric 
Figure 31. Model for ALT by homologous 
recombination in APBs. 
The scheme shows a model for alternative 
lengthening of telomeres (ALT) by homologous 
recombination. PML forms APBs around 
telomeres leading to telomere clustering. 
Recruitment of factors involved in DNA repair 
and homologous recombination (HR) enables 
telomeric recombination resulting in the 
generation of C-circles and telomere 
elongation. 
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repeats accumulate in APBs and thus lead to an increase of the signal in addition to telomere clustering. 
However, it appears more likely that more than one telomere cluster together in APBs and that ECTRs, 
e.g. C-circles, join the ensemble. Since C-circle levels increased only 4 days after induction and telomere 
clustering was already observed after 24 h, generation of C-circles can be considered as a subsequent 
event, taking place after the formation of APBs and telomere clustering (Figure 31). One can imagine 
that C-circles are as well amplified by homologous recombination as chromosomal telomeres are, or 
that they result from trimming events, contributing to heterogeneous telomere length. In summary, these 
results show that PML recruitment to telomeres is sufficient to establish a setting that enables telomere 
clustering and subsequent generation of extrachromosomal telomeric repeats, and thus contribute to the 
understanding of ALT induction mechanisms. 
In future experiments, it will be exciting to see if the combination with other factors will have an effect 
on ALT induction, even when its single perturbation did not show a change in TMM. Different scenarios 
can be imagined: (i) Overexpression of an ALT repressor in ALT-positive U2OS cells, e.g. ATRX. 
Since, ATRX is a recurrently mutated gene in ALT-positive tumors and most ALT cell lines lack ATRX, 
it is considered as an ALT repressor. In normal or telomerase-positive cells, ATRX has been observed 
to localize at PML-NBs, however the connection between APBs and ATRX remains elusive. The PML 
recruitment system could be combined with a re-activation of ATRX in ATRX-negative U2OS cells, 
already available in our group Deeg, 2015), to explore the effect on telomere lengthening. (ii) Depletion 
of an ALT repressor in telomerase-positive HeLa cells, e.g. ATRX or ASF1. ASF1 kd in HeLa cells 
with long telomeres results in rapid ALT induction, however if telomeres are short, no effect is observed. 
Therefore, it might be interesting to investigate the combination of PML recruitment with ASF1 kd in 
HeLa cells with short telomeres. (iii) Overexpression or co-recruitment of an ALT enhancer, e.g. BLM 
or WRN in telomerase-positive cells. Depletion of both BLM and WRN has been reported to block ALT 
induction by ASF1 kd in HeLa cells. Therefore, these proteins are considered as ALT enhancers and 
might facilitate ALT induction when overexpressed or recruited. 
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4 Conc0usions 
In this thesis, the approach depicted in Figure 32 was advanced and applied, which consists of four major 
steps: (i) perturbation of TMM, (ii) bioinformatics analysis, including TelNet, (iii) prediction of factors 
and pathways that (anti-)correlate with the presence of ALT, and (iv) functional validation of predicted 
candidate genes. In the first step, ALT was perturbed in different cellular model systems to identify 
candidate genes with a potential role in the mechanisms of ALT induction or suppression (Figure 32). 
This was achieved by (i) treatment with the HDACi SAHA to suppress ALT, (ii) ALT induction by 
ASF1 depletion, and (iii) deletion of EST2 in budding yeast cells to induce formation of ALT-like 
survivors. The next step comprised a differential gene expression analysis of perturbed vs unperturbed 
conditions that identified deregulated genes. To identify those deregulated genes linked to TM, the 
TelNet database developed in this thesis was applied. TelNet retrieves human and budding yeast genes 
with a reported role in TM via its list search tool (Figure 32). In addition, a conventional GO pathway 
analysis of the sets of deregulated genes associates them with pathways. From combined analysis novel 
ALT candidate genes and (anti-)correlated pathways are predicted, e.g. KCTD15 and TNNC1 as 
potential ALT enhancer genes that were upregulated upon ALT induction and/ or downregulated due to 
ALT suppression. In addition, an ALT enhancing role for proteins of the WNT family as well as TGFb 
signaling was suggested as well as an ALT repressive role for NFkB/ p38 MAP kinase signaling 
(Figure 32). The final part of the workflow involves the further evaluation and validation of the novel 
genes and signaling pathways identified in this manner with respect to their ALT enhancing or repressive 
features. Knockdown of potential ALT enhancing proteins in combination with ASF1 kd might be suited 
to reveal a requirement of the protein for ALT induction. In addition, kd experiments in ALT-positive 
cell lines might result in the decrease of ALT markers. Another option is the protein overexpression in 
ALT-negative cell lines that might induce ALT features, but could also require the combination with 
another ALT enhancing factor, e.g. TERT inhibition or ASF1 depletion. A third option is the recruitment 
of the protein of interest to telomeres of telomerase-positive cells in order to measure ongoing ALT 
activity. This was demonstrated here for the essential APB component PML. Upon PML recruitment, 
telomeres clustered and subsequently extrachromosomal telomere repeats were generated, indicating 
the induction of ALT. This method can be combined with transient transfection of a protein of interest, 
tagged with a GFP-binder protein that is recruited to artificial APBs upon induction of TRF1-PML-GFP 
expression or to telomeres upon induction of TRF1-GFP (Figure 32). Follow-up experiments measuring 
ALT activity might confirm ALT enhancing features of candidate genes.  
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Figure 32. Workflow of strategies to investigate TMMs. 
The workflow shows strategies to study ALT by perturbing TMMs. Comparing the original state with the 
perturbed state by bioinformatics pipelines generate gene lists reflecting e.g. differences in expression. 
The TelNet database can be used to identify known TMM genes. Next, a model for ALT can be 
developed that requires further validation experiments involving protein knockdown, overexpression, or 
recruitment to telomeres. A factor of interest tagged with a GFP-binder protein can be recruited to TRF1-
PML-GFP, expressed upon DOX induction, and in turn to telomeres. Subsequent validation of induced 
ALT features will enable confirmation of an ALT enhancing phenotype. 
Thus, the results obtained in this thesis provide new insight into gene networks that drive or suppress 
ALT. Identified candidate genes could represent putative novel drug targets specific for ALT tumor 
cells. Furthermore, it contributes to developing prognostic expression profiles for patient stratification 
into ALT-positive and ALT-negative groups. The latter is particularly relevant for several many tumor 
entities with a high incidence of ALT, e.g., leiomyosarcoma (53-78%) or pediatric glioblastoma (44%) 
that are often incurable or show a poor clinical outcome (Heaphy et al., 2011b; Sturm et al., 2014; 
Chudasama et al., 2018; De Vitis et al., 2018). 
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  Appendix 
Suppl. table S1. Components of ALT-associated PML-NBs. 
protein 
name (a) 
localized at APBs in ALT-
positive cells (b) 
localized 
in PML-
NBs (c) 
localized at 
normal 
telomeres (d) 
effect of APBs upon 
protein depletion/ 
knockdown (e) 
effect of APBs 
upon 
overexpression/ 
recruitment (f) 
ASF1A/ B    de novo APB formation (O'Sullivan et al., 2014)  
ATM yes (Stagno D'Alcontres et al., 2007) yes  
no effect (Osterwald et 
al., 2012; Flynn et al., 
2015; Osterwald et al., 
2015) 
 
ATR yes (Fan et al., 2009) yes  
no sign. effect 
(Osterwald et al., 2015); 
decrease (Flynn et al., 
2015) 
 
BLM 
yes (Yankiwski et al., 2000; 
Stavropoulos et al., 2002; 
Bhattacharyya et al., 2009; 
O'Sullivan et al., 2014; Osterwald 
et al., 2015; Sobinoff et al., 2017) 
yes 
(Yankiwski 
et al., 2000; 
Stavropoulos 
et al., 2002) 
no (Yankiwski et 
al., 2000; 
Stavropoulos et 
al., 2002) 
decrease (Gocha et al., 
2014; Osterwald et al., 
2015) 
overexpression leads to 
increase (Sobinoff et al., 
2017) 
BRCA1 yes (Wu et al., 2003; Gocha et al., 2014) 
no (Wu et 
al., 2003)  
no effect (Osterwald et 
al., 2015)  
BRCA2 
(aka 
FANCD1) 
yes (Spardy et al., 2008) 
    
CDK2 partly (Jiang et al., 2009)   no effect (Osterwald et al., 2015)  
CDKN1A 
(aka p21 
partly (Jiang et al., 2009) 
 no (Jiang et al., 2009) 
decrease (Osterwald et 
al., 2015) 
upregulation upon p53 
activation leads to 
increase (Jiang et al., 
2009)  
CTC1 yes (Huang et al., 2017)  no (Huang et al., 2017) 
no effect (Huang et al., 
2017)  
DNA2    increase (O'Sullivan et al., 2014)  
DNMT1    decrease (Osterwald et al., 2015)  
ERCC1 yes (Nabetani et al., 2004) (Zhu et al., 2003)  
yes (Zhu et al., 
2003) 
no effect (Osterwald et 
al., 2015)  
ERCC4 
(aka XPF) 
yes (Zhu et al., 2003)  yes (Zhu et al., 2003) 
decrease (Osterwald et 
al., 2015)  
EXO1    increase (O'Sullivan et al., 2014)  
FANCA    no effect (Osterwald et al., 2015)  
FANCD2 yes (Spardy et al., 2008; Fan et al., 2009; Root et al., 2016)  
no (Fan et al., 
2009) 
increase (Osterwald et 
al., 2015; Root et al., 
2016) 
 
FANCJ 
(aka 
BRIP1) 
partly (Garcia-Exposito et al., 
2016) 
no (Garcia-
Exposito et 
al., 2016) 
 no effect (Osterwald et al., 2015)  
FANCL    increase (Osterwald et al., 2015)  
FEN1    decrease (Osterwald et al., 2015)  
HDAC7    decrease (Osterwald et al., 2015)  
HDAC9    decrease (Jamiruddin et al., 2016)  
HMGN5    increase (Osterwald et al., 2015) 
no de novo APB 
formation (telomeric 
sites) (Osterwald et al., 
2015) 
hnRNP 
A2/B1 
yes (Moran-Jones et al., 2005)  yes (McKay & Cooke, 1992)   
HP1a (aka 
CBX1) yes (Jiang et al., 2009) 
yes (Lang et 
al., 2010)  
no effect (Osterwald et 
al., 2015); decrease 
(Jiang et al., 2009) 
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protein 
name (a) 
localized at APBs in ALT-
positive cells (b) 
localized 
in PML-
NBs (c) 
localized at 
normal 
telomeres (d) 
effect of APBs upon 
protein depletion/ 
knockdown (e) 
effect of APBs 
upon 
overexpression/ 
recruitment (f) 
HP1b (aka 
CBX3) yes (Jiang et al., 2009)   
no effect (Osterwald et 
al., 2015); decrease 
(Jiang et al., 2009) 
 
HP1g (aka 
CBX5) yes (Jiang et al., 2009)   
decrease (Osterwald et 
al., 2015); decrease 
(Jiang et al., 2009) 
de novo APB formation 
at telomeric sites 
(Osterwald et al., 2015) 
HSP90 yes (Bhattacharyya et al., 2009)  
no 
(Bhattacharyya 
et al., 2009) 
  
HUS1 yes (Nabetani et al., 2004)   no sign. effect (Osterwald et al., 2015)  
KAT2A 
(aka 
GCN5) 
  yes (Jeitany et al., 2017) 
no effect (Jeitany et al., 
2017) 
overexpression leads to 
decrease (Jeitany et al., 
2017) 
KAT2B 
(aka 
PCAF) 
  no (Jeitany et al., 2017) 
decrease (Jeitany et al., 
2017)  
LSD1 (aka 
KDM1A)    
decrease (Osterwald et 
al., 2015)  
MDC1    no effect (Osterwald et al., 2015)  
MORC3    decrease (Osterwald et al., 2015)  
MRE11 yes (Zhu et al., 2000; Spardy et al., 2008; Cesare et al., 2009) 
yes 
(Lombard & 
Guarente, 
2000) 
 
decrease (Jiang et al., 
2007; Zhong et al., 
2007; O'Sullivan et al., 
2014); no sign. effect 
(Osterwald et al., 2015) 
 
MUS81 yes (Spardy et al., 2008; Zeng et al., 2009)  
no (Zeng et al., 
2009) 
no effect (Osterwald et 
al., 2015)  
NBS1 (aka 
NBN or 
p95) 
yes (Wu et al., 2000; Zhu et al., 
2000; Johnson et al., 2001; Wu et 
al., 2003; Cesare et al., 2009; 
Wilson et al., 2016) 
no (Wu et 
al., 2000)  
decrease (Wu et al., 
2003; Jiang et al., 2007; 
Zhong et al., 2007); no 
effect (Osterwald et al., 
2015) 
de novo APB(-like) 
formation at telomeric 
and pericentric sites 
(Chung et al., 2011) 
NR2C2 yes (Marzec et al., 2015)   decrease (Osterwald et al., 2015)  
NR2F1    no effect (Osterwald et al., 2015)  
NR2F2 yes (Marzec et al., 2015)   decrease (Osterwald et al., 2015)  
NSMCE2 
(aka 
MMS21) 
yes (Potts & Yu, 2007; Chung et 
al., 2011) 
no (Potts & 
Yu, 2007)  
decrease (Potts & Yu, 
2007; Osterwald et al., 
2012; Osterwald et al., 
2015) 
de novo APB(-like) 
formation at telomeric 
and pericentric sites 
(Chung et al., 2011) 
P300    decrease (Jeitany et al., 2017)  
p53 (aka 
TP53) 
partly (Stagno D'Alcontres et al., 
2007)   
no effect (Osterwald et 
al., 2015)  
PARP2 yes (Dantzer et al., 2004)  no (Dantzer et al., 2004) 
decrease (Osterwald et 
al., 2015)  
PCNA yes (Jiang et al., 2009)   
no effect (Jiang et al., 
2009); increase 
(Osterwald et al., 2015) 
 
PML yes (Yeager et al., 1999) yes no (Yeager et al., 1999) 
decrease (Jiang et al., 
2007; Osterwald et al., 
2012; O'Sullivan et al., 
2014; Osterwald et al., 
2015) 
de novo APB(-like) 
formation at telomeric 
and pericentric sites 
(Chung et al., 2011) 
POLH (aka 
Pol h) 
partly (Garcia-Exposito et al., 
2016) 
no (Garcia-
Exposito et 
al., 2016) 
 increase (Garcia-Exposito et al., 2016) 
oe leads to decrease 
(Garcia-Exposito et al., 
2016) 
POT1 yes (Temime-Smaali et al., 2008)   increase (Osterwald et al., 2015)  
RAD1 yes (Nabetani et al., 2004)   no effect (Osterwald et al., 2015)  
RAD17 
yes (Nabetani et al., 2004) partly 
(Nabetani et 
al., 2004) 
no (Nabetani et 
al., 2004) 
no effect (Osterwald et 
al., 2012; O'Sullivan et 
al., 2014; Osterwald et 
al., 2015) 
no effect upon 
recruitment to telomeric 
or pericentric sites 
(Chung et al., 2011) 
RAD18 partly (Garcia-Exposito et al., 2016) 
no (Garcia-
Exposito et 
al., 2016) 
 increase (Garcia-Exposito et al., 2016)  
RAD21 partly (Spardy et al., 2008)     
RAD50 yes (Zhu et al., 2000; Jiang et al., 2007)   
decrease (Jiang et al., 
2007) (Zhong et al., 
2007; Osterwald et al., 
2015) 
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protein 
name (a) 
localized at APBs in ALT-
positive cells (b) 
localized 
in PML-
NBs (c) 
localized at 
normal 
telomeres (d) 
effect of APBs upon 
protein depletion/ 
knockdown (e) 
effect of APBs 
upon 
overexpression/ 
recruitment (f) 
RAD51 yes
 (Yeager et al., 1999; Wu et al., 
2003; Tarsounas et al., 2004)  
yes (Tarsounas 
et al., 2004) 
no effect (Potts & Yu, 
2007; Osterwald et al., 
2015); decrease 
(O'Sullivan et al., 2014) 
de novo APB formation 
at telomeric but not at 
sites) (Chung et al., 
2011) 
RAD51D yes (Tarsounas et al., 2004)  yes (Tarsounas et al., 2004) 
no effect (Osterwald et 
al., 2015)  
RAD52 yes
 (Yeager et al., 1999)   no sign. effect (Osterwald et al., 2015)  
RAD9 
yes (Nabetani et al., 2004) no (Nabetani 
et al., 2004) 
no (Nabetani et 
al., 2004) 
no sign. effect 
(Osterwald et al., 2015) 
de novo APB formation 
at telomeric sites 
(Chung et al., 2011) 
RAP1 
yes (Yeager et al., 1999; Wu et al., 
2003; Cesare et al., 2009; Wilson 
et al., 2016) 
 yes decrease (Jiang et al., 2007)  
RBBP8 
(aka CTIP)    
decrease (O'Sullivan et 
al., 2014)  
RIF1 yes (Silverman et al., 2004)  no (Silverman et al., 2004) 
no effect (Osterwald et 
al., 2015)  
RPA1 
yes (Yeager et al., 1999; Grudic et 
al., 2007; Spardy et al., 2008; 
Cesare et al., 2009) 
no 
(Yankiwski 
et al., 2000; 
Grudic et al., 
2007) 
no (Grudic et 
al., 2007) 
increase (Osterwald et 
al., 2015)  
RPA2 yes
 (Yeager et al., 1999; Grudic et 
al., 2007; O'Sullivan et al., 2014) 
no 
(Yankiwski 
et al., 2000; 
Grudic et al., 
2007) 
no (Grudic et 
al., 2007; 
O'Sullivan et al., 
2014) 
increase (Osterwald et 
al., 2015)  
SENP6    increase (Osterwald et al., 2015)  
SLX4 yes (Sobinoff et al., 2017)    
overexpression leads to 
decrease (Sobinoff et 
al., 2017) 
SMC5 yes (Potts & Yu, 2007) no (Potts & Yu, 2007)  
decrease (Potts & Yu, 
2007)  
SMC6 yes (Potts & Yu, 2007) no (Potts & Yu, 2007)  
decrease (Potts & Yu, 
2007)  
SP100 yes (Chung et al., 2011) yes  
no effect (Jiang et al., 
2007; Osterwald et al., 
2012; Osterwald et al., 
2015) 
overexpression leads to 
a decrease in APBs 
(Jiang et al., 2005) 
STN1 yes (Huang et al., 2017)  no (Huang et al., 2017) 
no effect (Osterwald et 
al., 2015; Huang et al., 
2017) 
 
SUMO1 yes (Chung et al., 2011) 
yes (Muller 
et al., 1998; 
Lang et al., 
2010) 
 
decrease (Osterwald et 
al., 2012; Osterwald et 
al., 2015) 
de novo APB formation 
at telomeric sites 
(Chung et al., 2011) 
SUMO2/3 yes (Chung et al., 2011) partly (Lang et al., 2010)  
decrease (Osterwald et 
al., 2012; Osterwald et 
al., 2015) 
de novo APB formation 
at telomeric sites 
(Chung et al., 2011) 
SUV420H2    decrease (Osterwald et al., 2015)  
TEP1 yes (Bhattacharyya et al., 2009),   
no 
(Bhattacharyya 
et al., 2009) 
no sign. effect 
(Osterwald et al., 2015)  
TIN2 
yes (Cesare et al., 2009; Wilson et 
al., 2016)  yes 
decrease (Jiang et al., 
2007; Osterwald et al., 
2015) 
 
TOP2A yes (Bhattacharyya et al., 2009; Hsieh et al., 2015)  
no 
(Bhattacharyya 
et al., 2009) 
no effect (Osterwald et 
al., 2015); decreased 
(Hsieh et al., 2015) 
 
TOP2B yes (Hsieh et al., 2015)   decreased (Hsieh et al., 2015)  
TOP3A yes (Temime-Smaali et al., 2008)   decrease (Osterwald et al., 2015)  
TP53BP1 
(aka 
53BP1) 
partly (Jiang et al., 2007) 
  
no effect (Jiang et al., 
2007) (Osterwald et al., 
2012; Osterwald et al., 
2015) 
 
TRF1 
yes (Yeager et al., 1999) (Zeng et 
al., 2009; Wilson et al., 2016) 
no yes 
decrease (Jiang et al., 
2007);  
increase (Osterwald et 
al., 2012; Osterwald et 
al., 2015) 
de novo APB(-like) 
formation at telomeric 
and pericentric sites 
(Chung et al., 2011) 
TRF2 
yes (Yeager et al., 1999; Cesare et 
al., 2009; Zeng et al., 2009; 
Osterwald et al., 2012; O'Sullivan 
et al., 2014; Wilson et al., 2016) 
no yes 
decrease (Jiang et al., 
2007; O'Sullivan et al., 
2014);  
no effect (Osterwald et 
al., 2015) 
de novo APB(-like) 
formation at telomeric 
and pericentric sites 
(Chung et al., 2011) 
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protein 
name (a) 
localized at APBs in ALT-
positive cells (b) 
localized 
in PML-
NBs (c) 
localized at 
normal 
telomeres (d) 
effect of APBs upon 
protein depletion/ 
knockdown (e) 
effect of APBs 
upon 
overexpression/ 
recruitment (f) 
UBE2I 
(aka 
UBC9) 
   
decrease (Osterwald et 
al., 2012; Osterwald et 
al., 2015) 
 
USP22 yes (Jeitany et al., 2017) yes (Jeitany et al., 2017) 
no (Jeitany et 
al., 2017) 
no effect (Jeitany et al., 
2017)  
WRN yes (Johnson et al., 2001) no (Johnson et al., 2001)  
no effect (Osterwald et 
al., 2015); decrease 
(Gocha et al., 2014); 
increase (O'Sullivan et 
al., 2014) 
overexpression leads to 
increase 
XRCC6    decrease (Osterwald et al., 2015)  
gH2AX 
yes (Nabetani et al., 2004) (Spardy 
et al., 2008; Cesare et al., 2009; 
Chung et al., 2011) 
  no effect (Osterwald et al., 2015)  
Suppl. table S1. Components of ALT-associated PML-NBs. The table shows a collection of proteins 
that have been reported in the literature in relation to APBs. (a) The first column contains the protein 
name and in some cases an alias. aka stands for also known as. (b) References confirming the 
localization to APBs are listed in the second column. (c) + (d) Some of the proteins also localize to PML-
NBs or telomeres in ALT-negative cells, which is indicated in the third column, whenever information 
was available. (e) + (f) For those protein that have been investigating with regard to APB formation by 
depletion or overexpression, the phenotype is given in column 4 and 5.  
Suppl. table S2. TelNet genes from TCGA data analysis. 
gene symbol gene ID Rho 
p-value  
(Rho) 
log2 expression  
ratio (tumor/normal) 
p-value  
(expr.) 
PRPS2 5634 0.25 4.7E-04 0.21 4.4E-01 
GATA3 2625 0.23 1.1E-03 -0.26 3.6E-01 
ARL4D 379 0.22 1.8E-03 -1.02 8.6E-04 
PDK3 5165 0.22 2.4E-03 0.21 4.5E-01 
FAM58A 92002 0.20 4.2E-03 0.35 2.3E-01 
MRPL34 64981 0.20 5.4E-03 -0.25 3.8E-01 
TSPYL5 85453 0.19 7.6E-03 -0.63 3.5E-02 
SUMO3 6612 0.19 7.8E-03 0.16 5.4E-01 
RGMA 56963 0.16 2.3E-02 -1.10 3.5E-04 
MT1X 4501 0.13 6.0E-02 -1.34 1.4E-05 
FOXP3 50943 0.13 7.3E-02 1.33 1.8E-05 
PPM1K 152926 0.12 8.1E-02 -0.84 5.9E-03 
PAFAH1B3 5050 0.11 1.1E-01 1.41 5.2E-06 
PDGFRA 5156 0.11 1.2E-01 -1.15 1.9E-04 
SLC7A5 8140 0.10 1.6E-01 1.22 7.6E-05 
TAGLN 6876 0.10 1.6E-01 -1.07 4.7E-04 
PYCRL 65263 0.10 1.7E-01 0.93 2.3E-03 
ARHGAP10 79658 0.08 2.4E-01 -0.84 5.5E-03 
SNCG 6623 0.08 2.5E-01 -1.40 6.2E-06 
CHEK1 1111 0.08 2.6E-01 1.03 7.6E-04 
CSRP1 1465 0.08 2.7E-01 -1.10 3.4E-04 
LPIN1 23175 0.08 2.8E-01 -0.78 9.8E-03 
RARRES2 5919 0.07 2.9E-01 -0.92 2.6E-03 
RMI2 116028 0.07 3.0E-01 1.43 3.6E-06 
RECQL4 9401 0.07 3.5E-01 1.77 1.2E-08 
CDC25A 993 0.06 3.8E-01 1.42 4.5E-06 
ATAD2 29028 0.06 4.0E-01 1.13 2.3E-04 
PHYHD1 254295 0.06 4.2E-01 -1.84 3.6E-09 
USP2 9099 0.05 4.5E-01 -1.88 1.6E-09 
CHAF1B 8208 0.05 4.5E-01 1.11 3.2E-04 
EPHX2 2053 0.05 4.7E-01 -1.27 3.7E-05 
HAAO 23498 0.05 4.7E-01 -1.14 2.0E-04 
MCM2 4171 0.05 4.8E-01 1.43 3.8E-06 
MCM4 4173 0.05 4.8E-01 1.13 2.5E-04 
PRKAR2B 5577 0.05 4.9E-01 -1.65 1.1E-07 
TUBB3 10381 0.05 5.0E-01 2.18 2.7E-12 
PRKCB 5579 0.05 5.1E-01 -1.14 2.0E-04 
HMGA1 3159 0.03 6.3E-01 1.18 1.3E-04 
HMGB3 3149 0.03 6.3E-01 1.25 5.3E-05 
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gene symbol gene ID Rho 
p-value  
(Rho) 
log2 expression  
ratio (tumor/normal) 
p-value  
(expr.) 
RNASEH2A 10535 0.03 6.3E-01 1.18 1.3E-04 
DSCC1 79075 0.03 6.4E-01 1.20 9.7E-05 
CCNE1 898 0.03 6.6E-01 1.64 1.2E-07 
POC1A 25886 0.03 6.6E-01 1.15 1.8E-04 
PALM 5064 0.03 7.0E-01 -0.99 1.3E-03 
FEN1 2237 0.03 7.1E-01 1.05 6.4E-04 
RFC4 5984 0.03 7.1E-01 1.04 6.8E-04 
HIST2H4A 8370 0.03 7.1E-01 0.87 4.1E-03 
PDE1B 5153 0.03 7.1E-01 -1.27 3.9E-05 
FOXO1 2308 0.03 7.2E-01 -0.90 3.3E-03 
MCM7 4176 0.02 7.7E-01 0.88 3.7E-03 
CHEK2 11200 0.02 7.7E-01 0.87 4.4E-03 
TNFRSF6B 8771 0.02 7.8E-01 1.16 1.7E-04 
KPNA2 3838 0.02 7.9E-01 1.29 2.9E-05 
PRDM16 63976 0.02 7.9E-01 -1.35 1.2E-05 
BDKRB2 624 0.02 8.0E-01 -0.81 7.8E-03 
HIST1H4H 8365 0.02 8.1E-01 0.94 2.2E-03 
H2AFX 3014 0.01 8.5E-01 0.99 1.2E-03 
EME1 146956 0.01 9.2E-01 1.90 1.1E-09 
NFE2L3 9603 0.01 9.2E-01 1.53 7.5E-07 
FOXN3 1112 0.01 9.3E-01 -0.79 9.0E-03 
CDK1 983 0.00 9.4E-01 1.89 1.2E-09 
CDC20 991 0.00 9.5E-01 2.59 2.2E-16 
PDK4 5166 0.00 9.5E-01 -2.98 <1.0E-17 
CCNB1 891 0.00 9.5E-01 1.71 4.0E-08 
SERPINH1 871 0.00 9.7E-01 0.99 1.3E-03 
PARM1 25849 0.00 9.6E-01 -1.14 2.1E-04 
HNMT 3176 0.00 9.5E-01 -0.80 8.8E-03 
CDCA8 55143 0.00 9.3E-01 2.17 3.4E-12 
NR2F1 7025 -0.01 9.0E-01 -0.94 2.1E-03 
KLF9 687 -0.01 9.0E-01 -1.44 3.4E-06 
ORC1 4998 -0.01 9.0E-01 1.92 6.8E-10 
ORC6 23594 -0.01 8.9E-01 2.01 1.1E-10 
EGR1 1958 -0.01 8.9E-01 -1.41 5.1E-06 
XRCC2 7516 -0.01 8.7E-01 1.77 1.2E-08 
AURKA 6790 -0.01 8.7E-01 1.83 4.1E-09 
CKB 1152 -0.01 8.7E-01 -1.03 8.2E-04 
RACGAP1 29127 -0.01 8.6E-01 1.21 8.5E-05 
TXNIP 10628 -0.01 8.6E-01 -1.21 8.8E-05 
PDLIM2 64236 -0.01 8.5E-01 -0.80 8.6E-03 
ZEB2 9839 -0.01 8.4E-01 -0.97 1.5E-03 
ALPL 249 -0.01 8.4E-01 -0.93 2.3E-03 
PLCL2 23228 -0.02 8.2E-01 -1.11 3.2E-04 
TRIP13 9319 -0.02 8.1E-01 2.14 6.3E-12 
RCC2 55920 -0.02 8.0E-01 1.00 1.1E-03 
ECT2 1894 -0.02 8.0E-01 1.65 1.1E-07 
DNMT3B 1789 -0.02 7.9E-01 1.39 6.9E-06 
BLM 641 -0.02 7.8E-01 1.61 2.3E-07 
CCNA2 890 -0.02 7.6E-01 1.99 1.6E-10 
DDX39A 10212 -0.02 7.3E-01 0.91 2.9E-03 
RAD51AP1 10635 -0.03 7.0E-01 1.66 9.8E-08 
ALDH1A1 216 -0.03 6.9E-01 -1.68 6.7E-08 
RAD51 5888 -0.03 6.9E-01 1.85 2.8E-09 
RAPGEF3 10411 -0.04 5.8E-01 -1.00 1.0E-03 
PRX 57716 -0.04 5.8E-01 -1.21 8.4E-05 
FOXO4 4303 -0.04 5.6E-01 -0.82 7.0E-03 
LMNB1 4001 -0.04 5.4E-01 1.37 8.8E-06 
FOSB 2354 -0.04 5.3E-01 -2.41 1.4E-14 
FOXM1 2305 -0.05 5.1E-01 2.54 4.4E-16 
KIF4A 24137 -0.05 5.1E-01 2.99 <1.0E-17 
FOS 2353 -0.05 4.9E-01 -1.66 9.7E-08 
EXO1 9156 -0.05 4.8E-01 2.57 2.2E-16 
FHL1 2273 -0.05 4.6E-01 -2.63 <1.0E-17 
FOXD2 2306 -0.05 4.6E-01 0.93 2.5E-03 
FANCD2 2177 -0.05 4.5E-01 1.22 8.0E-05 
PLK1 5347 -0.05 4.4E-01 2.46 3.6E-15 
JUN 3725 -0.05 4.4E-01 -0.81 7.8E-03 
MACROD2 140733 -0.05 4.4E-01 -0.90 3.1E-03 
ARRB1 408 -0.06 4.2E-01 -0.98 1.4E-03 
TAL1 6886 -0.06 4.1E-01 -1.40 5.7E-06 
EZH2 2146 -0.06 3.9E-01 1.78 9.9E-09 
E2F1 1869 -0.07 3.5E-01 1.65 1.1E-07 
BRCA2 675 -0.07 3.4E-01 1.29 2.9E-05 
FANCI 55215 -0.07 3.3E-01 1.58 3.3E-07 
AHNAK 79026 -0.07 3.0E-01 -0.92 2.5E-03 
FANCA 2175 -0.09 2.3E-01 1.74 2.3E-08 
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log2 expression  
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ALDH2 217 -0.09 2.3E-01 -1.39 6.8E-06 
TOP2A 7153 -0.09 2.1E-01 2.72 <1.0E-17 
CENPF 1063 -0.09 2.1E-01 2.43 8.4E-15 
ASF1B 55723 -0.09 2.0E-01 2.16 4.4E-12 
KLF4 9314 -0.09 2.0E-01 -1.30 2.7E-05 
PLCE1 51196 -0.09 1.9E-01 -0.86 4.9E-03 
KLF6 1316 -0.10 1.8E-01 -0.87 4.5E-03 
MKI67 4288 -0.10 1.5E-01 2.48 2.0E-15 
KLF2 10365 -0.11 1.4E-01 -1.14 2.2E-04 
BRCA1 672 -0.11 1.3E-01 0.94 2.2E-03 
PPARG 5468 -0.11 1.1E-01 -1.51 1.2E-06 
EPAS1 2034 -0.11 1.1E-01 -1.08 4.5E-04 
SLC7A11 23657 -0.12 1.0E-01 1.85 2.7E-09 
GIGYF2 26058 -0.19 6.6E-03 -0.08 7.2E-01 
PPM1D 8493 -0.20 5.9E-03 -0.30 2.9E-01 
CTNNA1 1495 -0.21 3.6E-03 -0.14 5.9E-01 
ERCC5 2073 -0.21 3.1E-03 -0.18 5.0E-01 
Suppl. table S2. TelNet genes from TCGA data analysis. The table shows a list of TelNet genes that 
were extracted from TCGA data set because their expression either correlates or anti-correlates with 
telomere length changes, or the gene expression is significantly different in tumor over normal samples. 
The columns show the official gene symbol, Entrez gene ID, Correlation coefficient Rho from Pearson 
correlation (telomere length ratio vs log2 expression ratio), p-value of the correlation, log2 expression 
ratio (tumor/normal) and p-value of the expression data. 
Suppl. table S3. DESeq results of SAHA treated U2OS cells. 
gene symbol RefSeq ID 2 µM SAHA/ EtOH 0.5 µM SAHA/ EtOH log2 fold change padj log2 fold change padj 
LOC107985745 XR_001738282 9.67 2.72E-09 5.47 4.35E-03 
LOC105369504 XR_948035 9.43 3.30E-09 5.96 1.23E-03 
CYP4F2 NM_001082 8.95 1.80E-66 5.08 2.10E-20 
LOC105373286 XR_938455 8.34 9.77E-07 6.23 1.32E-03 
LL22NC03-75H12.2 NR_109967 7.94 3.73E-10 4.72 1.16E-03 
LOC101929181 NR_104624 7.54 2.65E-56 3.40 1.07E-10 
LOC105377520 XR_939419 7.48 8.82E-07 4.93 5.94E-03 
LOC105378800 XR_947517 7.15 7.35E-10 3.63 1.11E-02 
LOC102724895 XR_430113 7.14 8.99E-22 4.18 3.99E-07 
CCL20 NM_001130046 7.09 2.50E-66 3.51 1.08E-15 
LOC105374126 XR_924532 7.02 2.68E-13 3.81 6.77E-04 
ARL14EPL NM_001195581 6.95 1.79E-20 3.50 4.07E-05 
LOC105374346 XR_925043 6.95 1.64E-04 5.52 1.07E-02 
LOC107986608 XR_001744188 6.93 7.67E-27 4.16 3.87E-09 
LOC101927421 NR_109882 6.83 8.85E-57 4.86 8.54E-28 
FAM9B NM_205849 6.42 4.22E-53 4.16 3.92E-21 
LOC105374523 XR_001741614 6.36 1.80E-29 2.54 1.62E-04 
LOC105373914 XR_001739905 6.34 1.53E-62 3.56 1.72E-18 
LINC01214 NR_110186 6.05 9.93E-25 2.91 1.93E-05 
LINC01608 NR_125416 5.64 7.89E-23 1.68 3.17E-02 
LINC01517 NR_120652 5.56 5.72E-10 3.38 1.25E-03 
LINC01091 NR_027105 5.54 1.83E-43 4.04 4.00E-22 
LOC107986820 XR_001745270 5.41 2.02E-98 2.79 1.77E-24 
TEX19° NM_207459 5.39 6.31E-57 2.98 3.17E-16 
LOC101929470 NR_125817 5.38 4.02E-29 2.87 8.91E-08 
MYOZ2 NM_016599 5.25 6.63E-17 2.98 2.28E-05 
HLA-DRA NM_019111 5.22 4.21E-13 3.88 8.59E-07 
LOC107987110 XR_001746873 5.21 4.72E-59 3.27 8.67E-22 
MYCT1 NM_025107 5.21 6.26E-65 2.62 3.84E-15 
IL21R NM_021798 5.20 4.12E-61 2.72 1.61E-15 
LOC105373186 XR_949035 5.06 3.39E-17 3.28 8.59E-07 
ERICH1-AS1 NR_073397 5.05 6.09E-174 3.81 6.54E-96 
LOC107986489 XR_001743018 5.04 1.38E-12 2.58 2.46E-03 
SYP NM_003179 5.02 1.60E-136 4.11 6.31E-90 
LOC107986884 XR_001745703 5.01 3.32E-18 2.41 4.13E-04 
CYLC1 NM_001271680 4.98 2.31E-04 3.75 2.02E-02 
LOC105377721 XR_941213 4.98 1.02E-05 3.00 3.31E-02 
NLRP10 NM_176821 4.96 6.18E-30 3.24 5.42E-12 
STMN2 NM_001199214 4.95 1.37E-56 3.35 1.90E-24 
SLC35F4 NM_001206920 4.85 1.40E-42 1.93 3.07E-06 
SLN NM_003063 4.82 3.80E-44 2.64 2.45E-12 
EID3 NM_001008394 4.80 3.50E-43 3.47 3.02E-21 
LOC105377087 XR_001740698 4.77 1.44E-14 2.43 1.03E-03 
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gene symbol RefSeq ID 2 µM SAHA/ EtOH 0.5 µM SAHA/ EtOH log2 fold change padj log2 fold change padj 
LOC105370731 XR_001751442 4.76 8.62E-78 1.99 1.76E-12 
UBE2QL1 NM_001145161 4.75 2.96E-99 2.91 1.15E-35 
PCDH1 NM_001278613 4.74 3.95E-113 3.01 1.94E-43 
LOC105376639 XR_931213 4.71 5.76E-20 2.08 7.27E-04 
LOC107986068 XR_001740619 4.71 6.88E-70 2.62 3.66E-20 
LOC102467223 NR_104678 4.68 1.44E-11 3.50 4.63E-06 
TEKT5 NM_144674 4.66 5.79E-49 2.69 3.03E-15 
LOC105373682 XR_923467 4.60 8.43E-32 3.03 8.22E-13 
LOC105372948 XR_001755437 4.58 2.12E-30 2.40 9.48E-08 
LOC105372773 XR_937655 4.55 3.44E-13 2.44 7.02E-04 
RAB3C NM_001317915 4.54 2.46E-64 3.08 8.13E-28 
LOC107986623 XR_001744259 4.52 5.12E-14 3.61 2.40E-08 
LOC105370302 XR_001749950 4.52 4.03E-71 3.74 6.94E-47 
HLA-DMB NM_002118 4.52 1.24E-22 3.68 4.06E-14 
BIRC3° NM_001165 4.48 5.21E-270 1.61 1.18E-32 
LOC339166 NR_040000 4.44 1.76E-60 1.72 2.36E-08 
FGD2 NM_173558 4.42 1.80E-21 2.96 5.00E-09 
KCNJ15 NM_001276435 4.41 2.08E-27 2.70 1.53E-09 
LINC01317 NR_126403 4.40 2.00E-16 1.94 3.16E-03 
SLC16A12 NM_213606 4.36 3.50E-67 2.72 1.78E-24 
MAPK8IP2 NM_012324 4.36 4.83E-63 2.09 2.70E-13 
XKR7 NM_001011718 4.36 2.66E-32 2.94 1.03E-13 
CXCL8° NM_000584 4.36 6.52E-25 2.38 2.76E-07 
ETV7 NM_001207035 4.33 9.12E-60 1.09 1.10E-03 
TRAF1° NM_001190945 4.32 3.29E-69 2.29 2.33E-18 
DAW1 NM_178821 4.29 7.92E-17 2.82 7.24E-07 
JAKMIP1 NM_001099433 4.28 2.45E-22 2.74 1.32E-08 
IL24° NM_001185156 4.28 1.20E-13 2.27 6.42E-04 
IQGAP2 NM_001285460 4.25 9.68E-123 1.64 4.28E-17 
GABRA1 NM_000806 4.24 2.56E-43 2.14 3.48E-10 
AREG° NM_001657 4.22 4.66E-88 1.82 5.38E-15 
NOL4 NM_001198546 4.21 1.06E-37 2.14 4.97E-09 
KCNK9 NM_001282534 4.21 4.63E-34 2.68 7.39E-13 
TMEM145 NM_173633 4.19 7.31E-14 2.71 1.88E-05 
RGS4 NM_001102445 4.17 8.27E-63 2.46 2.28E-20 
HTR3A NM_000869 4.14 1.88E-35 2.49 7.86E-12 
LOC105376987 XR_001740620 4.13 1.22E-15 1.75 6.78E-03 
LOC105373627 XR_001739714 4.13 2.04E-14 3.31 1.20E-08 
BCO2 NM_001037290 4.11 1.36E-41 1.39 1.51E-04 
LOC105377865 XR_942710 4.10 4.52E-73 0.84 3.91E-03 
LOC101928767 NR_110155 4.10 5.76E-88 1.06 1.61E-05 
LOC105372666 XR_001754669 4.07 8.91E-121 2.43 3.13E-41 
DNAJC12 NM_021800 4.05 1.49E-27 2.85 1.09E-12 
SP140 NM_001005176 4.05 9.38E-106 2.60 1.16E-41 
LOC101928277 XR_001744363 4.04 3.77E-50 1.27 1.25E-04 
LOC105369832 XR_001749198 4.04 1.61E-09 1.85 3.24E-02 
KRT34 NM_021013 4.03 5.57E-19 2.53 2.95E-07 
LOC105379387 XR_001745881 4.00 4.73E-26 3.39 1.18E-17 
LINC01615 NR_132622 4.00 5.56E-23 1.83 1.24E-04 
LOC107985960 XR_001739773 3.98 1.49E-27 2.16 1.42E-07 
CHODL NM_001204174 3.97 1.01E-40 1.19 1.25E-03 
PSG9 NM_001301707 3.96 3.80E-18 3.87 3.07E-16 
LOC101928106 XR_241972 3.93 1.50E-31 1.54 1.19E-04 
ARL14° NM_025047 3.92 3.28E-23 1.88 4.72E-05 
LOC107986429 XR_001742762 3.92 3.56E-68 2.24 5.67E-21 
FILIP1 NM_001289987 3.88 3.09E-22 3.01 1.52E-12 
SYT5 NM_001297774 3.88 5.78E-13 2.53 3.33E-05 
PROSER2-AS1 NR_038222 3.87 7.02E-43 2.12 4.75E-12 
INSL4 NM_002195 3.87 9.70E-04 2.97 3.60E-02 
LIPH° NM_139248 3.86 3.18E-28 2.09 1.02E-07 
LCAL1 NR_130915 3.85 1.35E-59 2.61 4.33E-26 
CYTH4 NM_001318024 3.81 2.24E-29 1.86 1.55E-06 
LOC105374888 XR_926394 3.74 1.80E-11 2.46 9.66E-05 
DES NM_001927 3.74 2.54E-33 0.95 2.12E-02 
COL26A1 NM_001278563 3.69 3.56E-40 0.82 2.92E-02 
SLCO5A1 NM_001146008 3.67 7.41E-69 2.53 3.65E-31 
LOC101926940 NR_104632 3.66 1.35E-32 3.27 1.25E-24 
CHAT NM_001142929 3.66 2.61E-37 2.02 1.29E-10 
LINC00534 NR_051989 3.63 7.57E-05 3.20 1.94E-03 
LINC01088 NR_038342 3.62 1.51E-38 1.46 6.80E-06 
CFAP58-AS1 NR_108036 3.62 2.79E-10 1.94 5.54E-03 
LOC101928477 XR_001748340 3.61 6.95E-33 1.05 6.54E-03 
SPANXD NM_032417 3.58 8.51E-09 1.37 1.14E-01 
DEC1 NM_017418 3.57 3.36E-43 1.96 2.80E-12 
LOC105379849 XR_001747342 3.56 6.43E-07 1.51 1.28E-01 
LOC102724465 XR_001751744 3.56 1.56E-08 1.70 3.61E-02 
LINC00189 NR_027072 3.55 3.19E-32 1.90 1.38E-08 
SCEL NM_001160706 3.55 5.30E-62 2.49 5.43E-29 
NRG3 NM_001010848 3.53 5.13E-14 1.29 2.84E-02 
CCL4 NM_002984 3.52 1.97E-16 2.48 1.27E-07 
LOC107985543 XR_001755440 3.50 2.21E-13 1.85 1.12E-03 
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CTNNA2 NM_001164883 3.49 3.16E-78 2.99 1.90E-55 
C10ORF113 NM_001010896 3.49 1.72E-07 1.52 9.02E-02 
LINC00243 NR_130726 3.48 1.53E-10 2.55 2.72E-05 
LOC107986046 XR_001740566 3.48 3.73E-17 2.83 1.23E-10 
LINC01204 NR_104644 3.47 2.96E-17 1.87 7.31E-05 
LIPK NM_001080518 3.45 4.49E-05 3.26 4.57E-04 
LOC101929294 NR_125808 3.43 7.15E-31 2.40 3.97E-14 
HES7 NM_001165967 3.42 4.24E-10 2.87 1.49E-06 
GLIS3 NM_001042413 3.42 1.57E-12 1.98 3.06E-04 
LOC100507477 NR_121622 3.42 4.86E-18 1.14 2.80E-02 
HECTD2-AS1 NR_024467 3.40 8.48E-27 0.86 4.96E-02 
LOC100996643 XM_003846387 3.38 6.27E-22 2.12 3.57E-08 
LOC285629 NR_027111 3.36 1.47E-121 2.97 1.42E-93 
LGR5 NM_001277226 3.36 2.37E-35 2.32 7.13E-16 
ADCY8 NM_001115 3.34 2.89E-40 1.46 2.77E-07 
B3GALT1 NM_020981 3.33 1.48E-13 1.27 2.39E-02 
PAEP° NM_001018048 3.32 5.66E-07 1.41 1.22E-01 
ACTBL2 NM_001017992 3.31 1.58E-80 1.58 4.28E-17 
OTOGL NM_173591 3.30 1.07E-38 2.60 8.60E-23 
HIST1H1T NM_005323 3.28 8.62E-10 0.85 3.19E-01 
LOC107986098 XR_001740754 3.26 1.38E-07 2.82 3.37E-05 
LOC105376567 XR_001748139 3.26 2.09E-09 3.32 6.41E-09 
LOC107985072 XR_001752885 3.25 7.78E-08 2.04 4.32E-03 
RPLP0P2 NR_002775 3.25 2.03E-59 1.92 2.12E-19 
PTGS1 NM_000962 3.24 7.17E-27 1.83 5.01E-08 
TMEM132C NM_001136103 3.21 1.76E-33 1.72 5.53E-09 
LOC105376387 XR_001747351 3.21 4.01E-08 1.90 6.71E-03 
PMEL NM_001200053 3.20 5.16E-15 1.66 5.26E-04 
TMEM198 NM_001005209 3.19 7.52E-20 1.21 5.51E-03 
LOC146795 NR_135222 3.18 1.65E-54 2.49 6.45E-32 
KCNK15-AS1 NR_132377 3.17 1.46E-08 2.07 1.47E-03 
LOC152225 NR_026934 3.17 7.51E-38 1.79 3.25E-11 
LOC101927947 XR_001741892 3.16 2.52E-24 1.05 7.28E-03 
ANKRD1 NM_014391 3.16 4.38E-176 1.00 3.95E-17 
LOC105376440 XR_930720 3.15 1.98E-03 1.44 3.37E-01 
HYDIN NM_001198542 3.15 3.76E-44 1.78 3.80E-13 
PI3 NM_002638 3.14 4.13E-05 1.55 1.36E-01 
C1ORF54 NM_001301039 3.14 3.08E-07 2.70 6.50E-05 
SYN1 NM_006950 3.14 3.47E-22 1.20 2.59E-03 
RUNDC3A NM_001144825 3.13 4.02E-22 1.98 2.47E-08 
NRG2 NM_001184935 3.13 3.57E-19 1.79 5.34E-06 
MTSS1 NM_001282971 3.12 3.68E-44 1.86 9.21E-15 
DACH2 NM_001139514 3.11 3.29E-25 1.27 3.33E-04 
LOC105375370 XR_001744960 3.11 3.49E-04 3.50 1.66E-04 
SPANXC NM_022661 3.10 2.93E-35 1.55 3.04E-08 
SYN3 NM_001135774 3.10 4.66E-55 1.47 1.43E-11 
FXYD1 NM_001278717 3.09 1.28E-08 1.90 3.14E-03 
PAG1 NM_018440 3.09 7.05E-58 1.32 6.48E-10 
LOC107986639 XR_001744317 3.07 2.79E-13 1.53 2.43E-03 
CYP1A1° NM_000499 3.07 2.70E-22 2.10 9.05E-10 
GRAMD1C NM_001172105 3.07 2.71E-109 1.18 4.10E-15 
TNFRSF19 NM_001204458 3.06 2.42E-23 1.81 1.21E-07 
CLUL1 NM_001289036 3.05 2.06E-12 1.63 1.49E-03 
KCNIP4 NM_001035003 3.05 3.40E-09 1.52 1.46E-02 
LOC107987059 XR_001746645 3.04 8.55E-03 2.65 5.45E-02 
LOC105373954 XR_001739961 3.04 1.73E-14 2.27 1.59E-07 
LOC105377955 XR_942893 3.03 1.78E-07 2.83 6.65E-06 
LOC105378486 XR_946321 3.03 1.45E-19 1.76 2.74E-06 
SFMBT2 NM_001018039 3.03 1.08E-66 1.10 1.60E-08 
SERPINI1 NM_001122752 3.02 2.01E-22 1.71 8.74E-07 
RAET1E NM_001243325 3.01 1.69E-08 1.73 7.33E-03 
LOC107985983 XR_001739876 3.01 1.14E-11 2.31 1.84E-06 
ROBO2 NM_001128929 3.00 3.84E-48 2.52 2.00E-32 
LOC100506922 XR_001739698 3.00 7.24E-49 1.78 3.07E-16 
LOC105376235 XR_930270 3.00 1.04E-05 1.39 1.32E-01 
ADAM28 NM_001304351 2.99 1.78E-25 2.35 9.47E-15 
CD274 NM_001267706 2.97 1.82E-62 2.04 7.55E-28 
ADGRF5 NM_001098518 2.97 1.28E-26 1.30 5.66E-05 
SPANXN3 NM_001009609 2.97 2.30E-32 1.76 1.45E-10 
ADAMTSL1 NM_001040272 2.97 1.78E-70 1.66 7.74E-21 
NCKAP5 NM_207363 2.96 2.61E-18 2.93 7.62E-17 
PPM1J NM_005167 2.95 3.00E-37 1.82 2.88E-13 
FGD6 NM_018351 2.95 3.69E-96 1.18 1.78E-14 
LINC00595 NR_073447 2.95 3.62E-05 1.77 5.00E-02 
PRUNE2 NM_001308047 2.95 1.09E-71 1.92 3.26E-29 
LOC105376602 XR_931143 2.95 4.88E-25 1.78 1.30E-08 
ENPP2 NM_001040092 2.95 2.77E-38 1.66 2.72E-11 
DOCK4 NM_014705 2.95 3.09E-94 1.45 4.37E-22 
LOC105370529 XR_943932 2.94 1.27E-08 1.35 4.29E-02 
LOC107985366 XR_001738535 2.93 6.56E-11 0.93 1.44E-01 
MYOM1 NM_003803 2.92 3.34E-60 0.81 1.58E-04 
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LINC01405 NR_036513 2.92 1.83E-25 1.91 3.92E-10 
SLC18A3 NM_003055 2.92 4.41E-13 1.49 1.83E-03 
TSPAN7 NM_004615 2.91 9.39E-38 1.96 6.29E-16 
KCNA4 NM_002233 2.91 7.59E-15 2.40 2.03E-09 
TET2-AS1 NR_126420 2.91 1.66E-13 0.96 7.31E-02 
LOC105378813 XR_001738114 2.91 1.93E-80 0.66 3.76E-04 
MTUS2 NM_001033602 2.91 2.89E-31 0.89 3.58E-03 
RGS9 NM_001081955 2.91 2.59E-41 1.96 1.28E-17 
LOC105376234 XR_930268 2.91 1.77E-03 2.33 3.65E-02 
LOC105377732 XR_001743000 2.90 5.14E-20 1.70 1.75E-06 
DNM3° NM_001136127 2.90 5.24E-94 1.87 1.39E-37 
HCG27 NR_026791 2.90 1.61E-22 0.71 8.67E-02 
LINC01033 NR_126379 2.90 8.53E-08 1.30 6.72E-02 
UBD NM_006398 2.90 1.17E-04 2.17 1.55E-02 
PAGE4° NM_001318877 2.89 4.01E-07 2.34 2.49E-04 
MIR3189 NR_036156 2.89 5.45E-06 0.60 6.08E-01 
G0S2 NM_015714 2.89 2.46E-10 1.07 8.34E-02 
NID2 NM_007361 2.88 2.58E-19 2.20 1.88E-10 
LINC01456 NR_133641 2.86 1.07E-02 2.68 4.15E-02 
RARB NM_000965 2.86 6.73E-77 1.40 2.13E-17 
LOC105372681 XR_936894 2.86 2.56E-04 4.27 6.72E-08 
ERBB4 NM_001042599 2.86 7.17E-41 1.98 1.65E-18 
LINC00693 NR_038840 2.86 1.35E-14 0.87 8.44E-02 
LINC01449 NR_110832 2.85 1.00E-08 1.76 2.43E-03 
LINC00589 NR_026765 2.84 9.57E-09 1.52 1.28E-02 
TSSC2 NR_024248 2.83 2.38E-11 0.90 1.28E-01 
IL1RAPL1 NM_014271 2.83 1.13E-38 1.17 2.29E-06 
AGBL4-IT1 NR_046839 2.83 1.46E-03 1.49 2.30E-01 
LINC00936 NR_028138 2.82 9.30E-21 1.16 1.48E-03 
ENOX1 NM_001127615 2.81 4.93E-48 1.63 3.29E-15 
ARHGAP22 NM_001256024 2.80 6.53E-28 1.59 1.73E-08 
LOC105377199 XR_001755529 2.80 1.72E-14 1.50 4.33E-04 
HPSE NM_001098540 2.80 7.76E-74 1.35 2.55E-16 
FAM19A3 NM_001004440 2.80 4.47E-07 1.31 7.19E-02 
NECAB1 NM_022351 2.79 1.52E-13 2.42 1.90E-09 
SPANXB1 NM_032461 2.79 4.04E-83 1.36 1.08E-18 
KRTAP2-3 NM_001165252 2.78 2.05E-10 1.37 1.09E-02 
LOC102723803 XR_001746597 2.77 1.84E-12 2.59 4.32E-10 
LOC107986806 XR_001745227 2.77 3.75E-12 1.96 9.78E-06 
ABCB1 NM_000927 2.76 4.54E-95 1.24 4.10E-18 
CRYM NM_001888 2.75 6.85E-24 1.84 4.83E-10 
KCNH7 NM_033272 2.75 2.09E-66 1.42 1.02E-16 
TCEAL7° NM_152278 2.74 2.10E-08 2.03 2.41E-04 
DIRAS2 NM_017594 2.73 3.01E-34 1.82 3.07E-14 
TRIM9 NM_015163 2.73 1.23E-29 1.25 6.14E-06 
NGFR NM_002507 2.73 1.16E-31 1.81 4.07E-13 
LOC102724904 XM_011518105 2.73 4.59E-05 0.89 3.98E-01 
PSG5 NM_001130014 2.72 9.29E-07 2.00 1.66E-03 
MEIKIN NM_001303622 2.72 2.84E-20 2.00 2.89E-10 
ABCD2 NM_005164 2.71 2.32E-18 1.89 2.26E-08 
CD3D NM_000732 2.71 3.16E-05 1.46 8.56E-02 
ARHGDIB NM_001175 2.71 3.29E-07 1.61 1.30E-02 
LOC105377374 XR_939085 2.70 3.02E-22 1.83 1.50E-09 
COL5A3 NM_015719 2.70 1.16E-29 1.05 1.96E-04 
LINC01500 NR_110547 2.69 2.08E-09 0.54 4.89E-01 
ESRRG NM_001134285 2.69 4.14E-41 1.37 5.68E-10 
LOC102724566 XR_001751649 2.68 3.46E-10 1.87 1.12E-04 
LOC107985869 XR_001739409 2.68 4.66E-38 1.21 2.35E-07 
HLA-DQB1 NM_001243961 2.68 2.80E-10 1.96 3.38E-05 
ID4° NM_001546 2.68 6.66E-29 0.45 2.24E-01 
LOC105372572 XR_937384 2.67 2.82E-07 0.79 3.28E-01 
KHDRBS2 NM_152688 2.67 3.97E-54 1.79 5.12E-23 
LOC107984509 XR_001749000 2.66 2.84E-06 0.15 9.07E-01 
LOC101929021 XR_428765 2.66 6.34E-04 1.90 4.72E-02 
ZNF280A NM_080740 2.65 2.57E-12 1.39 2.06E-03 
GDF15° NM_004864 2.65 4.73E-53 1.09 1.66E-08 
SLC5A4 NM_014227 2.63 2.19E-11 0.96 6.93E-02 
ME3 NM_001014811 2.63 9.41E-16 1.12 4.83E-03 
KATNBL1 NM_024713 2.63 4.75E-86 0.42 1.45E-02 
SYTL5 NM_001163334 2.63 1.65E-88 1.99 2.76E-49 
BTG4 NM_017589 2.63 7.65E-16 0.91 3.48E-02 
DIRC3-AS1 NR_133642 2.62 5.56E-46 1.48 7.20E-14 
LOC107985677 XR_001755774 2.62 4.94E-10 2.13 3.67E-06 
PSG4 NM_001276495 2.62 7.83E-36 1.95 1.36E-18 
KCNA1° NM_000217 2.62 2.21E-41 1.08 1.09E-06 
ATP1A3 NM_001256213 2.62 2.46E-35 1.57 7.75E-12 
CRLF2 NM_001012288 2.61 2.32E-17 2.03 7.49E-10 
SP110 NM_001185015 2.61 3.22E-57 0.84 8.35E-06 
XIRP2-AS1 NR_046665 2.61 2.15E-13 1.99 2.62E-07 
MT1X NM_005952 2.61 2.09E-67 0.79 5.56E-06 
ADTRP NM_001143948 2.60 3.71E-24 1.97 4.93E-13 
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ZMAT4 NM_001135731 2.60 2.07E-28 1.02 2.57E-04 
LOC105378481 XR_946316 2.59 4.19E-15 1.49 9.00E-05 
ADAMTS9 NM_001318781 2.59 2.75E-25 0.73 2.48E-02 
GOLGA8IP NR_024074 2.59 1.87E-06 1.98 1.33E-03 
RND1 NM_014470 2.58 3.06E-07 1.82 1.80E-03 
LOC107985325 XR_001754012 2.58 1.62E-08 1.39 1.41E-02 
N4BP3 NM_015111 2.58 1.81E-32 1.42 3.07E-09 
CDA NM_001785 2.57 1.25E-18 0.93 1.23E-02 
LOC107984782 XR_001751569 2.57 2.97E-04 1.28 1.95E-01 
HPCAL4 NM_001282396 2.57 2.21E-48 1.70 5.70E-20 
PAQR5 NM_001104554 2.57 3.60E-37 1.09 1.85E-06 
LOC105369949 XR_001749294 2.56 4.07E-08 1.40 1.47E-02 
TNFSF9 NM_003811 2.55 1.07E-74 0.72 8.86E-06 
NEBL NM_001173484 2.55 1.33E-56 1.07 1.73E-09 
CYP4F11 NM_001128932 2.55 5.89E-23 1.36 3.08E-06 
LOC101928046 XR_943988 2.55 2.94E-05 0.41 7.13E-01 
PLCXD2 NM_001185106 2.54 2.25E-98 0.88 3.10E-11 
MALAT1 XR_001748267 2.54 3.41E-08 0.35 6.71E-01 
ROS1 NM_002944 2.54 1.78E-51 1.70 4.94E-22 
OLAH NM_001039702 2.54 1.67E-38 1.80 2.52E-18 
GMFG NM_001301008 2.53 2.02E-11 0.66 2.46E-01 
XIRP1 NM_001198621 2.53 1.62E-27 0.64 4.13E-02 
LOC101929541 NR_125982 2.53 2.06E-04 0.86 4.27E-01 
RIMKLA NM_173642 2.52 8.57E-39 1.26 3.12E-09 
APBA1 NM_001163 2.51 8.00E-44 1.29 6.07E-11 
LUM NM_002345 2.51 2.62E-68 1.40 1.43E-20 
EGOT NR_004428 2.51 2.52E-09 1.58 1.21E-03 
GPRIN3 NM_198281 2.51 4.35E-33 1.18 5.01E-07 
DNAAF3 NM_001256714 2.50 9.37E-27 1.66 4.02E-11 
DGKI NM_001321708 2.50 1.67E-18 1.40 1.53E-05 
LOC105378394 XR_946141 2.50 2.69E-14 2.87 1.29E-17 
LOC101927653 NR_120452 2.50 2.99E-24 2.49 1.20E-22 
KCTD15 NM_001129994 -2.51 1.48E-46 -1.10 1.35E-09 
CCNB2° NM_004701 -2.51 2.16E-71 -0.81 8.48E-08 
PLK4° NM_001190799 -2.52 1.11E-50 -0.57 3.22E-03 
STAT5A NM_001288718 -2.52 1.21E-16 -1.15 4.57E-04 
ZWINT NM_001005413 -2.52 1.64E-80 -0.34 4.97E-02 
POU6F1 NM_002702 -2.53 2.04E-07 -1.17 3.92E-02 
LOC105372707 XR_936965 -2.53 7.32E-10 -0.90 6.98E-02 
FANCD2 NM_001018115 -2.54 1.29E-77 -0.60 7.34E-05 
ZNF726 NM_001244038 -2.55 1.55E-11 -0.41 4.67E-01 
LOC105374378 XM_011533215 -2.55 4.14E-29 -0.97 8.27E-05 
LOC100507377 NR_038300 -2.55 1.04E-03 -1.29 1.84E-01 
MCM5° NM_006739 -2.55 2.97E-104 -0.77 8.66E-10 
BMPR1B NM_001203 -2.57 8.98E-30 -1.83 5.29E-15 
HIST1H2AJ° NM_021066 -2.57 7.35E-58 -0.32 1.44E-01 
LOC102723591 XR_430558 -2.57 5.41E-11 -1.36 1.42E-03 
TMPO-AS1 NR_027157 -2.58 4.72E-07 -0.69 3.24E-01 
SOX2-OT NR_004053 -2.58 1.06E-22 -1.97 3.80E-13 
NAPA-AS1 NR_038452 -2.60 6.79E-08 -0.89 1.35E-01 
HIST1H4I NM_003495 -2.60 1.66E-72 -0.25 2.07E-01 
LPCAT2 NM_017839 -2.61 5.60E-17 -0.27 5.83E-01 
IL17RB NM_018725 -2.61 1.15E-08 -1.61 1.13E-03 
SYTL1 NM_001193308 -2.61 3.84E-09 -1.91 5.81E-05 
PLCH1 NM_001130960 -2.62 1.33E-15 -1.63 2.26E-06 
RBP4 NM_001323517 -2.63 2.92E-03 -2.73 6.53E-03 
TUBA1B° NM_006082 -2.63 2.10E-99 -0.59 2.94E-05 
TNFRSF11B NM_002546 -2.63 1.76E-60 -0.97 1.31E-08 
HIST1H2BN NM_003520 -2.64 1.54E-43 -0.60 5.37E-03 
CYBRD1 NM_001127383 -2.64 2.01E-50 -1.06 1.36E-08 
LOC105372652 XR_001754661 -2.64 4.24E-05 -2.09 3.36E-03 
KIAA0101° NM_001029989 -2.65 2.15E-85 -0.60 5.67E-05 
RAD51AP1 NM_001130862 -2.66 1.07E-57 -0.65 5.06E-04 
HIST1H2AI NM_003509 -2.67 2.97E-51 -0.43 5.98E-02 
TP73° NM_001126240 -2.67 5.04E-16 -0.54 2.00E-01 
MIAT NR_003491 -2.67 8.12E-28 -1.04 1.20E-04 
FLJ22447 NR_039985 -2.68 4.54E-63 -1.34 2.33E-16 
CERS3-AS1 NR_120374 -2.68 2.05E-18 -0.83 1.72E-02 
FAIM NM_001033030 -2.68 2.98E-14 -1.15 2.66E-03 
SPC25° NM_020675 -2.69 1.10E-54 -0.44 3.48E-02 
HIST1H2BL NM_003519 -2.69 2.96E-52 -0.20 4.80E-01 
EDN2 NM_001302269 -2.69 9.87E-17 -0.30 5.56E-01 
MXD3 NM_001142935 -2.70 1.86E-54 -1.02 1.95E-08 
FBXW4 NM_001323541 -2.71 8.02E-13 -1.47 2.50E-04 
NMI NM_004688 -2.71 2.10E-23 -1.34 2.25E-06 
MFAP2 NM_001135247 -2.71 1.72E-74 -0.98 1.22E-10 
MTMR9LP NR_026850 -2.72 1.55E-10 -0.81 1.14E-01 
TNNC1 NM_003280 -2.73 2.32E-55 -0.91 1.58E-06 
CD34 NM_001025109 -2.73 3.80E-07 -1.86 1.34E-03 
PMF1-BGLAP NM_001199661 -2.75 2.89E-54 -1.23 8.18E-12 
SELENOP° NM_001085486 -2.76 1.48E-14 -1.74 3.71E-06 
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CDK3 NM_001258 -2.76 1.13E-13 -1.12 5.84E-03 
CEBPD NM_005195 -2.76 9.52E-13 -1.64 6.04E-05 
SCARNA1 NR_002997 -2.76 1.26E-04 -0.80 4.13E-01 
MIR4771-2 NR_039929 -2.76 1.55E-02 -0.75 6.70E-01 
HIST1H2AH° NM_080596 -2.76 7.27E-98 -0.41 1.17E-02 
IQGAP3 NM_178229 -2.77 6.56E-111 -0.63 3.33E-06 
HIST1H2BM NM_003521 -2.77 2.88E-56 -0.23 3.88E-01 
LINC01348 NR_027454 -2.77 2.70E-21 -0.16 7.48E-01 
ABCB9 NM_001243013 -2.79 1.25E-61 -1.99 1.32E-31 
TMEM42° NM_144638 -2.80 4.47E-03 -0.57 7.09E-01 
PMF1 NM_001199653 -2.81 3.98E-54 -1.25 8.47E-12 
WNT3A NM_033131 -2.81 7.88E-21 -0.99 2.18E-03 
TRIL NM_014817 -2.81 3.01E-14 -1.50 1.12E-04 
ZNF428 NM_182498 -2.82 6.78E-52 -1.20 1.67E-10 
HIST1H2BF NM_003522 -2.82 2.72E-102 -0.52 5.85E-04 
CYS1 NM_001037160 -2.83 2.37E-22 -0.96 2.43E-03 
FOXM1 NM_001243088 -2.84 4.42E-95 -0.68 4.18E-06 
COL16A1 NM_001856 -2.84 8.61E-121 -0.77 2.42E-09 
HIST1H4H NM_003543 -2.84 4.38E-127 -0.66 3.43E-07 
AP1M2 NM_001300887 -2.84 8.97E-57 -1.12 2.44E-09 
MYH16 NR_002147 -2.86 4.40E-05 -1.21 1.51E-01 
PARP10 NM_001317895 -2.86 8.95E-56 -1.17 2.60E-10 
FOXS1 NM_004118 -2.87 1.92E-22 -1.76 3.46E-09 
GPR87 NM_023915 -2.88 1.77E-21 -0.95 3.78E-03 
CRYBB1 NM_001887 -2.88 7.15E-04 -0.22 8.81E-01 
HIST1H3D NM_003530 -2.88 4.28E-104 -0.53 5.62E-04 
EHF NM_001206615 -2.89 1.62E-09 -3.19 6.58E-10 
HAPLN1 NM_001884 -2.89 2.17E-88 -0.58 5.37E-04 
APOL6° NM_030641 -2.92 2.07E-41 -1.38 5.62E-10 
HIST1H2AD° NM_021065 -2.92 5.63E-88 -0.67 5.16E-05 
CDHR1 NM_001171971 -2.92 1.96E-35 -1.70 6.50E-13 
KLF17 NM_173484 -2.94 9.11E-10 -2.04 4.57E-05 
LOC105371204 XR_942166 -2.95 6.31E-57 -0.98 6.08E-07 
SERPINH1° NM_001207014 -2.96 2.80E-98 -1.00 2.69E-11 
LSP1 NM_001013253 -2.98 8.86E-16 -1.96 2.05E-07 
LOC107984172 XR_001747287 -2.98 2.34E-03 -1.75 1.30E-01 
JAM2 NM_001270407 -3.00 3.98E-24 -1.66 2.62E-08 
HOXD11 NM_021192 -3.00 3.53E-05 -1.42 9.18E-02 
GPR1 NM_001098199 -3.01 3.81E-16 -1.90 4.81E-07 
MIR6875 NR_106935 -3.02 2.76E-03 -0.31 8.57E-01 
HIST1H2BJ NM_021058 -3.02 2.60E-142 -0.56 2.71E-05 
GTF3C6 NM_138408 -3.02 6.66E-37 -1.42 4.38E-09 
LOC101929504 NR_125863 -3.03 3.29E-11 -0.56 3.62E-01 
LTBP2 NM_000428 -3.03 1.90E-130 -1.38 5.46E-28 
HIST1H2AG NM_021064 -3.04 1.54E-102 -0.52 1.93E-03 
LCTL NM_001278562 -3.04 2.49E-53 -1.72 7.75E-18 
H2AFY2 NM_018649 -3.05 5.65E-67 -1.29 3.90E-13 
MAP1LC3C NM_001004343 -3.06 7.94E-07 -1.50 2.96E-02 
LOC107984308 XR_001748118 -3.07 9.00E-04 -1.88 7.47E-02 
LOC107985534 XR_001755607 -3.07 4.84E-23 -0.41 3.21E-01 
MOV10L1 NM_001164104 -3.08 1.78E-18 -2.29 1.13E-10 
HIST1H3B° NM_003537 -3.08 6.45E-117 -0.67 1.01E-05 
HIST1H2BC NM_003526 -3.10 4.52E-121 -0.56 2.22E-04 
LOXL1 NM_005576 -3.11 1.72E-100 -0.66 2.61E-05 
TYMS NM_001071 -3.12 2.38E-113 -0.93 9.93E-11 
ALPL NM_000478 -3.12 1.58E-11 -2.37 6.34E-07 
JAK3 NM_000215 -3.16 1.47E-19 -1.56 1.32E-05 
NXPH2 NM_007226 -3.18 2.33E-45 -1.38 7.51E-10 
PHF11 NM_001040443 -3.19 5.13E-17 -1.37 4.30E-04 
CST5 NM_001900 -3.20 7.80E-04 -2.22 3.62E-02 
HIST2H2AB° NM_175065 -3.21 1.11E-116 -0.82 5.49E-08 
LOC105377390 XR_939106 -3.23 6.39E-08 -1.90 2.43E-03 
PRSS2 NM_001303414 -3.23 1.03E-03 -2.69 1.42E-02 
FAP NM_001291807 -3.24 1.17E-18 -1.50 5.23E-05 
HIST1H2AB NM_003513 -3.25 2.20E-106 -0.73 8.35E-06 
XKR5 NM_001289973 -3.26 4.74E-09 -1.23 4.72E-02 
LOC105377067 XR_940804 -3.27 7.24E-09 -1.67 5.55E-03 
EPCAM NM_002354 -3.30 4.71E-13 -1.48 1.79E-03 
GALNT15 NM_001319051 -3.31 8.63E-19 0.07 9.26E-01 
FGF21° NM_019113 -3.31 1.66E-10 -1.18 3.71E-02 
LRRN4 NM_152611 -3.31 1.31E-10 -0.98 9.70E-02 
SOX2° NM_003106 -3.32 1.73E-28 -2.30 2.71E-14 
MATN2 NM_001317748 -3.32 3.44E-70 -1.44 3.95E-15 
LOC105378314 XR_001747454 -3.33 8.26E-18 -1.81 3.44E-06 
LOC105378313 XR_001747453 -3.34 7.59E-05 -2.21 1.72E-02 
LINC01173 NR_132376 -3.36 1.76E-07 -1.29 7.19E-02 
LINC00452 NM_001278674 -3.38 6.74E-133 -0.54 4.86E-04 
HIST1H2AK NM_003510 -3.43 8.92E-68 -0.58 7.25E-03 
LOC105372981 XR_938124 -3.49 5.55E-48 -1.39 2.56E-09 
HIST1H4A NM_003538 -3.53 5.34E-94 -0.50 1.41E-02 
LINC00689° NR_024394 -3.55 3.51E-10 -1.16 6.13E-02 
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ANXA8L1 NM_001098845 -3.56 1.14E-07 -2.31 7.56E-04 
DMTN NM_001114135 -3.58 8.31E-17 -1.27 3.82E-03 
DENND2A NM_001318052 -3.58 3.51E-40 -1.06 1.13E-04 
MIR6799 NR_106857 -3.61 2.37E-11 -0.26 7.58E-01 
SERPINA3 NM_001085 -3.63 9.38E-05 -2.58 9.35E-03 
LOC102723594 XR_427017 -3.65 1.74E-04 -0.97 4.32E-01 
LOC105373411 XR_001739274 -3.69 1.23E-31 -2.40 2.71E-15 
MYCN NM_001293228 -3.70 1.06E-20 -1.17 3.69E-03 
CCL24 NM_002991 -3.70 1.19E-20 -2.01 1.52E-07 
DRD1 NM_000794 -3.74 1.59E-50 -1.61 6.57E-11 
MIR4635 NR_039778 -3.75 7.04E-05 -2.03 4.36E-02 
CCL2 NM_002982 -3.77 6.07E-79 -1.23 1.36E-09 
WNT5B NM_030775 -3.78 1.68E-19 -2.74 2.04E-11 
C5ORF46 NM_206966 -3.80 8.80E-62 -1.34 5.92E-09 
SLC12A7 NM_006598 -3.81 1.69E-175 -1.73 3.68E-38 
TRIM22 NM_001199573 -3.82 5.54E-64 -1.95 5.59E-19 
PTP4A3 NM_007079 -3.85 5.37E-24 -1.56 3.04E-04 
UBA7 NM_003335 -3.85 4.72E-12 -2.85 2.23E-07 
LOC107984684 XR_001750691 -3.92 5.27E-07 -3.09 1.04E-04 
KRT75 NM_004693 -4.00 2.60E-147 -0.90 2.13E-08 
HRCT1 NM_001039792 -4.02 2.06E-08 -2.48 4.22E-04 
KRT14 NM_000526 -4.09 3.02E-12 -2.82 6.32E-07 
LOC107985005 XR_001752991 -4.13 6.63E-04 -1.75 1.81E-01 
C6ORF15 NM_014070 -4.15 2.88E-89 -2.26 8.48E-30 
LOC105369395 XR_950328 -4.17 2.71E-06 -2.83 1.96E-03 
ZXDB NM_007157 -4.19 2.46E-151 -0.98 3.11E-09 
CACNG6 NM_031897 -4.23 6.88E-21 -2.99 1.78E-12 
ZXDA NM_007156 -4.25 6.76E-159 -0.81 5.58E-07 
LINC01429 NR_110016 -4.27 1.93E-19 -2.43 2.40E-08 
PALMD° NM_017734 -4.32 1.40E-05 -2.97 2.75E-03 
LOC105376672 XR_946890 -4.33 7.60E-10 -2.08 1.59E-03 
SCX NM_001080514 -4.41 2.88E-110 -1.05 1.53E-08 
LOC107985401 XR_001754648 -4.46 1.10E-25 -1.72 4.00E-06 
WNT11 NM_004626 -4.51 2.03E-10 -3.45 6.23E-06 
PODNL1 NM_001146254 -4.53 3.13E-14 -2.65 1.40E-06 
LOC105371401 XR_933873 -4.55 4.52E-62 -1.86 3.26E-15 
SALL4 NM_001318031 -4.63 1.70E-32 -2.95 7.91E-18 
LOC107985006 XR_001752992 -4.76 1.25E-05 -1.37 2.33E-01 
C2ORF54 NM_001085437 -4.81 1.97E-05 -3.87 4.47E-04 
TRIM17 NM_001024940 -4.82 4.19E-10 -2.52 2.07E-04 
LOC105377978 XR_942935 -4.92 3.46E-06 -2.62 4.96E-03 
LOC101928100 NR_120430 -4.99 1.16E-78 -1.84 1.99E-16 
CCDC129 NM_001257967 -5.14 7.67E-47 -1.20 1.47E-05 
CD180 NM_005582 -5.19 4.97E-04 -2.49 6.08E-02 
RARRES2 NM_002889 -5.29 3.30E-12 -3.58 1.73E-08 
LOC107986370 XR_001742490 -5.38 1.19E-14 -2.27 2.71E-03 
LOC105379461 XR_001752103 -5.39 1.57E-06 -0.57 6.58E-01 
LINC00639 NR_039982 -5.52 5.81E-21 -2.29 2.18E-07 
LOC107985377 XR_001737789 -6.25 1.93E-06 -3.38 1.84E-04 
TNNT2 NM_000364 -6.70 4.53E-31 -3.24 4.24E-21 
SYT8 NM_001290332 -6.85 1.82E-08 -3.82 1.25E-07 
SHISA3° NM_001080505 -7.44 7.56E-06 -3.11 5.45E-04 
CXCL14 NM_004887 -7.60 9.95E-35 -3.46 6.80E-08 
Suppl. table S3. DESeq results of SAHA treated U2OS cells. 318 up- and 183 downregulated genes 
with a log2 fold change (l2fc) <-2.5 or >2.5 for 2 µM SAHA over EtOH ctrl while the l2fc of 0.5 µM SAHA 
over EtOH ctrl was either not statistical significant or in the same direction. The adjusted p-value was 
set to padj <0.05 and genes with an RPKM >1 in the highest expressed sample were selected for this 
table. Genes were sorted by l2fc (2 µM SAHA over EtOH ctrl). Those genes implemented in the TelNet 
database were marked in bold, genes reported to be cell cycle-regulated in U2OS cells (Grant et al., 
2013) were marked with a °circle. 
Suppl. table S4. Differentially expressed genes in HeLa LT vs ST cells. 
 
gene symbol RefSeq ID log2 fold change padj 
DPT NM_001937 10.06 3.24E-104 
CCL2 NM_002982 9.24 4.30E-09 
LOC107985950 XR_001739738 9.15 3.85E-08 
CDH19 NM_001271028 8.96 2.11E-20 
SLC16A14 NM_152527 8.85 2.66E-35 
LINC01234 NR_110025 8.67 2.01E-02 
RARRES2 NM_002889 8.26 1.35E-35 
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SSTR2 NM_001050 8.24 3.65E-11 
ATF7IP2 NM_001256160 8.20 2.78E-21 
GREM2 NM_022469 8.17 1.90E-78 
C14ORF132 NM_001252507 8.16 3.05E-36 
PBDC1 NM_001300888 8.14 3.99E-06 
LOC102723724 XR_001744390 7.99 4.66E-02 
MIR3606 NR_037401 7.84 4.12E-07 
ANXA3 NM_005139 7.82 5.29E-44 
LOC107986438 XR_001742827 7.81 1.33E-17 
SNTB1 NM_021021 7.74 1.18E-21 
GBP1 NM_002053 7.61 4.26E-05 
ARMCX1 NM_016608 7.56 7.29E-09 
SLC1A3 NM_001166695 7.55 1.54E-33 
COL3A1 NM_000090 7.49 4.56E-07 
LOC107985951 XR_001739740 7.46 1.18E-08 
NPY1R NM_000909 7.44 2.23E-03 
MIR1266 NR_031670 7.43 1.22E-03 
M1AP NM_001281295 7.43 2.48E-03 
SLC12A7 NM_006598 7.42 9.15E-08 
MPZL2 NM_005797 7.33 1.61E-04 
EMB NM_198449 7.28 2.61E-08 
KCNG1 NM_002237 7.21 2.13E-14 
MIR1245A NR_031647 7.20 4.94E-02 
LINC00517 NR_135286 7.20 3.96E-05 
SMIM3 NM_032947 7.19 1.44E-11 
TRIM6 NM_001003818 7.18 1.07E-04 
TSTD1 NM_001113205 7.18 1.23E-11 
CARD16 NM_001017534 7.11 3.13E-64 
LOC105370057 XR_001749368 7.04 4.43E-03 
GPR183 NM_004951 6.97 1.01E-41 
LGALS8 NM_006499 6.95 5.00E-32 
MIR3611 NR_037405 6.91 7.37E-03 
DCP1B NM_001319292 6.89 4.92E-07 
LOC101060400 XR_934821 6.88 3.85E-04 
TMEM47 NM_031442 6.84 4.49E-59 
PLPPR4 NM_001166252 6.83 8.96E-04 
DIO3 NM_001362 6.82 4.30E-04 
LOC107986653 XR_001744391 6.81 1.14E-02 
GYS2 NM_021957 6.77 1.68E-48 
LOC440934 NR_136638 6.75 1.11E-06 
LOC107985369 XR_001738560 6.71 7.22E-09 
PCDHB12 NM_018932 6.70 1.54E-02 
FUT4 NM_002033 6.63 1.97E-02 
LOC107985638 XR_001755998 6.63 2.73E-06 
MYOM3 NM_152372 6.62 6.88E-04 
LOC728755 XR_943665 6.58 8.75E-14 
EPHX4 NM_173567 6.56 4.52E-09 
LUM NM_002345 6.56 1.23E-50 
LOC107986128 XR_001740894 6.55 2.62E-02 
AGK NM_018238 6.54 8.81E-55 
LOC107984581 XR_001750003 6.49 2.87E-02 
THBD NM_000361 6.48 3.10E-02 
ZC4H2 NM_001178032 6.48 1.80E-10 
MIR4755 NR_039911 6.43 2.13E-03 
LOC105374144 XR_001740944 6.41 3.70E-02 
GSTM1 NM_000561 6.41 1.12E-10 
KCNJ18 NM_001194958 6.41 3.84E-02 
B3GNT5 NM_032047 6.39 4.04E-03 
ZNF726 NM_001244038 6.38 3.26E-03 
PLBD1 NM_024829 6.38 3.20E-03 
RGS18 NM_130782 6.36 3.10E-02 
SLC22A15 NM_018420 6.33 4.81E-08 
DOK7 NM_001164673 6.32 7.89E-08 
PARP8 NM_001178055 6.25 1.79E-32 
MYO5C NM_018728 6.24 3.68E-57 
C22ORF34 NM_001289922 6.23 4.14E-03 
CNNM1 NM_020348 6.23 1.65E-09 
MIR4635 NR_039778 6.21 4.82E-02 
LINC00960 NR_040004 6.16 8.87E-03 
KCNE4 NM_080671 6.13 2.17E-09 
LOC101929028 XR_001745817 6.04 6.91E-24 
LBH NM_030915 6.03 5.01E-22 
NKD2 NM_001271082 6.01 1.16E-02 
ZNF32 NM_001005368 6.00 6.83E-27 
RORA NM_002943 5.97 7.70E-24 
DEFB1 NM_005218 5.93 8.78E-03 
ADARB2 NM_018702 5.91 1.17E-03 
MAN1A1 NM_005907 5.90 2.64E-03 
HSD17B2 NM_002153 5.88 2.35E-19 
HMX2 NM_005519 5.88 1.21E-02 
CCDC152 NM_001134848 5.88 1.86E-11 
   Appendix 
 127 
 
gene symbol RefSeq ID log2 fold change padj 
LOC107985961 XR_001739793 5.82 1.18E-09 
SYTL4 NM_001129896 5.82 2.14E-03 
ETV1 NM_001163147 5.81 7.97E-32 
TSPAN15 NM_012339 5.76 2.13E-07 
FAM169A NM_015566 5.75 2.38E-10 
MCOLN2 NM_153259 5.74 1.73E-19 
LOC101929494 XR_429962 5.74 1.30E-03 
ATP6V0E2 NM_001100592 5.73 1.72E-18 
LOC105373936 XR_923998 5.72 5.15E-04 
PCDHB15 NM_018935 5.72 1.99E-03 
MPPED2 NM_001145399 5.72 9.19E-04 
PCDHB11 NM_018931 5.66 3.70E-02 
CD70 NM_001252 5.64 6.08E-25 
STARD5 NM_181900 5.63 4.22E-02 
ECHDC2 NM_001198961 5.59 3.24E-16 
ARSD NM_001669 5.59 1.43E-06 
CTSH NM_001319137 5.58 2.04E-10 
CHRM3 NM_000740 5.56 9.86E-19 
GGT5 NM_001099781 5.55 1.06E-03 
FAM155A-IT1 NR_046848 5.54 1.29E-03 
CYP39A1 NM_001278738 5.52 1.13E-03 
CARD6 NM_032587 5.47 1.40E-55 
LINC00051 NR_024378 5.47 1.80E-03 
ARHGAP22 NM_001256024 5.47 8.33E-09 
COL6A1 NM_001848 5.47 4.92E-12 
PDGFD NM_025208 5.46 4.12E-10 
PNMA2 NM_007257 5.45 1.28E-20 
LINC00996 NR_034033 5.45 4.90E-02 
STAP2 NM_001013841 5.44 1.06E-12 
UCHL1 NM_004181 5.44 7.47E-08 
KIAA1107 NM_015237 5.43 1.88E-10 
MSR1 NM_002445 5.40 3.81E-02 
SULF2 NM_001161841 5.39 8.25E-03 
MCF2L2 NM_015078 5.38 2.65E-09 
ISL1 NM_002202 5.37 4.81E-02 
TNFRSF11B NM_002546 5.36 1.44E-22 
TARP NM_001003799 5.35 4.72E-04 
LOC107985702 XR_001755822 5.34 9.07E-03 
TSNARE1 NM_001291931 5.34 4.31E-09 
INTS6L NM_182540 5.32 6.43E-07 
SLC40A1 NM_014585 5.31 2.55E-03 
PTGS1 NM_000962 5.28 1.05E-30 
EGF NM_001178130 5.25 3.51E-08 
FAM43A NM_153690 5.24 1.06E-26 
CPEB1 NM_001079533 5.23 2.88E-06 
ACTG2 NM_001199893 5.20 8.19E-11 
LINC00623 NR_024510 5.18 2.28E-03 
SEMA3A NM_006080 5.17 1.55E-03 
RIMS4 NM_001205317 5.14 5.52E-07 
JSRP1 NM_144616 5.12 2.98E-06 
TSPAN2 NM_001308315 5.11 1.79E-10 
CACHD1 NM_001293274 5.11 2.84E-12 
IGFBP1 NM_000596 5.08 7.87E-03 
LOC100506691 NR_135044 5.07 1.62E-20 
PTPRE NM_001316676 5.06 9.42E-07 
ATP6V0E2-AS1 NR_027040 5.04 9.78E-05 
NRG1 NM_001159995 5.04 8.85E-27 
SNPH NM_001318234 5.01 1.59E-02 
PLXDC2 NM_001282736 5.01 2.04E-07 
NME8 NM_016616 5.01 4.87E-11 
ADAM19 NM_033274 5.01 1.80E-02 
RYR2 NM_001035 4.99 1.53E-32 
HPGD NM_000860 4.98 1.81E-11 
CMTM8 NM_001320308 4.98 1.29E-06 
LOC101927503 NM_001323425 4.96 9.78E-05 
EREG NM_001432 4.95 9.21E-04 
GPX7 NM_015696 4.95 2.63E-02 
FAM155A NM_001080396 4.93 4.01E-13 
LINC00942 NR_028415 4.89 7.41E-21 
PCDHB2 NM_018936 4.89 1.77E-02 
NKX3-1 NM_001256339 4.89 2.67E-14 
MAGEA3 NM_005362 4.89 6.46E-30 
SLITRK6 NM_032229 4.88 1.40E-06 
CTSS NM_001199739 4.87 1.89E-15 
SLC25A27° NM_001204051 4.87 1.01E-11 
RANBP3L NM_001161429 4.86 1.39E-03 
SASH1 NM_015278 4.86 5.19E-10 
PTGS2 NM_000963 4.85 3.27E-53 
STK39 NM_013233 4.81 6.33E-32 
MIR6724-3 NR_128716 4.78 3.62E-03 
HYLS1 NM_001134793 4.78 5.26E-04 
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LOC105377794 XR_941373 4.73 3.80E-03 
ANGPT1 NM_001146 4.70 3.61E-41 
MMP7 NM_002423 4.68 3.64E-03 
PRCD NM_001077620 4.68 5.07E-07 
PIEZO2 NM_022068 4.66 5.68E-18 
FST NM_006350 4.66 1.81E-18 
ADGRG6° NM_001032394 4.62 6.50E-08 
MGLL NM_001003794 4.61 1.13E-27 
LOXL1 NM_005576 4.61 9.60E-06 
CPXM2 NM_198148 4.59 1.28E-03 
LOC101927787 NR_125944 4.59 7.60E-03 
RDM1 NM_001034836 4.55 2.74E-04 
LOC102723704 NR_125932 4.51 3.77E-02 
GABBR1 NM_001319053 4.50 3.80E-07 
RASSF6 NM_001270391 4.49 4.95E-04 
SESN3 NM_001271594 4.48 7.57E-10 
PDGFRL NM_006207 4.48 7.35E-13 
SATB1 NM_001131010 4.47 3.83E-16 
C7ORF31 NM_138811 4.45 2.71E-02 
CYFIP2 NM_001037333 4.45 4.93E-06 
GRIP2 NM_001080423 4.43 2.89E-07 
FIBIN NM_203371 4.42 1.63E-08 
LINC01429 NR_110016 4.40 1.03E-21 
TNFSF10 NM_001190942 4.40 1.99E-30 
LANCL3 NM_001170331 4.38 4.54E-05 
RARRES3 NM_004585 4.38 2.31E-17 
CCL26 NM_006072 4.36 1.12E-05 
EPB41L4A NM_022140 4.35 3.71E-13 
XKRX NM_212559 4.35 2.12E-09 
SLC7A2 NM_001008539 4.35 8.42E-44 
PRDM1 NM_001198 4.33 3.76E-08 
HNMT NM_001024074 4.33 6.44E-03 
IQCA1 NM_001270584 4.32 2.33E-06 
TNFAIP6 NM_007115 4.31 7.15E-16 
TNNC1 NM_003280 4.30 3.27E-03 
NOSTRIN NM_001039724 4.28 4.50E-04 
LOC105377329 XR_001741764 4.26 1.34E-02 
OLFML3 NM_001286352 4.25 5.11E-05 
ANGPTL2 NM_012098 4.24 2.17E-05 
LOC105379109 XR_948638 4.24 3.13E-02 
CLDN4 NM_001305 4.22 6.22E-09 
PRR15 NM_175887 4.21 8.78E-03 
SLC19A3 NM_025243 4.20 4.80E-02 
CDHR5 NM_001171968 4.20 1.19E-02 
MPP1 NM_001166460 4.19 4.33E-10 
NIPAL1 NM_207330 4.16 3.13E-19 
GLIPR1 NM_006851 4.15 6.44E-12 
ALS2CL NM_001190707 4.15 1.49E-04 
RBP4 NM_001323517 4.14 4.20E-08 
SLC51B NM_178859 4.14 3.07E-02 
PLEKHH2 NM_172069 4.10 1.03E-10 
AS3MT NM_020682 4.10 9.71E-11 
PLEK2 NM_016445 4.09 3.13E-19 
CPA5 NM_001127441 4.08 2.32E-03 
MMP24 NM_006690 4.07 8.02E-19 
SERPINB5 NM_002639 4.04 1.08E-04 
MMP2 NM_001127891 4.04 4.67E-23 
LOC105379362 XR_949653 4.03 8.14E-04 
SLC2A6 NM_001145099 4.02 3.04E-22 
CCL5 NM_001278736 4.02 7.75E-05 
LINGO2 NM_001258282 -4.00 4.10E-21 
LOC107984928 XR_001737926 -4.02 4.94E-02 
UGT1A9 NM_021027 -4.05 1.01E-03 
KLRK1 NM_007360 -4.08 6.16E-34 
GGT7 NM_178026 -4.12 9.86E-12 
STAC2 NM_198993 -4.16 1.92E-24 
FOXL1 NM_005250 -4.20 6.48E-04 
NLRP1 NM_001033053 -4.21 2.13E-06 
PDK4 NM_002612 -4.22 9.70E-34 
LOC105376346 XR_930538 -4.28 6.52E-03 
ADGRG1 NM_001145770 -4.29 2.14E-22 
HEY2 NM_012259 -4.30 9.82E-03 
A1BG NM_130786 -4.32 3.70E-02 
ADGRG3 NM_001308360 -4.36 4.22E-03 
MYHAS NR_125367 -4.40 1.90E-02 
PCDH7 NM_001173523 -4.41 3.06E-20 
ANKRD18A NM_147195 -4.46 1.97E-12 
UGT1A7 NM_019077 -4.47 4.83E-04 
TLE1 NM_001303103 -4.47 3.89E-04 
KCTD12 NM_138444 -4.47 2.83E-19 
ABCC2° NM_000392 -4.61 1.15E-42 
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ST6GAL1 NM_003032 -4.63 1.06E-14 
ACSL5 NM_016234 -4.75 1.11E-05 
LOC101927523 NR_120624 -4.85 6.68E-03 
MKX NM_001242702 -4.96 3.90E-43 
VIT NM_001177969 -5.02 2.43E-19 
ZNF718 NM_001039127 -5.13 3.76E-16 
LOC284930 NR_122046 -5.14 1.01E-12 
SYTL5 NM_001163334 -5.21 4.75E-35 
UGT1A6 NM_001072 -5.38 2.27E-03 
LOC105371291 XR_933625 -5.41 1.73E-03 
DNM1 NM_001005336 -5.43 1.90E-19 
ISPD NM_001101417 -5.52 1.27E-08 
LOC105369881 XR_945161 -5.58 5.04E-05 
SBSPON NM_153225 -5.68 2.63E-02 
EPB41L3 NM_001281533 -5.76 1.45E-49 
GUCY1A2 NM_000855 -5.80 2.12E-20 
MEF2C NM_001131005 -5.91 5.29E-09 
MCTP2 NM_001159643 -5.93 9.98E-35 
PHF21B NM_001135862 -5.93 1.28E-06 
ZNF91 NM_001300951 -6.03 5.26E-28 
UGT1A1 NM_000463 -6.06 1.10E-02 
UGT1A3 NM_019093 -6.08 1.07E-02 
UGT1A4 NM_007120 -6.14 8.67E-03 
P2RY6 NM_001277204 -6.15 3.97E-15 
RTN4RL2 NM_178570 -6.19 4.30E-19 
UGT1A5 NM_019078 -6.19 7.98E-03 
LOC100128905 NR_136175 -6.33 4.32E-02 
LOC102724488 XM_006718093 -6.38 3.90E-02 
SPARC NM_001309443 -6.39 7.12E-74 
LOC105369688 XR_931419 -6.48 2.93E-02 
MIR5009 NR_049807 -6.53 2.51E-02 
A1BG-AS1 NR_015380 -6.64 2.03E-03 
LOC101928080 XR_930619 -6.66 2.00E-06 
HRCT1 NM_001039792 -6.68 1.62E-02 
MKX-AS1 NR_121652 -6.81 1.07E-02 
HPD NM_001171993 -6.95 3.15E-53 
OTOG NM_001277269 -6.96 6.79E-07 
FAM95C NR_047651 -7.11 3.77E-03 
PALMD NM_017734 -7.12 3.43E-26 
UGT8 NM_001128174 -7.40 8.02E-19 
SPINK13 NM_001040129 -7.59 2.17E-20 
CH17-360D5.1 NM_001278795 -7.60 2.68E-06 
IGSF10 NM_001178145 -7.99 2.88E-53 
NPY4R NM_001278794 -8.28 2.24E-07 
LPL NM_000237 -8.54 1.15E-42 
SLC6A15 NM_001146335 -8.58 3.40E-51 
PRRX1 NM_006902 -8.84 1.58E-08 
LOC105377180 XR_001740794 -8.94 6.19E-14 
LOC105378220 XM_011537717 -9.03 2.54E-14 
PLIN2 NM_001122 -10.24 5.15E-19 
USH1C NM_001297764 -10.61 1.62E-38 
SPINK6 NM_001195290 -11.26 1.65E-08 
PLAC4 NM_182832 -12.42 2.82E-02 
Suppl. table S4. Differentially expressed genes in HeLa LT vs ST cells. 229 higher and 74 lower 
expressed genes with a log2 fold change <-4 or >4 in HeLa LT versus HeLa ST cells. The adjusted p-
value was set to padj<0.05 and only genes with an RPKM >1 in the higher expressed sample were 
selected for this table. Genes were sorted by log2 fold change. Those genes implemented in the TelNet 
database were marked in bold. None of the genes was reported to be cell cycle-regulated in HeLa cells 
(Grant et al., 2013). 
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Suppl. table S5. DESeq results of ASF1 depletion in HeLa ST cells. 
gene symbol RefSeq ID log2 fold change padj 
MIR3975 NR_039771 8.04 3.19E-02 
LOC107984532 XR_001749079 7.12 4.39E-03 
MMP7 NM_002423 6.50 3.27E-03 
CCR4 NM_005508 6.25 4.39E-03 
KBTBD13 NM_001101362 6.15 5.15E-03 
PGPEP1L NM_001102612 5.11 4.43E-02 
CCL5 NM_001278736 3.04 3.64E-05 
CARD16 NM_001017534 3.00 4.93E-06 
SUSD2 NM_019601 2.72 1.63E-03 
NDRG4 NM_001130487 2.42 2.61E-03 
TNFSF15 NM_001204344 2.36 6.47E-04 
SEMA3A NM_006080 2.35 3.85E-02 
MYEOV NM_001293291 2.22 1.64E-04 
ALS2CL NM_001190707 2.21 1.33E-02 
IL7R NM_002185 2.21 9.20E-07 
EPGN NM_001270989 2.12 5.74E-06 
CD177 NM_020406 2.08 1.58E-02 
LOC105371267 NR_136518 2.06 3.08E-02 
LOC101059954 XR_171071 2.06 2.95E-02 
IFIT2 NM_001547 2.02 2.34E-04 
IL6 NM_000600 2.01 2.75E-02 
OASL NM_001261825 2.01 3.85E-04 
SCG2 NM_003469 2.00 1.06E-02 
OAS2 NM_001032731 1.99 3.68E-02 
LOC541472 NR_131935 1.98 4.57E-02 
SRPX2 NM_014467 1.87 7.93E-05 
IFIT3 NM_001031683 1.84 9.60E-04 
THSD4 NM_001286429 1.81 3.62E-08 
LOC105369165 XR_001739464 1.81 4.28E-02 
FAM9B NM_205849 1.79 6.35E-04 
LINC00882 NR_028303 1.75 1.36E-02 
MGC27382 NR_027310 1.74 1.56E-02 
NT5E NM_001204813 1.73 1.72E-02 
H1F0° NM_005318 1.72 5.16E-06 
RARRES3 NM_004585 1.69 4.26E-02 
INPP4B NM_001101669 1.69 1.33E-06 
PARP10 NM_001317895 1.68 4.75E-04 
ISG15 NM_005101 1.67 2.32E-03 
ITGB2 NM_000211 1.66 1.49E-02 
TMEM198 NM_001005209 1.65 3.74E-02 
DHX58 NM_024119 1.64 1.37E-02 
DGKI NM_001321708 1.63 3.00E-02 
LOC105378797 XR_001737670 1.62 4.46E-03 
CEMIP NM_001293298 1.60 2.61E-05 
IFIT1° NM_001270927 1.57 2.15E-02 
GRB7 NM_001030002 1.56 8.51E-03 
NOS1AP NM_001126060 1.55 2.85E-02 
LINC01031 NR_125789 1.54 4.37E-02 
COL7A1° NM_000094 1.52 1.36E-02 
GLIS3 NM_001042413 1.48 6.31E-03 
TNS4 NM_032865 1.47 5.55E-06 
DDX58 NM_014314 1.46 9.98E-06 
IFI44 NM_006417 1.45 3.28E-02 
CPA4 NM_001163446 1.43 2.15E-02 
ITGB4 NM_000213 1.41 8.10E-04 
COL16A1 NM_001856 1.39 8.67E-03 
FIBIN NM_203371 1.37 4.95E-02 
ABCA10 NM_080282 1.35 4.33E-03 
FRY NM_023037 1.34 7.75E-04 
FBXO2 NM_012168 1.33 7.04E-05 
CRABP2 NM_001199723 1.32 2.68E-04 
ANPEP NM_001150 1.32 2.37E-02 
LAMB3 NM_000228 1.30 1.22E-04 
FAAH2 NM_174912 1.30 5.16E-03 
PPM1L NM_001317911 1.28 6.83E-03 
ST18 NM_014682 1.26 1.79E-02 
SETBP1 NM_001130110 1.26 4.36E-02 
CASC15 NR_015410 1.26 2.41E-02 
FST NM_006350 1.25 3.87E-02 
PCED1B NM_001281429 1.23 2.32E-02 
LOC107986812 XR_001745252 1.23 2.90E-02 
SNCG NM_003087 1.21 2.70E-02 
EHF NM_001206615 1.20 2.06E-02 
PLEK2 NM_016445 1.20 3.87E-02 
TNFAIP6 NM_007115 -1.49 3.42E-02 
Suppl. table S5. DESeq results of ASF1 depletion in HeLa ST cells. See next page for table legend.  
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Suppl. table S5. DESeq results of ASF1 depletion in HeLa ST cells. 74 up- and 1 downregulated 
genes with a log2 fold change (l2fc) <-1.2 or >1.2 for siASF1 over siCtrl in HeLa ST cells excluding 
deregulated genes with a l2fc <-1.6 or >1.6 for siASF1 over siCtrl in HeLa LT cells. The adjusted p-value 
was set to padj<0.05 and only genes with an RPKM >1 in the highest expressed sample were selected 
for this table. Genes were sorted by l2fc. Those genes implemented in the TelNet database were marked 
in bold, genes reported to be cell cycle-regulated in HeLa cells (Grant et al., 2013) were marked with a 
°circle. 
Suppl. table S6. DESeq results of ASF1 depletion in HeLa LT cells. 
gene symbol RefSeq ID log2 fold change padj 
RBBP8NL NM_080833 9.10 1.06E-13 
LOC105378977 XR_948342 9.00 2.08E-04 
LOC105372646 XR_936817 8.97 9.42E-08 
CEACAM20 NM_001102597 8.88 2.69E-07 
LOC101928362 XR_001749028 8.86 1.54E-07 
IRGM NM_001145805 8.58 2.54E-04 
LOC105376956 XR_940599 8.56 1.05E-06 
RHAG NM_000324 8.47 2.48E-06 
LOC107985745 XR_001738282 8.13 2.84E-10 
LOC105373471 XR_001738273 7.73 3.94E-09 
LOC105378649 XR_001737980 7.68 7.98E-05 
LOC105377394 XR_939120 7.46 2.53E-08 
LOC107985561 XR_001755499 7.39 3.98E-03 
LOC107986570 XR_001743975 7.38 2.93E-04 
PAEP NM_001018048 7.36 4.41E-03 
LOC101928046 XR_943988 7.28 4.93E-04 
S100A9 NM_002965 7.14 8.01E-03 
LINC01511 NR_125810 7.05 1.25E-06 
HIST3H3 NM_003493 6.99 9.37E-04 
LY86-AS1 NR_026970 6.98 1.12E-20 
SLC5A4 NM_014227 6.78 2.83E-06 
LOC107984272 XR_001747594 6.78 2.92E-03 
LOC105370880 XR_932425 6.75 1.20E-03 
LOC105369520 XR_001748413 6.72 3.32E-02 
LOC105376713 XR_001751508 6.65 2.69E-03 
LINC01468 NR_120641 6.64 2.41E-03 
HIST1H2BA NM_170610 6.61 1.81E-15 
LOC107986116 XR_001740859 6.38 9.86E-03 
HIST1H2AA NM_170745 6.37 4.52E-05 
LOC101927467 XR_245182 6.26 7.17E-05 
TPO NM_000547 5.99 1.39E-07 
PSG6 NM_001031850 5.96 8.89E-04 
LOC105370981 XR_001751668 5.90 1.75E-02 
CD52 NM_001803 5.84 3.36E-02 
LOC105374910 XR_001743950 5.68 4.80E-03 
LOC105371896 XR_934982 5.62 1.21E-10 
LOC100507140 NR_037886 5.61 9.90E-05 
DMKN NM_001035516 5.54 8.11E-03 
KCNAB1 NM_001308217 5.51 7.01E-10 
LINC01554 NR_026936 5.51 3.70E-25 
LOC105369689 XR_931420 5.42 4.27E-07 
LINC01091 NR_027105 5.40 4.63E-07 
LOC105371619 XR_922291 5.38 4.27E-04 
IL24 NM_001185156 5.36 3.46E-12 
LOC107985089 XR_001753021 5.34 2.06E-02 
TCN2 NM_000355 5.32 6.45E-10 
CARD18 NM_021571 5.29 2.74E-02 
LOC107984384 XR_001748372 5.29 2.41E-06 
LINC01214 NR_110186 5.28 5.25E-04 
LOC105374394 XR_001741652 5.23 1.42E-05 
SMIM24 NM_001136503 5.19 8.97E-06 
LOC101448202 NR_103451 5.13 1.15E-07 
LOC105378668 XR_947223 5.08 3.48E-02 
LOC107984545 XR_001749266 5.07 1.80E-02 
LOC102724520 XR_427882 5.03 2.92E-03 
LOC105374924 XR_926466 4.96 9.60E-06 
MAFA NM_201589 4.95 4.27E-13 
CCBE1 NM_133459 4.94 9.42E-18 
LOC101928371 NR_110236 4.86 7.85E-04 
WNT11 NM_004626 4.82 8.54E-06 
MLK7-AS1 NR_033882 4.80 1.12E-13 
PGF NM_001207012 4.75 1.35E-14 
GAS6-AS1 NR_044995 4.73 2.99E-03 
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LOC105371703 NR_135673 4.71 2.94E-03 
CYSLTR2 NM_001308465 4.70 5.38E-17 
SLC17A1 NM_005074 4.68 7.53E-09 
NPPC NM_024409 4.64 1.62E-04 
LOC101928573 XR_001744019 4.60 2.08E-02 
LOC101927745 XR_001754962 4.57 2.60E-06 
COL5A3 NM_015719 4.57 2.05E-11 
LOC102724234 XR_427872 4.54 2.47E-03 
TRIML2 NM_001303419 4.54 3.72E-14 
LOC105376346 XR_930538 4.49 4.66E-02 
PLIN5 NM_001013706 4.46 7.62E-11 
LOC101927902 XR_001744977 4.45 4.53E-05 
MMP13 NM_002427 4.45 2.35E-12 
LOC105377557 XR_001741925 4.41 1.01E-03 
LOC105370982 XR_001751669 4.41 1.15E-06 
CCM2L NM_080625 4.39 8.04E-05 
NGFR NM_002507 4.36 2.18E-06 
LOC102800447 NR_110564 4.33 2.87E-04 
ZDHHC11B XM_017010110 4.30 4.53E-06 
LOC105370969 XR_001751655 4.24 6.53E-03 
CXCL13 NM_006419 4.22 3.74E-04 
DLL4 NM_019074 4.09 1.06E-13 
LOC105372950 XR_001738483 4.05 4.27E-03 
RRAD NM_001128850 4.03 7.30E-14 
LINC01006 NR_103858 3.99 4.60E-02 
LOC105376872 XR_001753496 3.94 4.95E-02 
CES3 NM_001185176 3.92 1.62E-06 
ANO2 NM_001278596 3.88 2.79E-08 
RNF223 NM_001205252 3.86 5.91E-06 
CEBPA NM_001285829 3.86 8.26E-12 
DIO3 NM_001362 3.84 1.96E-05 
ATP1B2 NM_001303263 3.79 3.93E-05 
LOC107983965 XM_017011612 3.78 2.37E-05 
F10 NM_000504 3.78 1.87E-03 
CRISPLD2 NM_031476 3.77 1.62E-20 
LOC105378992 XR_001742669 3.63 2.99E-03 
LOC101928004 XR_001743942 3.63 4.30E-11 
SLC39A12 NM_001145195 3.60 3.28E-06 
LOC105376244 XR_001746915 3.53 1.69E-05 
FAM46C NM_017709 3.52 6.47E-09 
LOC100505817 NR_038340 3.51 9.38E-05 
LOC107984121 XR_001744347 3.51 2.27E-02 
LOC101928277 XR_001744363 3.49 6.50E-03 
KCCAT333 NR_110014 3.41 3.01E-05 
LOC101929450 NR_125814 3.40 6.64E-04 
TCN1 NM_001062 3.37 1.07E-08 
SPATA22 NM_001170695 3.34 1.54E-03 
ADGRG1 NM_001145770 3.30 1.59E-12 
SEMA4D NM_001142287 3.27 2.71E-24 
LOC105378314 XR_001747454 3.27 2.89E-02 
LOC105374985 XR_926612 3.25 5.14E-19 
LOC105370027 XR_001749346 3.25 4.64E-02 
CPA2 NM_001869 3.24 7.75E-06 
BIK NM_001197 3.22 2.43E-03 
LINC00589 NR_026765 3.22 2.95E-03 
RND1 NM_014470 3.21 2.29E-03 
AREG NM_001657 3.19 1.05E-21 
PINLYP NM_001193621 3.18 8.16E-03 
HAP1 NM_001079870 3.15 2.46E-05 
A2M NM_000014 3.14 1.38E-04 
MIR711 NR_031756 3.14 2.15E-04 
FOXJ1 NM_001454 3.05 3.25E-03 
ADGRD1 NM_198827 3.03 2.19E-08 
LOC105376755 XR_001739834 3.00 1.30E-05 
TUBB3 NM_001197181 2.99 4.62E-15 
NKD2 NM_001271082 2.98 3.13E-03 
EPB41L3 NM_001281533 2.97 4.07E-07 
LOC100288175 XR_001737597 2.97 1.45E-03 
LOC107987209 XR_001750914 2.96 2.57E-03 
FIBCD1 NM_001145106 2.93 5.66E-12 
CTB-12O2.1 NR_109876 2.93 4.41E-02 
NRIP3 NM_020645 2.90 1.38E-04 
C5AR1 NM_001736 2.89 5.34E-04 
FAM174B NM_207446 2.84 8.69E-04 
LOC101929475 XR_001747416 2.83 2.03E-13 
LINC01239 NR_038977 2.82 2.52E-03 
TRNP1 NM_001013642 2.80 2.04E-03 
LOC105369332 NR_135084 2.78 2.27E-02 
GALR2 NM_003857 2.74 1.57E-04 
LINC01010 NR_038216 2.72 4.11E-02 
LINC01399 NR_126356 2.71 8.23E-04 
CCRL2 NM_001130910 2.70 8.93E-03 
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PILRA NM_013439 2.69 2.00E-02 
C1ORF61 NM_001320453 2.68 7.25E-03 
COL11A2 NM_001163771 2.67 2.26E-02 
LAMA5-AS1 NR_109922 2.66 4.12E-02 
LOC105374902 XR_926428 2.65 1.24E-03 
RASD1 NM_001199989 2.62 7.19E-11 
PPP1R1C NM_001080545 2.60 7.55E-06 
C9 NM_001737 2.59 2.67E-04 
LOC105374907 XR_926438 2.55 6.10E-03 
ID2 NM_002166 2.53 2.57E-03 
RNF219-AS1 NR_047001 2.48 1.85E-03 
AGR2 NM_006408 2.47 2.11E-04 
TUBB2A° NM_001069 2.47 3.32E-04 
SPINT1 NM_001032367 2.46 1.42E-07 
LGSN NM_001143940 2.45 2.77E-11 
STXBP5-AS1 NR_034115 2.45 3.57E-03 
LOC105376617 XR_001748167 2.45 1.11E-02 
CASC21 NR_117099 2.45 3.94E-02 
NPC1 NM_000271 2.44 1.13E-17 
C5AR2 NM_001271749 2.43 6.82E-05 
MFGE8 NM_001114614 2.42 8.02E-04 
NPTXR NM_014293 2.42 2.29E-04 
SVOPL NM_001139456 2.41 8.43E-03 
KLF17 NM_173484 2.40 5.38E-06 
NTRK1 NM_001007792 2.39 4.47E-03 
LOC105376626 XR_001748179 2.38 3.56E-02 
ADGRG3 NM_001308360 2.37 2.59E-02 
THBS1 NM_003246 2.37 7.49E-16 
KCNK6 NM_004823 2.37 1.26E-02 
TNNC1 NM_003280 2.36 1.57E-02 
PRRX2 NM_016307 2.34 8.95E-03 
VWA7 NM_025258 2.33 1.24E-02 
LOC101929710 NR_130776 2.33 1.18E-04 
MAFB NM_005461 2.33 7.65E-04 
CRLF1 NM_004750 2.31 1.03E-04 
NEDD9 NM_001142393 2.31 1.28E-07 
KLHL3 NM_001257194 2.30 4.00E-05 
CHAC1 NM_001142776 2.28 1.95E-05 
ERFE NM_001291832 2.28 1.62E-02 
PSG4 NM_001276495 2.28 1.49E-05 
FGFBP1 NM_005130 2.27 1.12E-03 
LOC101928465 XR_244126 2.23 8.26E-04 
HECTD2-AS1 NR_024467 2.19 5.73E-03 
MIR3189 NR_036156 2.17 5.97E-07 
TAS1R3 NM_152228 2.16 1.46E-02 
CREG2 NM_153836 2.15 1.92E-02 
DKK1 NM_012242 2.13 1.12E-09 
AOX1 NM_001159 2.13 2.44E-04 
FAM46B NM_052943 2.12 1.14E-02 
OTUD7A NM_130901 2.12 1.63E-06 
INSL4 NM_002195 2.12 7.13E-06 
MYT1L NM_001303052 2.10 1.57E-05 
BMP6 NM_001718 2.10 4.06E-12 
AP3B2 NM_001278511 2.07 1.71E-02 
DLK2 NM_001286655 2.06 4.93E-04 
HBEGF NM_001945 2.06 2.18E-04 
LOC643542 NR_033921 2.06 2.53E-02 
LINGO2 NM_001258282 2.06 2.09E-02 
DENND3 NM_014957 2.05 3.05E-06 
COL8A1 NM_001850 2.05 2.00E-08 
PFKFB4 NM_001317134 2.05 1.47E-10 
LOC101928389 NR_135631 2.05 3.99E-02 
BMP2° NM_001200 2.05 1.13E-10 
ADAM32 NM_001313994 2.04 2.22E-05 
LOC107986931 XR_001745844 2.04 7.62E-03 
LOC105379219 XR_001745785 2.03 3.47E-02 
PLXNB3 NM_001163257 2.03 1.67E-03 
C1S NM_001734 2.02 1.50E-11 
MST1R NM_001244937 2.01 1.39E-03 
LOC102724948 XR_001739319 2.01 3.18E-02 
FBXO32 NM_001242463 2.01 2.32E-04 
RGL1 NM_001297669 2.00 4.72E-04 
HDAC9 NM_001204144 2.00 2.47E-03 
GDF15°° NM_004864 1.98 7.62E-11 
COL1A1 NM_000088 1.98 2.19E-05 
RPL13AP20 NR_003932 1.98 1.51E-02 
MAPK4 NM_001292039 1.98 1.36E-08 
HAS2 NM_005328 1.98 1.01E-09 
CDHR5 NM_001171968 1.97 2.31E-02 
GFPT2 NM_005110 1.96 3.36E-06 
LOC105379109 XR_948638 1.95 1.77E-02 
STYK1 NM_018423 1.94 4.19E-03 
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SLC41A2 NM_032148 1.94 2.84E-07 
AKAP12 NM_005100 1.94 8.36E-09 
SERPINE1 NM_000602 1.93 7.02E-09 
ULBP2 NM_025217 1.93 6.40E-03 
LOC107987138 XR_001746966 1.92 5.69E-05 
CSPG4 NM_001897 1.90 3.16E-07 
KREMEN2 NM_001253725 1.90 8.68E-04 
MIG7 XR_001737684 1.89 2.16E-09 
CMAHP NR_002174 1.88 8.87E-04 
PLIN4 NM_001080400 1.87 1.44E-03 
SYNM NM_015286 1.86 3.19E-05 
LOC284561 XR_001737736 1.86 2.95E-04 
TENM2 NM_001080428 1.85 3.21E-04 
SNAI1 NM_005985 1.83 3.80E-05 
NXPH4 NM_007224 1.83 4.40E-02 
NEBL NM_001173484 1.82 7.64E-04 
LOC105373463 XR_001739316 1.82 8.40E-03 
LINC01484 NR_108027 1.81 4.93E-03 
IRF7 NM_001572 1.80 1.74E-02 
LOC105374995 XR_001744070 1.79 4.92E-02 
LRP1 NM_002332 1.78 1.03E-05 
CLIP2 NM_003388 1.78 3.03E-04 
SNED1 NM_001080437 1.77 9.65E-07 
TSPAN10 NM_001290212 1.76 3.53E-03 
PMEL NM_001200053 1.76 9.58E-03 
S100A2 NM_005978 1.75 3.26E-04 
SEMA7A NM_001146029 1.74 5.38E-03 
UNC5B NM_001244889 1.74 2.27E-03 
EEF1A2 NM_001958 1.73 4.40E-06 
DNER NM_139072 1.73 4.17E-07 
ADAP1 NM_001284308 1.73 3.26E-02 
DCN NM_001920 1.72 3.83E-03 
PCSK9 NM_174936 1.71 1.16E-06 
SYT7 NM_001252065 1.71 1.63E-02 
TARID NR_109982 1.70 3.06E-03 
FAM227B NM_152647 1.70 2.01E-02 
SERPINB5 NM_002639 1.70 3.81E-03 
ATP8B2 NM_001005855 1.69 4.55E-03 
FAM65C NM_001290268 1.69 1.72E-02 
ACP6 NM_001323625 1.68 1.69E-02 
WNT9A NM_003395 1.68 2.36E-02 
PPL NM_002705 1.68 9.09E-06 
CASC8 NR_024393 1.66 8.67E-04 
KRT80 NM_001081492 1.65 3.06E-05 
OLFML2A NM_001282715 1.64 2.02E-05 
LOC105372663 XR_936848 1.64 3.74E-04 
MYLK4 NM_001012418 1.64 2.53E-02 
STC1 NM_003155 1.64 9.42E-08 
FAM222A NM_032829 1.63 1.91E-02 
SYNGR1 NM_004711 1.63 1.64E-03 
PLXNA3 NM_017514 1.63 1.01E-05 
F11R NM_016946 1.63 1.60E-06 
ICAM1 NM_000201 1.62 2.33E-04 
EGFEM1P NR_021485 1.62 8.08E-03 
CRIM1 NM_016441 1.61 2.37E-06 
MAP3K9 NM_001284230 1.61 1.19E-03 
MICALL2 NM_182924 1.60 5.62E-05 
HIST1H2AM° NM_003514 -1.60 8.20E-07 
HIST1H2BO NM_003527 -1.63 3.85E-07 
HIST1H3D NM_003530 -1.64 5.37E-07 
HIST2H3D NM_001123375 -1.64 3.15E-06 
OSGEPL1 NM_022353 -1.67 5.26E-05 
HIST1H2BH NM_003524 -1.67 2.08E-07 
HIST2H2AC NM_003517 -1.68 8.43E-08 
SNORA74A NR_002915 -1.68 9.64E-03 
RARRES2 NM_002889 -1.69 1.12E-04 
HIST1H1E NM_005321 -1.70 4.76E-08 
HIST1H1B NM_005322 -1.70 2.95E-07 
HIST1H2AB NM_003513 -1.71 6.90E-08 
HIST4H4 NM_175054 -1.72 3.52E-07 
HIST1H2BJ NM_021058 -1.72 2.90E-08 
NOTUM NM_178493 -1.74 3.24E-05 
HIST1H3F NM_021018 -1.75 3.64E-08 
HIST2H2AB NM_175065 -1.75 7.97E-07 
HIST1H2BN NM_003520 -1.76 3.96E-07 
HIST1H2AK NM_003510 -1.77 1.77E-07 
HIST1H3H NM_003536 -1.78 2.47E-08 
SNORD17 NR_003045 -1.79 9.49E-05 
CENPX NM_001271006 -1.81 7.43E-08 
HIST1H4B° NM_003544 -1.82 1.42E-07 
HIST1H2AL NM_003511 -1.82 3.88E-08 
HAGHL NM_001290137 -1.87 1.63E-06 
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HIST1H2AD NM_021065 -1.89 1.05E-09 
HIST1H3G NM_003534 -1.89 3.28E-09 
HIST1H4K NM_003541 -2.18 4.22E-08 
LOC105379506 XR_951149 -2.41 3.73E-02 
LOC107987293 XR_001754938 -2.41 3.73E-02 
TYRO3P NR_028510 -2.93 2.33E-03 
RNU5D-1 NR_002755 -3.76 6.24E-03 
SNORA53 NR_003015 -3.90 1.28E-20 
MIR3121 NR_036067 -5.74 3.08E-05 
HLA-J NR_024240 -6.86 2.36E-37 
MIR151A NR_029892 -7.61 1.72E-03 
Suppl. table S6. DESeq results of ASF1 depletion in HeLa LT cells. 284 up- and 36 downregulated 
genes with a log2 fold change (l2fc) <-1.6 or >1.6 for siASF1 over siCtrl in HeLa LT cells excluding 
deregulated genes with a l2fc <-1.2 or >1.2 for siASF1 over siCtrl in HeLa ST cells. The adjusted p-
value was set to padj<0.05 and only genes with an RPKM >2 in the highest expressed sample were 
selected for this table. Genes were sorted by l2fc. Those genes implemented in the TelNet database 
were marked in bold, genes reported to be cell cycle-regulated in HeLa cells (Grant et al., 2013) were 
marked with a °circle. 
 
 
Suppl. table S7. DESeq results of ASF1 depleted HeLa LT cells treated with SAHA.  
gene symbol RefSeq ID 2 µM SAHA/ EtOH ctrl 0.5 µM SAHA/ EtOH ctrl log2 fold change padj log2 fold change padj 
FABP4 NM_001442 6.71 3.24E-06 4.16 6.71E-02 
HLA-DQB1 NM_001243961 6.02 1.95E-06 1.96 3.38E-05 
RNASE1 NM_002933 5.84 1.86E-03 0.40 7.68E-01 
LGI3 NM_139278 5.48 1.44E-11 0.84 3.95E-01 
LOC105371671 XR_922391 5.45 6.38E-03 1.46 3.31E-01 
DIRAS1 NM_145173 5.36 1.53E-19 0.47 4.52E-02 
IL17RD NM_001318864 5.22 4.79E-28 0.51 1.77E-03 
EDA NM_001005609 5.13 8.60E-47 1.20 5.12E-11 
HPCAL4 NM_001282396 5.05 2.56E-12 1.70 5.70E-20 
TNIK NM_001161560 4.97 4.18E-11 1.03 2.31E-11 
PPP4R4 NM_020958 4.93 5.45E-18 0.31 2.06E-01 
CD33 NM_001082618 4.92 3.20E-07 0.36 5.59E-01 
CCDC85A NM_001080433 4.88 4.00E-20 0.96 1.50E-06 
CD40 NM_001250 4.83 4.86E-08 -0.02 9.57E-01 
KCNH2 NM_000238 4.82 1.73E-07 -0.17 6.81E-01 
HLA-DMB NM_002118 4.81 4.79E-28 3.68 4.06E-14 
LOC102724548 XR_426710 4.70 1.78E-02 3.21 3.21E-04 
NELL2 NM_001145107 4.66 1.61E-15 1.74 1.12E-39 
STXBP6 NM_001304476 4.64 2.09E-06 0.86 5.81E-05 
EBF1 NM_001290360 4.64 1.22E-12 0.24 4.90E-01 
LOC105369563 XR_001748439 4.62 2.45E-07 1.84 9.81E-04 
TMSB15A NM_021992 4.57 1.10E-05 -0.02 9.55E-01 
ZNF204P NR_002722 4.55 4.14E-43 1.69 9.16E-14 
ELSPBP1 NM_022142 4.53 7.15E-03 3.29 2.60E-02 
RGS9 NM_001081955 4.49 1.26E-03 1.96 1.28E-17 
GRID2 NM_001286838 4.45 2.95E-24 -0.34 1.74E-01 
SLC6A12 NM_001122847 4.43 1.27E-04 -0.16 9.12E-01 
AGMO NM_001004320 4.40 5.47E-04 0.27 6.59E-01 
ALOX5 NM_000698 4.37 8.70E-09 -0.11 7.07E-01 
AZGP1 NM_001185 4.37 2.13E-04 2.21 4.87E-03 
PRKAR2B NM_002736 4.37 3.43E-10 0.95 1.95E-10 
C2CD4C NM_001136263 4.35 4.83E-08 -0.12 7.47E-01 
RAB37 NM_001006638 4.35 1.03E-12 0.36 5.59E-01 
LDLRAD4 NM_001003674 4.30 5.15E-06 -0.30 1.09E-01 
PDZD4 NM_001303512 4.30 4.56E-10 1.28 1.23E-11 
PURG NM_001015508 4.30 1.55E-13 0.47 1.03E-01 
CREB3L3 NM_001271995 4.28 2.75E-21 0.79 7.31E-01 
OSBPL6 NM_001201480 4.28 3.67E-17 0.41 2.73E-02 
FAM167A NM_053279 4.27 7.59E-05 0.44 3.68E-01 
GPR143 NM_000273 4.26 2.89E-04 0.31 8.77E-01 
FXYD1 NM_001278717 4.26 2.89E-06 1.90 3.14E-03 
MYCT1 NM_025107 4.26 1.75E-03 2.62 3.84E-15 
DENND2C NM_001256404 4.25 5.52E-15 0.80 3.41E-05 
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CGN NM_020770 4.23 3.95E-08 0.78 3.07E-05 
TMOD2 NM_001142885 4.22 3.74E-22 0.93 5.35E-05 
IGF2BP2 NM_001007225 4.21 3.55E-09 0.28 1.01E-01 
MYH14 NM_001077186 4.21 9.34E-04 0.29 2.12E-01 
LOC105373890 XR_001739233 4.20 1.58E-02 1.11 2.31E-04 
LOC105376626 XR_001748179 4.20 8.80E-05 1.64 1.87E-01 
FOXD1 NM_004472 4.19 2.44E-11 -0.22 3.13E-01 
PPP2R2C NM_001206994 4.17 1.21E-05 0.57 4.56E-04 
CAMSAP3 NM_001080429 4.14 5.77E-08 0.70 1.98E-02 
COL5A3 NM_015719 4.13 7.72E-04 1.05 1.96E-04 
CABP1 NM_001033677 4.12 2.24E-03 -0.17 9.22E-01 
CRMP1 NM_001014809 4.09 5.94E-30 0.27 2.01E-01 
UNC13A NM_001080421 4.07 6.02E-08 0.65 3.95E-03 
AGPAT4 NM_020133 4.07 3.77E-15 0.03 9.21E-01 
FAM171A1 NM_001010924 4.07 1.89E-05 0.06 8.50E-01 
C7ORF57 NM_001100159 4.03 5.90E-35 1.30 5.18E-02 
HLA-F-AS1 NR_026972 4.02 1.82E-16 0.33 3.37E-01 
PSG4 NM_001276495 4.02 7.17E-14 1.95 1.36E-18 
PAGE2B NM_001015038 4.01 2.45E-03 -0.27 3.28E-01 
LOC107986215 XM_017008885 4.00 1.36E-04 0.62 3.90E-01 
TMEM59L NM_012109 3.99 2.06E-12 1.35 3.55E-07 
LOC105379102 XR_001742829 3.97 1.09E-07 1.13 5.06E-01 
SND1-IT1 NR_027330 3.96 3.05E-03 -0.16 9.52E-01 
TP53I11 NM_001258320 3.95 1.04E-09 0.22 4.16E-01 
LOC101929305 XR_001738364 3.95 1.34E-02 1.72 8.00E-02 
CDC42EP5 NM_145057 3.91 3.83E-10 -0.37 5.84E-01 
HMCN1 NM_031935 3.91 4.94E-33 0.18 4.78E-01 
ADGRE1 NM_001256252 3.90 2.96E-16 1.18 1.63E-04 
IGSF1 NM_001170961 3.87 1.55E-122 0.56 5.59E-01 
TMEM86A NM_153347 3.86 2.26E-32 0.56 8.30E-02 
LOC101928216 XR_001737945 3.85 7.59E-07 1.02 3.38E-01 
FNDC4 NM_022823 3.84 3.94E-05 0.28 5.80E-01 
GPR162 NM_014449 3.83 4.91E-14 0.04 9.24E-01 
KHDRBS3 NM_006558 3.82 8.84E-15 -0.21 2.40E-01 
KCNK9 NM_001282534 3.81 1.20E-07 2.68 7.39E-13 
RTBDN NM_001080997 3.77 1.67E-04 1.59 1.96E-01 
EPYC NM_004950 3.77 3.74E-02 0.38 8.35E-01 
LOC107986838 XR_001745337 3.77 7.32E-12 1.48 5.40E-02 
ABAT NM_000663 3.76 3.71E-08 0.82 5.51E-08 
RASAL1 NM_001193520 3.76 2.48E-05 0.25 5.56E-01 
SCN9A NM_002977 3.75 3.23E-63 1.09 1.74E-08 
PRKD1 NM_002742 3.74 3.04E-20 -0.17 5.20E-01 
DACT3 NM_001301046 3.72 2.56E-04 1.10 2.26E-05 
REEP1° NM_001164730 3.71 3.92E-11 0.25 5.51E-01 
OR51B5 NM_001005567 3.71 8.55E-06 0.87 1.53E-05 
TENM1 NM_001163278 3.70 2.86E-02 1.42 1.67E-06 
YPEL4 NM_145008 3.68 5.18E-09 0.34 7.21E-01 
AIM1L NM_001039775 3.66 1.69E-08 0.88 1.68E-02 
ADRA1B NM_000679 3.65 1.71E-07 0.69 2.08E-04 
LOC105373891 XR_001739888 3.64 3.33E-02 1.12 5.20E-02 
PIK3R1 NM_001242466 3.64 1.47E-19 -0.18 3.94E-01 
SORBS1 NM_001034954 3.63 1.75E-07 0.81 1.81E-06 
TPPP NM_007030 3.61 7.34E-03 0.85 1.10E-03 
LINC00922 NR_027755 3.60 4.42E-04 -0.32 8.45E-01 
PTN NM_001321386 3.60 5.55E-05 0.17 5.67E-01 
MAP2 NM_001039538 3.59 2.37E-21 1.09 1.78E-14 
LOC102724434 NR_130921 3.59 2.76E-21 2.55 4.80E-02 
ANKRD24 NM_133475 3.57 1.38E-09 2.15 3.90E-16 
WBSCR28 NM_182504 3.57 1.58E-09 1.61 2.38E-01 
LOC105377706 XR_941182 3.56 4.77E-02 0.99 6.14E-01 
MIR4300HG NR_120571 3.56 5.50E-04 1.27 3.68E-01 
LINC01162 NR_126381 3.55 4.41E-03 0.86 6.00E-01 
C1ORF116 NM_001083924 3.55 1.84E-06 1.50 1.15E-03 
TDRKH NM_001083963 3.54 2.31E-15 0.62 2.55E-03 
IGSF10 NM_001178145 3.54 2.61E-13 0.16 7.40E-01 
CFAP58-AS1 NR_108036 3.52 8.67E-16 1.94 5.54E-03 
ANKRD1 NM_014391 3.52 6.60E-04 1.00 3.95E-17 
GPR4 NM_005282 3.51 9.82E-05 1.36 2.94E-02 
CALB2 NM_001740 3.51 1.71E-03 0.04 9.14E-01 
MARCH4 NM_020814 3.51 5.36E-03 0.67 1.97E-02 
LOC101930114 NR_134509 3.51 2.05E-02 1.04 4.82E-01 
CDH12 NM_001317227 3.50 1.58E-07 0.06 8.46E-01 
PSG5 NM_001130014 3.49 5.85E-04 2.00 1.66E-03 
APLP1 NM_001024807 3.48 4.25E-20 0.93 1.57E-08 
ADRA2C NM_000683 3.45 2.87E-02 0.03 9.62E-01 
FLJ25758 NR_024372 3.44 1.33E-02 3.84 1.15E-01 
ITGA7 NM_001144996 3.43 7.48E-04 0.73 2.23E-04 
LINGO2 NM_001258282 3.42 1.87E-08 0.07 8.51E-01 
SRRM3 NM_001110199 3.40 3.04E-07 0.13 7.00E-01 
ADAMTS16 NM_139056 3.40 1.95E-05 0.48 1.23E-02 
COL6A2 NM_001849 3.39 1.23E-08 0.15 4.19E-01 
   Appendix 
 137 
gene symbol RefSeq ID 2 µM SAHA/ EtOH ctrl 0.5 µM SAHA/ EtOH ctrl log2 fold change padj log2 fold change padj 
SLC29A4 NM_001040661 3.39 1.56E-09 0.04 8.95E-01 
COL4A3 NM_000091 3.38 4.52E-11 0.23 8.97E-01 
GRID1 NM_017551 3.38 2.02E-04 -0.32 6.23E-01 
IL3RA NM_001267713 3.38 1.45E-04 0.50 7.93E-01 
SLC2A4 NM_001042 3.38 9.40E-31 0.85 7.03E-04 
NEO1 NM_001172623 3.36 1.26E-26 0.25 1.90E-01 
DNM1 NM_001005336 3.35 9.85E-07 -0.22 3.32E-01 
ZNF467 NM_207336 3.34 3.87E-16 -0.37 5.33E-01 
SEPT4 NM_001198713 3.34 5.40E-08 0.97 2.42E-02 
HOMER2 NM_004839 3.33 5.68E-05 0.07 8.11E-01 
BCO2 NM_001037290 3.32 4.72E-08 1.39 1.51E-04 
SH2D3C NM_001142531 3.32 8.62E-04 1.13 3.67E-03 
DCN NM_001920 3.31 8.83E-15 3.31 1.36E-01 
LOC105369484 XR_948004 3.31 9.84E-07 0.32 9.08E-01 
PPM1J NM_005167 3.31 1.07E-18 1.82 2.88E-13 
MAP1B NM_001324255 3.31 3.27E-02 0.31 4.43E-02 
DAW1 NM_178821 3.30 1.34E-02 2.82 7.24E-07 
RGS17 NM_012419 3.30 1.02E-12 0.76 6.53E-04 
SLC16A12 NM_213606 3.29 2.12E-03 2.72 1.78E-24 
LOC105369438 NR_135093 3.28 1.28E-03 0.52 7.41E-01 
ARFGEF3 NM_020340 3.28 2.66E-08 0.22 2.89E-01 
KIAA0319 NM_001168374 3.27 4.56E-10 1.69 3.46E-04 
HECTD2-AS1 NR_024467 3.26 1.30E-08 0.86 4.96E-02 
CGNL1 NM_001252335 3.26 7.66E-16 0.68 1.25E-04 
CHRM4 NM_000741 3.25 3.22E-07 0.98 1.79E-03 
ZNF365 NM_014951 3.24 5.52E-14 1.06 6.87E-13 
CYP4F12 NM_023944 3.23 2.14E-02 3.77 5.15E-06 
DIRC3-AS1 NR_133642 3.23 1.34E-03 1.48 7.20E-14 
RASGRP2 NM_001098670 3.23 3.54E-04 0.63 3.54E-01 
C14ORF37 NM_001001872 3.22 6.74E-04 0.74 3.19E-06 
NOTCH3 NM_000435 3.22 2.08E-09 0.19 3.95E-01 
NRXN3 NM_001105250 3.21 1.59E-10 0.99 2.40E-02 
SRPX NM_001170750 3.21 9.23E-39 -0.28 1.08E-01 
STAC2 NM_198993 3.20 4.40E-07 0.21 9.31E-01 
HAPLN3 NM_001307952 3.19 3.92E-04 0.03 9.38E-01 
TRNP1 NM_001013642 3.19 1.74E-05 0.25 2.74E-01 
LOC105374523 XR_001741614 3.18 1.17E-02 2.54 1.62E-04 
LOC105369881 XR_945161 3.17 4.50E-03 0.29 7.01E-01 
LOC105371308 XR_001752232 3.16 1.06E-04 0.37 2.56E-01 
SLC45A1 NM_001080397 3.16 4.02E-12 0.81 1.54E-01 
LOC105373893 XR_001739889 3.16 1.81E-02 0.96 6.46E-02 
LOC105375508 XR_001744984 3.16 5.49E-05 0.03 9.80E-01 
DKK3 NM_001018057 3.15 8.28E-148 0.55 1.76E-04 
NXN NM_001205319 3.14 3.14E-09 0.03 9.11E-01 
TMEM63C NM_020431 3.13 5.84E-04 1.15 3.15E-06 
CHRD NM_001304472 3.12 4.73E-04 -0.19 6.55E-01 
KLC3 NM_177417 3.12 4.20E-03 1.03 8.41E-04 
PHOSPHO1 NM_001143804 3.11 5.70E-28 1.27 7.27E-04 
LINC00431 NR_126378 3.11 6.51E-03 1.47 1.68E-01 
ATP1A3 NM_001256213 3.09 4.49E-02 1.57 7.75E-12 
GPRIN3 NM_198281 3.09 1.39E-21 1.18 5.01E-07 
NR3C2 NM_000901 3.08 8.62E-07 -0.10 7.66E-01 
TMC3-AS1 NR_120365 3.07 9.39E-05 1.09 1.41E-05 
SLC17A7 NM_020309 3.07 4.31E-03 1.04 1.12E-02 
KANK3 NM_198471 3.07 1.08E-03 1.08 3.21E-04 
MAST1 NM_014975 3.06 2.05E-26 1.19 3.53E-05 
LOC105373592 XR_001739684 3.06 2.24E-02 0.26 6.86E-01 
ATP8B2 NM_001005855 3.06 2.19E-14 0.26 1.91E-01 
MIR6124 NR_106739 3.05 2.83E-02 0.52 4.71E-01 
RTN4RL2 NM_178570 3.05 4.11E-24 0.27 6.52E-01 
S1PR1 NM_001320730 3.05 1.31E-22 1.61 6.41E-04 
LOC101927880 XR_001747321 3.04 2.11E-07 -0.32 7.81E-01 
SEMA6B NM_032108 3.03 1.41E-06 0.18 3.75E-01 
TNFRSF9 NM_001561 3.03 4.40E-06 0.90 1.64E-06 
IQUB NM_001282855 3.03 1.59E-15 1.04 1.87E-02 
LHFP NM_005780 3.03 1.28E-03 -0.23 4.99E-01 
NTNG2 NM_032536 3.03 9.64E-03 0.39 9.09E-02 
REEP2 NM_001271803 3.02 3.15E-35 0.47 7.00E-02 
PTX3 NM_002852 3.01 4.13E-09 0.38 6.03E-01 
SLC2A9 NM_001001290 3.01 3.93E-02 0.17 8.90E-01 
CADM4 NM_145296 3.00 1.23E-21 0.06 8.29E-01 
HMSD NM_001123366 2.99 3.06E-04 0.98 3.17E-01 
LINC01170 NR_125774 2.98 8.35E-05 -0.47 5.39E-01 
PRR16° NM_001300783 2.97 4.59E-18 -0.15 8.77E-01 
RGL1 NM_001297669 2.96 1.82E-06 0.54 1.34E-03 
SULT2B1 NM_004605 2.96 5.99E-08 0.78 4.21E-01 
ABCA3 NM_001089 2.96 1.18E-23 0.91 1.00E-04 
LOC105374678 XR_001742406 2.95 5.92E-04 0.07 9.71E-01 
RAB3B NM_002867 2.95 9.67E-03 -0.11 6.95E-01 
LOC107984502 XR_001749075 2.95 1.25E-05 0.07 9.32E-01 
LYPD5 NM_001031749 2.94 8.69E-08 2.21 4.38E-09 
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MAN1C1 NM_001289010 2.94 9.54E-08 0.43 2.02E-01 
TSPAN9 NM_001168320 2.94 3.15E-07 0.23 3.03E-01 
GALNT12 NM_024642 2.94 1.65E-29 0.50 2.70E-01 
TNFAIP8L3 NM_001311175 2.93 1.90E-03 1.25 1.68E-01 
HMGA2 NM_001300918 2.93 2.33E-02 0.03 9.32E-01 
TMCC2 NM_001242925 2.92 2.44E-12 1.20 5.04E-10 
SEPT5 NM_001009939 2.92 4.77E-35 0.23 2.30E-01 
PMEL NM_001200053 2.92 1.12E-11 1.66 5.26E-04 
FGF13 NM_001139498 2.91 2.03E-04 -0.05 9.27E-01 
LOC100506113 XR_001748304 2.91 1.59E-08 0.36 7.93E-01 
NPL NM_001200050 2.90 2.67E-05 0.47 1.24E-01 
CREB5 NM_001011666 2.90 3.73E-09 0.36 5.78E-01 
DCDC1 NM_181807 2.90 4.99E-14 1.45 2.02E-03 
LOC107001062 NR_134500 2.89 8.12E-03 0.09 9.65E-01 
ADAMTS10 NM_001282352 2.89 3.61E-20 -0.21 4.74E-01 
SPOCK3 NM_001040159 2.89 1.78E-31 -0.15 8.38E-01 
LOC255187 NR_122044 2.89 1.42E-02 -0.60 5.52E-01 
CCDC69 NM_015621 2.88 1.19E-08 0.74 8.35E-06 
RARB NM_000965 2.88 1.81E-06 1.40 2.13E-17 
LINC01098 NR_028342 2.88 1.05E-03 1.38 3.00E-01 
RDH12 NM_152443 2.87 7.33E-03 1.24 1.43E-02 
PCDH1 NM_001278613 2.87 1.32E-29 3.01 1.94E-43 
LOC101928419 XR_241794 2.86 1.71E-04 2.11 6.82E-02 
ARHGAP44 NM_001321164 2.86 3.61E-28 0.43 6.08E-02 
LOC101928599 XR_001750839 2.85 6.55E-08 -0.12 8.85E-01 
MAPK8IP2 NM_012324 2.84 1.18E-05 2.09 2.70E-13 
SYNPO2 NM_001128933 2.84 8.25E-07 2.26 9.64E-05 
AHNAK2 NM_138420 2.84 3.43E-13 0.01 9.66E-01 
MFGE8 NM_001114614 2.83 1.59E-06 0.22 2.19E-01 
TSPAN33 NM_178562 2.82 1.27E-33 0.92 2.06E-05 
NRG2 NM_001184935 2.82 3.27E-03 1.79 5.34E-06 
CLCN4 NM_001256944 2.82 1.15E-16 0.49 9.64E-03 
LRRC17° NM_001031692 2.82 4.60E-02 0.78 1.65E-01 
ATP7B NM_000053 2.82 1.79E-14 0.58 1.30E-02 
KLLN NM_001126049 2.82 3.86E-11 0.08 9.70E-01 
SLC9A9 NM_173653 2.81 4.57E-43 0.95 1.39E-04 
LOC105378800 XR_947517 2.81 2.58E-02 3.63 1.11E-02 
ATP8A1 NM_001105529 2.81 3.84E-23 0.58 3.15E-05 
ARMC12 NM_001286574 2.80 4.42E-09 0.38 7.19E-01 
YBX2 NM_015982 2.78 1.21E-05 0.65 6.10E-02 
CDS1 NM_001263 2.76 4.27E-24 1.26 5.69E-10 
RBM20 NM_001134363 2.76 7.91E-10 0.33 3.40E-01 
LOC105373215 XR_001738537 2.75 2.00E-03 -0.11 8.99E-01 
SLC2A12 NM_145176 2.75 1.99E-57 -0.15 4.91E-01 
LOC283352 NR_104172 2.75 3.23E-03 0.58 6.91E-03 
LOC107986606 XR_001744176 2.74 5.74E-06 2.51 2.78E-04 
LOC102546294 NR_105057 2.74 1.06E-26 0.94 1.15E-01 
LINC00707 NR_038291 2.74 2.72E-04 0.32 8.13E-01 
ICA1 NM_001136020 2.74 7.33E-06 -0.08 9.11E-01 
CCL20 NM_001130046 2.73 4.69E-02 3.51 1.08E-15 
SAMD14 NM_001257359 2.73 2.89E-05 1.11 2.88E-03 
FRMD5 NM_001286490 2.72 2.44E-04 0.00 9.95E-01 
CNBD1 NM_173538 2.71 2.19E-03 0.11 9.39E-01 
MAP1A NM_002373 2.69 3.10E-07 0.50 9.00E-03 
LOC105369349 XR_950211 2.68 1.01E-02 0.22 8.87E-01 
OR1J2 NM_054107 2.68 1.31E-05 0.72 2.58E-02 
LOC101927947 XR_001741892 2.68 2.93E-02 1.05 7.28E-03 
VPS37D NM_001077621 2.68 2.79E-07 0.08 8.86E-01 
CETN4P NR_024041 2.68 3.80E-07 1.20 2.69E-01 
CYTH4 NM_001318024 2.67 3.23E-02 1.86 1.55E-06 
C2ORF70 NM_001105519 2.66 3.43E-07 0.83 3.83E-01 
CTB-12O2.1 NR_109876 2.66 2.22E-02 0.19 8.25E-01 
GALNT18 NM_198516 2.66 3.32E-09 0.90 3.38E-08 
LOC102724895 XR_430113 2.65 1.39E-03 4.18 3.99E-07 
LOC107986824 XR_001745287 2.65 8.50E-03 -0.14 9.08E-01 
LARGE2 NM_001300721 2.64 5.98E-14 -0.01 9.79E-01 
EEPD1 NM_030636 2.64 4.82E-06 0.70 2.83E-03 
CTTNBP2 NM_033427 2.64 2.39E-07 -0.19 6.97E-01 
LOC107985325 XR_001754012 2.62 1.54E-03 1.39 1.41E-02 
PAG1 NM_018440 2.61 6.23E-07 1.32 6.48E-10 
MAK NM_001242385 2.61 1.32E-02 0.53 5.03E-01 
LOC105373369 XR_001755974 2.61 2.50E-11 0.00 9.99E-01 
LOC105373463 XR_001739316 2.61 3.13E-04 0.15 9.07E-01 
MYZAP NM_001018100 2.60 3.92E-50 1.10 5.49E-09 
RTN4RL1 NM_178568 2.60 2.64E-04 0.19 9.14E-01 
MATN3 NM_002381 2.60 1.60E-05 -0.49 7.36E-02 
LOC101927252 XR_001739825 2.60 2.52E-04 0.37 7.07E-01 
LOC107985339 XR_001753852 2.60 1.24E-07 2.55 4.39E-02 
DNAH11 NM_001277115 2.60 1.66E-32 0.44 4.12E-01 
HOXA1 NM_005522 2.59 6.05E-06 0.63 4.73E-02 
HDAC9 NM_001204144 2.59 6.65E-05 0.17 4.89E-01 
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CCDC148 NM_001301684 2.59 1.79E-03 1.62 1.87E-13 
LOC554206 NR_038379 2.59 3.95E-08 1.08 4.42E-01 
DIRAS3 NM_004675 2.58 1.38E-12 -0.18 9.20E-01 
MIR137HG NR_046105 2.58 4.56E-07 0.19 8.11E-01 
CRLF1 NM_004750 2.57 8.92E-06 1.23 1.69E-05 
LOC105372424 XR_935996 2.57 1.35E-06 -0.03 9.76E-01 
AREG NM_001657 2.56 1.37E-02 1.82 5.38E-15 
TJP3 NM_001267560 2.56 2.84E-10 1.15 4.26E-06 
PELI2 NM_021255 2.56 9.20E-10 -0.10 7.40E-01 
LOC107986884 XR_001745703 2.55 4.30E-02 2.41 4.13E-04 
SEPT5-GP1BB NR_037611 2.55 3.22E-30 0.22 2.53E-01 
PALM3 NM_001145028 2.54 1.29E-04 0.71 1.39E-01 
LINC01057 NR_104131 2.54 6.02E-04 -0.02 9.76E-01 
STAT4 NM_001243835 2.54 2.50E-08 0.65 5.95E-01 
TPPP3 NM_015964 2.53 1.44E-03 -0.16 9.39E-01 
SCIN NM_001112706 2.53 1.86E-05 0.42 3.29E-01 
BEX2 NM_001168399 2.52 9.02E-10 0.54 1.74E-02 
LINC01182 NR_121681 2.52 4.20E-06 -0.02 9.86E-01 
KCTD12 NM_138444 2.52 3.99E-07 0.02 9.70E-01 
TMEM232 NM_001039763 2.52 3.03E-09 0.85 3.57E-02 
PSG10P NR_026824 2.52 8.93E-03 1.96 1.09E-01 
LOC105369344 XR_001748261 2.52 1.42E-13 -0.08 9.65E-01 
LOC107986412 XR_001742638 2.51 3.01E-02 2.69 8.44E-02 
NMRAL2P NR_033752 2.51 4.39E-12 -0.11 9.26E-01 
PRRT3 NM_001318871 2.51 5.43E-16 0.59 1.17E-02 
LOC105375746 XR_001746072 2.51 2.40E-02 0.76 2.38E-01 
GBP2 NM_004120 2.50 1.30E-32 0.25 5.44E-01 
DPF3 NM_001280542 2.50 2.49E-08 0.80 1.52E-01 
CPM NM_001005502 2.49 6.51E-11 0.74 7.64E-03 
LINC00871 NR_102699 2.48 1.01E-02 0.18 9.49E-01 
IQGAP2 NM_001285460 2.48 5.93E-05 1.64 4.28E-17 
GIPR NM_000164 2.48 1.56E-05 0.24 8.21E-01 
SMIM1 NM_001163724 2.48 2.01E-19 0.30 7.56E-01 
GRB14 NM_001303422 2.47 3.96E-34 0.57 1.66E-02 
RPLP0P2 NR_002775 2.47 7.34E-03 1.92 2.12E-19 
KCNIP4 NM_001035003 2.47 1.84E-02 1.52 1.46E-02 
KIF21B NM_001252100 2.47 2.63E-08 0.84 2.08E-05 
NRTN NM_004558 2.46 6.65E-14 -0.09 8.99E-01 
DNM3 NM_001136127 2.46 2.92E-07 1.87 1.39E-37 
CHODL NM_001204174 2.46 4.19E-02 1.19 1.25E-03 
NR2F2-AS1 NR_102743 2.46 1.06E-03 0.69 2.20E-03 
RASD2 NM_014310 2.45 1.17E-03 1.13 1.34E-03 
PTK7 NM_001270398 2.45 1.27E-08 -0.02 9.61E-01 
OLFM2 NM_001304347 2.45 4.86E-06 0.46 4.78E-02 
LINC01461 NR_125761 2.45 8.25E-04 0.74 5.05E-01 
LOC105369949 XR_001749294 2.45 1.14E-04 1.40 1.47E-02 
PLEKHB1 NM_001130033 2.45 3.64E-06 0.20 6.38E-01 
PTHLH NM_002820 2.43 2.14E-05 0.45 2.57E-01 
LOC107987105 XR_001746865 2.43 1.65E-05 0.81 4.64E-01 
NMNAT2 NM_015039 2.42 5.15E-07 1.70 1.20E-22 
LOC101927967 NR_110288 2.42 3.45E-02 0.50 4.39E-01 
DNAJC28 NM_001040192 2.41 3.92E-11 0.57 2.90E-01 
CASZ1 NM_001079843 2.41 6.86E-05 0.64 1.03E-02 
FBLN5 NM_006329 2.41 4.00E-20 0.42 3.52E-01 
C10ORF113 NM_001010896 2.41 3.00E-03 1.52 9.02E-02 
STK11 NM_000455 2.41 4.27E-11 0.00 9.88E-01 
IL18 NM_001243211 2.40 2.70E-12 0.66 2.67E-08 
KCNH3 NM_001314030 2.39 1.58E-12 0.97 1.91E-09 
LOC105375751 XR_001746076 2.39 1.01E-03 0.24 5.42E-01 
LOC105372281 XR_936336 2.39 3.19E-08 0.62 3.70E-01 
EML5 NM_183387 2.39 1.02E-21 0.39 6.61E-01 
ATL1 NM_001127713 2.39 9.71E-04 -0.05 8.91E-01 
EEF1A2 NM_001958 2.39 5.78E-09 0.21 2.21E-01 
PDZD7 NM_001195263 2.38 3.97E-14 1.64 4.97E-08 
LOC105376615 XR_001748166 2.38 2.73E-03 0.13 9.25E-01 
LOC105373805 NR_136318 2.38 6.79E-03 0.46 8.16E-01 
LINC01399 NR_126356 2.38 2.70E-02 0.36 2.87E-02 
BMF NM_001003940 2.37 1.46E-08 -0.29 3.24E-01 
JAG2 NM_002226 2.37 1.04E-24 0.01 9.84E-01 
SYTL2 NM_001162951 2.37 3.84E-06 0.85 8.74E-11 
LOC105378992 XR_001742669 2.37 3.94E-03 0.03 9.41E-01 
PITPNM3 NM_001165966 2.37 6.30E-09 -0.51 8.77E-02 
SCAMP5 NM_001178111 2.37 1.36E-29 0.74 8.57E-04 
LMO1 NM_001270428 2.36 3.23E-03 0.44 7.30E-01 
MAPK8IP1 NM_005456 2.36 1.10E-08 1.03 4.63E-11 
SAMD11 NM_152486 2.36 9.26E-07 -0.15 6.59E-01 
IL1A NM_000575 2.36 1.36E-04 2.02 1.14E-05 
LOC105377732 XR_001743000 2.35 4.23E-02 1.70 1.75E-06 
NKILA NR_131157 2.34 8.85E-18 0.94 1.40E-10 
LINC00936 NR_028138 2.34 2.31E-25 1.16 1.48E-03 
KCNJ2 NM_000891 2.34 1.99E-45 0.50 6.13E-01 
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DAPK1 NM_001288729 2.33 5.77E-08 -0.02 9.74E-01 
DNER NM_139072 2.33 2.00E-08 1.01 1.05E-01 
PLCL1 NM_006226 2.33 2.90E-04 -0.34 8.11E-01 
HS6ST3 NM_153456 2.32 1.86E-17 0.87 1.83E-01 
DNAAF3 NM_001256714 2.32 1.71E-15 1.66 4.02E-11 
CACNA1G NM_001256324 2.31 1.02E-08 0.88 3.95E-04 
CCDC110 NM_001145411 2.31 3.19E-29 1.64 2.23E-03 
AFDN° NM_001040000 2.31 6.46E-20 0.11 5.83E-01 
TRPM4 NM_001195227 2.31 3.79E-31 0.10 7.46E-01 
PPFIBP2 NM_001256568 2.30 1.95E-03 0.43 1.34E-01 
STMN3 NM_001276310 2.30 1.03E-04 1.10 1.18E-10 
MORN3 NM_173855 2.30 2.53E-06 0.22 8.93E-01 
DNAH2 NM_001303270 2.30 2.78E-06 0.43 5.49E-01 
PGM5P2 NR_002836 2.30 7.72E-06 0.32 6.24E-01 
STARD5 NM_181900 2.29 2.68E-08 -0.36 4.51E-01 
SNPH NM_001318234 2.29 1.62E-12 0.63 2.81E-04 
PLCXD2 NM_001185106 2.29 2.03E-12 0.88 3.10E-11 
LINC01619 NR_046159 2.29 3.50E-03 0.07 8.81E-01 
COL4A4 NM_000092 2.28 7.67E-05 0.09 7.78E-01 
MMP9 NM_004994 2.28 3.31E-02 0.51 1.01E-01 
MIR4260 NR_036213 2.28 2.99E-06 0.88 4.28E-02 
PRSS16 NM_005865 2.28 1.49E-09 0.00 9.96E-01 
LOC100288798 NR_125377 2.28 3.46E-02 0.77 1.28E-01 
SLC27A1 NM_198580 2.28 1.01E-11 0.24 3.06E-01 
HS1BP3-IT1 NR_046836 2.28 4.02E-03 0.06 9.73E-01 
IL12A NM_000882 2.28 1.28E-03 1.01 2.01E-01 
GNAO1 NM_020988 2.27 1.07E-08 0.46 1.16E-01 
LOC105378482 XR_001747585 2.27 2.85E-04 -0.13 9.15E-01 
SYT7 NM_001252065 2.26 1.80E-07 1.67 4.75E-13 
MTUS2 NM_001033602 2.26 3.05E-28 0.89 3.58E-03 
SLC1A1 NM_004170 2.25 1.56E-30 0.97 2.72E-04 
CITED1 NM_001144885 2.25 1.39E-02 0.85 2.56E-01 
CTSV NM_001201575 2.25 1.24E-07 0.31 1.65E-01 
FER1L4 NR_119376 2.24 3.54E-04 0.44 4.69E-01 
FAM129A NM_052966 2.24 1.50E-15 -0.73 6.23E-01 
SH2D5 NM_001103160 2.24 8.65E-19 -0.21 2.95E-01 
LOC105373044 NR_134631 2.23 1.47E-02 -0.39 7.42E-01 
EML6 NM_001039753 2.23 8.56E-15 0.21 4.03E-01 
NECTIN1 NM_002855 2.23 4.29E-26 0.14 7.18E-01 
LOC105378316 XR_945981 2.22 4.75E-02 0.65 6.12E-01 
LOC105377199 XR_001755529 2.22 4.23E-05 1.50 4.33E-04 
LOC107986198 XR_001741448 2.22 3.32E-02 1.96 7.83E-06 
GLI2 NM_005270 2.22 4.49E-12 -0.45 9.11E-02 
CREG2 NM_153836 2.22 1.48E-05 0.15 8.81E-01 
SERPINI1 NM_001122752 2.22 1.74E-13 1.71 8.74E-07 
PRSS3 NM_001197097 2.22 2.02E-02 2.61 2.03E-02 
GSDMB NM_001042471 2.22 1.07E-09 0.46 2.15E-01 
CAPN5 NM_004055 2.22 3.60E-03 0.18 5.17E-01 
CCDC3 NM_001282658 2.21 1.32E-02 0.91 3.59E-12 
CYFIP2 NM_001037333 2.21 4.64E-37 0.87 1.73E-10 
MYH10 NM_001256012 2.21 5.75E-22 0.09 6.90E-01 
SLC44A3 NM_001114106 2.21 3.61E-10 0.69 1.85E-03 
TUB NM_003320 2.20 1.58E-17 -0.15 6.26E-01 
LINC01411 NR_125806 2.19 3.46E-02 1.37 2.54E-16 
MGC27382 NR_027310 2.19 4.47E-03 0.18 9.15E-01 
NLGN1 NM_014932 2.19 4.69E-05 -0.07 8.75E-01 
CHSY3 NM_175856 2.19 1.03E-08 -0.23 3.65E-01 
LOC105375716 XR_001746038 2.19 2.97E-02 0.26 7.31E-01 
CTSH NM_001319137 2.19 4.71E-16 -0.02 9.69E-01 
DUSP9 NM_001318503 2.19 3.41E-18 -0.56 8.28E-02 
LOC105377700 XR_001742961 2.18 5.19E-03 0.29 6.92E-01 
LRRC75A NM_001113567 2.18 5.93E-05 0.11 8.48E-01 
MIR6843 NR_106902 2.17 3.85E-03 0.45 7.82E-01 
ANG NM_001097577 2.17 7.15E-20 0.69 2.20E-02 
ARHGAP26 NM_001135608 2.17 7.16E-06 0.53 3.53E-03 
AOX1 NM_001159 2.17 1.12E-03 -0.09 8.10E-01 
SLC38A3 NM_006841 2.17 1.66E-03 -0.03 9.84E-01 
LOC102723648 XR_001744105 2.17 1.24E-09 0.17 9.18E-01 
ELOVL7 NM_001104558 2.16 1.66E-03 0.34 1.58E-01 
HID1 NM_030630 2.16 2.50E-08 1.26 1.54E-02 
DES NM_001927 2.15 3.85E-06 0.95 2.12E-02 
LOC107983953 XM_006715813 2.15 4.37E-02 -0.46 7.05E-01 
JMJD1C-AS1 NR_027182 2.15 4.41E-17 0.22 7.08E-01 
LOC101930275 XR_428319 2.15 6.14E-09 -0.20 6.97E-01 
TGFB2-AS1 NR_046268 2.15 8.57E-06 0.78 4.80E-01 
LOC105374888 XR_926394 2.15 1.09E-06 2.46 9.66E-05 
LOC283140 NR_126004 2.14 5.83E-10 0.80 9.13E-05 
LOC101927421 NR_109882 2.14 3.61E-02 4.86 8.54E-28 
GNG4 NM_001098721 2.14 1.18E-02 -0.35 5.38E-01 
GATM NM_001321015 2.14 2.13E-03 1.11 2.49E-01 
GPR155 NM_001033045 2.13 5.99E-39 1.26 4.25E-07 
   Appendix 
 141 
gene symbol RefSeq ID 2 µM SAHA/ EtOH ctrl 0.5 µM SAHA/ EtOH ctrl log2 fold change padj log2 fold change padj 
MKLN1-AS NR_125364 2.13 5.74E-52 0.79 3.66E-02 
NEBL NM_001173484 2.12 1.32E-04 1.07 1.73E-09 
LOC148709 NR_002929 2.12 6.62E-06 1.26 7.57E-02 
ARL14EPL NM_001195581 2.11 3.10E-02 3.50 4.07E-05 
LOC105371932 XM_017025492 2.11 2.13E-14 1.04 2.53E-02 
LOC105369791 XR_001749167 2.11 2.68E-04 0.47 4.60E-01 
LOC107987295 XR_001754961 2.10 2.73E-03 -0.26 7.44E-01 
KLHL3 NM_001257194 2.10 4.77E-02 -0.37 6.25E-01 
LOC105373428 XR_922797 2.10 2.95E-06 0.95 2.12E-02 
LOC100130370 NM_001272086 2.09 1.72E-04 -0.56 6.11E-01 
LOC101928424 NR_135053 2.09 3.23E-04 0.88 5.98E-01 
MURC NM_001018116 2.09 8.75E-17 0.39 5.41E-01 
BAIAP3 NM_001199096 2.09 2.59E-02 0.62 2.72E-02 
LRGUK NM_144648 2.09 1.03E-06 0.95 2.96E-02 
STON1-GTF2A1L NM_001198593 2.09 3.20E-11 0.21 4.16E-01 
ADTRP NM_001143948 2.08 1.13E-10 1.97 4.93E-13 
GPC2 NM_152742 2.08 1.66E-17 0.64 1.83E-02 
LURAP1L-AS1 NR_125775 2.08 3.20E-08 0.57 1.46E-02 
HOXD8 NM_001199746 2.08 8.68E-08 0.28 4.05E-01 
MAPRE3 NM_001303050 2.07 2.93E-20 0.98 3.87E-05 
LOC105372353 XR_935896 2.07 2.03E-09 1.16 7.20E-02 
PDE5A NM_001083 2.07 2.20E-19 0.10 6.61E-01 
C1QL4 NM_001008223 2.07 2.15E-02 0.15 6.56E-01 
KREMEN1 NM_001039570 2.07 1.38E-17 0.19 4.91E-01 
SCN1B NM_001037 2.06 3.46E-13 0.31 4.45E-01 
ADAMTS7 NM_014272 2.06 4.50E-10 -0.29 6.70E-01 
SPATA6 NM_001286238 2.06 2.75E-19 0.15 6.30E-01 
AMZ1 NM_001284355 2.06 1.30E-03 -0.12 9.09E-01 
FAM131C NM_182623 2.06 7.39E-08 0.92 3.23E-01 
FKBP1B NM_001322963 2.06 9.39E-16 -0.26 5.67E-01 
LOC105373303 XR_001755938 2.05 7.68E-08 -0.20 8.53E-01 
LOC105369165 XR_001739464 2.05 9.65E-03 -0.36 5.86E-01 
LOC107985284 XR_001753854 2.05 2.40E-02 0.49 6.57E-01 
CLU NM_001831 2.05 2.89E-07 0.64 1.41E-05 
PFKFB1 NM_001271804 2.05 3.22E-07 0.54 5.80E-01 
RAP2C-AS1 NR_110410 2.05 5.65E-32 0.59 1.31E-01 
CASC11 NR_117101 2.04 1.87E-08 -0.01 9.97E-01 
BAIAP2-AS1 NR_026857 2.04 4.72E-24 0.30 2.08E-01 
FAM47E NM_001136570 2.04 1.03E-07 -0.19 8.26E-01 
STON1 NM_001198595 2.04 1.78E-09 0.16 5.52E-01 
MICAL2 NM_001282663 2.03 4.87E-14 0.58 5.20E-05 
GATA5 NM_080473 2.03 1.67E-03 -0.70 6.28E-01 
C1ORF228 NM_001145636 2.03 1.89E-06 0.19 8.02E-01 
CFL1P1 NR_028492 2.03 1.73E-08 1.50 3.08E-02 
UBASH3B NM_032873 2.02 1.12E-04 0.05 8.72E-01 
LOC105370348 XR_931705 2.02 6.00E-07 0.14 9.31E-01 
LOC102724623 NR_125826 2.02 5.48E-03 -0.32 4.78E-01 
LOC285692 NR_027112 2.02 2.53E-03 -0.04 9.72E-01 
LOC105375186 XR_927096 2.02 1.60E-02 0.72 5.96E-01 
PTGFR NM_000959 2.02 2.09E-07 0.03 9.49E-01 
LRP1 NM_002332 2.02 3.47E-05 -0.13 5.37E-01 
RAB6B NM_016577 2.00 6.21E-27 0.68 4.69E-03 
P4HA3 NM_001288748 2.00 2.98E-09 0.46 4.58E-01 
BORCS7-ASMT NR_037644 -2.00 1.93E-32 -0.75 1.15E-03 
MIR4635 NR_039778 -2.01 2.29E-07 -2.03 4.36E-02 
GPER1 NM_001039966 -2.02 2.09E-16 -1.20 3.37E-03 
PARP10 NM_001317895 -2.03 9.35E-54 -1.17 2.60E-10 
KCTD15 NM_001129994 -2.13 7.42E-40 -1.10 1.35E-09 
ABHD14A NM_015407 -2.13 9.33E-19 -0.92 5.61E-02 
EMP3 NM_001313905 -2.17 2.79E-37 -0.88 1.49E-08 
OLFML3 NM_001286352 -2.17 3.42E-09 -0.56 1.75E-03 
PCBD1 NM_000281 -2.17 9.36E-11 -0.71 8.22E-06 
C1QTNF6 NM_031910 -2.23 3.48E-80 -0.20 7.18E-01 
CTSS NM_001199739 -2.24 2.93E-04 -0.41 7.52E-01 
NDUFB2 NM_004546 -2.27 5.85E-21 -0.40 3.80E-02 
FAIM NM_001033030 -2.37 9.18E-33 -1.15 2.66E-03 
DUS3L NM_001161619 -2.48 9.65E-34 -0.71 2.81E-04 
NMI NM_004688 -2.53 1.56E-22 -1.34 2.25E-06 
GTF3C6 NM_138408 -2.53 3.01E-19 -1.42 4.38E-09 
SLC16A6 NM_001174166 -2.54 1.79E-39 0.06 9.75E-01 
LOC105372233 XR_936223 -2.55 1.32E-29 -0.74 2.44E-01 
UFC1 NM_016406 -2.56 3.73E-26 -1.16 2.60E-12 
PSMB10 NM_002801 -2.56 1.65E-43 -0.99 1.67E-06 
PHF11 NM_001040443 -2.64 1.23E-39 -1.37 4.30E-04 
PMF1-BGLAP NM_001199661 -2.65 1.80E-25 -1.23 8.18E-12 
APOL6 NM_030641 -2.69 3.88E-99 -1.38 5.62E-10 
PMF1 NM_001199653 -2.73 7.10E-26 -1.25 8.47E-12 
AS3MT NM_020682 -2.84 1.02E-21 -0.30 8.61E-01 
IFIT2 NM_001547 -2.93 5.14E-34 0.26 8.25E-01 
SLC16A14 NM_152527 -3.10 6.05E-139 0.41 7.33E-01 
MYLK3 NM_001308301 -3.20 2.67E-25 0.54 6.88E-01 
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gene symbol RefSeq ID 2 µM SAHA/ EtOH ctrl 0.5 µM SAHA/ EtOH ctrl log2 fold change padj log2 fold change padj 
ADI1 NM_001306077 -3.26 2.14E-59 -0.92 2.30E-07 
DDX60 NM_017631 -3.57 6.87E-63 -0.34 4.07E-01 
ISG15 NM_005101 -3.64 8.93E-28 -0.13 7.47E-01 
IFIT3 NM_001031683 -3.65 1.99E-49 -0.32 7.10E-01 
NUPR1 NM_001042483 -3.84 3.39E-14 -1.06 1.26E-05 
OASL NM_001261825 -4.07 1.37E-22 -1.04 4.29E-04 
IFI44 NM_006417 -4.30 1.11E-41 0.02 9.86E-01 
Suppl. table S7. DESeq results of ASF1 depleted HeLa LT cells treated with SAHA. 501 up- and 
35 downregulated genes with a log2 fold change (l2fc) <-2.0 or >2.0 for 2 µM SAHA over EtOH ctrl were 
identified, while the l2fc of 0.5 µM SAHA over EtOH ctrl was either not statistical significant or in the 
same direction. The adjusted p-value was set to padj<0.05 and genes with an RPKM >1 in the highest 
expressed sample were selected for this table. Genes were sorted by l2fc (2 µM SAHA over EtOH ctrl). 
Those genes implemented in the TelNet database were marked in bold, genes reported to be cell cycle-
regulated in HeLa cells (Grant et al., 2013) were marked with a °circle. 
Suppl. table S8. DESeq results of type II survivor formation in budding yeast. 
gene symbol RefSeq ID log2 fold change padj 
YER078W-A NM_001184548 3.47 2.56E-04 
YPL185W NC_001148 2.82 1.55E-03 
YLR101C NC_001144 2.18 1.29E-02 
YPR108W-A NM_001184581 2.05 6.77E-03 
YER079W NM_001178970 1.80 1.53E-03 
YER158W-A - 1.79 1.32E-04 
ALD6 NM_001183875 1.21 1.25E-08 
PGM2 NM_001182605 1.05 4.54E-03 
YFR052C-A - 1.03 3.39E-02 
VID24 NM_001178453 0.98 8.44E-03 
YLR108C NM_001181995 0.97 5.83E-03 
ALD4 NM_001183794 0.92 3.64E-03 
TIR1 NM_001178902 -0.92 2.31E-05 
ARN2 NM_001179127 -0.99 1.15E-07 
FIT3 NM_001183803 -1.00 4.35E-08 
TPO2 NM_001181267 -1.02 8.44E-03 
FRE4 NM_001183237 -1.07 4.49E-02 
FIT2 NM_001183802 -1.14 2.54E-10 
YMR013W-A NC_001145 -1.22 1.15E-12 
YAL037W NM_001178182 -1.31 3.41E-03 
EDS1 NM_001178381 -1.32 1.38E-02 
YJL047C-A NM_001184635 -1.37 2.83E-13 
COS12 NM_001181129 -1.42 5.83E-03 
YBR113W NC_001134 -1.93 2.56E-02 
FIT1 NM_001180842 -1.95 2.65E-14 
YMR317W NM_001182830 -2.10 8.79E-09 
YGR270C-A - -4.34 1.51E-04 
The table shows significantly deregulated genes with a log2 fold change <-0.9 or >0.9 and padj <0.05. 
Genes were sorted by log2 fold change. Those genes implemented in the TelNet database were marked 
in bold. 
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